{"PMC7087659": [["IntroductionRecurrent respiratory tract infections (RTIs) have a significant health and socioeconomic impact.", [["respiratory tract", "ANATOMY", 22, 39], ["respiratory tract infections", "DISEASE", 22, 50], ["RTIs", "DISEASE", 52, 56], ["tract", "ORGANISM_SUBDIVISION", 34, 39], ["IntroductionRecurrent respiratory tract infections", "PROBLEM", 0, 50], ["respiratory tract", "ANATOMY", 22, 39], ["infections", "OBSERVATION", 40, 50], ["significant", "OBSERVATION_MODIFIER", 65, 76]]], ["Recurrent infections of the upper and lower respiratory tract often require multiple treatment modalities, including the use of antibiotics [1\u20134].", [["upper", "ANATOMY", 28, 33], ["lower respiratory tract", "ANATOMY", 38, 61], ["infections of the upper and lower respiratory tract", "DISEASE", 10, 61], ["upper", "ORGANISM_SUBDIVISION", 28, 33], ["lower", "ORGANISM_SUBDIVISION", 38, 43], ["respiratory tract", "ORGANISM_SUBDIVISION", 44, 61], ["Recurrent infections of the upper and lower respiratory tract", "PROBLEM", 0, 61], ["multiple treatment modalities", "TREATMENT", 76, 105], ["antibiotics", "TREATMENT", 128, 139], ["infections", "OBSERVATION", 10, 20], ["upper", "ANATOMY_MODIFIER", 28, 33], ["lower", "ANATOMY_MODIFIER", 38, 43], ["respiratory tract", "ANATOMY", 44, 61], ["multiple", "OBSERVATION_MODIFIER", 76, 84], ["treatment", "OBSERVATION", 85, 94]]], ["The high incidence of these diseases in combination with the substantial morbidity, clinical sequelae, and associated overuse and misuse of antibiotics contribute towards the overall disease burden that includes the direct costs of healthcare and indirect economic costs to society [4, 5].IntroductionThe vast majority of recurrent RTIs are triggered by viruses, but these are frequently followed by bacterial superinfections [6].", [["RTIs", "DISEASE", 332, 336], ["these diseases", "PROBLEM", 22, 36], ["the substantial morbidity", "PROBLEM", 57, 82], ["clinical sequelae", "PROBLEM", 84, 101], ["antibiotics", "TREATMENT", 140, 151], ["the overall disease burden", "PROBLEM", 171, 197], ["recurrent RTIs", "PROBLEM", 322, 336], ["viruses", "PROBLEM", 354, 361], ["bacterial superinfections", "PROBLEM", 400, 425], ["high", "OBSERVATION_MODIFIER", 4, 8], ["diseases", "OBSERVATION", 28, 36], ["substantial", "OBSERVATION_MODIFIER", 61, 72], ["morbidity", "OBSERVATION", 73, 82], ["disease", "OBSERVATION", 183, 190], ["recurrent", "OBSERVATION_MODIFIER", 322, 331], ["RTIs", "OBSERVATION", 332, 336], ["viruses", "OBSERVATION", 354, 361], ["superinfections", "OBSERVATION", 410, 425]]], ["There is extensive literature on the synergistic effect between viruses and bacteria in the pathogenesis of respiratory infections [2].", [["respiratory", "ANATOMY", 108, 119], ["respiratory infections", "DISEASE", 108, 130], ["the synergistic effect", "PROBLEM", 33, 55], ["viruses", "PROBLEM", 64, 71], ["bacteria", "PROBLEM", 76, 84], ["respiratory infections", "PROBLEM", 108, 130], ["extensive", "OBSERVATION_MODIFIER", 9, 18], ["bacteria", "OBSERVATION_MODIFIER", 76, 84], ["respiratory infections", "OBSERVATION", 108, 130]]], ["Regardless of whether they are viral or bacterial, the presence of pathogens in the respiratory tract triggers the involvement of the innate and adaptive mucosal immune systems.", [["respiratory tract", "ANATOMY", 84, 101], ["mucosal", "ANATOMY", 154, 161], ["respiratory tract", "ORGANISM_SUBDIVISION", 84, 101], ["mucosal", "ANATOMICAL_SYSTEM", 154, 161], ["viral", "PROBLEM", 31, 36], ["bacterial", "PROBLEM", 40, 49], ["pathogens", "PROBLEM", 67, 76], ["the respiratory tract", "PROBLEM", 80, 101], ["viral", "OBSERVATION", 31, 36], ["bacterial", "OBSERVATION", 40, 49], ["pathogens", "OBSERVATION", 67, 76], ["respiratory tract", "ANATOMY", 84, 101]]], ["Innate mucosal immunity is related to the function of the epithelial lining of the respiratory tract, including the production of antimicrobial peptides, the cytotoxic actions of NK cells, and the engulfment of pathogens by monocytes/macrophages and neutrophils.", [["mucosal", "ANATOMY", 7, 14], ["epithelial lining", "ANATOMY", 58, 75], ["respiratory tract", "ANATOMY", 83, 100], ["NK cells", "ANATOMY", 179, 187], ["monocytes", "ANATOMY", 224, 233], ["macrophages", "ANATOMY", 234, 245], ["neutrophils", "ANATOMY", 250, 261], ["mucosal", "MULTI-TISSUE_STRUCTURE", 7, 14], ["epithelial lining", "TISSUE", 58, 75], ["respiratory tract", "ORGANISM_SUBDIVISION", 83, 100], ["NK cells", "CELL", 179, 187], ["monocytes", "CELL", 224, 233], ["macrophages", "CELL", 234, 245], ["neutrophils", "CELL", 250, 261], ["NK cells", "CELL_TYPE", 179, 187], ["monocytes", "CELL_TYPE", 224, 233], ["macrophages", "CELL_TYPE", 234, 245], ["neutrophils", "CELL_TYPE", 250, 261], ["antimicrobial peptides", "TREATMENT", 130, 152], ["NK cells", "PROBLEM", 179, 187], ["monocytes/macrophages", "TEST", 224, 245], ["neutrophils", "TEST", 250, 261], ["mucosal immunity", "OBSERVATION", 7, 23], ["epithelial", "ANATOMY_MODIFIER", 58, 68], ["lining", "ANATOMY_MODIFIER", 69, 75], ["respiratory tract", "ANATOMY", 83, 100], ["antimicrobial peptides", "OBSERVATION", 130, 152], ["NK cells", "OBSERVATION", 179, 187]]], ["A key event among the actions of the acquired immune system is the production of IgA molecules.IntroductionPatients with impaired immunity and chronic inflammation are at greater risk of RTIs.", [["immune system", "ANATOMY", 46, 59], ["impaired immunity", "DISEASE", 121, 138], ["inflammation", "DISEASE", 151, 163], ["RTIs", "DISEASE", 187, 191], ["IgA", "GENE_OR_GENE_PRODUCT", 81, 84], ["IgA molecules", "PROTEIN", 81, 94], ["A key event", "PROBLEM", 0, 11], ["the acquired immune system", "TREATMENT", 33, 59], ["IgA molecules", "PROBLEM", 81, 94], ["impaired immunity", "PROBLEM", 121, 138], ["chronic inflammation", "PROBLEM", 143, 163], ["RTIs", "PROBLEM", 187, 191], ["IgA molecules", "OBSERVATION", 81, 94], ["impaired", "OBSERVATION_MODIFIER", 121, 129], ["immunity", "OBSERVATION", 130, 138], ["chronic", "OBSERVATION_MODIFIER", 143, 150], ["inflammation", "OBSERVATION", 151, 163], ["RTIs", "OBSERVATION", 187, 191]]], ["This is especially true for those with underlying conditions such as allergic rhinitis, asthma, or chronic obstructive pulmonary disease (COPD) [7, 8].", [["pulmonary", "ANATOMY", 119, 128], ["allergic rhinitis", "DISEASE", 69, 86], ["asthma", "DISEASE", 88, 94], ["chronic obstructive pulmonary disease", "DISEASE", 99, 136], ["COPD", "DISEASE", 138, 142], ["pulmonary", "ORGAN", 119, 128], ["underlying conditions", "PROBLEM", 39, 60], ["allergic rhinitis", "PROBLEM", 69, 86], ["asthma", "PROBLEM", 88, 94], ["chronic obstructive pulmonary disease (COPD)", "PROBLEM", 99, 143], ["allergic rhinitis", "OBSERVATION", 69, 86], ["asthma", "OBSERVATION", 88, 94], ["chronic", "OBSERVATION_MODIFIER", 99, 106], ["obstructive", "OBSERVATION_MODIFIER", 107, 118], ["pulmonary", "ANATOMY", 119, 128], ["disease", "OBSERVATION", 129, 136], ["COPD", "OBSERVATION", 138, 142]]], ["These disorders are highly prevalent worldwide and are of great public health concern [9, 10].", [["These disorders", "PROBLEM", 0, 15]]], ["Patients with these disorders have impaired immunologic response mechanisms such as a preponderance of Th2-driven responses and a reduction in protective Th1 responses [11].", [["Patients", "ORGANISM", 0, 8], ["Th2", "GENE_OR_GENE_PRODUCT", 103, 106], ["Patients", "SPECIES", 0, 8], ["these disorders", "PROBLEM", 14, 29], ["impaired immunologic response mechanisms", "PROBLEM", 35, 75]]], ["Furthermore, they have increased levels of IgE antibodies which are related to a stronger inflammatory response [12\u201314].IntroductionFrom the preventive and clinical point of view, there is a need for addressing the recurrence and severity of RTIs in this large patient population.", [["RTIs", "DISEASE", 242, 246], ["IgE antibodies", "GENE_OR_GENE_PRODUCT", 43, 57], ["patient", "ORGANISM", 261, 268], ["IgE antibodies", "PROTEIN", 43, 57], ["patient", "SPECIES", 261, 268], ["increased levels of IgE antibodies", "PROBLEM", 23, 57], ["a stronger inflammatory response", "PROBLEM", 79, 111], ["the recurrence", "PROBLEM", 211, 225], ["RTIs", "PROBLEM", 242, 246], ["this large patient population", "PROBLEM", 250, 279], ["increased", "OBSERVATION_MODIFIER", 23, 32], ["IgE antibodies", "OBSERVATION", 43, 57], ["large", "OBSERVATION_MODIFIER", 255, 260]]], ["OM-85 (Broncho-Vaxom\u00ae, Broncho-Munal\u00ae, Vaxoral\u00ae, Ommunal\u00ae, Paxoral\u00ae) is an immunomodulator comprising lyophilized bacterial lysates from the eight major strains responsible for RTIs (Haemophilus influenzae, Streptococcus pneumoniae, Klebsiellapneumoniae, Klebsiellaozaenae, Staphylococcusaureus, Streptococcuspyogenes, Streptococcus viridans, and Moraxella catarrhalis).", [["lysates", "ANATOMY", 124, 131], ["OM-85", "CHEMICAL", 0, 5], ["Broncho-Vaxom\u00ae", "CHEMICAL", 7, 21], ["RTIs", "DISEASE", 177, 181], ["Haemophilus influenzae", "DISEASE", 183, 205], ["Streptococcus viridans", "DISEASE", 319, 341], ["OM-85", "SIMPLE_CHEMICAL", 0, 5], ["Broncho-Vaxom\u00ae", "SIMPLE_CHEMICAL", 7, 21], ["Broncho-Munal\u00ae", "SIMPLE_CHEMICAL", 23, 37], ["Vaxoral\u00ae", "SIMPLE_CHEMICAL", 39, 47], ["Ommunal\u00ae", "SIMPLE_CHEMICAL", 49, 57], ["Paxoral\u00ae", "SIMPLE_CHEMICAL", 59, 67], ["Haemophilus influenzae", "ORGANISM", 183, 205], ["Streptococcus pneumoniae", "ORGANISM", 207, 231], ["Klebsiellapneumoniae", "ORGANISM", 233, 253], ["Klebsiellaozaenae", "ORGANISM", 255, 272], ["Staphylococcusaureus, Streptococcuspyogenes", "ORGANISM", 274, 317], ["Streptococcus viridans", "ORGANISM", 319, 341], ["Moraxella catarrhalis", "ORGANISM", 347, 368], ["Haemophilus influenzae", "SPECIES", 183, 205], ["Streptococcus pneumoniae", "SPECIES", 207, 231], ["Streptococcus viridans", "SPECIES", 319, 341], ["Moraxella catarrhalis", "SPECIES", 347, 368], ["Haemophilus influenzae", "SPECIES", 183, 205], ["Streptococcus pneumoniae", "SPECIES", 207, 231], ["Streptococcus viridans", "SPECIES", 319, 341], ["Moraxella catarrhalis", "SPECIES", 347, 368], ["OM", "TEST", 0, 2], ["Broncho", "TEST", 7, 14], ["Vaxom\u00ae", "TEST", 15, 21], ["Broncho", "TEST", 23, 30], ["Vaxoral\u00ae", "TREATMENT", 39, 47], ["Ommunal\u00ae, Paxoral\u00ae)", "TREATMENT", 49, 68], ["an immunomodulator", "TREATMENT", 72, 90], ["lyophilized bacterial lysates", "TREATMENT", 102, 131], ["RTIs", "PROBLEM", 177, 181], ["Haemophilus influenzae", "PROBLEM", 183, 205], ["Streptococcus pneumoniae", "PROBLEM", 207, 231], ["Klebsiellapneumoniae", "PROBLEM", 233, 253], ["Klebsiellaozaenae", "TEST", 255, 272], ["Staphylococcusaureus", "TEST", 274, 294], ["Streptococcuspyogenes", "PROBLEM", 296, 317], ["Streptococcus viridans", "PROBLEM", 319, 341], ["Moraxella catarrhalis", "PROBLEM", 347, 368], ["Streptococcus viridans", "OBSERVATION", 319, 341], ["Moraxella catarrhalis", "OBSERVATION", 347, 368]]], ["OM-85 has pleiotropic immunomodulating effects on both the innate and adaptive immune responses [15\u201317].", [["OM-85", "CHEMICAL", 0, 5], ["pleiotropic immunomodulating effects", "TREATMENT", 10, 46]]], ["There is an extensive body of evidence showing the safety and efficacy of OM-85 in the prevention of RTIs in children and adults regardless of the etiology, including in those with impaired immunity [15, 18\u201324].", [["OM-85", "CHEMICAL", 74, 79], ["RTIs", "DISEASE", 101, 105], ["impaired immunity", "DISEASE", 181, 198], ["OM-85", "SIMPLE_CHEMICAL", 74, 79], ["children", "ORGANISM", 109, 117], ["children", "SPECIES", 109, 117], ["RTIs", "PROBLEM", 101, 105], ["extensive", "OBSERVATION_MODIFIER", 12, 21], ["body", "OBSERVATION_MODIFIER", 22, 26]]], ["The use of OM-85 has been shown to have beneficial effects on the incidence, duration, and severity of RTIs [25\u201328].IntroductionThe aim of this study was to evaluate the efficacy of OM-85 in reducing the incidence of RTIs in patients with allergic rhinitis, asthma, or COPD and its effect on immunological parameters, namely serum and secretory IgA levels.Study Design ::: MethodsThis was an open-label, prospective, sequential study conducted in 2009 and 2010.", [["serum", "ANATOMY", 325, 330], ["OM-85", "CHEMICAL", 11, 16], ["RTIs", "DISEASE", 103, 107], ["OM-85", "CHEMICAL", 182, 187], ["RTIs", "DISEASE", 217, 221], ["allergic rhinitis", "DISEASE", 239, 256], ["asthma", "DISEASE", 258, 264], ["COPD", "DISEASE", 269, 273], ["OM-85", "CHEMICAL", 11, 16], ["OM-85", "SIMPLE_CHEMICAL", 11, 16], ["OM-85", "SIMPLE_CHEMICAL", 182, 187], ["patients", "ORGANISM", 225, 233], ["serum", "ORGANISM_SUBSTANCE", 325, 330], ["IgA", "GENE_OR_GENE_PRODUCT", 345, 348], ["IgA", "PROTEIN", 345, 348], ["patients", "SPECIES", 225, 233], ["RTIs", "PROBLEM", 103, 107], ["this study", "TEST", 139, 149], ["RTIs", "PROBLEM", 217, 221], ["allergic rhinitis", "PROBLEM", 239, 256], ["asthma", "PROBLEM", 258, 264], ["COPD", "PROBLEM", 269, 273], ["immunological parameters", "TEST", 292, 316], ["serum and secretory IgA levels", "TEST", 325, 355], ["Methods", "TREATMENT", 373, 380], ["sequential study", "TEST", 417, 433], ["RTIs", "OBSERVATION", 217, 221], ["allergic rhinitis", "OBSERVATION", 239, 256], ["asthma", "OBSERVATION", 258, 264], ["COPD", "OBSERVATION", 269, 273]]], ["A total of 84 consecutive patients presenting with three or more respiratory infections during the previous year, eligible according to the inclusion and exclusion criteria, and who had provided written informed consent were included.", [["respiratory", "ANATOMY", 65, 76], ["respiratory infections", "DISEASE", 65, 87], ["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["more respiratory infections", "PROBLEM", 60, 87], ["respiratory", "ANATOMY", 65, 76], ["infections", "OBSERVATION", 77, 87]]], ["Among these 84 patients, 29 had allergic rhinitis, 28 had asthma, and 27 had COPD.", [["allergic rhinitis", "DISEASE", 32, 49], ["asthma", "DISEASE", 58, 64], ["COPD", "DISEASE", 77, 81], ["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["allergic rhinitis", "PROBLEM", 32, 49], ["asthma", "PROBLEM", 58, 64], ["COPD", "PROBLEM", 77, 81], ["allergic rhinitis", "OBSERVATION", 32, 49], ["COPD", "OBSERVATION", 77, 81]]], ["All patients underwent a complete medical history, as well as testing for specific serum IgE and the allergen skin prick test, serum IgA, and salivary secretory IgA.", [["serum", "ANATOMY", 83, 88], ["skin", "ANATOMY", 110, 114], ["serum", "ANATOMY", 127, 132], ["salivary secretory IgA.", "ANATOMY", 142, 165], ["patients", "ORGANISM", 4, 12], ["serum", "ORGANISM_SUBSTANCE", 83, 88], ["IgE", "GENE_OR_GENE_PRODUCT", 89, 92], ["skin", "ORGAN", 110, 114], ["serum", "ORGANISM_SUBSTANCE", 127, 132], ["IgA", "GENE_OR_GENE_PRODUCT", 133, 136], ["salivary", "ORGANISM_SUBSTANCE", 142, 150], ["serum IgE", "PROTEIN", 83, 92], ["serum IgA", "PROTEIN", 127, 136], ["patients", "SPECIES", 4, 12], ["testing", "TEST", 62, 69], ["specific serum IgE", "TEST", 74, 92], ["the allergen skin prick test", "TEST", 97, 125], ["serum IgA", "TEST", 127, 136], ["skin", "ANATOMY", 110, 114]]], ["IgA levels only were tested again after 3 months.", [["IgA", "GENE_OR_GENE_PRODUCT", 0, 3], ["IgA", "PROTEIN", 0, 3], ["IgA levels", "TEST", 0, 10]]], ["After 9 months of observation, the same group of patients was re-assessed.", [["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57]]], ["All patients presented with respiratory infections despite optimization of the standard care regimen (standard optimized care [SOC]) and as they did not receive prophylaxis with a bacterial lysate they were included in the second phase of the study.", [["respiratory", "ANATOMY", 28, 39], ["lysate", "ANATOMY", 190, 196], ["respiratory infections", "DISEASE", 28, 50], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["respiratory infections", "PROBLEM", 28, 50], ["the standard care regimen", "TREATMENT", 75, 100], ["prophylaxis", "TREATMENT", 161, 172], ["a bacterial lysate", "TREATMENT", 178, 196], ["the study", "TEST", 239, 248], ["respiratory", "ANATOMY", 28, 39], ["infections", "OBSERVATION", 40, 50]]], ["In 2010, the same patients received treatment with OM-85 bacterial lysate (alongside SOC) and were evaluated in the same manner as the previous year.Study Design ::: MethodsThe study protocol was approved by the institutional Ethics Committee.", [["lysate", "ANATOMY", 67, 73], ["OM-85", "CHEMICAL", 51, 56], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["treatment", "TREATMENT", 36, 45], ["OM", "TREATMENT", 51, 53], ["bacterial lysate", "TREATMENT", 57, 73], ["Methods", "TREATMENT", 166, 173], ["The study protocol", "TEST", 173, 191]]], ["Written informed consent was obtained from all participants included in the study, and the study was conducted according to the principles of the 1964 Declaration of Helsinki and its amendments.Main Inclusion and Exclusion Criteria ::: MethodsThe study included male and female outpatients (aged 16\u201365 years) who had a confirmed history of perennial (\u22652 years) allergic rhinitis, asthma, or COPD and at least three RTIs in the previous year (assessed at the screening visit).", [["allergic rhinitis", "DISEASE", 361, 378], ["asthma", "DISEASE", 380, 386], ["COPD", "DISEASE", 391, 395], ["RTIs", "DISEASE", 415, 419], ["outpatients", "ORGANISM", 278, 289], ["participants", "SPECIES", 47, 59], ["outpatients", "SPECIES", 278, 289], ["the study", "TEST", 72, 81], ["the study", "TEST", 87, 96], ["Methods", "TREATMENT", 236, 243], ["The study", "TEST", 243, 252], ["allergic rhinitis", "PROBLEM", 361, 378], ["asthma", "PROBLEM", 380, 386], ["COPD", "PROBLEM", 391, 395], ["allergic", "OBSERVATION_MODIFIER", 361, 369], ["rhinitis", "OBSERVATION", 370, 378], ["asthma", "OBSERVATION", 380, 386], ["COPD", "OBSERVATION", 391, 395]]], ["Patients with allergic rhinitis or asthma had to have elevated serum IgE levels.", [["serum", "ANATOMY", 63, 68], ["allergic rhinitis", "DISEASE", 14, 31], ["asthma", "DISEASE", 35, 41], ["Patients", "ORGANISM", 0, 8], ["serum", "ORGANISM_SUBSTANCE", 63, 68], ["IgE", "GENE_OR_GENE_PRODUCT", 69, 72], ["IgE", "PROTEIN", 69, 72], ["Patients", "SPECIES", 0, 8], ["allergic rhinitis", "PROBLEM", 14, 31], ["asthma", "PROBLEM", 35, 41], ["elevated serum IgE levels", "PROBLEM", 54, 79], ["allergic", "OBSERVATION_MODIFIER", 14, 22], ["rhinitis", "OBSERVATION", 23, 31], ["asthma", "OBSERVATION", 35, 41]]], ["In addition, patients with allergic rhinitis or asthma had to have a positive skin prick test against one or more of the following allergens: dermatophagoides, cat dander, alternaria, and/or Aspergillus.", [["skin", "ANATOMY", 78, 82], ["allergic rhinitis", "DISEASE", 27, 44], ["asthma", "DISEASE", 48, 54], ["patients", "ORGANISM", 13, 21], ["skin", "ORGAN", 78, 82], ["dermatophagoides", "ORGANISM", 142, 158], ["cat", "ORGANISM", 160, 163], ["dander", "ORGANISM", 164, 170], ["patients", "SPECIES", 13, 21], ["cat", "SPECIES", 160, 163], ["cat dander", "SPECIES", 160, 170], ["allergic rhinitis", "PROBLEM", 27, 44], ["asthma", "PROBLEM", 48, 54], ["a positive skin prick test", "PROBLEM", 67, 93], ["dermatophagoides", "PROBLEM", 142, 158], ["cat dander", "PROBLEM", 160, 170], ["alternaria", "PROBLEM", 172, 182], ["Aspergillus", "PROBLEM", 191, 202], ["allergic", "OBSERVATION_MODIFIER", 27, 35], ["rhinitis", "OBSERVATION", 36, 44], ["skin", "ANATOMY", 78, 82], ["Aspergillus", "OBSERVATION", 191, 202]]], ["Key exclusion criteria included structural alterations of the nasal pyramid, the presence of any underlying medical condition that could interfere with the study results, pregnancy, or breastfeeding.Study Treatment ::: MethodsAfter 9 months of observation and SOC therapy, the patients received treatment with OM-85 (one 7 mg capsule daily for ten consecutive days per month, for 3 months), and were followed-up for 6 months after the treatment period (Fig. 1).", [["nasal pyramid", "ANATOMY", 62, 75], ["OM-85", "CHEMICAL", 310, 315], ["nasal pyramid", "MULTI-TISSUE_STRUCTURE", 62, 75], ["patients", "ORGANISM", 277, 285], ["patients", "SPECIES", 277, 285], ["structural alterations of the nasal pyramid", "PROBLEM", 32, 75], ["any underlying medical condition", "PROBLEM", 93, 125], ["the study", "TEST", 152, 161], ["MethodsAfter", "TREATMENT", 219, 231], ["SOC therapy", "TREATMENT", 260, 271], ["treatment", "TREATMENT", 295, 304], ["OM", "TREATMENT", 310, 312], ["the treatment period", "TREATMENT", 431, 451], ["nasal pyramid", "ANATOMY", 62, 75]]], ["In addition, 10 healthy subjects (with no underlying asthma, allergies, or COPD, but who occasionally visited the clinic for uncomplicated respiratory infections) were selected as normal controls for the measurement of IgA values.", [["respiratory", "ANATOMY", 139, 150], ["asthma", "DISEASE", 53, 59], ["allergies", "DISEASE", 61, 70], ["COPD", "DISEASE", 75, 79], ["respiratory infections", "DISEASE", 139, 161], ["IgA", "GENE_OR_GENE_PRODUCT", 219, 222], ["IgA", "PROTEIN", 219, 222], ["underlying asthma", "PROBLEM", 42, 59], ["allergies", "PROBLEM", 61, 70], ["COPD", "PROBLEM", 75, 79], ["uncomplicated respiratory infections", "PROBLEM", 125, 161], ["IgA values", "TEST", 219, 229], ["asthma", "OBSERVATION", 53, 59]]]], "da2662c4819deaa42fc36c7aeadeb3aff0dcc769": [["Original ArticleThe Effect of Viral Infection on Exhaled Nitric Oxide in Children with Acute Asthma Exacerbations Jonathan Malka, MD a,b , Ronina Covar, MD c,d , Anna Faino, MS e , Jennifer Fish, CPNP f , Paige Pickering, BS g , Preveen Ramamoorthy, MD g , Melanie Gleason, PAC b,h , and Joseph D. Spahn, MD b,h Aventura, Fla; Denver and Aurora, ColoOriginal ArticleWhat is already known about this topic?", [["Viral Infection", "DISEASE", 30, 45], ["Nitric Oxide", "CHEMICAL", 57, 69], ["Asthma", "DISEASE", 93, 99], ["Nitric Oxide", "CHEMICAL", 57, 69], ["Exhaled Nitric Oxide", "SIMPLE_CHEMICAL", 49, 69], ["Children", "SPECIES", 73, 81], ["Viral Infection", "PROBLEM", 30, 45], ["Exhaled Nitric Oxide", "TREATMENT", 49, 69], ["Acute Asthma Exacerbations", "PROBLEM", 87, 113], ["Viral", "OBSERVATION_MODIFIER", 30, 35], ["Infection", "OBSERVATION", 36, 45], ["Acute", "OBSERVATION_MODIFIER", 87, 92], ["Asthma", "OBSERVATION", 93, 99], ["Aurora", "ANATOMY", 338, 344]]], ["Fraction of exhaled nitric oxide (FENO) is a tool that can be used to diagnose asthma and to predict a positive response to inhaled steroid therapy, and can help measure adherence with inhaled steroid therapy in patients with chronic asthma.", [["nitric oxide", "CHEMICAL", 20, 32], ["asthma", "DISEASE", 79, 85], ["steroid", "CHEMICAL", 132, 139], ["steroid", "CHEMICAL", 193, 200], ["asthma", "DISEASE", 234, 240], ["nitric oxide", "CHEMICAL", 20, 32], ["steroid", "CHEMICAL", 132, 139], ["steroid", "CHEMICAL", 193, 200], ["exhaled nitric oxide", "SIMPLE_CHEMICAL", 12, 32], ["FENO", "SIMPLE_CHEMICAL", 34, 38], ["steroid", "SIMPLE_CHEMICAL", 132, 139], ["steroid", "SIMPLE_CHEMICAL", 193, 200], ["patients", "ORGANISM", 212, 220], ["patients", "SPECIES", 212, 220], ["exhaled nitric oxide", "TREATMENT", 12, 32], ["asthma", "PROBLEM", 79, 85], ["inhaled steroid therapy", "TREATMENT", 124, 147], ["inhaled steroid therapy", "TREATMENT", 185, 208], ["chronic asthma", "PROBLEM", 226, 240], ["exhaled", "OBSERVATION", 12, 19], ["nitric oxide", "OBSERVATION", 20, 32], ["chronic", "OBSERVATION_MODIFIER", 226, 233], ["asthma", "OBSERVATION", 234, 240]]], ["Unfortunately, its utility in the management of acute asthma has not been widely studied.Original ArticleWhat does this article add to our knowledge?", [["asthma", "DISEASE", 54, 60], ["acute asthma", "PROBLEM", 48, 60], ["acute", "OBSERVATION_MODIFIER", 48, 53], ["asthma", "OBSERVATION", 54, 60]]], ["This study found that in children with an acute asthma exacerbation, FENO levels are elevated compared with baseline levels.", [["asthma", "DISEASE", 48, 54], ["FENO", "CHEMICAL", 69, 73], ["children", "ORGANISM", 25, 33], ["FENO", "SIMPLE_CHEMICAL", 69, 73], ["children", "SPECIES", 25, 33], ["This study", "TEST", 0, 10], ["an acute asthma exacerbation", "PROBLEM", 39, 67], ["FENO levels", "TEST", 69, 80], ["elevated", "PROBLEM", 85, 93], ["acute", "OBSERVATION_MODIFIER", 42, 47], ["asthma", "OBSERVATION", 48, 54], ["elevated", "OBSERVATION_MODIFIER", 85, 93]]], ["In addition, FENO levels rise to a greater extent in children who do not have a viral-induced asthma exacerbation, suggesting that eosinophilic inflammation plays more of a role in noneviralinduced asthma exacerbations.", [["eosinophilic", "ANATOMY", 131, 143], ["FENO", "CHEMICAL", 13, 17], ["asthma", "DISEASE", 94, 100], ["eosinophilic inflammation", "DISEASE", 131, 156], ["asthma", "DISEASE", 198, 204], ["FENO", "GENE_OR_GENE_PRODUCT", 13, 17], ["children", "ORGANISM", 53, 61], ["children", "SPECIES", 53, 61], ["FENO levels", "TEST", 13, 24], ["a viral-induced asthma exacerbation", "PROBLEM", 78, 113], ["eosinophilic inflammation", "PROBLEM", 131, 156], ["noneviralinduced asthma exacerbations", "PROBLEM", 181, 218], ["greater extent", "OBSERVATION_MODIFIER", 35, 49], ["viral", "OBSERVATION", 80, 85], ["asthma", "OBSERVATION", 94, 100], ["eosinophilic", "OBSERVATION_MODIFIER", 131, 143], ["inflammation", "OBSERVATION", 144, 156], ["asthma", "OBSERVATION", 198, 204]]], ["Last, prednisone was effective in reducing FENO levels to their baseline state, with the biggest reduction seen in those with viral infections.Original ArticleHow does this study impact current management guidelines?", [["prednisone", "CHEMICAL", 6, 16], ["FENO", "CHEMICAL", 43, 47], ["viral infections", "DISEASE", 126, 142], ["prednisone", "CHEMICAL", 6, 16], ["prednisone", "SIMPLE_CHEMICAL", 6, 16], ["FENO", "SIMPLE_CHEMICAL", 43, 47], ["prednisone", "TREATMENT", 6, 16], ["viral infections", "PROBLEM", 126, 142], ["current management", "TREATMENT", 186, 204], ["viral infections", "OBSERVATION", 126, 142]]], ["This study suggests that FENO is a useful marker of inflammation during an acute asthma exacerbation and that prednisone therapy improves lung function and normalizes FENO levels in children with acute asthma regardless of the underlying cause of their exacerbation.Original ArticleBACKGROUND: Fraction of exhaled nitric oxide (FENO) level is used as an aid in the diagnosis and management of chronic asthma.", [["lung", "ANATOMY", 138, 142], ["FENO", "CHEMICAL", 25, 29], ["inflammation", "DISEASE", 52, 64], ["asthma", "DISEASE", 81, 87], ["prednisone", "CHEMICAL", 110, 120], ["FENO", "CHEMICAL", 167, 171], ["asthma", "DISEASE", 202, 208], ["nitric oxide", "CHEMICAL", 314, 326], ["FENO", "CHEMICAL", 328, 332], ["asthma", "DISEASE", 401, 407], ["prednisone", "CHEMICAL", 110, 120], ["nitric oxide", "CHEMICAL", 314, 326], ["FENO", "CHEMICAL", 328, 332], ["FENO", "SIMPLE_CHEMICAL", 25, 29], ["prednisone", "SIMPLE_CHEMICAL", 110, 120], ["lung", "ORGAN", 138, 142], ["FENO", "SIMPLE_CHEMICAL", 167, 171], ["children", "ORGANISM", 182, 190], ["exhaled nitric oxide", "SIMPLE_CHEMICAL", 306, 326], ["FENO", "SIMPLE_CHEMICAL", 328, 332], ["children", "SPECIES", 182, 190], ["This study", "TEST", 0, 10], ["inflammation", "PROBLEM", 52, 64], ["an acute asthma exacerbation", "PROBLEM", 72, 100], ["prednisone therapy", "TREATMENT", 110, 128], ["lung function", "TEST", 138, 151], ["FENO levels", "TEST", 167, 178], ["acute asthma", "PROBLEM", 196, 208], ["their exacerbation", "PROBLEM", 247, 265], ["exhaled nitric oxide", "TREATMENT", 306, 326], ["management", "TREATMENT", 379, 389], ["chronic asthma", "PROBLEM", 393, 407], ["inflammation", "OBSERVATION", 52, 64], ["acute", "OBSERVATION_MODIFIER", 75, 80], ["asthma", "OBSERVATION", 81, 87], ["acute", "OBSERVATION_MODIFIER", 196, 201], ["asthma", "OBSERVATION", 202, 208], ["exacerbation", "OBSERVATION", 253, 265], ["Fraction", "OBSERVATION_MODIFIER", 294, 302], ["exhaled nitric oxide", "OBSERVATION", 306, 326], ["chronic", "OBSERVATION_MODIFIER", 393, 400], ["asthma", "OBSERVATION", 401, 407]]], ["Its role in acute asthma remains to be studied.", [["asthma", "DISEASE", 18, 24], ["acute asthma", "PROBLEM", 12, 24], ["acute", "OBSERVATION_MODIFIER", 12, 17], ["asthma", "OBSERVATION", 18, 24]]], ["OBJECTIVE: To determine whether FENO levels are elevated in children with asthma exacerbations compared with baseline, and whether there is a difference in FENO levels based on PCR positive (D) (respiratory virus isolated by PCR analysis) versus PCR negative (L) (respiratory virus not isolated by PCR analysis) status.", [["FENO", "CHEMICAL", 32, 36], ["asthma", "DISEASE", 74, 80], ["FENO", "GENE_OR_GENE_PRODUCT", 32, 36], ["children", "ORGANISM", 60, 68], ["FENO", "SIMPLE_CHEMICAL", 156, 160], ["D", "GENE_OR_GENE_PRODUCT", 191, 192], ["children", "SPECIES", 60, 68], ["FENO levels", "TEST", 32, 43], ["elevated", "PROBLEM", 48, 56], ["asthma exacerbations", "PROBLEM", 74, 94], ["FENO levels", "TEST", 156, 167], ["PCR positive (D) (respiratory virus", "PROBLEM", 177, 212], ["PCR analysis", "TEST", 225, 237], ["PCR", "TEST", 246, 249], ["respiratory virus", "PROBLEM", 264, 281], ["PCR analysis", "TEST", 298, 310]]], ["METHODS: Children with a previous FENO level measurement while stable and who presented to an urgent care facility with an asthma exacerbation were enrolled.", [["asthma exacerbation", "DISEASE", 123, 142], ["Children", "ORGANISM", 9, 17], ["Children", "SPECIES", 9, 17], ["a previous FENO level measurement", "TEST", 23, 56], ["an asthma exacerbation", "PROBLEM", 120, 142], ["stable", "OBSERVATION_MODIFIER", 63, 69], ["asthma", "OBSERVATION", 123, 129]]], ["FENO levels, spirometry, and nasal swabs for viral PCR were obtained at the time of the exacerbation and following a course of prednisone.", [["nasal swabs", "ANATOMY", 29, 40], ["FENO", "CHEMICAL", 0, 4], ["prednisone", "CHEMICAL", 127, 137], ["prednisone", "CHEMICAL", 127, 137], ["FENO", "SIMPLE_CHEMICAL", 0, 4], ["prednisone", "SIMPLE_CHEMICAL", 127, 137], ["FENO levels", "TEST", 0, 11], ["spirometry", "TEST", 13, 23], ["nasal swabs", "TEST", 29, 40], ["viral PCR", "PROBLEM", 45, 54], ["the exacerbation", "PROBLEM", 84, 100], ["prednisone", "TREATMENT", 127, 137], ["nasal", "ANATOMY", 29, 34]]], ["Data were available on 66 children.", [["children", "ORGANISM", 26, 34], ["children", "SPECIES", 26, 34]]], ["Linear mixed models were used to regress the outcomes of interest (FEV 1 , FEV 1 /forced vital capacity, forced expiratory flow at 25% to 75% of forced vital capacity, and natural log FENO) on detected virus (yes/no), visit (baseline, exacerbation, follow-up), and the interaction between the detected virus and visit.", [["Linear mixed models", "PROBLEM", 0, 19], ["FEV", "TEST", 67, 70], ["FEV", "TEST", 75, 78], ["forced vital capacity", "TEST", 82, 103], ["forced expiratory flow", "TEST", 105, 127], ["forced vital capacity", "TEST", 145, 166], ["natural log FENO", "TEST", 172, 188], ["exacerbation", "PROBLEM", 235, 247], ["mixed models", "OBSERVATION", 7, 19]]], ["RESULTS: Compared with baseline, higher FENO values and lower lung function were found at the time of an exacerbation.", [["lung", "ANATOMY", 62, 66], ["FENO", "GENE_OR_GENE_PRODUCT", 40, 44], ["lung", "ORGAN", 62, 66], ["higher FENO values", "TEST", 33, 51], ["lower lung function", "PROBLEM", 56, 75], ["an exacerbation", "PROBLEM", 102, 117], ["lower", "ANATOMY_MODIFIER", 56, 61], ["lung", "ANATOMY", 62, 66], ["function", "OBSERVATION", 67, 75], ["exacerbation", "OBSERVATION", 105, 117]]], ["A respiratory virus was detected in 59% of the exacerbations.", [["A respiratory virus", "SPECIES", 0, 19], ["A respiratory virus", "PROBLEM", 0, 19], ["the exacerbations", "PROBLEM", 43, 60], ["respiratory virus", "OBSERVATION", 2, 19]]], ["The interaction between PCR (D) and PCR (L) groups and visit on log FENO was marginally significant (P [ .07).", [["PCR", "TEST", 24, 27], ["PCR", "TEST", 36, 39], ["log FENO", "TEST", 64, 72]]], ["There was no difference in log FENO between the PCR (D) and PCR (L) groups at baseline, while higher log FENO was found in the PCR (L) group at the time of exacerbation and following prednisone (P [ .05 and .001, respectively).", [["prednisone", "CHEMICAL", 183, 193], ["prednisone", "CHEMICAL", 183, 193], ["FENO", "GENE_OR_GENE_PRODUCT", 105, 109], ["prednisone", "SIMPLE_CHEMICAL", 183, 193], ["log FENO", "TEST", 27, 35], ["the PCR", "TEST", 44, 51], ["PCR", "TEST", 60, 63], ["higher log FENO", "TEST", 94, 109], ["the PCR", "TEST", 123, 130], ["exacerbation", "PROBLEM", 156, 168], ["prednisone", "TREATMENT", 183, 193], ["no", "UNCERTAINTY", 10, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23], ["exacerbation", "OBSERVATION", 156, 168]]], ["CONCLUSIONS: Higher FENO concentration in PCR (L) exacerbations suggests an eosinophilic predominance in nonviral compared with viral exacerbations.", [["FENO", "CHEMICAL", 20, 24], ["viral exacerbations", "DISEASE", 128, 147], ["FENO", "GENE_OR_GENE_PRODUCT", 20, 24], ["FENO", "PROTEIN", 20, 24], ["Higher FENO concentration in PCR (L) exacerbations", "PROBLEM", 13, 63], ["an eosinophilic predominance", "PROBLEM", 73, 101], ["viral exacerbations", "PROBLEM", 128, 147], ["eosinophilic predominance", "OBSERVATION", 76, 101], ["viral exacerbations", "OBSERVATION", 128, 147]]], ["\u00d3 2015 American Academy of Allergy, Asthma & Immunology (J Allergy Clin Immunol Pract 2015;3:913-9)Original ArticleKey words: Childhood asthma; Fraction of exhaled nitric oxide (FENO); Asthma exacerbations Abbreviations used ED-emergency department FEF 25-75 -forced expiratory flow at 25% to 75% of forced vital capacity FENO-fraction of exhaled nitric oxide FVC-forced vital capacity GC-glucocorticoid PCR (\u00fe)-respiratory virus isolated by PCR analysis PCR (\u00c0)-respiratory virus not isolated by PCR analysis Asthma is a chronic inflammatory disorder most commonly associated with eosinophilic infiltration into the airways and the release of several inflammatory mediators, 1 although other phenotypes of asthma are described, that is, neutrophilic and paucigraniolocytic.", [["airways", "ANATOMY", 617, 624], ["Asthma", "DISEASE", 36, 42], ["asthma", "DISEASE", 136, 142], ["nitric oxide", "CHEMICAL", 164, 176], ["FENO", "CHEMICAL", 178, 182], ["Asthma exacerbations", "DISEASE", 185, 205], ["nitric oxide", "CHEMICAL", 347, 359], ["Asthma", "DISEASE", 510, 516], ["inflammatory disorder", "DISEASE", 530, 551], ["asthma", "DISEASE", 707, 713], ["nitric oxide", "CHEMICAL", 164, 176], ["nitric oxide", "CHEMICAL", 347, 359], ["exhaled nitric oxide", "SIMPLE_CHEMICAL", 156, 176], ["FENO", "SIMPLE_CHEMICAL", 178, 182], ["FENO", "SIMPLE_CHEMICAL", 322, 326], ["exhaled nitric oxide", "SIMPLE_CHEMICAL", 339, 359], ["airways", "MULTI-TISSUE_STRUCTURE", 617, 624], ["inflammatory mediators", "PROTEIN", 652, 674], ["Asthma", "PROBLEM", 36, 42], ["Childhood asthma", "PROBLEM", 126, 142], ["exhaled nitric oxide", "TREATMENT", 156, 176], ["Asthma exacerbations", "PROBLEM", 185, 205], ["FEF", "TEST", 249, 252], ["forced expiratory flow", "TEST", 260, 282], ["forced vital capacity", "TEST", 300, 321], ["FENO", "TEST", 322, 326], ["exhaled nitric oxide", "TEST", 339, 359], ["FVC", "TEST", 360, 363], ["forced vital capacity", "TEST", 364, 385], ["GC", "TEST", 386, 388], ["glucocorticoid PCR", "TEST", 389, 407], ["respiratory virus", "PROBLEM", 412, 429], ["PCR analysis PCR", "TEST", 442, 458], ["respiratory virus", "PROBLEM", 463, 480], ["PCR analysis", "TEST", 497, 509], ["Asthma", "PROBLEM", 510, 516], ["a chronic inflammatory disorder", "PROBLEM", 520, 551], ["eosinophilic infiltration into the airways", "PROBLEM", 582, 624], ["several inflammatory mediators", "PROBLEM", 644, 674], ["asthma", "PROBLEM", 707, 713], ["neutrophilic and paucigraniolocytic", "PROBLEM", 738, 773], ["asthma", "OBSERVATION", 136, 142], ["chronic", "OBSERVATION_MODIFIER", 522, 529], ["inflammatory", "OBSERVATION", 530, 542], ["eosinophilic infiltration", "OBSERVATION", 582, 607], ["airways", "ANATOMY", 617, 624], ["several", "OBSERVATION_MODIFIER", 644, 651], ["inflammatory", "OBSERVATION_MODIFIER", 652, 664], ["asthma", "OBSERVATION", 707, 713], ["neutrophilic", "OBSERVATION_MODIFIER", 738, 750]]], ["Fractional exhaled nitric oxide (FENO) has been accepted as a noninvasive measure of airway inflammation that can be used in both the diagnosis and the management of asthma.", [["airway", "ANATOMY", 85, 91], ["nitric oxide", "CHEMICAL", 19, 31], ["FENO", "CHEMICAL", 33, 37], ["airway inflammation", "DISEASE", 85, 104], ["asthma", "DISEASE", 166, 172], ["nitric oxide", "CHEMICAL", 19, 31], ["exhaled nitric oxide", "SIMPLE_CHEMICAL", 11, 31], ["FENO", "SIMPLE_CHEMICAL", 33, 37], ["airway", "MULTI-TISSUE_STRUCTURE", 85, 91], ["Fractional exhaled nitric oxide", "TREATMENT", 0, 31], ["airway inflammation", "PROBLEM", 85, 104], ["asthma", "PROBLEM", 166, 172], ["exhaled", "OBSERVATION", 11, 18], ["nitric oxide", "OBSERVATION", 19, 31], ["airway", "ANATOMY", 85, 91], ["inflammation", "OBSERVATION", 92, 104], ["asthma", "OBSERVATION", 166, 172]]], ["2, 3 Studies have shown FENO to be as effective as beta-agonist reversibility and methacholine responsiveness in diagnosing asthma in both children and adults.", [["methacholine", "CHEMICAL", 82, 94], ["asthma", "DISEASE", 124, 130], ["methacholine", "CHEMICAL", 82, 94], ["FENO", "SIMPLE_CHEMICAL", 24, 28], ["methacholine", "SIMPLE_CHEMICAL", 82, 94], ["children", "ORGANISM", 139, 147], ["children", "SPECIES", 139, 147], ["3 Studies", "TEST", 3, 12], ["FENO", "TEST", 24, 28], ["beta-agonist reversibility", "PROBLEM", 51, 77], ["methacholine responsiveness", "PROBLEM", 82, 109], ["asthma", "PROBLEM", 124, 130], ["methacholine responsiveness", "OBSERVATION", 82, 109]]], ["4-6 FENO levels are positively correlated with bronchial wall inflammation, 7 induced-sputum eosinophilia, [8] [9] [10] and airway hyperresponsiveness.", [["bronchial wall", "ANATOMY", 47, 61], ["airway", "ANATOMY", 124, 130], ["eosinophilia", "DISEASE", 93, 105], ["4-6 FENO", "SIMPLE_CHEMICAL", 0, 8], ["bronchial wall", "MULTI-TISSUE_STRUCTURE", 47, 61], ["airway", "MULTI-TISSUE_STRUCTURE", 124, 130], ["FENO levels", "TEST", 4, 15], ["bronchial wall inflammation", "PROBLEM", 47, 74], ["sputum eosinophilia", "PROBLEM", 86, 105], ["airway hyperresponsiveness", "PROBLEM", 124, 150], ["bronchial wall", "ANATOMY", 47, 61], ["inflammation", "OBSERVATION", 62, 74], ["airway", "ANATOMY", 124, 130], ["hyperresponsiveness", "OBSERVATION", 131, 150]]], ["[11] [12] [13] Increases in FENO are associated with deterioration in asthma control with poor inhaled glucocorticoid (GC) adherence, 2,11 whereas FENO levels fall in a dose-dependent manner with inhaled GC treatment.", [["FENO", "CHEMICAL", 28, 32], ["asthma", "DISEASE", 70, 76], ["FENO", "CHEMICAL", 147, 151], ["[11] [12] [13]", "SIMPLE_CHEMICAL", 0, 14], ["FENO", "SIMPLE_CHEMICAL", 28, 32], ["glucocorticoid", "SIMPLE_CHEMICAL", 103, 117], ["FENO", "SIMPLE_CHEMICAL", 147, 151], ["Increases in FENO", "PROBLEM", 15, 32], ["deterioration in asthma control", "PROBLEM", 53, 84], ["poor inhaled glucocorticoid (GC) adherence", "PROBLEM", 90, 132], ["FENO levels", "TEST", 147, 158], ["inhaled GC treatment", "TREATMENT", 196, 216], ["asthma", "OBSERVATION", 70, 76], ["inhaled glucocorticoid", "OBSERVATION", 95, 117]]], ["11, 12 Despite enhanced knowledge of FENO in chronic asthma, little is known regarding its role in acute asthma.", [["FENO", "CHEMICAL", 37, 41], ["chronic asthma", "DISEASE", 45, 59], ["asthma", "DISEASE", 105, 111], ["FENO", "SIMPLE_CHEMICAL", 37, 41], ["FENO in chronic asthma", "PROBLEM", 37, 59], ["acute asthma", "PROBLEM", 99, 111], ["chronic", "OBSERVATION_MODIFIER", 45, 52], ["asthma", "OBSERVATION", 53, 59], ["acute", "OBSERVATION_MODIFIER", 99, 104], ["asthma", "OBSERVATION", 105, 111]]], ["In 1 of 2 recently published studies, FENO was not found to be useful in acute asthma because it could be measured only in 68% of the children presenting to the emergency department (ED) with acute asthma, 14 while in the second study, FENO failed to distinguish children requiring hospitalization from those who were discharged to home.", [["FENO", "CHEMICAL", 38, 42], ["asthma", "DISEASE", 79, 85], ["asthma", "DISEASE", 198, 204], ["FENO", "CHEMICAL", 38, 42], ["FENO", "SIMPLE_CHEMICAL", 38, 42], ["children", "ORGANISM", 134, 142], ["children", "ORGANISM", 263, 271], ["children", "SPECIES", 134, 142], ["children", "SPECIES", 263, 271], ["FENO", "TEST", 38, 42], ["acute asthma", "PROBLEM", 73, 85], ["acute asthma", "PROBLEM", 192, 204], ["acute", "OBSERVATION_MODIFIER", 73, 78], ["asthma", "OBSERVATION", 79, 85], ["acute", "OBSERVATION_MODIFIER", 192, 197], ["asthma", "OBSERVATION", 198, 204]]], ["15 In neither study were FENO levels available at baseline, nor an attempt was made to determine what role viral infections played in FENO levels.", [["viral infections", "DISEASE", 107, 123], ["FENO", "CHEMICAL", 134, 138], ["FENO", "SIMPLE_CHEMICAL", 25, 29], ["FENO", "SIMPLE_CHEMICAL", 134, 138], ["neither study", "TEST", 6, 19], ["FENO levels", "TEST", 25, 36], ["viral infections", "PROBLEM", 107, 123], ["FENO levels", "TEST", 134, 145]]], ["The aims of this study were 2-fold: to determine whether the FENO level is elevated during an acute asthma exacerbation compared with baseline in children with persistent asthma and to determine the influence of viral infections on FENO levels in children presenting with an acute asthma exacerbation requiring prednisone therapy.Study designIn this prospective cross-sectional study, informed consent was obtained from the parent or guardian and assent was obtained from the child when appropriate.", [["asthma", "DISEASE", 100, 106], ["asthma", "DISEASE", 171, 177], ["viral infections", "DISEASE", 212, 228], ["FENO", "CHEMICAL", 232, 236], ["asthma", "DISEASE", 281, 287], ["prednisone", "CHEMICAL", 311, 321], ["prednisone", "CHEMICAL", 311, 321], ["FENO", "GENE_OR_GENE_PRODUCT", 61, 65], ["children", "ORGANISM", 146, 154], ["FENO", "SIMPLE_CHEMICAL", 232, 236], ["children", "ORGANISM", 247, 255], ["prednisone", "SIMPLE_CHEMICAL", 311, 321], ["children", "SPECIES", 146, 154], ["children", "SPECIES", 247, 255], ["this study", "TEST", 12, 22], ["the FENO level", "TEST", 57, 71], ["elevated", "PROBLEM", 75, 83], ["an acute asthma exacerbation", "PROBLEM", 91, 119], ["persistent asthma", "PROBLEM", 160, 177], ["viral infections on FENO levels", "PROBLEM", 212, 243], ["an acute asthma exacerbation", "PROBLEM", 272, 300], ["prednisone therapy", "TREATMENT", 311, 329], ["elevated", "OBSERVATION_MODIFIER", 75, 83], ["acute", "OBSERVATION_MODIFIER", 94, 99], ["asthma", "OBSERVATION", 100, 106], ["persistent", "OBSERVATION_MODIFIER", 160, 170], ["asthma", "OBSERVATION", 171, 177], ["acute", "OBSERVATION_MODIFIER", 275, 280], ["asthma", "OBSERVATION", 281, 287], ["prednisone therapy", "OBSERVATION", 311, 329]]], ["The study was reviewed and approved by the National Jewish Health Institutional Review Board.", [["The study", "TEST", 0, 9]]], ["The study was performed at the National Jewish Health Urgent Care Clinic from June 2010 to May 2011.", [["The study", "TEST", 0, 9]]], ["A total of 70 participants aged 7 to 18 years were enrolled.", [["participants", "ORGANISM", 14, 26], ["participants", "SPECIES", 14, 26], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["We chose this age group because children of this age can perform adequate spirometry and exhaled nitric oxide measurements.Study designAll patients who presented to the Urgent Care Clinic at National Jewish Health for an acute asthma exacerbation and who had undergone spirometry and FENO measurements within the last 6 months when clinically stable (visit 1) were approached to participate in the study (Figure 1 ).", [["nitric oxide", "CHEMICAL", 97, 109], ["asthma", "DISEASE", 227, 233], ["nitric oxide", "CHEMICAL", 97, 109], ["children", "ORGANISM", 32, 40], ["nitric oxide", "SIMPLE_CHEMICAL", 97, 109], ["patients", "ORGANISM", 139, 147], ["children", "SPECIES", 32, 40], ["patients", "SPECIES", 139, 147], ["exhaled nitric oxide measurements", "TREATMENT", 89, 122], ["an acute asthma exacerbation", "PROBLEM", 218, 246], ["spirometry", "TREATMENT", 269, 279], ["FENO measurements", "TEST", 284, 301], ["the study", "TEST", 394, 403], ["acute", "OBSERVATION_MODIFIER", 221, 226], ["asthma", "OBSERVATION", 227, 233], ["stable", "OBSERVATION_MODIFIER", 343, 349]]], ["Patients who could not perform either spirometry or FENO measurements at the time of the exacerbation were ineligible as were patients who were on or had been treated with prednisone within 1 week before the urgent care visit.", [["prednisone", "CHEMICAL", 172, 182], ["prednisone", "CHEMICAL", 172, 182], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 126, 134], ["prednisone", "SIMPLE_CHEMICAL", 172, 182], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 126, 134], ["FENO measurements", "TEST", 52, 69], ["the exacerbation", "PROBLEM", 85, 101], ["prednisone", "TREATMENT", 172, 182]]], ["Children with a history of lung disease other than asthma and patients with a history of vocal cord dysfunction were also excluded from participating in the study.", [["lung", "ANATOMY", 27, 31], ["vocal cord", "ANATOMY", 89, 99], ["lung disease", "DISEASE", 27, 39], ["asthma", "DISEASE", 51, 57], ["vocal cord dysfunction", "DISEASE", 89, 111], ["Children", "ORGANISM", 0, 8], ["lung", "ORGAN", 27, 31], ["patients", "ORGANISM", 62, 70], ["vocal cord", "ORGAN", 89, 99], ["Children", "SPECIES", 0, 8], ["patients", "SPECIES", 62, 70], ["lung disease", "PROBLEM", 27, 39], ["asthma", "PROBLEM", 51, 57], ["vocal cord dysfunction", "PROBLEM", 89, 111], ["the study", "TEST", 153, 162], ["lung", "ANATOMY", 27, 31], ["disease", "OBSERVATION", 32, 39], ["asthma", "OBSERVATION", 51, 57], ["vocal cord", "ANATOMY", 89, 99], ["dysfunction", "OBSERVATION", 100, 111]]], ["Once consent and assent were obtained, participants completed a clinical questionnaire, spirometry, and FENO measurement and had a nasal swab obtained for viral PCR (visit 2).", [["nasal swab", "ANATOMY", 131, 141], ["participants", "SPECIES", 39, 51], ["spirometry", "TEST", 88, 98], ["FENO measurement", "TEST", 104, 120], ["a nasal swab", "TEST", 129, 141], ["viral PCR", "TEST", 155, 164], ["nasal", "ANATOMY", 131, 136]]], ["Urgent care physicians independently directed treatment and determined the participants' dispositions.", [["participants", "SPECIES", 75, 87], ["directed treatment", "TREATMENT", 37, 55]]], ["The treating physicians were not study investigators and the decision to treat with prednisone was at the discretion of the treating physician using treatment algorithms based on the National Asthma Education and Prevention Program guidelines.", [["prednisone", "CHEMICAL", 84, 94], ["Asthma", "DISEASE", 192, 198], ["prednisone", "CHEMICAL", 84, 94], ["prednisone", "SIMPLE_CHEMICAL", 84, 94], ["prednisone", "TREATMENT", 84, 94], ["treatment algorithms", "TREATMENT", 149, 169]]], ["16 Participants who were discharged home were instructed to continue usual controller medications, to take albuterol at a frequency directed by the urgent care physician, and to complete a 5-to 7-day course of oral prednisone (2 mg/kg/d; maximum daily dose 60 mg).", [["oral", "ANATOMY", 210, 214], ["albuterol", "CHEMICAL", 107, 116], ["prednisone", "CHEMICAL", 215, 225], ["albuterol", "CHEMICAL", 107, 116], ["prednisone", "CHEMICAL", 215, 225], ["albuterol", "SIMPLE_CHEMICAL", 107, 116], ["oral", "ORGANISM_SUBDIVISION", 210, 214], ["prednisone", "SIMPLE_CHEMICAL", 215, 225], ["Participants", "SPECIES", 3, 15], ["usual controller medications", "TREATMENT", 69, 97], ["albuterol", "TREATMENT", 107, 116], ["oral prednisone", "TREATMENT", 210, 225]]], ["All discharged participants were also scheduled for follow-up 1 week later (visit 3).", [["participants", "ORGANISM", 15, 27], ["participants", "SPECIES", 15, 27]]], ["At the follow-up visit, all participants underwent spirometry and had FENO levels measured.Lung function measurementAll participants underwent spirometry with at least 3 acceptable maneuvers.", [["Lung", "ANATOMY", 91, 95], ["participants", "ORGANISM", 28, 40], ["FENO", "SIMPLE_CHEMICAL", 70, 74], ["Lung", "ORGAN", 91, 95], ["participants", "SPECIES", 28, 40], ["participants", "SPECIES", 120, 132], ["spirometry", "TEST", 51, 61], ["FENO levels", "TEST", 70, 81], ["Lung function measurement", "TEST", 91, 116]]], ["The three highest forced vital capacity (FVC) and FEV 1 values were recorded according to the American Thoracic Society Guidelines 17 using a Jaeger MasterScreen Pneumo running JLab 5.20 software (Erich Jaeger, Inc, Wurzburg, Germany).", [["FEV 1", "GENE_OR_GENE_PRODUCT", 50, 55], ["FVC", "TEST", 41, 44], ["FEV 1 values", "TEST", 50, 62], ["Thoracic", "ANATOMY", 103, 111]]], ["The data for FEV 1 , FVC, and forced expiratory flow at 25% to 75% of forced vital capacity (FEF ) were expressed as % predicted using the NHANES III reference values.", [["The data", "TEST", 0, 8], ["FEV", "TEST", 13, 16], ["FVC", "TEST", 21, 24], ["forced expiratory flow", "PROBLEM", 30, 52], ["forced vital capacity", "TEST", 70, 91], ["forced", "OBSERVATION_MODIFIER", 30, 36], ["expiratory flow", "OBSERVATION", 37, 52]]], ["18FENO level measurementThe FENO level was obtained after spirometry, and before the administration of short-acting beta-agonist therapy.", [["18FENO", "GENE_OR_GENE_PRODUCT", 0, 6], ["FENO", "SIMPLE_CHEMICAL", 28, 32], ["18FENO", "PROTEIN", 0, 6], ["18FENO level measurement", "TEST", 0, 24], ["The FENO level", "TEST", 24, 38], ["spirometry", "TEST", 58, 68], ["short-acting beta-agonist therapy", "TREATMENT", 103, 136]]], ["The FENO level was measured using the online technique recommended by the American Thoracic Society with the Niox Mino system (Aerocrine AB, Stockholm, Sweden).", [["FENO", "SIMPLE_CHEMICAL", 4, 8], ["The FENO level", "TEST", 0, 14], ["Thoracic", "ANATOMY", 83, 91]]], ["19 This technique uses a resistive device that provides a constant low expiratory flow rate and vellum closure.", [["This technique", "TREATMENT", 3, 17], ["a resistive device", "TREATMENT", 23, 41], ["a constant low expiratory flow rate", "TREATMENT", 56, 91], ["vellum closure", "TREATMENT", 96, 110], ["expiratory flow", "OBSERVATION", 71, 86], ["vellum closure", "OBSERVATION", 96, 110]]], ["The combination of vellum closure and low flow rate ensures accurate measurement of pulmonary-derived exhaled NO levels and excludes contamination from nasal NO.", [["vellum", "ANATOMY", 19, 25], ["pulmonary", "ANATOMY", 84, 93], ["nasal", "ANATOMY", 152, 157], ["NO", "CHEMICAL", 110, 112], ["NO", "CHEMICAL", 158, 160], ["NO", "CHEMICAL", 110, 112], ["NO", "CHEMICAL", 158, 160], ["vellum", "MULTI-TISSUE_STRUCTURE", 19, 25], ["pulmonary", "ORGAN", 84, 93], ["NO", "SIMPLE_CHEMICAL", 110, 112], ["NO", "SIMPLE_CHEMICAL", 158, 160], ["vellum closure", "TREATMENT", 19, 33], ["low flow rate", "PROBLEM", 38, 51], ["contamination", "PROBLEM", 133, 146], ["vellum closure", "OBSERVATION", 19, 33], ["low flow", "OBSERVATION", 38, 46], ["pulmonary", "ANATOMY", 84, 93]]], ["Participants exhale to their residual volume, insert the mouthpiece, inhale to total lung capacity, and then exhale for 10 seconds at a steady rate of 50 mL/s.", [["lung", "ANATOMY", 85, 89], ["lung", "ORGAN", 85, 89], ["Participants", "SPECIES", 0, 12], ["the mouthpiece", "TREATMENT", 53, 67], ["lung", "ANATOMY", 85, 89], ["capacity", "OBSERVATION", 90, 98]]], ["Visual incentives provide feedback for flow rate compliance.", [["flow rate compliance", "TREATMENT", 39, 59]]], ["The end point of measurement occurred when a plateau for 4 seconds was observed.", [["plateau", "ANATOMY", 45, 52]]], ["Only 1 measurement was obtained because the repeatability of FENO obtained with the Niox Mino is very high.", [["FENO", "TEST", 61, 65], ["the Niox Mino", "TREATMENT", 80, 93]]], ["20Statistical analysisComparisons between PCR (\u00fe) (respiratory virus isolated by PCR analysis) and PCR (\u00c0) (respiratory virus not isolated by PCR analysis) groups at baseline and at the time of an exacerbation were evaluated using independent sample t tests (for normally distributed continuous variables), or Wilcoxon rank-sum tests (for variables that were not normally distributed), and using either c 2 tests or the Fisher exact test (for small expected numbers) for categorical variables.", [["PCR", "TEST", 42, 45], ["respiratory virus", "PROBLEM", 51, 68], ["PCR analysis", "TEST", 81, 93], ["PCR", "TEST", 99, 102], ["respiratory virus", "PROBLEM", 108, 125], ["PCR analysis", "TEST", 142, 154], ["an exacerbation", "PROBLEM", 194, 209], ["independent sample t tests", "TEST", 231, 257], ["Wilcoxon rank", "TEST", 310, 323], ["sum tests", "TEST", 324, 333], ["the Fisher exact test", "TEST", 416, 437], ["categorical variables", "TEST", 471, 492]]], ["Linear mixed models were used to regress the outcomes of interest (FEV 1 , FEV 1 /FVC, FEF 25/75 , and natural log FENO) on detected virus (yes/no), visit (baseline, exacerbation, follow-up), and the interaction between the detected virus and visit.", [["Linear mixed models", "PROBLEM", 0, 19], ["FEV", "TEST", 67, 70], ["FEV", "TEST", 75, 78], ["FVC", "TEST", 82, 85], ["FEF", "TEST", 87, 90], ["exacerbation", "PROBLEM", 166, 178], ["mixed models", "OBSERVATION", 7, 19]]], ["Covariates of interest for adjusted models were season (winter, spring, summer, and fall) and inhaled GC therapy (yes/no), and also sex, weight, height, and race (Hispanic, African American, or Caucasian) for the adjusted FENO model.", [["inhaled GC therapy", "TREATMENT", 94, 112], ["the adjusted FENO model", "TREATMENT", 209, 232]]], ["Backwards selection using a P-value cutoff of .15 was used to remove insignificant covariates.", [["a P-value cutoff", "TREATMENT", 26, 42]]], ["To account for repeated measures and unequal times between visits across subjects, a Spatial Power covariance structure based on days from exacerbation was used.", [["repeated measures", "TREATMENT", 15, 32], ["exacerbation", "PROBLEM", 139, 151]]], ["All analyses were done in SAS version 9.4.", [["All analyses", "TEST", 0, 12], ["SAS version", "TEST", 26, 37]]], ["Plots were generated in R version 3.1.0.RESULTSBetween June 2010 and May 2011, 70 participants were enrolled (Table I) .", [["participants", "SPECIES", 82, 94], ["Plots", "TEST", 0, 5]]], ["Five subjects did not return for visit 3 and were not included in the analysis.", [["the analysis", "TEST", 66, 78]]], ["The mean age was 11 AE 3.2 years, 67% were male, 88% were atopic (presence of !1 positive skin test result to an aeroallergen), and 31% were obese.", [["skin", "ANATOMY", 90, 94], ["atopic", "DISEASE", 58, 64], ["skin", "ORGAN", 90, 94], ["The mean age", "TEST", 0, 12], ["atopic", "PROBLEM", 58, 64], ["skin test", "TEST", 90, 99], ["an aeroallergen", "TEST", 110, 125], ["obese", "PROBLEM", 141, 146], ["obese", "OBSERVATION", 141, 146]]], ["Fortythree percent of the enrolled children were Caucasian, 38% were Hispanic, and 18% were African American.", [["children", "ORGANISM", 35, 43], ["children", "SPECIES", 35, 43]]], ["Fourteen percent carried the diagnosis of mild-persistent, 67% moderatepersistent, and 18% severe-persistent asthma.", [["moderatepersistent", "DISEASE", 63, 81], ["asthma", "DISEASE", 109, 115], ["mild-persistent, 67% moderatepersistent, and 18% severe-persistent asthma", "PROBLEM", 42, 115], ["mild", "OBSERVATION_MODIFIER", 42, 46], ["persistent", "OBSERVATION_MODIFIER", 47, 57], ["persistent", "OBSERVATION_MODIFIER", 98, 108], ["asthma", "OBSERVATION", 109, 115]]], ["Seventy-five percent of the subjects were on inhaled GC therapy (15% on inhaled GC monotherapy and 60% on combination inhaled GC/long-acting beta-agonist therapy).", [["beta-agonist", "CHEMICAL", 141, 153], ["subjects", "ORGANISM", 28, 36], ["inhaled GC therapy", "TREATMENT", 45, 63], ["inhaled GC monotherapy", "TREATMENT", 72, 94], ["inhaled GC", "TREATMENT", 118, 128], ["long-acting beta-agonist therapy", "TREATMENT", 129, 161]]], ["More than 40% reported having an ED visit for acute asthma in the past year, requiring systemic steroids in the last 6 months, and having a history of hospital admissions for acute asthma.", [["asthma", "DISEASE", 52, 58], ["steroids", "CHEMICAL", 96, 104], ["asthma", "DISEASE", 181, 187], ["steroids", "CHEMICAL", 96, 104], ["acute asthma", "PROBLEM", 46, 58], ["systemic steroids", "TREATMENT", 87, 104], ["acute asthma", "PROBLEM", 175, 187], ["acute", "OBSERVATION_MODIFIER", 46, 51], ["asthma", "OBSERVATION", 52, 58], ["acute", "OBSERVATION_MODIFIER", 175, 180], ["asthma", "OBSERVATION", 181, 187]]], ["Review of medication use at baseline (visit 1) compared with the time of exacerbation (visit 2) found no significant difference in the percentage of study participants on inhaled GC therapy alone or in combination with a long-acting beta-agonist, nor were significant differences found in the inhaled GC dose at visit 1 compared with visit 2.", [["participants", "SPECIES", 155, 167], ["exacerbation", "PROBLEM", 73, 85], ["inhaled GC therapy", "TREATMENT", 171, 189], ["a long-acting beta-agonist", "TREATMENT", 219, 245], ["no", "UNCERTAINTY", 102, 104], ["significant", "OBSERVATION_MODIFIER", 105, 116]]], ["In addition, both FENO level and lung function were in the normal range at visit 1 (geometric mean FENO level \u00bc 20.7 ppb;RESULTSFour of the 70 subjects were missing recorded calendar dates for their visits and were excluded from the mixed models (total of 66 subjects for FEV 1 , FEV 1 /FVC, and FEF 25-75 models).", [["lung", "ANATOMY", 33, 37], ["FENO", "GENE_OR_GENE_PRODUCT", 18, 22], ["lung", "ORGAN", 33, 37], ["FENO", "PROTEIN", 18, 22], ["both FENO level", "TEST", 13, 28], ["lung function", "TEST", 33, 46], ["geometric mean FENO level", "TEST", 84, 109], ["ppb", "TEST", 117, 120], ["FEV", "TEST", 272, 275], ["FEV", "TEST", 280, 283], ["FVC", "TEST", 287, 290], ["FEF", "TEST", 296, 299], ["lung", "ANATOMY", 33, 37]]], ["In addition, 2 subjects were missing both baseline and follow-up FENO measurements and 1 subject was missing race information (total of 63 subjects for FENO models).RESULTSAt visit 2, the subjects had median daytime symptoms of 3 d/wk, nighttime symptoms 3 times a month, and required rescue albuterol for 1-day duration.", [["albuterol", "CHEMICAL", 292, 301], ["albuterol", "CHEMICAL", 292, 301], ["subjects", "ORGANISM", 188, 196], ["albuterol", "SIMPLE_CHEMICAL", 292, 301], ["follow-up FENO measurements", "TEST", 55, 82], ["FENO models", "TEST", 152, 163], ["median daytime symptoms", "PROBLEM", 201, 224], ["nighttime symptoms", "PROBLEM", 236, 254], ["rescue albuterol", "TREATMENT", 285, 301]]], ["Compared with baseline, a significant increase in log exhaled NO (\u00fe0.76), and decrease in lung function (FEV 1 % predicted, \u00c024; FEV 1 /FVC, \u00c012%;, and FEF 25-75 % predicted, \u00c034), was noted at the time of exacerbation (all P values <.001) (Tables II and III) .RESULTSAt visit 3, a significant decrease in log exhaled NO (\u00c00.76) and improvement in lung function parameters (FEV 1 % predicted, \u00fe21; FEV 1 /FVC, \u00fe9%; and FEF 25-75 % predicted, \u00fe29, respectively) (P < .001) were found from the time of exacerbation measurement and after the initiation of prednisone (Table III) .", [["lung", "ANATOMY", 90, 94], ["lung", "ANATOMY", 348, 352], ["NO", "CHEMICAL", 62, 64], ["NO", "CHEMICAL", 318, 320], ["prednisone", "CHEMICAL", 553, 563], ["NO", "CHEMICAL", 62, 64], ["NO", "CHEMICAL", 318, 320], ["prednisone", "CHEMICAL", 553, 563], ["NO", "SIMPLE_CHEMICAL", 62, 64], ["lung", "ORGAN", 90, 94], ["NO", "SIMPLE_CHEMICAL", 318, 320], ["lung", "ORGAN", 348, 352], ["prednisone", "SIMPLE_CHEMICAL", 553, 563], ["FEF", "PROTEIN", 152, 155], ["a significant increase", "PROBLEM", 24, 46], ["log exhaled", "TEST", 50, 61], ["decrease in lung function", "PROBLEM", 78, 103], ["FEV", "TEST", 105, 108], ["FEV", "TEST", 129, 132], ["FVC", "TEST", 136, 139], ["FEF", "TEST", 152, 155], ["exacerbation", "PROBLEM", 206, 218], ["all P values", "TEST", 220, 232], ["lung function parameters", "TEST", 348, 372], ["FEV", "TEST", 374, 377], ["FEV", "TEST", 398, 401], ["FVC", "TEST", 405, 408], ["\u00fe", "TEST", 410, 411], ["FEF", "TEST", 419, 422], ["exacerbation measurement", "PROBLEM", 500, 524], ["prednisone (Table III", "TREATMENT", 553, 574], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["increase", "OBSERVATION_MODIFIER", 38, 46], ["log exhaled", "OBSERVATION", 50, 61], ["decrease", "OBSERVATION_MODIFIER", 78, 86], ["lung", "ANATOMY", 90, 94], ["exacerbation", "OBSERVATION", 206, 218], ["significant", "OBSERVATION_MODIFIER", 282, 293], ["decrease", "OBSERVATION_MODIFIER", 294, 302], ["lung", "ANATOMY", 348, 352], ["exacerbation", "OBSERVATION", 500, 512]]], ["There were no differences between log FENO (P \u00bc .99), FEV 1 % predicted (P \u00bc .1), FEV 1 /FVC (P \u00bc .07), and FEF 25-75 % predicted (P \u00bc .2) after the initiation of prednisone treatment and baseline measurements.", [["prednisone", "CHEMICAL", 163, 173], ["prednisone", "CHEMICAL", 163, 173], ["prednisone", "SIMPLE_CHEMICAL", 163, 173], ["FEF", "PROTEIN", 108, 111], ["log FENO", "TEST", 34, 42], ["P", "TEST", 44, 45], ["FEV", "TEST", 54, 57], ["P", "TEST", 73, 74], ["FEV", "TEST", 82, 85], ["FVC", "TEST", 89, 92], ["P", "TEST", 94, 95], ["FEF", "TEST", 108, 111], ["P", "TEST", 131, 132], ["prednisone treatment", "TREATMENT", 163, 183], ["baseline measurements", "TEST", 188, 209], ["no", "UNCERTAINTY", 11, 13]]], ["Fifty-six percent of the children had evidence for a PCR (\u00fe) exacerbation, with 1 or more respiratory viruses identified by PCR.", [["children", "ORGANISM", 25, 33], ["children", "SPECIES", 25, 33], ["a PCR (\u00fe) exacerbation", "PROBLEM", 51, 73], ["more respiratory viruses", "PROBLEM", 85, 109], ["PCR", "TEST", 124, 127], ["respiratory viruses", "OBSERVATION", 90, 109]]], ["No differences in patients' demographic characteristics were noted at baseline between children with PCR (\u00fe) versus PCR (\u00c0) asthma exacerbations (Table I) .", [["asthma", "DISEASE", 124, 130], ["patients", "ORGANISM", 18, 26], ["children", "ORGANISM", 87, 95], ["patients", "SPECIES", 18, 26], ["children", "SPECIES", 87, 95], ["PCR (\u00fe) versus PCR", "PROBLEM", 101, 119], ["asthma exacerbations", "PROBLEM", 124, 144]]], ["The most commonly identified virus was rhinovirus, occurring in 62% of the participants followed by corona virus in 13%, influenza or metapneumovirus in 10%, and parainfluenza in 5%.", [["rhinovirus", "DISEASE", 39, 49], ["influenza or metapneumovirus", "DISEASE", 121, 149], ["parainfluenza", "DISEASE", 162, 175], ["rhinovirus", "ORGANISM", 39, 49], ["corona virus", "ORGANISM", 100, 112], ["metapneumovirus", "ORGANISM", 134, 149], ["parainfluenza", "ORGANISM", 162, 175], ["participants", "SPECIES", 75, 87], ["influenza or metapneumovirus", "SPECIES", 121, 149], ["parainfluenza", "SPECIES", 162, 175], ["corona virus", "SPECIES", 100, 112], ["virus", "PROBLEM", 29, 34], ["rhinovirus", "PROBLEM", 39, 49], ["corona virus", "PROBLEM", 100, 112], ["influenza", "PROBLEM", 121, 130], ["metapneumovirus", "PROBLEM", 134, 149], ["parainfluenza", "PROBLEM", 162, 175], ["most commonly", "OBSERVATION_MODIFIER", 4, 17], ["virus", "OBSERVATION", 29, 34], ["rhinovirus", "OBSERVATION", 39, 49], ["metapneumovirus", "OBSERVATION", 134, 149]]], ["Of the 39 children with positive viral PCR, 11 had more than 1 virus identified at the time of the exacerbation.RESULTSUsing unadjusted and adjusted models, changes in the following outcomes (log FENO, FEV 1 , FEV 1 /FVC, and FEF were evaluated between PCR (\u00fe) and PCR (\u00c0) groups.", [["children", "ORGANISM", 10, 18], ["FEV 1", "GENE_OR_GENE_PRODUCT", 202, 207], ["FEV 1", "GENE_OR_GENE_PRODUCT", 210, 215], ["FEF", "PROTEIN", 226, 229], ["children", "SPECIES", 10, 18], ["positive viral PCR", "PROBLEM", 24, 42], ["1 virus", "PROBLEM", 61, 68], ["the exacerbation", "PROBLEM", 95, 111], ["log FENO", "TEST", 192, 200], ["FEV", "TEST", 202, 205], ["FEV", "TEST", 210, 213], ["FVC", "TEST", 217, 220], ["FEF", "TEST", 226, 229], ["PCR", "TEST", 253, 256], ["PCR", "TEST", 265, 268], ["viral PCR", "OBSERVATION", 33, 42], ["exacerbation", "OBSERVATION", 99, 111]]], ["In the unadjusted log FENO model, the interaction between PCR (\u00fe) and PCR (\u00c0) groups and visit was marginally significant (P \u00bc .06; Figure 2 , A).", [["PCR", "TEST", 58, 61], ["PCR", "TEST", 70, 73], ["Figure", "TEST", 132, 138]]], ["A trend was also found using adjusted analysis (P \u00bc .07; Figure 2 , B).", [["adjusted analysis", "TEST", 29, 46], ["P", "TEST", 48, 49]]], ["In both the unadjusted and adjusted models, there was no difference in log FENO between the 2 exacerbation groups by PCR viral detection at baseline (or steady state), but higher log FENO was found in PCR (\u00c0) than in PCR (\u00fe) children at the time of exacerbation and after the initiation of a prednisone course (P \u00bc .05 and .001, respectively, from adjusted analysis).", [["prednisone", "CHEMICAL", 292, 302], ["prednisone", "CHEMICAL", 292, 302], ["FENO", "SIMPLE_CHEMICAL", 75, 79], ["FENO", "GENE_OR_GENE_PRODUCT", 183, 187], ["children", "ORGANISM", 225, 233], ["prednisone", "SIMPLE_CHEMICAL", 292, 302], ["children", "SPECIES", 225, 233], ["log FENO", "TEST", 71, 79], ["the 2 exacerbation groups", "PROBLEM", 88, 113], ["PCR viral detection", "TEST", 117, 136], ["higher log FENO", "PROBLEM", 172, 187], ["PCR", "TEST", 201, 204], ["exacerbation", "PROBLEM", 249, 261], ["a prednisone course", "TREATMENT", 290, 309], ["no", "UNCERTAINTY", 54, 56], ["exacerbation", "OBSERVATION", 249, 261]]], ["No differences were found between PCR (\u00c0) and PCR (\u00fe) groups in the measures of lung function studied across visits.DISCUSSIONIn this study of children with asthma, we sought to determine whether FENO levels were elevated during acute asthma exacerbations.", [["lung", "ANATOMY", 80, 84], ["asthma", "DISEASE", 157, 163], ["FENO", "CHEMICAL", 196, 200], ["asthma exacerbations", "DISEASE", 235, 255], ["lung", "ORGAN", 80, 84], ["children", "ORGANISM", 143, 151], ["FENO", "GENE_OR_GENE_PRODUCT", 196, 200], ["children", "SPECIES", 143, 151], ["PCR", "TEST", 34, 37], ["PCR", "TEST", 46, 49], ["asthma", "PROBLEM", 157, 163], ["FENO levels", "TEST", 196, 207], ["elevated", "PROBLEM", 213, 221], ["acute asthma exacerbations", "PROBLEM", 229, 255], ["lung", "ANATOMY", 80, 84], ["acute", "OBSERVATION_MODIFIER", 229, 234], ["asthma", "OBSERVATION", 235, 241]]], ["We also sought to determine the role PCR (\u00fe) exacerbations had on FENO levels and, last, we sought to determine the effect of prednisone on FENO levels and whether there were differences in response to prednisone based on whether the exacerbation was PCR (\u00fe).", [["prednisone", "CHEMICAL", 126, 136], ["prednisone", "CHEMICAL", 202, 212], ["prednisone", "CHEMICAL", 126, 136], ["prednisone", "CHEMICAL", 202, 212], ["FENO", "SIMPLE_CHEMICAL", 66, 70], ["prednisone", "SIMPLE_CHEMICAL", 126, 136], ["FENO", "SIMPLE_CHEMICAL", 140, 144], ["prednisone", "SIMPLE_CHEMICAL", 202, 212], ["the role PCR", "TEST", 28, 40], ["exacerbations", "PROBLEM", 45, 58], ["FENO levels", "TEST", 66, 77], ["prednisone", "TREATMENT", 126, 136], ["FENO levels", "TEST", 140, 151], ["prednisone", "TREATMENT", 202, 212], ["the exacerbation", "PROBLEM", 230, 246], ["PCR", "TEST", 251, 254]]], ["We found FENO levels to rise significantly during an acute exacerbation of asthma, with the biggest increase noted in PCR (\u00c0)-associated exacerbations.", [["asthma", "DISEASE", 75, 81], ["FENO", "GENE_OR_GENE_PRODUCT", 9, 13], ["FENO levels", "TEST", 9, 20], ["an acute exacerbation", "PROBLEM", 50, 71], ["asthma", "PROBLEM", 75, 81], ["the biggest increase", "PROBLEM", 88, 108], ["PCR", "TEST", 118, 121], ["associated exacerbations", "PROBLEM", 126, 150], ["FENO", "OBSERVATION", 9, 13], ["acute", "OBSERVATION_MODIFIER", 53, 58], ["exacerbation", "OBSERVATION", 59, 71], ["asthma", "OBSERVATION", 75, 81], ["biggest", "OBSERVATION_MODIFIER", 92, 99], ["increase", "OBSERVATION_MODIFIER", 100, 108], ["exacerbations", "OBSERVATION", 137, 150]]], ["Following a short course of prednisone therapy, FENO levels fell to near baseline levels, with the greatest reduction in PCR (\u00fe) exacerbations.DISCUSSIONFew studies have sought to evaluate FENO levels in acute asthma.", [["prednisone", "CHEMICAL", 28, 38], ["FENO", "CHEMICAL", 48, 52], ["FENO", "CHEMICAL", 189, 193], ["asthma", "DISEASE", 210, 216], ["prednisone", "CHEMICAL", 28, 38], ["prednisone", "SIMPLE_CHEMICAL", 28, 38], ["FENO", "SIMPLE_CHEMICAL", 48, 52], ["FENO", "SIMPLE_CHEMICAL", 189, 193], ["prednisone therapy", "TREATMENT", 28, 46], ["FENO levels", "TEST", 48, 59], ["the greatest reduction in PCR", "PROBLEM", 95, 124], ["exacerbations", "PROBLEM", 129, 142], ["DISCUSSIONFew studies", "TEST", 143, 164], ["FENO levels", "TEST", 189, 200], ["acute asthma", "PROBLEM", 204, 216], ["greatest", "OBSERVATION_MODIFIER", 99, 107], ["reduction", "OBSERVATION_MODIFIER", 108, 117], ["acute", "OBSERVATION_MODIFIER", 204, 209], ["asthma", "OBSERVATION", 210, 216]]], ["Lanz et al 21 found FENO levels to be elevated in children with acute asthma compared with levels in atopic children without asthma and normal control children and following a course of prednisone, FENO levels fell to those of controls without asthma.", [["acute asthma", "DISEASE", 64, 76], ["asthma", "DISEASE", 125, 131], ["prednisone", "CHEMICAL", 186, 196], ["FENO", "CHEMICAL", 198, 202], ["asthma", "DISEASE", 244, 250], ["prednisone", "CHEMICAL", 186, 196], ["FENO", "GENE_OR_GENE_PRODUCT", 20, 24], ["children", "ORGANISM", 50, 58], ["children", "ORGANISM", 108, 116], ["children", "ORGANISM", 151, 159], ["prednisone", "SIMPLE_CHEMICAL", 186, 196], ["FENO", "SIMPLE_CHEMICAL", 198, 202], ["FENO", "PROTEIN", 20, 24], ["children", "SPECIES", 50, 58], ["children", "SPECIES", 108, 116], ["children", "SPECIES", 151, 159], ["Lanz et al", "TEST", 0, 10], ["FENO levels", "TEST", 20, 31], ["elevated", "PROBLEM", 38, 46], ["acute asthma", "PROBLEM", 64, 76], ["asthma", "PROBLEM", 125, 131], ["prednisone", "TREATMENT", 186, 196], ["FENO levels", "TEST", 198, 209], ["asthma", "PROBLEM", 244, 250], ["elevated", "OBSERVATION_MODIFIER", 38, 46], ["acute", "OBSERVATION_MODIFIER", 64, 69], ["asthma", "OBSERVATION", 70, 76], ["without", "UNCERTAINTY", 236, 243], ["asthma", "OBSERVATION", 244, 250]]], ["Limitations of this study included the small number of children studied and the lack of preexacerbation FENO levels.", [["FENO", "CHEMICAL", 104, 108], ["children", "ORGANISM", 55, 63], ["FENO", "GENE_OR_GENE_PRODUCT", 104, 108], ["children", "SPECIES", 55, 63], ["this study", "TEST", 15, 25], ["FENO levels", "TEST", 104, 115], ["small", "OBSERVATION_MODIFIER", 39, 44]]], ["Kwok et al, 14 using a tidal breathing technique to assess FENO levels in children presenting to the ED with an asthma exacerbation, found that only 68% of the children were able to successfully perform the maneuver.", [["FENO", "CHEMICAL", 59, 63], ["asthma", "DISEASE", 112, 118], ["FENO", "GENE_OR_GENE_PRODUCT", 59, 63], ["children", "ORGANISM", 74, 82], ["children", "ORGANISM", 160, 168], ["children", "SPECIES", 74, 82], ["children", "SPECIES", 160, 168], ["a tidal breathing technique", "TREATMENT", 21, 48], ["an asthma exacerbation", "PROBLEM", 109, 131], ["asthma", "OBSERVATION", 112, 118]]], ["Of those who were able to provide an adequate sample, no differences were found in FENO levels among those with mild, moderate, and severe exacerbations.", [["FENO", "SIMPLE_CHEMICAL", 83, 87], ["FENO levels", "TEST", 83, 94], ["mild, moderate, and severe exacerbations", "PROBLEM", 112, 152], ["mild", "OBSERVATION_MODIFIER", 112, 116], ["moderate", "OBSERVATION_MODIFIER", 118, 126], ["severe", "OBSERVATION_MODIFIER", 132, 138], ["exacerbations", "OBSERVATION", 139, 152]]], ["This study was limited by the technique used to measure FENO levels and the lack of baseline FENO levels.", [["FENO", "SIMPLE_CHEMICAL", 56, 60], ["FENO", "GENE_OR_GENE_PRODUCT", 93, 97], ["This study", "TEST", 0, 10], ["the technique", "TEST", 26, 39], ["FENO levels", "TEST", 56, 67], ["baseline FENO levels", "TEST", 84, 104]]], ["Nelson et al 15 sought to determine whether FENO levels at the time of an ED visit could predict children requiring hospitalization for acute asthma and found that FENO levels could not distinguish children requiring hospitalization from those who were discharged to home.", [["asthma", "DISEASE", 142, 148], ["FENO", "CHEMICAL", 164, 168], ["FENO", "GENE_OR_GENE_PRODUCT", 44, 48], ["children", "ORGANISM", 97, 105], ["FENO", "SIMPLE_CHEMICAL", 164, 168], ["children", "ORGANISM", 198, 206], ["children", "SPECIES", 97, 105], ["children", "SPECIES", 198, 206], ["FENO levels", "TEST", 44, 55], ["acute asthma", "PROBLEM", 136, 148], ["FENO levels", "TEST", 164, 175], ["asthma", "OBSERVATION", 142, 148]]], ["This study was limited by the small number of children who required hospitalization compared with those who were discharged to home.DISCUSSIONOur study is novel in that we collected baseline, exacerbation, and postprednisone FENO levels in addition to attempting to determine the etiology of the acute asthma exacerbation.", [["FENO", "CHEMICAL", 225, 229], ["asthma", "DISEASE", 302, 308], ["children", "ORGANISM", 46, 54], ["FENO", "SIMPLE_CHEMICAL", 225, 229], ["children", "SPECIES", 46, 54], ["This study", "TEST", 0, 10], ["DISCUSSIONOur study", "TEST", 132, 151], ["exacerbation", "PROBLEM", 192, 204], ["postprednisone FENO levels", "TEST", 210, 236], ["the acute asthma exacerbation", "PROBLEM", 292, 321], ["small", "OBSERVATION_MODIFIER", 30, 35], ["acute", "OBSERVATION_MODIFIER", 296, 301], ["asthma", "OBSERVATION", 302, 308]]], ["We found FENO levels to be the highest in children with acute asthma exacerbations that were not associated with viral infections [PCR(\u00c0)].", [["asthma exacerbations", "DISEASE", 62, 82], ["viral infections", "DISEASE", 113, 129], ["FENO", "GENE_OR_GENE_PRODUCT", 9, 13], ["children", "ORGANISM", 42, 50], ["children", "SPECIES", 42, 50], ["FENO levels", "TEST", 9, 20], ["acute asthma exacerbations", "PROBLEM", 56, 82], ["viral infections", "PROBLEM", 113, 129], ["FENO levels", "OBSERVATION", 9, 20], ["acute", "OBSERVATION_MODIFIER", 56, 61], ["asthma", "OBSERVATION", 62, 68], ["not associated with", "UNCERTAINTY", 93, 112]]], ["In this group of children, the exacerbation was likely allergen-driven.", [["children", "ORGANISM", 17, 25], ["children", "SPECIES", 17, 25], ["the exacerbation", "PROBLEM", 27, 43], ["allergen", "PROBLEM", 55, 63]]], ["In this situation, the offending allergen triggers both immediate and late-phase allergic responses, leading to bronchoconstriction and airway edema as a consequence of FIGURE 2.", [["airway", "ANATOMY", 136, 142], ["allergic", "DISEASE", 81, 89], ["bronchoconstriction", "DISEASE", 112, 131], ["airway edema", "DISEASE", 136, 148], ["airway edema", "PATHOLOGICAL_FORMATION", 136, 148], ["late-phase allergic responses", "PROBLEM", 70, 99], ["bronchoconstriction", "PROBLEM", 112, 131], ["airway edema", "PROBLEM", 136, 148], ["airway", "ANATOMY", 136, 142], ["edema", "OBSERVATION", 143, 148]]], ["A, Exhaled nitric oxide levels at baseline, during an exacerbation, and following a course of prednisone in unadjusted models.", [["nitric oxide", "CHEMICAL", 11, 23], ["prednisone", "CHEMICAL", 94, 104], ["nitric oxide", "CHEMICAL", 11, 23], ["prednisone", "CHEMICAL", 94, 104], ["Exhaled nitric oxide", "SIMPLE_CHEMICAL", 3, 23], ["prednisone", "SIMPLE_CHEMICAL", 94, 104], ["Exhaled nitric oxide levels", "TEST", 3, 30], ["an exacerbation", "PROBLEM", 51, 66], ["prednisone in unadjusted models", "TREATMENT", 94, 125], ["exacerbation", "OBSERVATION", 54, 66]]], ["Plotted values are mean estimates (AE standard errors) from unadjusted linear mixed models.", [["Plotted values", "TEST", 0, 14]]], ["Black circles and dotted lines correspond to the PCR (\u00c0) group; gray squares and solid lines correspond to the PCR (\u00fe) group.", [["solid lines", "ANATOMY", 81, 92], ["lines", "CELL", 25, 30], ["solid lines", "CELL", 81, 92], ["dotted lines", "CELL_LINE", 18, 30], ["PCR (\u00c0) group", "DNA", 49, 62], ["solid lines", "CELL_LINE", 81, 92], ["Black circles and dotted lines", "PROBLEM", 0, 30], ["the PCR", "TEST", 45, 52], ["gray squares", "TEST", 64, 76], ["solid lines", "PROBLEM", 81, 92], ["the PCR", "TEST", 107, 114], ["circles", "OBSERVATION_MODIFIER", 6, 13], ["dotted lines", "OBSERVATION", 18, 30], ["solid lines", "OBSERVATION", 81, 92]]], ["B, Change in exhaled nitric oxide levels from baseline, during an exacerbation, and following a course of prednisone in adjusted models.", [["nitric oxide", "CHEMICAL", 21, 33], ["prednisone", "CHEMICAL", 106, 116], ["nitric oxide", "CHEMICAL", 21, 33], ["prednisone", "CHEMICAL", 106, 116], ["B", "GENE_OR_GENE_PRODUCT", 0, 1], ["exhaled nitric oxide", "SIMPLE_CHEMICAL", 13, 33], ["prednisone", "SIMPLE_CHEMICAL", 106, 116], ["Change in exhaled nitric oxide levels", "TREATMENT", 3, 40], ["an exacerbation", "PROBLEM", 63, 78], ["prednisone in adjusted models", "TREATMENT", 106, 135], ["Change", "OBSERVATION_MODIFIER", 3, 9], ["exhaled", "OBSERVATION", 13, 20], ["nitric oxide", "OBSERVATION", 21, 33], ["exacerbation", "OBSERVATION", 66, 78]]], ["Plotted values are mean estimates (AE standard errors) from adjusted linear mixed models.", [["Plotted values", "TEST", 0, 14]]], ["All models have been adjusted for season (fall); FENO model also adjusted for age and race.", [["FENO model", "TEST", 49, 59]]], ["Plotted mean estimates for FENO correspond to white subjects of mean age 10.9 years.", [["FENO", "TEST", 27, 31]]], ["Black circles and dotted lines correspond to the PCR (\u00c0) group; gray squares and solid lines correspond to the PCR (\u00fe) group. ppb, Parts per billion.DISCUSSIONpreformed mediators of inflammation and the influx of eosinophils.", [["solid lines", "ANATOMY", 81, 92], ["eosinophils", "ANATOMY", 213, 224], ["inflammation", "DISEASE", 182, 194], ["lines", "CELL", 25, 30], ["solid lines", "CELL", 81, 92], ["eosinophils", "CELL", 213, 224], ["dotted lines", "CELL_LINE", 18, 30], ["PCR (\u00c0) group", "DNA", 49, 62], ["solid lines", "CELL_LINE", 81, 92], ["eosinophils", "CELL_TYPE", 213, 224], ["Black circles and dotted lines", "PROBLEM", 0, 30], ["the PCR", "TEST", 45, 52], ["gray squares", "TEST", 64, 76], ["solid lines", "PROBLEM", 81, 92], ["the PCR", "TEST", 107, 114], ["inflammation", "PROBLEM", 182, 194], ["the influx of eosinophils", "PROBLEM", 199, 224], ["circles", "OBSERVATION_MODIFIER", 6, 13], ["dotted lines", "OBSERVATION", 18, 30], ["solid lines", "OBSERVATION", 81, 92], ["billion", "OBSERVATION", 141, 148], ["inflammation", "OBSERVATION", 182, 194]]], ["Because FENO levels serve as a surrogate for eosinophilic inflammation, 6-9 elevated FENO levels likely represent an influx of eosinophils and eosinophil-derived airway epithelial damage.DISCUSSIONFENO levels were also increased (albeit to a lesser extent than PCR(\u00c0)-driven exacerbations) in PCR (\u00fe) exacerbations of asthma, with this increase coming largely from children infected with rhinovirus.", [["eosinophilic", "ANATOMY", 45, 57], ["eosinophils", "ANATOMY", 127, 138], ["eosinophil", "ANATOMY", 143, 153], ["airway epithelial", "ANATOMY", 162, 179], ["inflammation", "DISEASE", 58, 70], ["asthma", "DISEASE", 318, 324], ["rhinovirus", "DISEASE", 388, 398], ["FENO", "GENE_OR_GENE_PRODUCT", 8, 12], ["FENO", "GENE_OR_GENE_PRODUCT", 85, 89], ["eosinophils", "CELL", 127, 138], ["eosinophil", "CELL", 143, 153], ["airway epithelial", "TISSUE", 162, 179], ["children", "ORGANISM", 365, 373], ["rhinovirus", "ORGANISM", 388, 398], ["eosinophils", "CELL_TYPE", 127, 138], ["eosinophil", "CELL_TYPE", 143, 153], ["children", "SPECIES", 365, 373], ["FENO levels", "TEST", 8, 19], ["eosinophilic inflammation", "PROBLEM", 45, 70], ["9 elevated FENO levels", "PROBLEM", 74, 96], ["an influx of eosinophils", "PROBLEM", 114, 138], ["eosinophil", "TEST", 143, 153], ["airway epithelial damage", "PROBLEM", 162, 186], ["DISCUSSIONFENO levels", "TEST", 187, 208], ["PCR", "TEST", 261, 264], ["driven exacerbations) in PCR", "PROBLEM", 268, 296], ["exacerbations", "PROBLEM", 301, 314], ["asthma", "PROBLEM", 318, 324], ["rhinovirus", "PROBLEM", 388, 398], ["likely represent", "UNCERTAINTY", 97, 113], ["influx of eosinophils", "OBSERVATION", 117, 138], ["airway epithelial damage", "OBSERVATION", 162, 186], ["asthma", "OBSERVATION", 318, 324], ["rhinovirus", "OBSERVATION", 388, 398]]], ["Viral-induced asthma exacerbations are often associated with the influx of neutrophils into the airways.", [["neutrophils", "ANATOMY", 75, 86], ["airways", "ANATOMY", 96, 103], ["asthma", "DISEASE", 14, 20], ["neutrophils", "CELL", 75, 86], ["airways", "MULTI-TISSUE_STRUCTURE", 96, 103], ["neutrophils", "CELL_TYPE", 75, 86], ["Viral-induced asthma exacerbations", "PROBLEM", 0, 34], ["asthma", "OBSERVATION", 14, 20], ["airways", "ANATOMY", 96, 103]]], ["22, 23 In adults with asthma in whom sputum induction was performed at the time of an acute exacerbation, neutrophilic inflammation was noted in 68% of the cases.", [["sputum", "ANATOMY", 37, 43], ["neutrophilic", "ANATOMY", 106, 118], ["asthma", "DISEASE", 22, 28], ["inflammation", "DISEASE", 119, 131], ["neutrophilic", "PATHOLOGICAL_FORMATION", 106, 118], ["asthma", "PROBLEM", 22, 28], ["sputum induction", "TEST", 37, 53], ["an acute exacerbation", "PROBLEM", 83, 104], ["neutrophilic inflammation", "PROBLEM", 106, 131], ["asthma", "OBSERVATION", 22, 28], ["acute", "OBSERVATION_MODIFIER", 86, 91], ["exacerbation", "OBSERVATION", 92, 104], ["neutrophilic", "OBSERVATION_MODIFIER", 106, 118], ["inflammation", "OBSERVATION", 119, 131]]], ["24 This may not come as much of a surprise because up to 80% of acute asthma exacerbations are caused by respiratory viruses.", [["asthma", "DISEASE", 70, 76], ["respiratory viruses", "DISEASE", 105, 124], ["acute asthma exacerbations", "PROBLEM", 64, 90], ["respiratory viruses", "PROBLEM", 105, 124], ["acute", "OBSERVATION_MODIFIER", 64, 69], ["asthma", "OBSERVATION", 70, 76], ["respiratory viruses", "OBSERVATION", 105, 124]]], ["[25] [26] [27] Past studies in adults with asthma have demonstrated that neutrophil-driven inflammation is not associated with elevated FENO levels.", [["neutrophil", "ANATOMY", 73, 83], ["asthma", "DISEASE", 43, 49], ["inflammation", "DISEASE", 91, 103], ["adults", "ORGANISM", 31, 37], ["neutrophil", "CELL", 73, 83], ["FENO", "GENE_OR_GENE_PRODUCT", 136, 140], ["neutrophil", "CELL_TYPE", 73, 83], ["FENO", "PROTEIN", 136, 140], ["Past studies", "TEST", 15, 27], ["asthma", "PROBLEM", 43, 49], ["neutrophil", "TEST", 73, 83], ["inflammation", "PROBLEM", 91, 103], ["elevated FENO levels", "PROBLEM", 127, 147], ["neutrophil", "OBSERVATION", 73, 83]]], ["28 The mechanisms by which viral infections contribute to changes in airway inflammation and altered physiology that result in asthma exacerbations remain incompletely understood.", [["airway", "ANATOMY", 69, 75], ["viral infections", "DISEASE", 27, 43], ["airway inflammation", "DISEASE", 69, 88], ["asthma", "DISEASE", 127, 133], ["airway", "MULTI-TISSUE_STRUCTURE", 69, 75], ["viral infections", "PROBLEM", 27, 43], ["changes in airway inflammation", "PROBLEM", 58, 88], ["altered physiology", "PROBLEM", 93, 111], ["asthma exacerbations", "PROBLEM", 127, 147], ["viral", "OBSERVATION_MODIFIER", 27, 32], ["infections", "OBSERVATION", 33, 43], ["airway", "ANATOMY", 69, 75], ["inflammation", "OBSERVATION", 76, 88], ["asthma", "OBSERVATION", 127, 133]]], ["29 Message et al 30 addressed this issue by inoculating those with asthma and healthy controls with human rhinovirus.", [["asthma", "DISEASE", 67, 73], ["human", "ORGANISM", 100, 105], ["rhinovirus", "ORGANISM", 106, 116], ["human", "SPECIES", 100, 105], ["human rhinovirus", "SPECIES", 100, 116], ["asthma", "PROBLEM", 67, 73], ["human rhinovirus", "PROBLEM", 100, 116], ["rhinovirus", "OBSERVATION", 106, 116]]], ["Both groups developed respiratory symptoms, but those with asthma had lung function impairment and heightened bronchial responsiveness and developed eosinophilic inflammation.", [["respiratory", "ANATOMY", 22, 33], ["lung", "ANATOMY", 70, 74], ["bronchial", "ANATOMY", 110, 119], ["eosinophilic", "ANATOMY", 149, 161], ["respiratory symptoms", "DISEASE", 22, 42], ["asthma", "DISEASE", 59, 65], ["lung function impairment", "DISEASE", 70, 94], ["eosinophilic inflammation", "DISEASE", 149, 174], ["lung", "ORGAN", 70, 74], ["bronchial", "MULTI-TISSUE_STRUCTURE", 110, 119], ["respiratory symptoms", "PROBLEM", 22, 42], ["asthma", "PROBLEM", 59, 65], ["lung function impairment", "PROBLEM", 70, 94], ["heightened bronchial responsiveness", "PROBLEM", 99, 134], ["eosinophilic inflammation", "PROBLEM", 149, 174], ["respiratory symptoms", "OBSERVATION", 22, 42], ["lung", "ANATOMY", 70, 74], ["bronchial", "ANATOMY", 110, 119], ["eosinophilic inflammation", "OBSERVATION", 149, 174]]], ["Unlike respiratory syncytial virus and influenza virus, rhinovirus is unique in that infection in those with asthma results in increased FENO levels 31-33 by way of increased inducible nitric oxide synthase expression in airway epithelial cells.", [["airway epithelial cells", "ANATOMY", 221, 244], ["respiratory syncytial virus", "DISEASE", 7, 34], ["influenza virus", "DISEASE", 39, 54], ["infection", "DISEASE", 85, 94], ["asthma", "DISEASE", 109, 115], ["FENO", "CHEMICAL", 137, 141], ["nitric oxide", "CHEMICAL", 185, 197], ["nitric oxide", "CHEMICAL", 185, 197], ["respiratory syncytial virus", "ORGANISM", 7, 34], ["influenza virus", "ORGANISM", 39, 54], ["rhinovirus", "ORGANISM", 56, 66], ["FENO", "SIMPLE_CHEMICAL", 137, 141], ["nitric oxide synthase", "GENE_OR_GENE_PRODUCT", 185, 206], ["airway epithelial cells", "CELL", 221, 244], ["nitric oxide synthase", "PROTEIN", 185, 206], ["airway epithelial cells", "CELL_TYPE", 221, 244], ["syncytial virus and influenza virus", "SPECIES", 19, 54], ["respiratory syncytial virus", "SPECIES", 7, 34], ["influenza virus", "SPECIES", 39, 54], ["respiratory syncytial virus", "PROBLEM", 7, 34], ["influenza virus", "PROBLEM", 39, 54], ["rhinovirus", "PROBLEM", 56, 66], ["asthma", "PROBLEM", 109, 115], ["increased FENO levels", "TEST", 127, 148], ["increased inducible nitric oxide synthase expression", "TREATMENT", 165, 217], ["airway epithelial cells", "PROBLEM", 221, 244], ["respiratory syncytial virus", "OBSERVATION", 7, 34], ["influenza virus", "OBSERVATION", 39, 54], ["infection", "OBSERVATION", 85, 94], ["nitric oxide", "OBSERVATION", 185, 197], ["synthase expression", "OBSERVATION", 198, 217], ["airway epithelial cells", "OBSERVATION", 221, 244]]], ["34 Indeed, when children with viral-associated exacerbations caused by rhinovirus were excluded from those with other respiratory viruses, FENO levels were not elevated.DISCUSSIONBoth viral infections and allergic inflammation can damage the airway epithelium, which results in asthma worsening.", [["airway epithelium", "ANATOMY", 242, 259], ["viral-associated exacerbations", "DISEASE", 30, 60], ["viral infections", "DISEASE", 184, 200], ["allergic inflammation", "DISEASE", 205, 226], ["asthma", "DISEASE", 278, 284], ["children", "ORGANISM", 16, 24], ["rhinovirus", "ORGANISM", 71, 81], ["FENO", "GENE_OR_GENE_PRODUCT", 139, 143], ["airway epithelium", "TISSUE", 242, 259], ["children", "SPECIES", 16, 24], ["viral-associated exacerbations", "PROBLEM", 30, 60], ["rhinovirus", "PROBLEM", 71, 81], ["other respiratory viruses", "PROBLEM", 112, 137], ["FENO levels", "TEST", 139, 150], ["elevated", "PROBLEM", 160, 168], ["viral infections", "PROBLEM", 184, 200], ["allergic inflammation", "PROBLEM", 205, 226], ["the airway epithelium", "PROBLEM", 238, 259], ["asthma worsening", "PROBLEM", 278, 294], ["exacerbations", "OBSERVATION", 47, 60], ["rhinovirus", "OBSERVATION", 71, 81], ["respiratory", "ANATOMY", 118, 129], ["viruses", "OBSERVATION", 130, 137], ["viral", "OBSERVATION_MODIFIER", 184, 189], ["infections", "OBSERVATION", 190, 200], ["allergic inflammation", "OBSERVATION", 205, 226], ["airway", "ANATOMY", 242, 248], ["asthma", "OBSERVATION", 278, 284], ["worsening", "OBSERVATION_MODIFIER", 285, 294]]], ["Viralinduced damage to the airway epithelium can lead to enhanced absorption of allergens, resulting in worsening airway inflammation.", [["airway epithelium", "ANATOMY", 27, 44], ["airway", "ANATOMY", 114, 120], ["airway inflammation", "DISEASE", 114, 133], ["airway epithelium", "TISSUE", 27, 44], ["airway", "MULTI-TISSUE_STRUCTURE", 114, 120], ["Viralinduced damage to the airway epithelium", "PROBLEM", 0, 44], ["enhanced absorption of allergens", "PROBLEM", 57, 89], ["worsening airway inflammation", "PROBLEM", 104, 133], ["airway", "ANATOMY", 27, 33], ["epithelium", "ANATOMY_MODIFIER", 34, 44], ["allergens", "OBSERVATION", 80, 89], ["worsening", "OBSERVATION_MODIFIER", 104, 113], ["airway", "ANATOMY", 114, 120], ["inflammation", "OBSERVATION", 121, 133]]], ["Likewise, damage of the airway epithelium from allergic inflammation may promote viral replication and more severe clinical illness.", [["airway epithelium", "ANATOMY", 24, 41], ["allergic inflammation", "DISEASE", 47, 68], ["airway epithelium", "TISSUE", 24, 41], ["damage of the airway epithelium", "PROBLEM", 10, 41], ["allergic inflammation", "PROBLEM", 47, 68], ["viral replication", "PROBLEM", 81, 98], ["more severe clinical illness", "PROBLEM", 103, 131], ["airway", "ANATOMY", 24, 30], ["epithelium", "ANATOMY_MODIFIER", 31, 41], ["allergic inflammation", "OBSERVATION", 47, 68], ["viral replication", "OBSERVATION", 81, 98], ["severe", "OBSERVATION_MODIFIER", 108, 114]]], ["29 Thus, in our children with PCR (\u00fe) asthma exacerbations, there is likely to be a mixture of both eosinophilic and neutrophilic inflammation, which results in the moderate elevation in FENO levels we noted.", [["neutrophilic", "ANATOMY", 117, 129], ["asthma exacerbations", "DISEASE", 38, 58], ["inflammation", "DISEASE", 130, 142], ["children", "ORGANISM", 16, 24], ["FENO", "SIMPLE_CHEMICAL", 187, 191], ["FENO", "PROTEIN", 187, 191], ["children", "SPECIES", 16, 24], ["PCR", "TEST", 30, 33], ["asthma exacerbations", "PROBLEM", 38, 58], ["both eosinophilic and neutrophilic inflammation", "PROBLEM", 95, 142], ["the moderate elevation in FENO levels", "PROBLEM", 161, 198], ["asthma", "OBSERVATION", 38, 44], ["likely to be", "UNCERTAINTY", 69, 81], ["both", "OBSERVATION_MODIFIER", 95, 99], ["eosinophilic", "OBSERVATION", 100, 112], ["neutrophilic inflammation", "OBSERVATION", 117, 142], ["moderate", "OBSERVATION_MODIFIER", 165, 173], ["elevation", "OBSERVATION_MODIFIER", 174, 183], ["FENO levels", "OBSERVATION", 187, 198]]], ["In contrast, the inflammation underlying PCR (\u00c0) exacerbations is more likely to be a purely eosinophil-driven process and as a result, FENO levels would be expected to be higher.DISCUSSIONOur study has a number of limitations.", [["eosinophil", "ANATOMY", 93, 103], ["inflammation", "DISEASE", 17, 29], ["eosinophil", "CELL", 93, 103], ["FENO", "SIMPLE_CHEMICAL", 136, 140], ["the inflammation underlying PCR", "PROBLEM", 13, 44], ["exacerbations", "PROBLEM", 49, 62], ["a purely eosinophil-driven process", "PROBLEM", 84, 118], ["FENO levels", "TEST", 136, 147], ["DISCUSSIONOur study", "TEST", 179, 198], ["inflammation", "OBSERVATION", 17, 29], ["more likely", "UNCERTAINTY", 66, 77], ["eosinophil", "OBSERVATION", 93, 103]]], ["First, from a methodological standpoint, it would have been preferable to perform FENO measurements before spirometry because spirometry can result in a transient reduction in FENO levels.", [["FENO", "SIMPLE_CHEMICAL", 82, 86], ["FENO", "SIMPLE_CHEMICAL", 176, 180], ["FENO measurements", "TEST", 82, 99], ["spirometry", "TEST", 126, 136], ["a transient reduction in FENO levels", "PROBLEM", 151, 187], ["transient", "OBSERVATION_MODIFIER", 153, 162], ["reduction", "OBSERVATION_MODIFIER", 163, 172], ["FENO levels", "OBSERVATION", 176, 187]]], ["Past studies have shown the reduction to be modest (2 ppb or <10%) 35 and unlikely to have significantly altered our results.", [["Past studies", "TEST", 0, 12]]], ["Second, we did not inquire as to whether our patients had recently ingested foods containing high levels of nitrates, or whether they were exposed to household cigarette smoke or were currently smoking cigarettes.", [["nitrates", "CHEMICAL", 108, 116], ["nitrates", "CHEMICAL", 108, 116], ["patients", "ORGANISM", 45, 53], ["nitrates", "SIMPLE_CHEMICAL", 108, 116], ["patients", "SPECIES", 45, 53], ["nitrates", "TREATMENT", 108, 116]]], ["Ingestion of foods containing high levels of nitrates can cause the FENO level to be elevated for up to 15 hours, 36 while current cigarette smoking can reduce the FENO levels by 60%.", [["nitrates", "CHEMICAL", 45, 53], ["FENO", "CHEMICAL", 68, 72], ["smoking", "CHEMICAL", 141, 148], ["FENO", "CHEMICAL", 164, 168], ["nitrates", "CHEMICAL", 45, 53], ["nitrates", "SIMPLE_CHEMICAL", 45, 53], ["FENO", "SIMPLE_CHEMICAL", 68, 72], ["cigarette", "ORGANISM", 131, 140], ["FENO", "SIMPLE_CHEMICAL", 164, 168], ["high levels of nitrates", "TREATMENT", 30, 53], ["the FENO level", "PROBLEM", 64, 78], ["elevated", "PROBLEM", 85, 93], ["the FENO levels", "TEST", 160, 175]]], ["37 In addition, we reported the FEV 1 /FVC ratio as a percentage, as opposed to the FEV 1 /FVC percent predicted.", [["FEV 1", "GENE_OR_GENE_PRODUCT", 32, 37], ["FVC", "GENE_OR_GENE_PRODUCT", 39, 42], ["the FEV", "TEST", 28, 35], ["FVC ratio", "TEST", 39, 48], ["the FEV", "TEST", 80, 87], ["FVC", "TEST", 91, 94]]], ["Because the ratio varies with age and sex, using percentage only misses this information and can give a false sense of abnormalities.", [["a false sense of abnormalities", "PROBLEM", 102, 132]]], ["Another limitation is that we were unable to identify the triggering agent(s) involved in the acute exacerbation in the PCR (\u00c0) group.", [["the acute exacerbation", "PROBLEM", 90, 112], ["the PCR", "TEST", 116, 123], ["acute", "OBSERVATION_MODIFIER", 94, 99], ["exacerbation", "OBSERVATION", 100, 112]]], ["It is possible that these subjects were reacting to inhaled seasonal allergens or newly acquired perennial allergens such as cat or dog dander.", [["cat", "ORGANISM", 125, 128], ["dog", "ORGANISM", 132, 135], ["dander", "ORGANISM_SUBDIVISION", 136, 142], ["cat", "SPECIES", 125, 128], ["dog", "SPECIES", 132, 135], ["dog dander", "SPECIES", 132, 142], ["inhaled seasonal allergens", "PROBLEM", 52, 78], ["newly acquired perennial allergens", "PROBLEM", 82, 116]]], ["Alternatively, some of our patients may have had a falsely negative PCR result.", [["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["a falsely negative PCR result", "PROBLEM", 49, 78]]], ["Last, although we speculate that PCR (\u00c0) exacerbations were likely eosinophil driven, we did not perform sputum induction or collect peripheral blood to assess for eosinophilia.DISCUSSIONIn conclusion, FENO levels are elevated in acute childhood asthma, with higher levels seen in children with PCR (\u00c0) exacerbations.", [["eosinophil", "ANATOMY", 67, 77], ["sputum", "ANATOMY", 105, 111], ["peripheral blood", "ANATOMY", 133, 149], ["eosinophilia", "DISEASE", 164, 176], ["asthma", "DISEASE", 246, 252], ["eosinophil", "CELL", 67, 77], ["peripheral blood", "ORGANISM_SUBSTANCE", 133, 149], ["FENO", "SIMPLE_CHEMICAL", 202, 206], ["children", "ORGANISM", 281, 289], ["eosinophil", "CELL_TYPE", 67, 77], ["children", "SPECIES", 281, 289], ["PCR", "TEST", 33, 36], ["exacerbations", "PROBLEM", 41, 54], ["eosinophil", "PROBLEM", 67, 77], ["sputum induction", "TEST", 105, 121], ["peripheral blood", "TEST", 133, 149], ["eosinophilia", "PROBLEM", 164, 176], ["FENO levels", "TEST", 202, 213], ["elevated", "PROBLEM", 218, 226], ["acute childhood asthma", "PROBLEM", 230, 252], ["PCR", "TEST", 295, 298], ["exacerbations", "PROBLEM", 303, 316], ["likely", "UNCERTAINTY", 60, 66], ["eosinophil driven", "OBSERVATION", 67, 84], ["eosinophilia", "OBSERVATION", 164, 176], ["elevated", "OBSERVATION_MODIFIER", 218, 226], ["acute", "OBSERVATION_MODIFIER", 230, 235], ["childhood", "OBSERVATION_MODIFIER", 236, 245], ["asthma", "OBSERVATION", 246, 252]]], ["A short course of prednisone resulted in significant reductions in FENO levels.", [["prednisone", "CHEMICAL", 18, 28], ["prednisone", "CHEMICAL", 18, 28], ["prednisone", "SIMPLE_CHEMICAL", 18, 28], ["FENO", "SIMPLE_CHEMICAL", 67, 71], ["prednisone", "TREATMENT", 18, 28], ["significant reductions in FENO levels", "PROBLEM", 41, 78], ["significant", "OBSERVATION_MODIFIER", 41, 52], ["reductions", "OBSERVATION_MODIFIER", 53, 63], ["FENO levels", "OBSERVATION", 67, 78]]], ["Future studies are needed to better understand the underlying pathophysiologic differences between PCR (\u00fe) and PCR (\u00c0) asthma exacerbations.", [["asthma", "DISEASE", 119, 125], ["Future studies", "TEST", 0, 14], ["the underlying pathophysiologic differences", "PROBLEM", 47, 90], ["PCR", "TEST", 99, 102], ["PCR", "TEST", 111, 114], ["asthma exacerbations", "PROBLEM", 119, 139]]], ["This is of potential importance because therapy may be altered on the basis of the underlying inflammatory process.", [["therapy", "TREATMENT", 40, 47], ["the underlying inflammatory process", "PROBLEM", 79, 114], ["underlying", "OBSERVATION_MODIFIER", 83, 93], ["inflammatory", "OBSERVATION", 94, 106]]], ["By providing optimal therapy at the time of an exacerbation, attenuation of airway remodeling and loss of lung function as a result of the exacerbation may be achieved.", [["airway", "ANATOMY", 76, 82], ["lung", "ANATOMY", 106, 110], ["loss of lung function", "DISEASE", 98, 119], ["airway", "MULTI-TISSUE_STRUCTURE", 76, 82], ["lung", "ORGAN", 106, 110], ["optimal therapy", "TREATMENT", 13, 28], ["an exacerbation", "PROBLEM", 44, 59], ["airway remodeling", "TREATMENT", 76, 93], ["loss of lung function", "PROBLEM", 98, 119], ["the exacerbation", "PROBLEM", 135, 151], ["exacerbation", "OBSERVATION", 47, 59], ["airway", "ANATOMY", 76, 82], ["lung", "ANATOMY", 106, 110]]]], "6e135b945acd2b748148e9b1775450551588560b": [["To the Editor: Recently we have read an interesting report concerning a mild course of novel coronavirus disease 2019 in children.", [["coronavirus disease", "DISEASE", 93, 112], ["coronavirus", "ORGANISM", 93, 104], ["children", "ORGANISM", 121, 129], ["children", "SPECIES", 121, 129], ["novel coronavirus disease", "PROBLEM", 87, 112], ["mild", "OBSERVATION_MODIFIER", 72, 76], ["coronavirus disease", "OBSERVATION", 93, 112]]], ["1 The disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is defined by its high infectiousness, with 2 263 056 cases registered as of 18 April 2020.", [["acute respiratory syndrome coronavirus", "DISEASE", 32, 70], ["SARS-CoV-2", "ORGANISM", 74, 84], ["severe acute respiratory syndrome coronavirus", "SPECIES", 25, 70], ["SARS-CoV-2", "SPECIES", 74, 84], ["The disease", "PROBLEM", 2, 13], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 25, 70], ["SARS-CoV", "TEST", 74, 82], ["its high infectiousness", "PROBLEM", 101, 124], ["disease", "OBSERVATION", 6, 13], ["severe", "OBSERVATION_MODIFIER", 25, 31], ["acute", "OBSERVATION_MODIFIER", 32, 37], ["respiratory syndrome coronavirus", "OBSERVATION", 38, 70], ["high", "OBSERVATION_MODIFIER", 105, 109], ["infectiousness", "OBSERVATION", 110, 124]]], ["Surprisingly, its most severe course, with mortality of 6.8% (154 827 lethal cases up to 18 April 2020), almost exclusively affects adults.", [["mortality", "TEST", 43, 52], ["most severe", "OBSERVATION_MODIFIER", 18, 29]]], ["Children below the age of 10 usually remain asymptomatic or develop mild symptoms, with case fatality rate nearly 0%.", [["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8], ["mild symptoms", "PROBLEM", 68, 81], ["case fatality rate", "TEST", 88, 106], ["mild", "OBSERVATION_MODIFIER", 68, 72]]], ["2 The reason for mild presentation of COVID-19 in children remains unclear.", [["COVID-19", "CHEMICAL", 38, 46], ["COVID-19", "CHEMICAL", 38, 46], ["children", "ORGANISM", 50, 58], ["children", "SPECIES", 50, 58], ["COVID", "TEST", 38, 43], ["mild", "OBSERVATION_MODIFIER", 17, 21]]], ["Although several ideas have been discussed so far, there is still no definitive explanation for this issue.", [["no definitive explanation for", "UNCERTAINTY", 66, 95]]], ["Here we propose a new hypothesis that might have practical implications.", [["a new hypothesis", "PROBLEM", 16, 32]]]], "1ff255719ae770ac447902320cf19bd3c7e895b7": [["BackgroundHigh population density, in addition to physical and mental stress to adapt to a new environment, has been recognized to contribute to increased susceptibility of military recruits to respiratory infection [1] .", [["respiratory", "ANATOMY", 194, 205], ["respiratory infection", "DISEASE", 194, 215], ["BackgroundHigh population density", "PROBLEM", 0, 33], ["physical and mental stress", "PROBLEM", 50, 76], ["respiratory infection", "PROBLEM", 194, 215], ["population", "OBSERVATION_MODIFIER", 15, 25], ["density", "OBSERVATION", 26, 33], ["respiratory", "ANATOMY", 194, 205], ["infection", "OBSERVATION", 206, 215]]], ["To better protect the recruits and reduce loss in training time, a surveillance programme was put in place to monitor the etiological agents responsible for febrile respiratory illnesses (FRIs) among Singapore military recruits since 2009.", [["respiratory", "ANATOMY", 165, 176], ["febrile respiratory illnesses", "DISEASE", 157, 186], ["FRIs", "DISEASE", 188, 192], ["a surveillance programme", "TEST", 65, 89], ["febrile respiratory illnesses", "PROBLEM", 157, 186]]], ["Data from the surveillance programme showed that Influenza, Coxsackie, Rhinovirus and Adenovirus are the primary causative agents of FRIs in military camps [2, 3] .", [["Influenza, Coxsackie, Rhinovirus", "DISEASE", 49, 81], ["FRIs", "DISEASE", 133, 137], ["Coxsackie", "ORGANISM", 60, 69], ["Adenovirus", "ORGANISM", 86, 96], ["Influenza", "SPECIES", 49, 58], ["Coxsackie", "SPECIES", 60, 69], ["Adenovirus", "SPECIES", 86, 96], ["the surveillance programme", "TEST", 10, 36], ["Influenza", "PROBLEM", 49, 58], ["Coxsackie", "PROBLEM", 60, 69], ["Rhinovirus", "PROBLEM", 71, 81], ["Adenovirus", "TREATMENT", 86, 96]]], ["Mass vaccination of military recruits against pandemic H1N1 (A(H1N1)pdm09) in 2009 demonstrated that such a policy can reduce disease burden among recruits [4] .", [["pandemic H1N1", "DISEASE", 46, 59], ["pandemic H1N1", "ORGANISM", 46, 59], ["A(H1N1)pdm09", "ORGANISM", 61, 73], ["pandemic H1N1", "SPECIES", 46, 59], ["pandemic H1N1", "PROBLEM", 46, 59], ["disease burden", "PROBLEM", 126, 140]]], ["A subsequent study also showed that routine administration of influenza vaccine to recruits resulted in significant protection against both A(H1N1)pdm09 and influenza B, and thus, was recommended for all military personnel since [5] .BackgroundWhile the initial focus of the surveillance programme is on etiological agents that cause febrile illnesses, some recruits were excluded from the programme as they only presented respiratory symptoms without elevation in body temperature (termed as Acute Respiratory Illnesses (ARIs)).", [["respiratory", "ANATOMY", 423, 434], ["body", "ANATOMY", 465, 469], ["influenza B", "DISEASE", 157, 168], ["febrile illnesses", "DISEASE", 334, 351], ["respiratory symptoms", "DISEASE", 423, 443], ["Acute Respiratory Illnesses", "DISEASE", 493, 520], ["A(H1N1)pdm09", "ORGANISM", 140, 152], ["influenza B", "ORGANISM", 157, 168], ["body", "ORGANISM_SUBDIVISION", 465, 469], ["A subsequent study", "TEST", 0, 18], ["influenza vaccine", "TREATMENT", 62, 79], ["pdm09", "PROBLEM", 147, 152], ["influenza B", "PROBLEM", 157, 168], ["etiological agents", "TREATMENT", 304, 322], ["febrile illnesses", "PROBLEM", 334, 351], ["respiratory symptoms", "PROBLEM", 423, 443], ["elevation in body temperature", "PROBLEM", 452, 481], ["Acute Respiratory Illnesses (ARIs)", "PROBLEM", 493, 527], ["Acute", "OBSERVATION_MODIFIER", 493, 498], ["Respiratory Illnesses", "OBSERVATION", 499, 520]]], ["Since late 2015, the surveillance programme was expanded to monitor the etiological agents responsible for ARIs cases as well, owing to the paucity of information on causative agents for ARI cases.", [["ARIs", "DISEASE", 107, 111], ["ARI", "DISEASE", 187, 190], ["the surveillance programme", "TEST", 17, 43], ["ARIs cases", "PROBLEM", 107, 117], ["ARI cases", "PROBLEM", 187, 196]]], ["Using molecular diagnostic technology, the current study aimed to evaluate the contribution of 26 different pathogens to FRI and ARI cases.", [["ARI", "DISEASE", 129, 132], ["the current study", "TEST", 39, 56], ["26 different pathogens", "PROBLEM", 95, 117]]], ["This report highlights findings on both the FRI and ARI cases captured by the surveillance programme in its first year of ARI survey.", [["ARI", "DISEASE", 52, 55]]], ["Additionally, there is a focus on significant relationship between pathogens presented as co-infections.SamplesThe Singapore military started a respiratory diseases surveillance programme in 2009 [2] .", [["respiratory", "ANATOMY", 144, 155], ["co-infections", "DISEASE", 90, 103], ["respiratory diseases", "DISEASE", 144, 164], ["pathogens", "PROBLEM", 67, 76], ["co-infections", "PROBLEM", 90, 103], ["a respiratory diseases", "PROBLEM", 142, 164], ["significant", "OBSERVATION_MODIFIER", 34, 45], ["pathogens", "OBSERVATION", 67, 76], ["co-infections", "OBSERVATION", 90, 103], ["respiratory diseases", "OBSERVATION", 144, 164]]], ["From 4th January 2016 through 6th January 2017, servicemen who visited the medical center in a recruit training camp and presented with respiratory symptoms were enrolled in the study.", [["respiratory", "ANATOMY", 136, 147], ["respiratory symptoms", "DISEASE", 136, 156], ["respiratory symptoms", "PROBLEM", 136, 156], ["the study", "TEST", 174, 183]]], ["Healthcare workers obtained written informed consent, administered a questionnaire and measured the body temperature using an ear thermometer.", [["body", "ANATOMY", 100, 104], ["ear", "ANATOMY", 126, 129], ["body", "ORGANISM_SUBDIVISION", 100, 104], ["ear", "ORGAN", 126, 129], ["the body temperature", "TEST", 96, 116], ["an ear thermometer", "TREATMENT", 123, 141], ["ear", "ANATOMY", 126, 129]]], ["After a clinical examination on each participant, nasal wash (4 mL per nostril) was collected.", [["nasal", "ANATOMY", 50, 55], ["nostril", "ANATOMY", 71, 78], ["nasal", "ORGANISM_SUBDIVISION", 50, 55], ["nostril", "ORGANISM_SUBDIVISION", 71, 78], ["participant", "SPECIES", 37, 48], ["a clinical examination", "TEST", 6, 28], ["nasal wash", "TREATMENT", 50, 60]]], ["The cases were stratified into two groups, namely: Acute Respiratory Illness (ARI): cases with respiratory symptoms and body temperature below 37.5\u00b0C; and Febrile Respiratory Illness (FRI): cases with respiratory symptoms and body temperature equal to or above 37.5\u00b0C. In addition, control samples were obtained from those reported sick without respiratory symptoms / fever.", [["respiratory", "ANATOMY", 95, 106], ["body", "ANATOMY", 120, 124], ["respiratory", "ANATOMY", 201, 212], ["body", "ANATOMY", 226, 230], ["samples", "ANATOMY", 290, 297], ["respiratory", "ANATOMY", 345, 356], ["Respiratory Illness", "DISEASE", 57, 76], ["ARI", "DISEASE", 78, 81], ["respiratory symptoms", "DISEASE", 95, 115], ["Febrile Respiratory Illness", "DISEASE", 155, 182], ["respiratory symptoms", "DISEASE", 201, 221], ["respiratory symptoms", "DISEASE", 345, 365], ["fever", "DISEASE", 368, 373], ["body", "ORGANISM_SUBDIVISION", 120, 124], ["body", "ORGANISM_SUBDIVISION", 226, 230], ["Acute Respiratory Illness", "PROBLEM", 51, 76], ["respiratory symptoms", "PROBLEM", 95, 115], ["body temperature", "TEST", 120, 136], ["Febrile Respiratory Illness", "PROBLEM", 155, 182], ["respiratory symptoms", "PROBLEM", 201, 221], ["body temperature", "TEST", 226, 242], ["respiratory symptoms", "PROBLEM", 345, 365], ["fever", "PROBLEM", 368, 373], ["Acute", "OBSERVATION_MODIFIER", 51, 56], ["Respiratory", "ANATOMY", 57, 68], ["Illness", "OBSERVATION", 69, 76], ["fever", "OBSERVATION", 368, 373]]], ["The study was reviewed and approved by DSO-SAF Institutional Review Board (IRB).Detection of respiratory virusesThe nasal wash samples in viral transport media were sent to a laboratory for diagnostic testing within 24 h after collection.", [["nasal", "ANATOMY", 116, 121], ["samples", "ANATOMY", 127, 134], ["respiratory viruses", "DISEASE", 93, 112], ["The study", "TEST", 0, 9], ["respiratory viruses", "PROBLEM", 93, 112], ["The nasal wash samples", "TREATMENT", 112, 134], ["viral transport media", "TREATMENT", 138, 159], ["diagnostic testing", "TEST", 190, 208], ["respiratory viruses", "OBSERVATION", 93, 112], ["nasal", "ANATOMY", 116, 121]]], ["Extraction of viral genetic materials and subsequent qualitative nucleic acid multiplex diagnostic assay were carried out according to ISO 15189 standard and have been previously described in detail [2] .", [["nucleic acid", "CHEMICAL", 65, 77], ["Extraction", "TREATMENT", 0, 10], ["viral genetic materials", "PROBLEM", 14, 37], ["subsequent qualitative nucleic acid multiplex diagnostic assay", "TEST", 42, 104], ["viral genetic materials", "OBSERVATION", 14, 37]]], ["Briefly, total nucleic acids were extracted from each specimen using the MagNA Pure 96 system (F. Hoffmann-La Roche Ltd) and screened for the presence of different pathogens using RT-PCR methodology with in-house developed primers and probes.", [["specimen", "ANATOMY", 54, 62], ["nucleic acids", "CHEMICAL", 15, 28], ["total nucleic acids", "TREATMENT", 9, 28], ["different pathogens", "PROBLEM", 154, 173], ["RT-PCR methodology", "TREATMENT", 180, 198], ["primers", "PROBLEM", 223, 230]]], ["For specimens that were positive for Influenza A, Adenovirus and Coronavirus, they were further subtyped using subtype-specific primers.", [["specimens", "ANATOMY", 4, 13], ["specimens", "CANCER", 4, 13], ["Influenza A", "ORGANISM", 37, 48], ["Adenovirus", "ORGANISM", 50, 60], ["Influenza A", "SPECIES", 37, 48], ["Adenovirus", "SPECIES", 50, 60], ["Coronavirus", "SPECIES", 65, 76], ["specimens", "TEST", 4, 13], ["Influenza A", "PROBLEM", 37, 48], ["Adenovirus", "PROBLEM", 50, 60], ["Coronavirus", "PROBLEM", 65, 76], ["subtype-specific primers", "TREATMENT", 111, 135]]], ["A total of 26 bacterial and viral pathogens can be detected in this workflow.", [["26 bacterial and viral pathogens", "PROBLEM", 11, 43], ["viral pathogens", "OBSERVATION", 28, 43]]], ["These assays were run using the 7500 Fast Real-Time PCR system (Applied Biosystems, ThermoFisher Scientific).", [["These assays", "TEST", 0, 12]]], ["The performance of the Real-Time PCR assays has been validated through regular participation in external proficiency programs such as Quality Control for Molecular Diagnostics (QCMD) External Quality Assessment (EQA) programs.Statistical methodsThe significance of the difference between any two different groups was assessed by the Mann-Whitney test using Prism 5 (GraphPad Software, CA).", [["Time PCR assays", "TEST", 28, 43], ["external proficiency programs", "TREATMENT", 96, 125], ["External Quality Assessment", "TEST", 183, 210]]], ["P value of < 0.05 is considered statistically significant.Distribution of etiological agents responsible for FRI and ARI casesA total of 2647 cases with respiratory symptoms were recruited in the study.", [["respiratory", "ANATOMY", 153, 164], ["ARI", "DISEASE", 117, 120], ["respiratory symptoms", "DISEASE", 153, 173], ["P value", "TEST", 0, 7], ["FRI and ARI cases", "PROBLEM", 109, 126], ["respiratory symptoms", "PROBLEM", 153, 173], ["the study", "TEST", 192, 201], ["significant", "OBSERVATION_MODIFIER", 46, 57]]], ["Of these, 1095 (41%) cases were presented with a body temperature above 37.5\u00b0C (termed as FRI cases) and in the remaining 1552 (59%) cases, the subjects had normal body temperature (termed as ARI cases).", [["body", "ANATOMY", 49, 53], ["body", "ANATOMY", 164, 168], ["body", "ORGANISM_SUBDIVISION", 49, 53], ["subjects", "ORGANISM", 144, 152], ["body", "ORGANISM_SUBDIVISION", 164, 168], ["a body temperature", "TEST", 47, 65], ["body temperature", "OBSERVATION_MODIFIER", 164, 180]]], ["Twenty-five participants with neither fever nor respiratory illnesses, were recruited as normal control.Distribution of etiological agents responsible for FRI and ARI casesThe nasal wash samples were tested for the presence of 26 different pathogens by RT-PCR methods.", [["respiratory", "ANATOMY", 48, 59], ["nasal", "ANATOMY", 176, 181], ["samples", "ANATOMY", 187, 194], ["fever", "DISEASE", 38, 43], ["respiratory illnesses", "DISEASE", 48, 69], ["ARI", "DISEASE", 163, 166], ["participants", "ORGANISM", 12, 24], ["participants", "SPECIES", 12, 24], ["fever", "PROBLEM", 38, 43], ["respiratory illnesses", "PROBLEM", 48, 69], ["etiological agents", "TREATMENT", 120, 138], ["FRI and ARI cases", "PROBLEM", 155, 172], ["The nasal wash samples", "TEST", 172, 194], ["26 different pathogens", "PROBLEM", 227, 249], ["PCR methods", "TEST", 256, 267], ["nasal", "ANATOMY", 176, 181]]], ["For the ARI cases, 738 (47.6%) and 371 (23.9%) of the tested samples were found positive for one and two pathogens respectively (Fig. 1) .", [["samples", "ANATOMY", 61, 68], ["ARI", "DISEASE", 8, 11], ["samples", "CANCER", 61, 68], ["the ARI cases", "TEST", 4, 17], ["the tested samples", "TEST", 50, 68]]], ["Eleven cases (0.7%) were found positive for four different pathogens.", [["four different pathogens", "PROBLEM", 44, 68], ["pathogens", "OBSERVATION", 59, 68]]], ["Finally, one ARI case was found positive for five pathogens, which is the maximum number of pathogens found in one sample for ARI group (Fig. 1 ).", [["ARI", "DISEASE", 126, 129], ["five pathogens", "PROBLEM", 45, 59], ["pathogens", "PROBLEM", 92, 101], ["maximum", "OBSERVATION_MODIFIER", 74, 81], ["pathogens", "OBSERVATION", 92, 101]]], ["The pathogen distribution pattern was similar for the FRI cases, with 45.4%, 30.9% and 7.5% of the cases detected with one, two and three pathogens in the sample extracts respectively (Fig. 1 ).", [["extracts", "ANATOMY", 162, 170], ["extracts", "ORGANISM_SUBSTANCE", 162, 170], ["The pathogen distribution pattern", "TEST", 0, 33], ["the FRI cases", "TEST", 50, 63], ["the cases", "TEST", 95, 104]]], ["Twelve cases (1.1%) had four pathogens detected in the samples.", [["samples", "ANATOMY", 55, 62], ["Twelve cases", "TEST", 0, 12], ["four pathogens", "PROBLEM", 24, 38]]], ["Finally, three cases had five pathogens detected.", [["five pathogens", "PROBLEM", 25, 39]]], ["The positivity rate for ARI and FRI samples was 77.2% and 85.1% respectively (Fig. 1) .Distribution of etiological agents responsible for FRI and ARI casesThe most common single pathogen found in ARI samples was Rhinovirus, which accounted for~47% of the samples (Table 1) .", [["samples", "ANATOMY", 36, 43], ["samples", "ANATOMY", 200, 207], ["samples", "ANATOMY", 255, 262], ["ARI", "DISEASE", 146, 149], ["ARI", "DISEASE", 196, 199], ["ARI samples", "CANCER", 196, 207], ["The positivity rate", "TEST", 0, 19], ["ARI", "TEST", 24, 27], ["FRI samples", "TEST", 32, 43], ["etiological agents", "TREATMENT", 103, 121], ["FRI and ARI cases", "PROBLEM", 138, 155], ["The most common single pathogen", "PROBLEM", 155, 186], ["ARI samples", "PROBLEM", 196, 207], ["Rhinovirus", "PROBLEM", 212, 222], ["most common", "OBSERVATION_MODIFIER", 159, 170], ["pathogen", "OBSERVATION", 178, 186], ["Rhinovirus", "OBSERVATION", 212, 222]]], ["Other significant pathogens found in the mono-infection samples were H. influenza (19%), Adenovirus E (5.3%) and Coronavirus (6.0%, including HKU1, NL63 and OC43).", [["mono-infection samples", "ANATOMY", 41, 63], ["H. influenza", "DISEASE", 69, 81], ["mono-infection samples", "CANCER", 41, 63], ["H. influenza", "ORGANISM", 69, 81], ["Adenovirus E", "ORGANISM", 89, 101], ["H. influenza", "SPECIES", 69, 81], ["H. influenza", "SPECIES", 69, 81], ["Adenovirus E", "SPECIES", 89, 101], ["Other significant pathogens", "PROBLEM", 0, 27], ["the mono-infection samples", "TEST", 37, 63], ["H. influenza", "TEST", 69, 81], ["Adenovirus E", "TEST", 89, 101], ["Coronavirus", "TEST", 113, 124], ["HKU1", "TEST", 142, 146], ["NL63", "TEST", 148, 152], ["OC43", "TEST", 157, 161], ["significant", "OBSERVATION_MODIFIER", 6, 17], ["pathogens", "OBSERVATION", 18, 27]]], ["Adenovirus E (27.4%), Rhinovirus (24.1%), and Influenza viruses (17.9%, H3 and influenza B) were the three most important pathogens for FRI mono-infection cases.", [["Influenza viruses", "DISEASE", 46, 63], ["influenza B", "DISEASE", 79, 90], ["mono-infection", "DISEASE", 140, 154], ["Adenovirus E", "ORGANISM", 0, 12], ["Influenza viruses", "ORGANISM", 46, 63], ["influenza B", "ORGANISM", 79, 90], ["Influenza", "SPECIES", 46, 55], ["Adenovirus E", "SPECIES", 0, 12], ["Influenza viruses", "SPECIES", 46, 63], ["Adenovirus E", "TEST", 0, 12], ["Rhinovirus", "TEST", 22, 32], ["Influenza viruses", "TEST", 46, 63], ["H3", "PROBLEM", 72, 74], ["influenza B", "PROBLEM", 79, 90], ["Influenza viruses", "OBSERVATION", 46, 63]]], ["For both FRI and ARI cases, H. influenzae was the most frequently found bacterial pathogen in samples.Distribution of etiological agents responsible for FRI and ARI casesFor the 25 normal controls, 17 of them (68%) were negative for all pathogens screened.", [["samples", "ANATOMY", 94, 101], ["ARI", "DISEASE", 17, 20], ["ARI", "DISEASE", 161, 164], ["H. influenzae", "ORGANISM", 28, 41], ["samples", "CANCER", 94, 101], ["H. influenzae", "SPECIES", 28, 41], ["H. influenzae", "SPECIES", 28, 41], ["ARI cases", "PROBLEM", 17, 26], ["H. influenzae", "PROBLEM", 28, 41], ["bacterial pathogen in samples", "PROBLEM", 72, 101], ["FRI", "PROBLEM", 153, 156], ["ARI cases", "TEST", 161, 170], ["all pathogens", "PROBLEM", 233, 246]]], ["For the remaining eight cases, five cases were found positive for H. influenza (2 cases as single positivity, Table 2 ).", [["H. influenza", "DISEASE", 66, 78], ["H. influenza", "ORGANISM", 66, 78], ["H. influenza", "SPECIES", 66, 78], ["H. influenza", "PROBLEM", 66, 78]]], ["One case was positive with Adenovirus and two were positive for both Influenza B with Rhinovirus (Table 2) .", [["Influenza B", "DISEASE", 69, 80], ["Adenovirus", "ORGANISM", 27, 37], ["Adenovirus", "SPECIES", 27, 37], ["Adenovirus", "PROBLEM", 27, 37], ["both Influenza B", "PROBLEM", 64, 80], ["Rhinovirus", "PROBLEM", 86, 96]]], ["For Adenovirus E, the majority of the Adenovirus E cases occurred in the second half of 2016.", [["Adenovirus E", "ORGANISM", 4, 16], ["Adenovirus E", "ORGANISM", 38, 50], ["Adenovirus E", "SPECIES", 4, 16], ["Adenovirus", "SPECIES", 38, 48], ["Adenovirus E", "TREATMENT", 4, 16], ["the Adenovirus E cases", "TEST", 34, 56]]], ["From Week 36 to Week 52, a total of 106 of FRI (red line) and 28 ARI (black line) cases were reported.", [["ARI", "DISEASE", 65, 68], ["FRI (red line", "TREATMENT", 43, 56], ["28 ARI (black line) cases", "PROBLEM", 62, 87]]], ["Eight recruits were diagnosed with pneumonia.", [["pneumonia", "DISEASE", 35, 44], ["pneumonia", "PROBLEM", 35, 44], ["pneumonia", "OBSERVATION", 35, 44]]], ["For Influenza H3 virus, there were three main peaks for FRI cases in 2016.", [["Influenza H3 virus", "ORGANISM", 4, 22], ["Influenza H3 virus", "SPECIES", 4, 22], ["Influenza H3 virus", "PROBLEM", 4, 22]]], ["The secondRise in body temperature caused by different pathogens in mono-infectionsAll the FRI and ARI cases with one pathogen detected were further stratified into groups; based on the pathogen detected in the samples.", [["body", "ANATOMY", 18, 22], ["samples", "ANATOMY", 211, 218], ["ARI", "DISEASE", 99, 102], ["body", "ORGANISM_SUBDIVISION", 18, 22], ["The secondRise in body temperature", "PROBLEM", 0, 34], ["different pathogens in mono-infections", "PROBLEM", 45, 83], ["ARI cases", "PROBLEM", 99, 108], ["one pathogen", "PROBLEM", 114, 126], ["the pathogen", "PROBLEM", 182, 194], ["different", "OBSERVATION_MODIFIER", 45, 54], ["pathogens", "OBSERVATION", 55, 64]]], ["The mean and standard error of the body temperature of each group was plotted (Fig. 3 ) and the significance of the difference between the FRI and ARI groups was determined.", [["body", "ANATOMY", 35, 39], ["body", "ORGANISM_SUBDIVISION", 35, 39], ["the body temperature", "TEST", 31, 51], ["the FRI and ARI groups", "TREATMENT", 135, 157], ["mean", "OBSERVATION_MODIFIER", 4, 8]]], ["All the FRI cases, irrespective of the etiological agent involved, had a significantly higher body temperature than the ARI cases (p < 0.05, Fig. 3 We also examined if cases with dual pathogen detected have higher body temperature elevation compared to the mono-infection.", [["body", "ANATOMY", 94, 98], ["body", "ANATOMY", 214, 218], ["ARI", "DISEASE", 120, 123], ["mono-infection", "DISEASE", 257, 271], ["body", "ORGANISM_SUBDIVISION", 94, 98], ["body", "ORGANISM_SUBDIVISION", 214, 218], ["a significantly higher body temperature", "PROBLEM", 71, 110], ["dual pathogen", "PROBLEM", 179, 192], ["higher body temperature elevation", "PROBLEM", 207, 240], ["the mono-infection", "PROBLEM", 253, 271]]], ["The result shows that the two a b Fig. 4 a Average body temperature of FRI mono-infection. b FRI and ARI distribution for each etiological agent.", [["body", "ANATOMY", 51, 55], ["body", "ORGANISM_SUBDIVISION", 51, 55], ["FRI mono-infection", "PROBLEM", 71, 89], ["ARI distribution", "PROBLEM", 101, 117], ["mono-infection", "OBSERVATION", 75, 89]]], ["Only those with more than 20 cases detected in 2016 were shown Pathogen distribution in cases with three or more agents detected Twelve (1.1%) and three (0.3%) FRI samples had four and five pathogens detected.", [["samples", "ANATOMY", 164, 171], ["FRI samples", "CANCER", 160, 171], ["FRI samples", "TEST", 160, 171]]], ["Although these cases had a higher average body temperature, the differences did not reach statistical significance (Fig. 5, p = 0.2065, 0.", [["body", "ANATOMY", 42, 46], ["body", "ORGANISM_SUBDIVISION", 42, 46], ["a higher average body temperature", "PROBLEM", 25, 58], ["p", "TEST", 124, 125]]], ["3547, 0.9328).Other significant pathogens detected in 2016A total of 17 cases were found positive for B. pertussis in 2016.", [["B. pertussis", "ORGANISM", 102, 114], ["B. pertussis", "SPECIES", 102, 114], ["B. pertussis", "SPECIES", 102, 114], ["Other significant pathogens", "PROBLEM", 14, 41], ["B. pertussis", "PROBLEM", 102, 114], ["significant", "OBSERVATION_MODIFIER", 20, 31], ["pathogens", "OBSERVATION", 32, 41]]], ["Four cases presented as mono-infection for ARI and three cases for FRI category.", [["ARI", "DISEASE", 43, 46], ["ARI", "PROBLEM", 43, 46]]], ["The remaining 10 cases, B. pertussis was detected among the multiple pathogens, consisted of five cases for each of the ARI and FRI category.", [["ARI", "DISEASE", 120, 123], ["B. pertussis", "ORGANISM", 24, 36], ["B. pertussis", "SPECIES", 24, 36], ["B. pertussis", "SPECIES", 24, 36], ["B. pertussis", "PROBLEM", 24, 36], ["the multiple pathogens", "PROBLEM", 56, 78], ["the ARI", "PROBLEM", 116, 123], ["multiple", "OBSERVATION_MODIFIER", 60, 68], ["pathogens", "OBSERVATION", 69, 78]]], ["For N. meningitides, 27 cases were found positive in 2016.", [["N. meningitides", "ORGANISM", 4, 19], ["N. meningitides", "SPECIES", 4, 19], ["N. meningitides", "TEST", 4, 19]]], ["Six cases of mono-infection, make up of four ARI and two FRI cases.", [["mono-infection", "DISEASE", 13, 27], ["ARI", "DISEASE", 45, 48], ["mono-infection", "PROBLEM", 13, 27]]], ["The remaining cases were with multiple pathogens detected, consisted of eight ARI and 13 FRI cases respectively.", [["ARI", "DISEASE", 78, 81], ["multiple pathogens", "PROBLEM", 30, 48], ["eight ARI", "TEST", 72, 81], ["multiple", "OBSERVATION_MODIFIER", 30, 38], ["pathogens", "OBSERVATION", 39, 48]]], ["Finally, one case of ARI was found positive for Bocavirus.", [["ARI", "DISEASE", 21, 24], ["ARI", "PROBLEM", 21, 24], ["Bocavirus", "PROBLEM", 48, 57]]], ["It was a co-infection case, with 3 additional pathogens (Coronavirus OC43, Enterovirus, H. influenzae) detected together.DiscussionIn a 2006 study, Influenza A and B viruses were reported as important etiological agents for FRI cases among the recruits in Singapore [3] .", [["Enterovirus, H. influenzae)", "DISEASE", 75, 102], ["Influenza A and B viruses", "DISEASE", 148, 173], ["Coronavirus OC43", "ORGANISM", 57, 73], ["Enterovirus", "ORGANISM", 75, 86], ["H. influenzae", "ORGANISM", 88, 101], ["Influenza A", "ORGANISM", 148, 159], ["B viruses", "ORGANISM", 164, 173], ["H. influenzae", "SPECIES", 88, 101], ["H. influenzae", "SPECIES", 88, 101], ["Influenza A", "SPECIES", 148, 159], ["B viruses", "SPECIES", 164, 173], ["a co-infection case", "PROBLEM", 7, 26], ["3 additional pathogens", "PROBLEM", 33, 55], ["Coronavirus OC43", "PROBLEM", 57, 73], ["Enterovirus", "PROBLEM", 75, 86], ["H. influenzae", "PROBLEM", 88, 101], ["a 2006 study", "TEST", 134, 146], ["Influenza A and B viruses", "PROBLEM", 148, 173], ["co-infection", "OBSERVATION", 9, 21]]], ["Thirty-six percent of FRI cases were positive for Influenza A and B viruses.", [["Influenza A and B viruses", "DISEASE", 50, 75], ["Influenza A", "ORGANISM", 50, 61], ["B viruses", "ORGANISM", 66, 75], ["Influenza A", "SPECIES", 50, 61], ["FRI cases", "TEST", 22, 31], ["Influenza", "PROBLEM", 50, 59], ["B viruses", "PROBLEM", 66, 75]]], ["Numerous outbreaks of Influenza virus in military camps have been reported [6, 7] , reviewed in [1] ) and one study showed that the attack rate of influenza infection for cadet was four times higher than that observed in high rank officers (31.4% v.s.", [["Influenza virus", "DISEASE", 22, 37], ["influenza infection", "DISEASE", 147, 166], ["Influenza virus", "ORGANISM", 22, 37], ["Influenza virus", "SPECIES", 22, 37], ["Influenza virus", "SPECIES", 22, 37], ["Influenza virus", "PROBLEM", 22, 37], ["one study", "TEST", 106, 115], ["influenza infection", "PROBLEM", 147, 166], ["cadet", "TEST", 171, 176], ["outbreaks", "OBSERVATION_MODIFIER", 9, 18], ["Influenza virus", "OBSERVATION", 22, 37], ["influenza", "OBSERVATION_MODIFIER", 147, 156], ["infection", "OBSERVATION", 157, 166]]], ["To mitigate the burden of Influenza illness among recruits in Singapore, routine influenza vaccine has been given to recruits since 2010.", [["Influenza illness", "DISEASE", 26, 43], ["Influenza illness", "PROBLEM", 26, 43], ["routine influenza vaccine", "TREATMENT", 73, 98], ["Influenza", "OBSERVATION", 26, 35]]], ["Ho et al. reported that the strategy was effective in reducing the risk of A(H1N1)pdm09 virus and Influenza B infection, but not for Influenza A (H3N2) [5] .", [["Influenza B infection", "DISEASE", 98, 119], ["A(H1N1)pdm09 virus", "ORGANISM", 75, 93], ["Influenza B", "ORGANISM", 98, 109], ["Influenza A (H3N2) [5", "ORGANISM", 133, 154], ["H1N1)pdm09 virus", "SPECIES", 77, 93], ["Influenza", "SPECIES", 98, 107], ["A(H1N1)pdm09 virus", "SPECIES", 75, 93], ["Influenza B", "SPECIES", 98, 109], ["Influenza A (H3N2)", "SPECIES", 133, 151], ["A(H1N1)pdm09 virus", "PROBLEM", 75, 93], ["Influenza B infection", "PROBLEM", 98, 119], ["Influenza", "PROBLEM", 133, 142], ["infection", "OBSERVATION", 110, 119]]], ["Data presented in this study are consistent with Ho et al. [5] -A(H1N1)pdm09 virus was no longer a significant FRI etiological agent in 2016.", [["[5] -A", "CHEMICAL", 59, 65], ["[5] -A(H1N1)pdm09 virus", "ORGANISM", 59, 82], ["this study", "TEST", 18, 28], ["A(H1N1)pdm09 virus", "PROBLEM", 64, 82], ["consistent with", "UNCERTAINTY", 33, 48], ["no longer", "UNCERTAINTY", 87, 96]]], ["Apart from a small scale outbreak of Influenza B infections in early 2016, there were only sporadic Influenza B cases reported for the rest of the year.", [["Influenza B infections", "DISEASE", 37, 59], ["Influenza B", "DISEASE", 100, 111], ["Influenza B", "ORGANISM", 37, 48], ["Influenza B", "SPECIES", 37, 48], ["Influenza B infections", "PROBLEM", 37, 59], ["sporadic Influenza B cases", "PROBLEM", 91, 117], ["small", "OBSERVATION_MODIFIER", 13, 18], ["scale", "OBSERVATION_MODIFIER", 19, 24], ["outbreak", "OBSERVATION_MODIFIER", 25, 33], ["Influenza B infections", "OBSERVATION", 37, 59], ["sporadic", "OBSERVATION_MODIFIER", 91, 99], ["Influenza", "OBSERVATION", 100, 109]]], ["The outbreak coincided with the prevalence of Influenza B in the community during that period.", [["Influenza B", "DISEASE", 46, 57], ["Influenza B", "ORGANISM", 46, 57], ["Influenza B", "PROBLEM", 46, 57], ["Influenza", "OBSERVATION", 46, 55]]], ["Similarly, during the H3 outbreak which peaked between Week 28-32, H3N2 Influenza A virus was the dominant circulating strain (82.6%-88.7%) in the community [8] .DiscussionAlthough recruits had restricted access to the community during the training period, other military personnel, that are not required to reside in camps at night, could carry the circulating strains from the community back to the camps to start the outbreaks.", [["H3N2", "ORGANISM", 67, 71], ["Influenza A virus", "ORGANISM", 72, 89], ["H3N2 Influenza A virus", "SPECIES", 67, 89], ["Influenza A virus", "SPECIES", 72, 89], ["the H3 outbreak", "PROBLEM", 18, 33], ["H3N2 Influenza A virus", "PROBLEM", 67, 89], ["the dominant circulating strain", "PROBLEM", 94, 125], ["the circulating strains", "PROBLEM", 346, 369]]], ["Given the dramatic reduction in FRI cases caused by Influenza A and B In the 2005 outbreak, 30 recruits were affected, and body ache, headache and nasal congestion were the most frequently reported symptoms.", [["body", "ANATOMY", 123, 127], ["nasal", "ANATOMY", 147, 152], ["Influenza A and B", "DISEASE", 52, 69], ["body ache", "DISEASE", 123, 132], ["headache", "DISEASE", 134, 142], ["nasal congestion", "DISEASE", 147, 163], ["body", "ORGANISM_SUBDIVISION", 123, 127], ["ache", "ORGANISM_SUBDIVISION", 128, 132], ["nasal", "ORGANISM_SUBDIVISION", 147, 152], ["Influenza A", "SPECIES", 52, 63], ["the dramatic reduction in FRI cases", "PROBLEM", 6, 41], ["Influenza A", "PROBLEM", 52, 63], ["body ache", "PROBLEM", 123, 132], ["headache", "PROBLEM", 134, 142], ["nasal congestion", "PROBLEM", 147, 163], ["symptoms", "PROBLEM", 198, 206], ["dramatic", "OBSERVATION_MODIFIER", 10, 18], ["reduction", "OBSERVATION_MODIFIER", 19, 28], ["Influenza", "OBSERVATION", 52, 61], ["nasal", "ANATOMY", 147, 152], ["congestion", "OBSERVATION", 153, 163]]], ["Adenovirus 11a was subsequently identified as the causative agent of that outbreak [9] .", [["Adenovirus 11a", "ORGANISM", 0, 14], ["Adenovirus", "SPECIES", 0, 10], ["Adenovirus", "PROBLEM", 0, 10]]], ["Adenovirus type 4, the only member in the species E, was also detected among military personnel with FRI in another study conducted between 2011 and 2012 [10] .", [["Adenovirus type 4", "ORGANISM", 0, 17], ["Adenovirus type 4", "PROBLEM", 0, 17]]], ["Currently, addition experiments are underway to better characterize the 2016 isolates and whether there are any new mutations in the viral genome.", [["viral genome", "DNA", 133, 145], ["any new mutations in the viral genome", "PROBLEM", 108, 145], ["new", "OBSERVATION_MODIFIER", 112, 115], ["mutations", "OBSERVATION", 116, 125], ["viral genome", "OBSERVATION", 133, 145]]], ["While the majority of adenoviral infections cause mild symptoms and are self-limiting, cases of fatality have been reported in other military forces [11] [12] [13] .", [["adenoviral infections", "DISEASE", 22, 43], ["fatality", "DISEASE", 96, 104], ["adenoviral", "ORGANISM", 22, 32], ["adenoviral", "SPECIES", 22, 32], ["adenoviral infections", "PROBLEM", 22, 43], ["mild symptoms", "PROBLEM", 50, 63], ["fatality", "PROBLEM", 96, 104], ["mild", "OBSERVATION_MODIFIER", 50, 54]]], ["In 2011, an outbreak of Adenovirus Type 7 was reported in a Malaysian police training centre, affecting 851 trainees, with 100 being hospitalized and 3 deaths [13] .", [["Adenovirus Type", "DISEASE", 24, 39], ["deaths", "DISEASE", 152, 158], ["Adenovirus Type 7", "ORGANISM", 24, 41], ["Adenovirus Type 7", "SPECIES", 24, 41]]], ["More recently, HDAdV-55 was found to be responsible for an outbreak among Korean military personnel with 1 case of fatality [11] .", [["HDAdV-55", "CHEMICAL", 15, 23], ["HDAdV-55", "GENE_OR_GENE_PRODUCT", 15, 23], ["HDAdV", "PROTEIN", 15, 20], ["HDAdV-55", "SPECIES", 15, 23], ["HDAdV", "TEST", 15, 20]]], ["Adenovirus B was also found to be responsible for febrile respiratory illness in a military training camp in China [14] .", [["respiratory", "ANATOMY", 58, 69], ["febrile respiratory illness", "DISEASE", 50, 77], ["Adenovirus B", "ORGANISM", 0, 12], ["Adenovirus B", "SPECIES", 0, 12], ["Adenovirus B", "PROBLEM", 0, 12], ["febrile respiratory illness", "PROBLEM", 50, 77]]], ["Serological surveillance on US military basic trainees showed that 66% and 73% of trainees were susceptible to Adenovirus Type 4 and 7 [15] .", [["Adenovirus Type 4", "ORGANISM", 111, 128], ["Serological surveillance", "TEST", 0, 24]]], ["Viral genetic material and virus could be recovered from various environmental samples, such as lockers, rifles, pillows, highlighting the possibility of transmission among the recruits.", [["samples", "ANATOMY", 79, 86], ["Viral genetic material", "PROBLEM", 0, 22], ["virus", "PROBLEM", 27, 32], ["pillows", "TREATMENT", 113, 120], ["virus", "OBSERVATION", 27, 32]]], ["For countermeasures, live oral vaccines against Types 4 and 7 have been given to the US army recruits from 1971 to 1999.", [["oral", "ANATOMY", 26, 30], ["oral", "ORGANISM_SUBDIVISION", 26, 30], ["countermeasures", "TREATMENT", 4, 19], ["live oral vaccines", "TREATMENT", 21, 39]]], ["Following the cessation of the vaccination programme between 1999 and 2011, there was a resurgence of adenovirus outbreaks [17] .", [["adenovirus", "ORGANISM", 102, 112], ["adenovirus outbreaks", "PROBLEM", 102, 122]]], ["The vaccination programme was re-introduced in 2011 and resulted in a dramatic reduction in cases, demonstrating the effectiveness of vaccination in controlling adenovirus respiratory illnesses among this high risk group [18] .DiscussionPertusis is another vaccine-preventable disease and pertussis vaccination has been given to all newborns in Singapore since 1957 [19] and sero-prevalence of pertussis antibodies in the adult population of Singapore (18-45 years) was 97% in 2002 [20] .", [["adenovirus respiratory illnesses", "DISEASE", 161, 193], ["DiscussionPertusis", "CHEMICAL", 227, 245], ["pertussis", "CHEMICAL", 289, 298], ["pertussis", "DISEASE", 394, 403], ["adenovirus", "ORGANISM", 161, 171], ["newborns", "ORGANISM", 333, 341], ["pertussis", "ORGANISM", 394, 403], ["pertussis antibodies", "PROTEIN", 394, 414], ["adenovirus", "SPECIES", 161, 171], ["The vaccination programme", "TREATMENT", 0, 25], ["a dramatic reduction in cases", "PROBLEM", 68, 97], ["vaccination", "TREATMENT", 134, 145], ["controlling adenovirus respiratory illnesses", "PROBLEM", 149, 193], ["another vaccine", "TREATMENT", 249, 264], ["preventable disease", "PROBLEM", 265, 284], ["pertussis vaccination", "TREATMENT", 289, 310], ["pertussis antibodies", "PROBLEM", 394, 414], ["dramatic", "OBSERVATION_MODIFIER", 70, 78], ["reduction", "OBSERVATION_MODIFIER", 79, 88]]], ["In 2015, there was a total of 56 local cases of pertussis reported in Singapore, a rise from the 19 cases in 2014.", [["pertussis", "DISEASE", 48, 57], ["pertussis", "PROBLEM", 48, 57]]], ["As vaccine-induced antibodies begin to wan significantly 4 years after the last dose [21] , a booster could be beneficial for optimal protection of the recruits against this highly contagious bacterial disease.DiscussionSuch benefit has recently been reported from a study involving military conscripts from Finland [22] .", [["bacterial disease", "DISEASE", 192, 209], ["vaccine-induced antibodies", "PROTEIN", 3, 29], ["vaccine", "TREATMENT", 3, 10], ["induced antibodies", "PROBLEM", 11, 29], ["a booster", "TREATMENT", 92, 101], ["this highly contagious bacterial disease", "PROBLEM", 169, 209], ["a study", "TEST", 265, 272], ["contagious", "OBSERVATION_MODIFIER", 181, 191], ["bacterial disease", "OBSERVATION", 192, 209]]], ["No cases for Adenovirus or Influenza A virus were reported during the study period.", [["Influenza A virus", "DISEASE", 27, 44], ["Adenovirus", "ORGANISM", 13, 23], ["Influenza A virus", "ORGANISM", 27, 44], ["Influenza A virus", "SPECIES", 27, 44], ["Adenovirus", "SPECIES", 13, 23], ["Influenza A virus", "SPECIES", 27, 44], ["Adenovirus", "PROBLEM", 13, 23], ["Influenza A virus", "PROBLEM", 27, 44], ["the study", "TEST", 66, 75]]], ["A high isolation rate of Adenovirus was reported in a study in Korea [24] .", [["Adenovirus", "ORGANISM", 25, 35], ["Adenovirus", "SPECIES", 25, 35], ["A high isolation rate of Adenovirus", "PROBLEM", 0, 35], ["a study", "TEST", 52, 59]]], ["However, another study performed in Korea, found that Rhinovirus, Enterovirus and Coronavirus OC43 were commonly found in recruits with respiratory symptom [25] .", [["respiratory", "ANATOMY", 136, 147], ["Enterovirus", "DISEASE", 66, 77], ["Enterovirus", "ORGANISM", 66, 77], ["Coronavirus OC43", "ORGANISM", 82, 98], ["another study", "TEST", 9, 22], ["Rhinovirus", "PROBLEM", 54, 64], ["Enterovirus", "PROBLEM", 66, 77], ["Coronavirus OC43", "PROBLEM", 82, 98], ["respiratory symptom", "PROBLEM", 136, 155], ["Rhinovirus", "OBSERVATION", 54, 64]]], ["Using paired samples, Eslami-Nejad et al. showed an increase in N. meningitidis carrier rate when recruits in Iran completed their basic training course [26] .", [["N. meningitidis", "ORGANISM", 64, 79], ["N. meningitidis", "SPECIES", 64, 79], ["N. meningitidis", "SPECIES", 64, 79], ["an increase in N. meningitidis", "PROBLEM", 49, 79], ["increase", "OBSERVATION_MODIFIER", 52, 60], ["N. meningitidis", "OBSERVATION", 64, 79]]], ["Similarly, bacterial infections caused by B. pertussis, Chlamydia pneumoniae, Mycoplasma pneumoniae could have occurred among the military service members deployed to Afghanistan [27] .", [["bacterial infections", "DISEASE", 11, 31], ["Chlamydia pneumoniae", "DISEASE", 56, 76], ["Mycoplasma pneumoniae", "DISEASE", 78, 99], ["B. pertussis", "ORGANISM", 42, 54], ["Chlamydia pneumoniae", "ORGANISM", 56, 76], ["Mycoplasma pneumoniae", "ORGANISM", 78, 99], ["B. pertussis", "SPECIES", 42, 54], ["Chlamydia pneumoniae", "SPECIES", 56, 76], ["Mycoplasma pneumoniae", "SPECIES", 78, 99], ["B. pertussis", "SPECIES", 42, 54], ["Chlamydia pneumoniae", "SPECIES", 56, 76], ["Mycoplasma pneumoniae", "SPECIES", 78, 99], ["bacterial infections", "PROBLEM", 11, 31], ["B. pertussis", "PROBLEM", 42, 54], ["Chlamydia pneumoniae", "PROBLEM", 56, 76], ["Mycoplasma pneumoniae", "PROBLEM", 78, 99], ["bacterial", "OBSERVATION_MODIFIER", 11, 20], ["infections", "OBSERVATION", 21, 31], ["Mycoplasma pneumoniae", "OBSERVATION", 78, 99]]], ["Clearly, multiple factors like the study population, the seasonality of the study period, the type of samples collected, the geographical location of the study, the level of herd immunity of the locals and the exposure of novel pathogens in a new operational environmentall could influence the type and variety of etiological agents to be found and reported in these studies.DiscussionFRI cases have been the main focus of our previous studies and they have provided valuable insights on the importance of various pathogens responsible for febrile respiratory illnesses in military recruits in Singapore [2, 3] .", [["respiratory", "ANATOMY", 548, 559], ["febrile respiratory illnesses", "DISEASE", 540, 569], ["herd", "ORGANISM_SUBDIVISION", 174, 178], ["the study", "TEST", 72, 81], ["the study", "TEST", 150, 159], ["novel pathogens", "PROBLEM", 222, 237], ["etiological agents", "TREATMENT", 314, 332], ["these studies", "TEST", 361, 374], ["our previous studies", "TEST", 423, 443], ["various pathogens", "PROBLEM", 506, 523], ["febrile respiratory illnesses", "PROBLEM", 540, 569]]], ["They also led to the implementation of effective countermeasures for better protection of the recruits.", [["effective countermeasures", "TREATMENT", 39, 64]]], ["The current study expanded from the previous studies by including respiratory cases without fever, so as to gain a more comprehensive understanding on the etiological agents circulating among the recruits.", [["fever", "DISEASE", 92, 97], ["The current study", "TEST", 0, 17], ["the previous studies", "TEST", 32, 52], ["fever", "PROBLEM", 92, 97]]], ["Data from this expanded study revealed that while Rhinovirus has been an important etiological agent for FRI cases, it plays an even bigger role for ARI cases.", [["Rhinovirus", "CHEMICAL", 50, 60], ["ARI", "DISEASE", 149, 152], ["Rhinovirus", "GENE_OR_GENE_PRODUCT", 50, 60], ["this expanded study", "TEST", 10, 29], ["Rhinovirus", "PROBLEM", 50, 60], ["ARI cases", "PROBLEM", 149, 158]]], ["Similarly, most of the cases caused by Parainfluenza 4 were presented as ARI cases.", [["ARI", "DISEASE", 73, 76], ["Parainfluenza", "PROBLEM", 39, 52], ["Parainfluenza", "OBSERVATION", 39, 52]]], ["Additionally, the most common ARI agents involved in dual infections were Rhinovirus and H. influenzae, while Adenovirus E and H. influenzae were commonly detected together in FRI cases.", [["infections", "DISEASE", 58, 68], ["Rhinovirus and H. influenzae", "DISEASE", 74, 102], ["H. influenzae", "ORGANISM", 89, 102], ["Adenovirus E", "ORGANISM", 110, 122], ["H. influenzae", "ORGANISM", 127, 140], ["H. influenzae", "SPECIES", 89, 102], ["H. influenzae", "SPECIES", 127, 140], ["H. influenzae", "SPECIES", 89, 102], ["Adenovirus E", "SPECIES", 110, 122], ["H. influenzae", "SPECIES", 127, 140], ["dual infections", "PROBLEM", 53, 68], ["Rhinovirus", "PROBLEM", 74, 84], ["H. influenzae", "PROBLEM", 89, 102], ["Adenovirus E", "TREATMENT", 110, 122], ["H. influenzae", "PROBLEM", 127, 140]]], ["In view of the new perspectives and insights into respiratory infections among recruits, gleaned from our findings, a surveillance programme with a wider scope should be continued.DiscussionThere are limitations to the present study.", [["respiratory", "ANATOMY", 50, 61], ["respiratory infections", "DISEASE", 50, 72], ["respiratory infections", "PROBLEM", 50, 72], ["a surveillance programme", "TEST", 116, 140], ["a wider scope", "TREATMENT", 146, 159], ["the present study", "TEST", 215, 232], ["new", "OBSERVATION_MODIFIER", 15, 18], ["respiratory", "ANATOMY", 50, 61], ["infections", "OBSERVATION", 62, 72]]], ["Firstly, some bacterial pathogens, such as H. influenzae and N. meningitidis, are present as commensals in certain individuals.", [["H. influenzae", "ORGANISM", 43, 56], ["N. meningitidis", "ORGANISM", 61, 76], ["H. influenzae", "SPECIES", 43, 56], ["N. meningitidis", "SPECIES", 61, 76], ["H. influenzae", "SPECIES", 43, 56], ["N. meningitidis", "SPECIES", 61, 76], ["some bacterial pathogens", "PROBLEM", 9, 33], ["H. influenzae", "PROBLEM", 43, 56], ["N. meningitidis", "PROBLEM", 61, 76], ["bacterial", "OBSERVATION_MODIFIER", 14, 23], ["pathogens", "OBSERVATION", 24, 33], ["meningitidis", "OBSERVATION", 64, 76]]], ["Detection of Rhinoviruses from asymptomatic individuals has been reported [28] , therefore, positive detection in the sample may not indicate that they are the etiological agents responsible for the disease.", [["sample", "ANATOMY", 118, 124], ["Rhinoviruses", "DISEASE", 13, 25], ["Rhinoviruses", "CANCER", 13, 25], ["Rhinoviruses", "PROBLEM", 13, 25], ["asymptomatic individuals", "PROBLEM", 31, 55], ["the disease", "PROBLEM", 195, 206], ["Rhinoviruses", "OBSERVATION", 13, 25]]], ["Similarly, for samples with multiple pathogens detected, it is not feasible to determine the respective contribution of each pathogen to the disease.", [["samples", "ANATOMY", 15, 22], ["multiple pathogens", "PROBLEM", 28, 46], ["the disease", "PROBLEM", 137, 148], ["disease", "OBSERVATION", 141, 148]]], ["Further investigations are needed to determine the clinical relevance of coinfections and their management.", [["coinfections", "DISEASE", 73, 85], ["Further investigations", "TEST", 0, 22], ["coinfections", "PROBLEM", 73, 85], ["their management", "TREATMENT", 90, 106], ["coinfections", "OBSERVATION", 73, 85]]], ["Secondly, our study was limited to pathogen identification, without consideration of the pathogen load in the sample.", [["sample", "ANATOMY", 110, 116], ["our study", "TEST", 10, 19], ["pathogen identification", "TEST", 35, 58], ["the pathogen load in the sample", "TEST", 85, 116]]], ["Thirdly, the study focused mainly on respiratory symptoms and did not track other serious conditions such as meningitis.", [["respiratory", "ANATOMY", 37, 48], ["meningitis", "DISEASE", 109, 119], ["the study", "TEST", 9, 18], ["respiratory symptoms", "PROBLEM", 37, 57], ["serious conditions", "PROBLEM", 82, 100], ["meningitis", "PROBLEM", 109, 119], ["meningitis", "OBSERVATION", 109, 119]]], ["Fourthly, due to the large number of samples, pathogen isolation from samples could not be done for further verification of the findings.", [["samples", "ANATOMY", 37, 44], ["samples", "ANATOMY", 70, 77], ["samples", "CANCER", 37, 44], ["samples", "CANCER", 70, 77], ["pathogen isolation from samples", "TEST", 46, 77], ["large", "OBSERVATION_MODIFIER", 21, 26]]], ["In addition, the sample size of the control samples was small.", [["samples", "ANATOMY", 44, 51], ["samples", "CANCER", 44, 51], ["the control samples", "TEST", 32, 51], ["size", "OBSERVATION_MODIFIER", 24, 28], ["small", "OBSERVATION_MODIFIER", 56, 61]]], ["Fifthly, since the classification of ARI and FRI is based on a single temperature measurement, we could not rule out the possibility that some ARI cases could have become FRI cases subsequently.", [["ARI", "DISEASE", 37, 40], ["ARI", "DISEASE", 143, 146], ["FRI", "DNA", 45, 48], ["ARI", "PROBLEM", 37, 40], ["a single temperature measurement", "TEST", 61, 93], ["some ARI cases", "PROBLEM", 138, 152]]], ["Lastly, the study predominantly involved young adult males in a semi-closed military setting, hence the findings reported in this study might not be applicable to the adult general population.ConclusionThe current study describes the etiological agents responsible for FRI and ARI among the military recruits in the tropical urban setting.", [["ARI", "DISEASE", 277, 280], ["the study", "TEST", 8, 17], ["this study", "TEST", 125, 135], ["The current study", "TEST", 202, 219], ["FRI", "PROBLEM", 269, 272], ["ARI", "PROBLEM", 277, 280]]], ["By studying both FRI and ARI cases in the same study period, it allowed a more complete picture of the respiratory pathogens circulating in the training camp.", [["respiratory", "ANATOMY", 103, 114], ["ARI", "DISEASE", 25, 28], ["the respiratory pathogens", "PROBLEM", 99, 124], ["respiratory", "ANATOMY", 103, 114], ["pathogens", "OBSERVATION", 115, 124]]], ["It also provides us with an unbiased assessment of the overall impact of a particular pathogen in causing respiratory illnesses.", [["respiratory", "ANATOMY", 106, 117], ["respiratory illnesses", "DISEASE", 106, 127], ["an unbiased assessment", "TEST", 25, 47], ["a particular pathogen", "PROBLEM", 73, 94], ["respiratory illnesses", "PROBLEM", 106, 127], ["respiratory illnesses", "OBSERVATION", 106, 127]]], ["This is exemplified with the observation that Rhinovirus, apart from being an important FRI agent, it plays an even bigger role for ARI cases.", [["ARI", "DISEASE", 132, 135], ["Rhinovirus", "PROBLEM", 46, 56], ["an important FRI agent", "TREATMENT", 75, 97], ["ARI cases", "PROBLEM", 132, 141], ["Rhinovirus", "OBSERVATION", 46, 56]]], ["With the rise in FRI cases by Adenovirus infection, apart from promoting personal hygiene awareness, it may be worthwhile to evaluate the risk-to-benefit ratio for introducing adenovirus vaccination to the recruits.", [["Adenovirus infection", "DISEASE", 30, 50], ["Adenovirus", "ORGANISM", 30, 40], ["adenovirus", "ORGANISM", 176, 186], ["Adenovirus", "SPECIES", 30, 40], ["adenovirus", "SPECIES", 176, 186], ["Adenovirus infection", "PROBLEM", 30, 50], ["ratio", "TREATMENT", 154, 159], ["introducing adenovirus vaccination", "TREATMENT", 164, 198], ["rise", "OBSERVATION_MODIFIER", 9, 13], ["infection", "OBSERVATION", 41, 50]]]], "77c9efeead1c9a877c5ce0192f00188537de235a": [["INTRODUCTION.There is already abundant information on the new coronavirus and its spread worldwide [1] [2] [3] , as well as the risks it poses to the population.", [["coronavirus", "DISEASE", 62, 73], ["coronavirus", "ORGANISM", 62, 73], ["the new coronavirus", "PROBLEM", 54, 73]]], ["The person infected with the severe acute respiratory syndrome coronavirus 2 (SARS-cov-2) [4] may develop the disease called COVID-19, which manifests with mild to severe symptoms of fever, cough, shortness of breath and other signs [5] .", [["acute respiratory syndrome coronavirus", "DISEASE", 36, 74], ["fever", "DISEASE", 183, 188], ["cough", "DISEASE", 190, 195], ["shortness of breath", "DISEASE", 197, 216], ["person", "SPECIES", 4, 10], ["severe acute respiratory syndrome coronavirus", "SPECIES", 29, 74], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 25, 74], ["the disease", "PROBLEM", 106, 117], ["COVID", "TEST", 125, 130], ["mild to severe symptoms", "PROBLEM", 156, 179], ["fever", "PROBLEM", 183, 188], ["cough", "PROBLEM", 190, 195], ["shortness of breath", "PROBLEM", 197, 216], ["severe", "OBSERVATION_MODIFIER", 29, 35], ["acute", "OBSERVATION_MODIFIER", 36, 41], ["respiratory syndrome", "OBSERVATION", 42, 62], ["disease", "OBSERVATION", 110, 117], ["mild", "OBSERVATION_MODIFIER", 156, 160], ["severe", "OBSERVATION_MODIFIER", 164, 170]]], ["In the most severe cases, the infection can lead to the development of acute respiratory distress syndrome (ARDS) causing respiratory failure, septic shock, or multiorgan failure, and even death [6] .INTRODUCTION.There is yet a lot about this new coronavirus that is still unknown.", [["respiratory", "ANATOMY", 77, 88], ["respiratory", "ANATOMY", 122, 133], ["multiorgan", "ANATOMY", 160, 170], ["infection", "DISEASE", 30, 39], ["acute respiratory distress syndrome", "DISEASE", 71, 106], ["ARDS", "DISEASE", 108, 112], ["respiratory failure", "DISEASE", 122, 141], ["septic shock", "DISEASE", 143, 155], ["multiorgan failure", "DISEASE", 160, 178], ["death", "DISEASE", 189, 194], ["coronavirus", "DISEASE", 247, 258], ["coronavirus", "ORGANISM", 247, 258], ["the infection", "PROBLEM", 26, 39], ["acute respiratory distress syndrome", "PROBLEM", 71, 106], ["ARDS", "PROBLEM", 108, 112], ["respiratory failure", "PROBLEM", 122, 141], ["septic shock", "PROBLEM", 143, 155], ["multiorgan failure", "PROBLEM", 160, 178], ["this new coronavirus", "PROBLEM", 238, 258], ["most severe", "OBSERVATION_MODIFIER", 7, 18], ["infection", "OBSERVATION", 30, 39], ["acute", "OBSERVATION_MODIFIER", 71, 76], ["respiratory distress syndrome", "OBSERVATION", 77, 106], ["respiratory failure", "OBSERVATION", 122, 141], ["septic shock", "OBSERVATION", 143, 155], ["multiorgan failure", "OBSERVATION", 160, 178], ["coronavirus", "OBSERVATION", 247, 258]]], ["Studies suggest that the case fatality rate of the virus is of about 3.5% in mainland China, but the authors suggest considering the range 0.2-3.0% [7] .", [["the virus", "PROBLEM", 47, 56], ["virus", "OBSERVATION", 51, 56]]], ["However, this value seems to be much higher in Italy [8] , suggesting its strong dependence on demographics.", [["strong", "OBSERVATION_MODIFIER", 74, 80], ["dependence", "OBSERVATION", 81, 91]]], ["In fact, the Chinese Center for Disease Control, released an analysis that showed that the case fatality rate ranged from 0% in children aged 0-9 years old to 14.8% in those over 80 [9] , which implies that countries with a high number of elderly citizens, as is the case of Italy and Portugal, are more prone to having higher death rates.", [["death", "DISEASE", 327, 332], ["children", "ORGANISM", 128, 136], ["children", "SPECIES", 128, 136], ["Disease Control", "TREATMENT", 32, 47], ["an analysis", "TEST", 58, 69], ["the case fatality rate", "TEST", 87, 109], ["higher death rates", "PROBLEM", 320, 338]]], ["The quick spread of the virus in Europe has led the WHO to declare Europe as the new epicentre of the disease on the 13th of March of 2020 [10] .", [["the virus", "PROBLEM", 20, 29], ["the disease", "PROBLEM", 98, 109], ["virus", "OBSERVATION", 24, 29], ["new", "OBSERVATION_MODIFIER", 81, 84], ["disease", "OBSERVATION", 102, 109]]], ["The rapid growth of the number of active cases presenting severe symptoms has saturated the health services in most countries in the continent, especially in Italy [11] .", [["severe symptoms", "PROBLEM", 58, 73], ["rapid", "OBSERVATION_MODIFIER", 4, 9], ["growth", "OBSERVATION_MODIFIER", 10, 16], ["active", "OBSERVATION_MODIFIER", 34, 40], ["severe", "OBSERVATION_MODIFIER", 58, 64]]], ["It is yet unknown when the epidemic will reach an end, but governments throughout Europe have implemented harsh measures to prevent and mitigate the spread of the virus.", [["harsh measures", "TREATMENT", 106, 120], ["the virus", "PROBLEM", 159, 168]]], ["Yet, as of today there are as many as 77,394 confirmed cases on the European continent, in 46 territories, resulting in 3,457 deaths, and rising [2] [3] .", [["deaths", "DISEASE", 126, 132]]], ["As of today, there are 642 confirmed cases, 2 deaths, and 3 recovered [12] .", [["deaths", "DISEASE", 46, 52]]], ["In this study, I adapted a model of the SIR type used in South-Korea to model the evolution of the active cases of the MERS outbreak in the country back in 2015 [13] .", [["MERS", "DISEASE", 119, 123], ["this study", "TEST", 3, 13], ["active", "OBSERVATION_MODIFIER", 99, 105]]], ["Although there are other models being used [14] [15] , this model seemed most appropriate given that the MERS and the SARS-cov-2 are related illnesses, both provoked by a coronavirus strand, and with similar symptoms, although MERS was much deadlier.", [["SARS", "DISEASE", 118, 122], ["cov-2", "GENE_OR_GENE_PRODUCT", 123, 128], ["coronavirus", "ORGANISM", 171, 182], ["illnesses", "PROBLEM", 141, 150], ["a coronavirus strand", "PROBLEM", 169, 189], ["similar symptoms", "PROBLEM", 200, 216], ["coronavirus strand", "OBSERVATION", 171, 189]]], ["This allowed me to fit the curve of current active cases in Portugal with a model, which I then use, by implementing the control measure parameters predicted in the model to predict the future number of cases, in three different scenarios (the outof-control scenario, a scenario in which the government is successful in applying control measures and citizens mildly adhere to self-protection measures, and a scenario in which the government fails to completely apply control measures, yet citizens still adhere to some measure of self-protection).METHODOLOGY.The model used is the model described in Xia et al [13] , which can be understood by the flow diagram shown in figure 1 (which was taken from the paper, page 4).", [["control measures", "TREATMENT", 329, 345], ["self-protection measures", "TREATMENT", 376, 400], ["control measures", "TREATMENT", 467, 483], ["self-protection", "TREATMENT", 530, 545], ["the flow diagram", "TEST", 644, 660]]], ["In this model, S corresponds to the number of susceptible individuals; E, the number of exposed individuals; A, the number of asymptomatic infected cases; I, the total number of mild-to-severe infected patients.", [["patients", "ORGANISM", 202, 210], ["patients", "SPECIES", 202, 210], ["susceptible individuals", "PROBLEM", 46, 69], ["asymptomatic infected cases", "PROBLEM", 126, 153], ["mild-to-severe infected patients", "PROBLEM", 178, 210], ["susceptible", "OBSERVATION_MODIFIER", 46, 57], ["individuals", "OBSERVATION", 58, 69], ["asymptomatic", "OBSERVATION_MODIFIER", 126, 138], ["infected", "OBSERVATION", 139, 147], ["mild", "OBSERVATION_MODIFIER", 178, 182], ["-to-severe", "OBSERVATION_MODIFIER", 182, 192], ["infected", "OBSERVATION", 193, 201]]], ["H, the number of hospitalized cases; R, the number of removed cases, and finally N, the total population of Portugal.METHODOLOGY.\u03b21 is the transmission coefficient of the asymptomatic infected cases, \u03b22 is the transmission coefficient of the symptomatic infected cases (mild infected person and severe patients) to the susceptible, \u03b23 is the transmission coefficient of the hospitalized cases to the susceptible, 1/\uf073 is the mean incubation period, 1/\uf06c is the mean time between symptom onset to hospitalization, 1/k1 is the mean infectious period of asymptomatic infected person for survivors, 1/k2 is the mean duration for hospitalized cases for survivors, 1/\uf064 is the mean time from hospitalization to death, \u03b3 is the clinical outbreak rate in all the infected cases.", [["death", "DISEASE", 702, 707], [".\u03b21", "GENE_OR_GENE_PRODUCT", 128, 131], ["\u03b22", "GENE_OR_GENE_PRODUCT", 200, 202], ["patients", "ORGANISM", 302, 310], ["\u03b23", "GENE_OR_GENE_PRODUCT", 332, 334], [".\u03b21", "PROTEIN", 128, 131], ["person", "SPECIES", 284, 290], ["patients", "SPECIES", 302, 310], ["person", "SPECIES", 571, 577], ["the symptomatic infected cases", "PROBLEM", 238, 268], ["symptomatic", "OBSERVATION_MODIFIER", 242, 253], ["infected", "OBSERVATION", 254, 262], ["mild", "OBSERVATION_MODIFIER", 270, 274], ["infected", "OBSERVATION", 752, 760]]], ["Flow chart of the SIR-type model used in this work, taken from [13] The set of differential equations can then be written as: (1)METHODOLOGY.Given that the available data for covid-19 is still very preliminary, the model was further adapted. the only parameters that were considered \"known\" were the mean incubation time, which was taken as 1/\uf073 =5.1 days from the literature (here using the median as equal to the mean) [16] , and the mean infectious period of asymptomatic people, where a conservative estimate of 1/k1=14 days was used.", [["people", "ORGANISM", 474, 480], ["people", "SPECIES", 474, 480], ["covid", "TEST", 175, 180], ["infectious", "OBSERVATION_MODIFIER", 440, 450]]], ["Finally, unlike Xia et al [13] , I consider that the epidemic starts with only one person infected (I0=1), being the rest of the values 0, except for S0 which is simply N-1.", [["person", "SPECIES", 83, 89]]], ["See table 1 for a breakdown of the different parameters of this model.METHODOLOGY.The solving of the system of differential equations was performed using the Mathematica code [17] , which also allows for the use of fittable parameters, using the function \"NonLinearModelFit\" [18] .", [["a breakdown", "PROBLEM", 16, 27], ["differential equations", "TEST", 111, 133], ["fittable parameters", "TREATMENT", 215, 234]]], ["In order to determine the parameters \uf06c\uf02c \uf064\uf02c I used the number of deaths, as reported by the Italian ministry of Health and available online [19] .", [["deaths", "DISEASE", 64, 70]]], ["After determining the values for these parameters, they were used to fit the curve of infected cases for Portugal, where the values of \uf062=\uf062\uf031=\uf062\uf032=\uf062\uf033 and \uf067 were fitted to obtain a model.", [["the values", "TEST", 121, 131]]], ["This model was then used to estimate the future evolution of future cases in Portugal, according to three different scenarios:METHODOLOGY.\u2022 Out-of-control scenario (nothing done, the virus is free to spread);METHODOLOGY.\u2022 Scenario in which the government takes severe mitigating measures and the population mildly adheres to self-protecting measures; \u2022 Scenario in which the government fails to implement mitigating measures, yet still implements some, and the population mildly adheres to selfprotecting measures.RESULTS.3.1.", [["Out-of-control scenario", "TREATMENT", 140, 163], ["the virus", "PROBLEM", 179, 188], ["Scenario", "TREATMENT", 222, 230], ["severe mitigating measures", "TREATMENT", 261, 287], ["self-protecting measures", "TREATMENT", 325, 349], ["mitigating measures", "TREATMENT", 405, 424], ["selfprotecting measures", "TREATMENT", 490, 513]]], ["Fitting of parameters \uf06c and \uf064 (Italy).RESULTS.The number of deaths in Italy was taken from [18], and the set of differential equations described in eq.", [["deaths", "DISEASE", 60, 66], ["differential equations", "TEST", 112, 134]]], ["1 fitted to obtain the best possible fit for parameters \uf06c and \uf064\uf02e An R2 value of 0.99255 was obtain with the fit.", [["parameters", "TEST", 45, 55], ["An R2 value", "TEST", 65, 76]]], ["Results are shown in figure 1. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not peer-reviewed)The copyright holder for this preprint . https://doi.org/10.1101/2020.03.18.20038612 doi: medRxiv preprint(which was not peer-reviewed)As can be seen, in the case of recovered cases, the fit has not the same quality as the fit in 3.1.", [["The copyright holder", "TREATMENT", 154, 174], ["this preprint", "TREATMENT", 179, 192], ["med", "ANATOMY", 69, 72]]], ["1 to the number of Portuguese active cases, in order to determine the value of \uf062 and \uf067\uf02e The number of Portuguese active cases was taken from [20], which is updated daily.(which was not peer-reviewed)The values previously obtained of parameters \uf06c\uf02c \uf064\uf02c and k2 were used.", [["The values", "TEST", 199, 209], ["parameters", "TEST", 233, 243]]], ["As explained previously, because the fitting was difficult to obtain, as a first approximation, we considered \u03b21= \u03b22 = \u03b23.", [["\u03b23", "GENE_OR_GENE_PRODUCT", 119, 121], ["\u03b23", "PROTEIN", 119, 121]]], ["The obtained values for \uf062 and \uf067 are given in table 4. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not peer-reviewed)The copyright holder for this preprint .", [["The copyright holder", "TREATMENT", 177, 197], ["this preprint", "TREATMENT", 202, 215], ["med", "ANATOMY", 92, 95]]], ["A graphical depiction of the fitted model is given in figure 3 .", [["the fitted model", "TREATMENT", 25, 41]]], ["In this scenario, the out-of-control scenario, in which the corona virus would be \"free\" to spread within the country would lead to a pic of ~40,000 infected around the 6th of April 2020.", [["corona virus", "ORGANISM", 60, 72], ["the corona virus", "PROBLEM", 56, 72], ["a pic", "TEST", 132, 137], ["corona virus", "ANATOMY", 60, 72], ["infected", "OBSERVATION", 149, 157]]], ["A scenario that will very likely be avoided given the strong containment measures implemented by the government. .", [["strong", "OBSERVATION_MODIFIER", 54, 60], ["containment", "OBSERVATION", 61, 72]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not peer-reviewed)The copyright holder for this preprint . https://doi.org/10.1101/2020.03.18.20038612 doi: medRxiv preprintDiscussion of the obtained values for \uf06c\uf02c\uf064\uf02c k2, \uf062\uf02c and \uf067\uf02eThe fitting of these parameters was difficult to obtain.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 187, 207], ["this preprint", "TREATMENT", 212, 225], ["\uf06c\uf02c\uf064\uf02c k2", "TEST", 331, 338], ["\uf062\uf02c", "TEST", 340, 342], ["these parameters", "TEST", 364, 380], ["med", "ANATOMY", 102, 105]]], ["There is enough systematic error and lack of statistics to make the present results very unreliable.", [["systematic error", "PROBLEM", 16, 32], ["systematic error", "OBSERVATION", 16, 32]]], ["In order to obtain the parameters for \uf06c\uf02c\uf064\uf02c and k2, an ersatz value for \uf067 had to be given.", [["an ersatz value", "TEST", 51, 66]]], ["In the cases of the fits of \uf06c\uf02c\uf064\uf02c and k2, the ersatz value used for \uf067 had a very strong impact in the results of the other parameters.", [["the ersatz value", "TEST", 41, 57]]], ["In fact, as it comes multiplied with \uf073 in the transfer from compartment E(t) to compartments A(t) and S(t), I think the high variation in this value could very well be due to the huge uncertainty there is at the moment for the appropriate incubation time of this virus, which some authors claim can be of up to 27 days [21] , although this number is probably an outlier.", [["the high variation", "PROBLEM", 116, 134], ["this virus", "PROBLEM", 258, 268], ["outlier", "OBSERVATION", 362, 369]]], ["Finally, a case of an incubation period of 18 days seems to have been confirmed by a recent study [22] .", [["a recent study", "TEST", 83, 97]]], ["The obtained value for \uf067=0.0168 is 50% the value obtained by Xia et al [13] of 0.0348, which shows the difference in case fatality rates between the SARS-covid-2 (7.2% currently for Italy), and MERS (estimated at 34%), but then again the value should be 20% of this value and not 50%, further implying that the case fatality rate of the SARScovid-2 is still difficult to determine, and could be higher than previously thought.Discussion of the obtained values for \uf06c\uf02c\uf064\uf02c k2, \uf062\uf02c and \uf067\uf02eFinally, from the obtained values it is also possible to determine a value for the basic reproduction number R0, which here I take as being simply the value R0=\uf062\uf02f\uf073=5.916 which demonstrates how strong the capacity for spreading of this particular virus is.", [["SARS", "DISEASE", 149, 153], ["the SARS", "TEST", 145, 153], ["covid", "TEST", 154, 159], ["this particular virus", "PROBLEM", 712, 733]]], ["In table 4, the final values of the obtained parameters are given.DIFFERENT SCENARIOS FOR THE EVOLUTION OF SARS-COVID-2 IN PORTUGAL.The paper by Xia et al [13] further presents an extra 7 parameters to take into account control measures in time evolution of the epidemic.", [["an extra 7 parameters", "TREATMENT", 177, 198], ["the epidemic", "PROBLEM", 258, 270], ["epidemic", "OBSERVATION", 262, 270]]], ["These parameters are meant to take into account two things: -Isolation and monitoring measures taken by the government (parameters d1, d2, d3, and d4); -Self-protection measures taken by the population (parameters l1, l2, and l3).DIFFERENT SCENARIOS FOR THE EVOLUTION OF SARS-COVID-2 IN PORTUGAL..", [["Isolation", "TREATMENT", 61, 70], ["monitoring measures", "TEST", 75, 94], ["Self-protection measures", "TREATMENT", 153, 177], ["l2", "ANATOMY_MODIFIER", 218, 220], ["l3", "ANATOMY", 226, 228]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["(2)DIFFERENT SCENARIOS FOR THE EVOLUTION OF SARS-COVID-2 IN PORTUGAL.The l1, l2, and l3 parameters are basically multiplication factors for the transmission parameter \uf062, so in our model we only consider one value for it as we did for \uf062.", [["l1", "GENE_OR_GENE_PRODUCT", 73, 75], ["l1", "ANATOMY_MODIFIER", 73, 75], ["l2", "ANATOMY_MODIFIER", 77, 79], ["l3", "ANATOMY", 85, 87]]], ["The d1, d2, d3, and d4 parameters are summed to the parameters of spread between the infected, asymptomatic and hospitalized cases, further stressing their connection to implemented government measures.", [["d1, d2, d3, and d4 parameters", "DNA", 4, 33], ["d3", "TEST", 12, 14], ["the infected, asymptomatic and hospitalized cases", "PROBLEM", 81, 130], ["infected", "OBSERVATION_MODIFIER", 85, 93]]], ["The values provided by Xia et al [13] , when applied to the Portuguese case, seem to provide a very unrealistic scenario, in which the values would immediately start to diminish.", [["The values", "TEST", 0, 10]]], ["Perhaps this made sense in the case of the MERS epidemic, given that it was much more localised that the one provoked by this virus.", [["this virus", "PROBLEM", 121, 131]]], ["As such, and for the lack of a better model, I devised two different scenarios in addition to the \"outof-control\" scenario described in the previous section:DIFFERENT SCENARIOS FOR THE EVOLUTION OF SARS-COVID-2 IN PORTUGAL.\u2022 Scenario in which the government takes severe mitigating measures and the population mildly adheres to self-protecting measures (scenario 1); \u2022 Scenario in which the government fails to implement mitigating measures, yet still implements some, and the population mildly adheres to selfprotecting measures (scenario 2).DIFFERENT SCENARIOS FOR THE EVOLUTION OF SARS-COVID-2 IN PORTUGAL.The values for these scenarios are given in table 5.", [["Scenario", "TREATMENT", 225, 233], ["severe mitigating measures", "TREATMENT", 264, 290], ["self-protecting measures", "TREATMENT", 328, 352], ["mitigating measures", "TREATMENT", 421, 440], ["selfprotecting measures", "TREATMENT", 506, 529], ["The values", "TEST", 609, 619], ["these scenarios", "TREATMENT", 624, 639]]], ["In the second scenario I keep the 50% reduction in the transmission rate but diminish the efforts of the government by half.", [["the 50% reduction", "TREATMENT", 30, 47], ["the transmission rate", "TEST", 51, 72]]], ["In the first scenario the effectiveness of the control measures seems to be at a maximum, and a maximum of just about 700 cases would be reached.", [["the control measures", "TREATMENT", 43, 63]]], ["This seems unlikely as of today, there are 641 active cases in the country.", [["seems unlikely", "UNCERTAINTY", 5, 19]]], ["In this scenario, the transmission rate has been cut to a half, but the government has not been effective in implementing control measures.", [["the transmission rate", "TEST", 18, 39]]], ["As said previously, in the out-of-control scenario, the peak would be reached at about ~40,000 people.LIMITATIONS OF THIS STUDY AND SCOPE OF APPLICATIONGiven the huge uncertainties concerning these numbers, and the current lack of knowledge of the ongoing epidemic, it is very hard to make sense of its evolution, even using well-established SIR methods.", [["people", "ORGANISM", 95, 101], ["people", "SPECIES", 95, 101], ["THIS STUDY", "TEST", 117, 127], ["these numbers", "TEST", 192, 205], ["the ongoing epidemic", "PROBLEM", 244, 264]]], ["The current work makes a series of assumptions which may or may not be proven correct in the future, including the incubation period of the virus, which is still not well-known.", [["the virus", "PROBLEM", 136, 145]]], ["This proved to be a major source of uncertainty to fit the results, because it had a great influence in the other parameters, especially parameter \uf067, which seems to describe a probability of the person being exposed to the virus being symptomatic or not.", [["person", "SPECIES", 195, 201], ["the virus", "PROBLEM", 219, 228], ["symptomatic", "PROBLEM", 235, 246]]], ["Instead this parameter seems to behave in this study as an indicator of the huge uncertainty of the value for the incubation period.", [["this study", "TEST", 42, 52]]], ["Finally, epidemiologists and pathologists will tell you that these parameters, unlike what is considered in this study, are not only not constant, but dependent on time, location, culture, and other factors.", [["this study", "TEST", 108, 118], ["culture", "TEST", 180, 187]]], ["It is therefore particularly hard to model the current epidemic of covid-19.", [["covid", "TEST", 67, 72]]], ["Also, this study takes into account the particular situation for one country (Portugal), and we know that in globalised times, the likelihood that new foci of infections arise from outside visitors is also very high.", [["infections", "DISEASE", 159, 169], ["this study", "TEST", 6, 16], ["new foci of infections", "PROBLEM", 147, 169], ["new", "OBSERVATION_MODIFIER", 147, 150], ["foci", "OBSERVATION", 151, 155], ["infections", "OBSERVATION", 159, 169]]], ["In fact, one of the major issues with the SARS-covid-2 virus is that, unlike the other SARS, it seems to be much less contained locally, as is evident by the amount of countries afflicted.", [["SARS", "DISEASE", 42, 46], ["SARS", "DISEASE", 87, 91], ["SARS-covid-2 virus", "ORGANISM", 42, 60], ["SARS-covid-2 virus", "SPECIES", 42, 60], ["the SARS", "PROBLEM", 38, 46], ["the other SARS", "PROBLEM", 77, 91]]], ["The amount of actual active cases is another clear source of uncertainty.", [["actual active cases", "PROBLEM", 14, 33], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["active", "OBSERVATION_MODIFIER", 21, 27], ["cases", "OBSERVATION", 28, 33]]], ["This model takes the values of active cases and compares them with official confirmed numbers, which not only may be smaller than the actual cases, as are released at an administratively defined time, which probably does not correspond to something realistic.LIMITATIONS OF THIS STUDY AND SCOPE OF APPLICATIONThe author believes that the values obtained in this study should be taken qualitatively rather than quantitatively.", [["THIS STUDY", "TEST", 274, 284], ["the values", "TEST", 334, 344], ["this study", "TEST", 357, 367], ["may be", "UNCERTAINTY", 110, 116], ["smaller", "OBSERVATION_MODIFIER", 117, 124], ["probably does not", "UNCERTAINTY", 207, 224]]], ["One can think of the scenarios as defining two limits of a likelihood interval, and as such, the actual figure of maximum number of active cases in Portugal will likely be in the interval ~700-7,000 between the 9th-20th of April.", [["active", "OBSERVATION_MODIFIER", 132, 138]]], ["It also serves to show the importance of control and self-protecting measures.", [["self-protecting measures", "TREATMENT", 53, 77]]], ["It is possible to bring down the number of affected people by following the recommendations of the WHO and health authorities.", [["people", "ORGANISM", 52, 58], ["people", "SPECIES", 52, 58]]], ["Without them, this model predicts that the figures of active cases would reach a staggering ~40,000 people.", [["people", "ORGANISM", 100, 106], ["people", "SPECIES", 100, 106]]]], "PMC5007427": [["IntroductionHuman parechoviruses (HPeVs) are newly recognized single-stranded RNA viruses that were formerly classified in the Enterovirus genus1).", [["parechoviruses", "GENE_OR_GENE_PRODUCT", 18, 32], ["HPeVs", "GENE_OR_GENE_PRODUCT", 34, 39], ["Enterovirus", "ORGANISM", 127, 138], ["genus1", "GENE_OR_GENE_PRODUCT", 139, 145], ["HPeVs", "DNA", 34, 39], ["Enterovirus genus1", "PROTEIN", 127, 145], ["stranded RNA viruses", "PROBLEM", 69, 89]]], ["Among 16 HPeV serotypes, HPeV-3 infection occurs most frequently among infants below the age of 3 months2).", [["infection", "DISEASE", 32, 41], ["HPeV-3", "ORGANISM", 25, 31], ["infants", "ORGANISM", 71, 78], ["infants", "SPECIES", 71, 78], ["HPeV", "SPECIES", 9, 13], ["HPeV-3", "SPECIES", 25, 31], ["HPeV serotypes", "PROBLEM", 9, 23], ["HPeV", "PROBLEM", 25, 29], ["infection", "PROBLEM", 32, 41]]], ["Since HPeV-3 was first isolated in Japan in 19991), the HPeV serotype has been increasingly identified as an important pathogen of sepsis-like illness and central nervous system infections in neonates and young infants3).", [["central nervous system", "ANATOMY", 155, 177], ["sepsis", "DISEASE", 131, 137], ["illness", "DISEASE", 143, 150], ["central nervous system infections", "DISEASE", 155, 188], ["HPeV-3", "GENE_OR_GENE_PRODUCT", 6, 12], ["HPeV serotype", "ORGANISM", 56, 69], ["central nervous system", "ANATOMICAL_SYSTEM", 155, 177], ["neonates", "ORGANISM", 192, 200], ["infant", "SPECIES", 211, 217], ["HPeV", "SPECIES", 56, 60], ["HPeV", "TEST", 6, 10], ["the HPeV serotype", "PROBLEM", 52, 69], ["sepsis", "PROBLEM", 131, 137], ["illness", "PROBLEM", 143, 150], ["central nervous system infections in neonates", "PROBLEM", 155, 200], ["sepsis", "OBSERVATION", 131, 137], ["central", "ANATOMY_MODIFIER", 155, 162], ["nervous system", "ANATOMY", 163, 177], ["infections", "OBSERVATION", 178, 188]]], ["Life-threatening illnesses such as hemophagocytic lymphohistiocytosis have been reported in neonatal HPeV-3 infection4).", [["hemophagocytic lymphohistiocytosis", "DISEASE", 35, 69], ["Life-threatening illnesses", "PROBLEM", 0, 26], ["hemophagocytic lymphohistiocytosis", "PROBLEM", 35, 69], ["neonatal HPeV", "PROBLEM", 92, 105], ["hemophagocytic lymphohistiocytosis", "OBSERVATION", 35, 69]]], ["However, the major clinical features displayed by patients with HPeV-3 infection are also common in those suffering from severe infectious diseases caused by other pathogens5).", [["infection", "DISEASE", 71, 80], ["infectious diseases", "DISEASE", 128, 147], ["patients", "ORGANISM", 50, 58], ["HPeV-3", "ORGANISM", 64, 70], ["patients", "SPECIES", 50, 58], ["HPeV", "PROBLEM", 64, 68], ["3 infection", "PROBLEM", 69, 80], ["severe infectious diseases", "PROBLEM", 121, 147], ["severe", "OBSERVATION_MODIFIER", 121, 127], ["infectious", "OBSERVATION", 128, 138]]], ["Thus, the diagnosis of HPeV-3 infection is difficult based only on clinical signs.IntroductionRecent studies have reported several clinical findings that are characteristic of HPeV-3 infection4678).", [["infection", "DISEASE", 30, 39], ["infection", "DISEASE", 183, 192], ["HPeV-3", "ORGANISM", 23, 29], ["HPeV-3", "GENE_OR_GENE_PRODUCT", 176, 182], ["HPeV-3", "SPECIES", 23, 29], ["HPeV", "PROBLEM", 23, 27], ["3 infection", "PROBLEM", 28, 39], ["clinical signs", "TEST", 67, 81], ["IntroductionRecent studies", "TEST", 82, 108], ["several clinical findings", "PROBLEM", 123, 148], ["HPeV", "PROBLEM", 176, 180], ["infection", "PROBLEM", 183, 192], ["HPeV", "OBSERVATION", 23, 27], ["infection", "OBSERVATION", 30, 39]]], ["Clinical features such as palmar-plantar erythema and hyperferritinemia might be diagnostic indicators of an HPeV3 infection in febrile neonates and young infants67).", [["palmar", "ANATOMY", 26, 32], ["plantar", "ANATOMY", 33, 40], ["erythema", "DISEASE", 41, 49], ["hyperferritinemia", "DISEASE", 54, 71], ["infection", "DISEASE", 115, 124], ["febrile", "DISEASE", 128, 135], ["HPeV3", "CANCER", 109, 114], ["neonates", "ORGANISM", 136, 144], ["infant", "SPECIES", 155, 161], ["Clinical features", "PROBLEM", 0, 17], ["palmar-plantar erythema", "PROBLEM", 26, 49], ["hyperferritinemia", "PROBLEM", 54, 71], ["an HPeV3 infection", "PROBLEM", 106, 124], ["febrile neonates", "PROBLEM", 128, 144], ["palmar", "ANATOMY", 26, 32], ["plantar", "ANATOMY", 33, 40], ["erythema", "OBSERVATION", 41, 49], ["hyperferritinemia", "OBSERVATION", 54, 71], ["infection", "OBSERVATION", 115, 124]]], ["This report describes 2 young infants with an HPeV3 infection who presented with a prolonged fever, palmar-plantar erythema, and hyperferritinemia (>500 ng/mL).", [["palmar", "ANATOMY", 100, 106], ["plantar", "ANATOMY", 107, 114], ["HPeV3 infection", "DISEASE", 46, 61], ["fever", "DISEASE", 93, 98], ["palmar-plantar erythema", "DISEASE", 100, 123], ["hyperferritinemia", "DISEASE", 129, 146], ["infants", "ORGANISM", 30, 37], ["plantar", "ORGANISM_SUBDIVISION", 107, 114], ["infants", "SPECIES", 30, 37], ["HPeV3", "SPECIES", 46, 51], ["an HPeV3 infection", "PROBLEM", 43, 61], ["a prolonged fever", "PROBLEM", 81, 98], ["palmar-plantar erythema", "PROBLEM", 100, 123], ["hyperferritinemia", "PROBLEM", 129, 146], ["infection", "OBSERVATION", 52, 61], ["palmar", "ANATOMY", 100, 106], ["plantar", "ANATOMY", 107, 114], ["erythema", "OBSERVATION", 115, 123], ["hyperferritinemia", "OBSERVATION", 129, 146]]], ["These cases may enhance our understanding of the unique features of HPeV-3 infection in young infants.1.", [["infection", "DISEASE", 75, 84], ["HPeV-3", "GENE_OR_GENE_PRODUCT", 68, 74], ["infants", "ORGANISM", 94, 101], ["infants", "SPECIES", 94, 101], ["HPeV-3", "SPECIES", 68, 74], ["HPeV", "PROBLEM", 68, 72], ["3 infection", "PROBLEM", 73, 84], ["HPeV", "OBSERVATION", 68, 72], ["infection", "OBSERVATION", 75, 84]]], ["Case 1 ::: Case reportsA 42-day-old male neonate was admitted to Gyeongsang National University of Hospital due to high fever and irritability.", [["fever", "DISEASE", 120, 125], ["irritability", "DISEASE", 130, 142], ["neonate", "ORGANISM", 41, 48], ["high fever", "PROBLEM", 115, 125], ["irritability", "PROBLEM", 130, 142], ["high", "OBSERVATION_MODIFIER", 115, 119], ["fever", "OBSERVATION", 120, 125]]], ["He was born at full-term gestational age at a weight of 3,200 g, and he was thriving until this hospital visit.", [["He", "ORGANISM", 0, 2]]], ["Localized symptoms were not detected, and the results of a physical examination were unremarkable.", [["Localized symptoms", "PROBLEM", 0, 18], ["a physical examination", "TEST", 57, 79], ["unremarkable", "OBSERVATION", 85, 97]]], ["His healthy older sister was reported to have had a recent febrile respiratory infection.", [["respiratory", "ANATOMY", 67, 78], ["febrile respiratory infection", "DISEASE", 59, 88], ["a recent febrile respiratory infection", "PROBLEM", 50, 88], ["febrile", "OBSERVATION_MODIFIER", 59, 66], ["respiratory", "ANATOMY", 67, 78], ["infection", "OBSERVATION", 79, 88]]], ["The patient's initial vital signs were as follows: blood pressure 80/50 mmHg, heart rate 168 beats/min, respiratory rate 38 breaths/min, and body temperature 38.8\u2103.", [["blood", "ANATOMY", 51, 56], ["heart", "ANATOMY", 78, 83], ["respiratory", "ANATOMY", 104, 115], ["body", "ANATOMY", 141, 145], ["patient", "ORGANISM", 4, 11], ["blood", "ORGANISM_SUBSTANCE", 51, 56], ["heart", "ORGAN", 78, 83], ["body", "ORGANISM_SUBDIVISION", 141, 145], ["patient", "SPECIES", 4, 11], ["The patient's initial vital signs", "TEST", 0, 33], ["blood pressure", "TEST", 51, 65], ["heart rate", "TEST", 78, 88], ["beats/min", "TEST", 93, 102], ["respiratory rate", "TEST", 104, 120], ["breaths", "TEST", 124, 131], ["body temperature", "TEST", 141, 157], ["heart", "ANATOMY", 78, 83]]], ["The laboratory findings at admission were as follows: hemoglobin, 9.0 g/dL; white blood cell (WBC) count, 1,990/mm3; absolute neutrophil count, 670/mm3; platelet count, 390\u00d7103/mm3; aspartate aminotransferase (AST), 42 U/L (range, 22\u201363 U/L); alanine aminotransferase (ALT), 23 U/L (range, 12\u201345 U/L); \u03b3-glutamyl transferase (\u03b3-GT), 36 U/L (range, 12\u2013123); creatine kinase (CK), 147 U/L (range, 5\u2013130 U/L); lactate dehydrogenase (LDH), 283 U/L (range, 170\u2013580 U/L); ferritin, 385 ng/mL (range, 0\u2013400 ng/mL); protein, 5.5 g/dL (range, 4.6\u20137.4 g/dL); albumin, 4.0 g/dL (range, 1.9\u20135.0 g/dL); and C-reactive protein (CRP), 0.5 mg/L (range, <7.9 mg/L).", [["white blood cell", "ANATOMY", 76, 92], ["WBC", "ANATOMY", 94, 97], ["neutrophil", "ANATOMY", 126, 136], ["platelet", "ANATOMY", 153, 161], ["aspartate", "CHEMICAL", 182, 191], ["alanine", "CHEMICAL", 243, 250], ["creatine", "CHEMICAL", 357, 365], ["lactate", "CHEMICAL", 407, 414], ["aspartate", "CHEMICAL", 182, 191], ["alanine", "CHEMICAL", 243, 250], ["\u03b3-glutamyl", "CHEMICAL", 302, 312], ["creatine", "CHEMICAL", 357, 365], ["lactate", "CHEMICAL", 407, 414], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 54, 64], ["white blood cell", "CELL", 76, 92], ["WBC", "CELL", 94, 97], ["neutrophil", "CELL", 126, 136], ["platelet", "CELL", 153, 161], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 182, 208], ["AST", "SIMPLE_CHEMICAL", 210, 213], ["alanine aminotransferase", "GENE_OR_GENE_PRODUCT", 243, 267], ["ALT", "SIMPLE_CHEMICAL", 269, 272], ["\u03b3-glutamyl transferase", "GENE_OR_GENE_PRODUCT", 302, 324], ["\u03b3-GT", "GENE_OR_GENE_PRODUCT", 326, 330], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 357, 372], ["CK", "GENE_OR_GENE_PRODUCT", 374, 376], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 407, 428], ["LDH", "GENE_OR_GENE_PRODUCT", 430, 433], ["ferritin", "GENE_OR_GENE_PRODUCT", 466, 474], ["albumin", "GENE_OR_GENE_PRODUCT", 549, 556], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 594, 612], ["CRP", "GENE_OR_GENE_PRODUCT", 614, 617], ["hemoglobin", "PROTEIN", 54, 64], ["aspartate aminotransferase", "PROTEIN", 182, 208], ["AST", "PROTEIN", 210, 213], ["alanine aminotransferase", "PROTEIN", 243, 267], ["ALT", "PROTEIN", 269, 272], ["\u03b3-glutamyl transferase", "PROTEIN", 302, 324], ["creatine kinase", "PROTEIN", 357, 372], ["CK", "PROTEIN", 374, 376], ["lactate dehydrogenase", "PROTEIN", 407, 428], ["LDH", "PROTEIN", 430, 433], ["ferritin", "PROTEIN", 466, 474], ["albumin", "PROTEIN", 549, 556], ["C-reactive protein", "PROTEIN", 594, 612], ["CRP", "PROTEIN", 614, 617], ["hemoglobin", "TEST", 54, 64], ["dL", "TEST", 72, 74], ["white blood cell", "TEST", 76, 92], ["WBC", "TEST", 94, 97], ["count", "TEST", 99, 104], ["mm3", "TEST", 112, 115], ["absolute neutrophil count", "TEST", 117, 142], ["mm3", "TEST", 148, 151], ["platelet count", "TEST", 153, 167], ["aspartate aminotransferase", "TEST", 182, 208], ["AST", "TEST", 210, 213], ["U", "TEST", 219, 220], ["U/L", "TEST", 237, 240], ["alanine aminotransferase", "TEST", 243, 267], ["ALT", "TEST", 269, 272], ["U/L", "TEST", 278, 281], ["U/L", "TEST", 296, 299], ["\u03b3-glutamyl transferase", "TEST", 302, 324], ["GT", "TEST", 328, 330], ["U/L", "TEST", 336, 339], ["creatine kinase", "TEST", 357, 372], ["CK", "TEST", 374, 376], ["U/L", "TEST", 383, 386], ["U/L", "TEST", 401, 404], ["lactate dehydrogenase", "TEST", 407, 428], ["LDH", "TEST", 430, 433], ["U/L", "TEST", 440, 443], ["U/L", "TEST", 460, 463], ["ferritin", "TEST", 466, 474], ["protein", "TEST", 508, 515], ["range", "TEST", 527, 532], ["dL", "TEST", 544, 546], ["albumin", "TEST", 549, 556], ["dL", "TEST", 564, 566], ["range", "TEST", 568, 573], ["C", "TEST", 594, 595], ["CRP", "TEST", 614, 617], ["neutrophil count", "OBSERVATION", 126, 142]]], ["No cerebrospinal fluid (CSF) pleocytosis or pyuria was observed.", [["cerebrospinal fluid", "ANATOMY", 3, 22], ["pleocytosis", "DISEASE", 29, 40], ["pyuria", "DISEASE", 44, 50], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 3, 22], ["CSF", "ORGANISM_SUBSTANCE", 24, 27], ["cerebrospinal fluid (CSF) pleocytosis", "PROBLEM", 3, 40], ["pyuria", "PROBLEM", 44, 50], ["cerebrospinal", "ANATOMY", 3, 16], ["fluid", "OBSERVATION", 17, 22], ["pyuria", "OBSERVATION", 44, 50]]], ["Cefotaxime and ampicillin/sulbactam were administered.1.", [["Cefotaxime", "CHEMICAL", 0, 10], ["ampicillin", "CHEMICAL", 15, 25], ["sulbactam", "CHEMICAL", 26, 35], ["Cefotaxime", "CHEMICAL", 0, 10], ["ampicillin", "CHEMICAL", 15, 25], ["sulbactam", "CHEMICAL", 26, 35], ["Cefotaxime", "SIMPLE_CHEMICAL", 0, 10], ["ampicillin", "SIMPLE_CHEMICAL", 15, 25], ["sulbactam", "SIMPLE_CHEMICAL", 26, 35], ["Cefotaxime", "TREATMENT", 0, 10], ["ampicillin", "TREATMENT", 15, 25], ["sulbactam", "TREATMENT", 26, 35]]], ["Case 1 ::: Case reportsNo bacteria were found in blood, CSF, or urine samples.", [["blood", "ANATOMY", 49, 54], ["CSF", "ANATOMY", 56, 59], ["urine samples", "ANATOMY", 64, 77], ["blood", "ORGANISM_SUBSTANCE", 49, 54], ["CSF", "ORGANISM_SUBSTANCE", 56, 59], ["urine samples", "ORGANISM_SUBSTANCE", 64, 77], ["bacteria", "PROBLEM", 26, 34], ["blood, CSF, or urine samples", "TEST", 49, 77]]], ["HPeV-3 was detected in CSF and serum samples by reverse transcription polymerase chain reaction (PCR) as described in our previous study9).", [["CSF", "ANATOMY", 23, 26], ["serum samples", "ANATOMY", 31, 44], ["HPeV-3", "GENE_OR_GENE_PRODUCT", 0, 6], ["CSF", "ORGANISM_SUBSTANCE", 23, 26], ["serum samples", "ORGANISM_SUBSTANCE", 31, 44], ["HPeV", "PROTEIN", 0, 4], ["HPeV", "TEST", 0, 4], ["CSF", "TEST", 23, 26], ["serum samples", "TEST", 31, 44], ["reverse transcription polymerase chain reaction", "PROBLEM", 48, 95], ["PCR", "TEST", 97, 100]]], ["CSF PCR tests were negative for herpes, enterovirus, cytomegalovirus, Epstein-Barr virus, and HPeV1.", [["herpes, enterovirus, cytomegalovirus", "DISEASE", 32, 68], ["CSF", "GENE_OR_GENE_PRODUCT", 0, 3], ["herpes", "ORGANISM", 32, 38], ["enterovirus", "ORGANISM", 40, 51], ["cytomegalovirus", "ORGANISM", 53, 68], ["Epstein-Barr virus", "ORGANISM", 70, 88], ["Epstein-Barr virus", "SPECIES", 70, 88], ["CSF PCR tests", "TEST", 0, 13], ["herpes", "PROBLEM", 32, 38], ["enterovirus", "PROBLEM", 40, 51], ["cytomegalovirus", "PROBLEM", 53, 68], ["Barr virus", "PROBLEM", 78, 88], ["HPeV1", "PROBLEM", 94, 99], ["Barr virus", "OBSERVATION", 78, 88]]], ["In addition, we found no respiratory viruses such as adenovirus, coronavirus, parainfluenza virus, rhinovirus, respiratory syncytial virus, influenza virus, bocavirus, and metapneumovirus.", [["parainfluenza virus", "DISEASE", 78, 97], ["rhinovirus", "DISEASE", 99, 109], ["respiratory syncytial virus", "DISEASE", 111, 138], ["influenza virus, bocavirus, and metapneumovirus", "DISEASE", 140, 187], ["adenovirus", "ORGANISM", 53, 63], ["coronavirus", "ORGANISM", 65, 76], ["parainfluenza virus", "ORGANISM", 78, 97], ["rhinovirus", "ORGANISM", 99, 109], ["respiratory syncytial virus", "ORGANISM", 111, 138], ["influenza virus", "ORGANISM", 140, 155], ["metapneumovirus", "ORGANISM", 172, 187], ["coronavirus", "SPECIES", 65, 76], ["parainfluenza virus, rhinovirus", "SPECIES", 78, 109], ["respiratory syncytial virus", "SPECIES", 111, 138], ["influenza virus", "SPECIES", 140, 155], ["parainfluenza virus", "SPECIES", 78, 97], ["respiratory syncytial virus", "SPECIES", 111, 138], ["influenza virus", "SPECIES", 140, 155], ["respiratory viruses", "PROBLEM", 25, 44], ["adenovirus", "PROBLEM", 53, 63], ["coronavirus", "PROBLEM", 65, 76], ["parainfluenza virus", "PROBLEM", 78, 97], ["rhinovirus", "PROBLEM", 99, 109], ["respiratory syncytial virus", "PROBLEM", 111, 138], ["influenza virus", "PROBLEM", 140, 155], ["bocavirus", "PROBLEM", 157, 166], ["metapneumovirus", "PROBLEM", 172, 187], ["no", "UNCERTAINTY", 22, 24], ["respiratory viruses", "OBSERVATION", 25, 44], ["respiratory syncytial virus", "OBSERVATION", 111, 138], ["metapneumovirus", "OBSERVATION", 172, 187]]], ["High fever and irritability persisted.", [["fever", "DISEASE", 5, 10], ["irritability", "DISEASE", 15, 27], ["High fever", "PROBLEM", 0, 10], ["irritability", "PROBLEM", 15, 27], ["fever", "OBSERVATION", 5, 10], ["irritability", "OBSERVATION_MODIFIER", 15, 27]]], ["At day 5 of admission, an erythematous rash and swelling were observed on the patient's hands and feet.", [["rash", "DISEASE", 39, 43], ["swelling", "DISEASE", 48, 56], ["patient", "ORGANISM", 78, 85], ["hands", "ORGANISM_SUBDIVISION", 88, 93], ["feet", "ORGANISM_SUBDIVISION", 98, 102], ["patient", "SPECIES", 78, 85], ["an erythematous rash", "PROBLEM", 23, 43], ["swelling", "PROBLEM", 48, 56], ["erythematous", "OBSERVATION_MODIFIER", 26, 38], ["rash", "OBSERVATION", 39, 43], ["swelling", "OBSERVATION", 48, 56], ["hands", "ANATOMY", 88, 93], ["feet", "ANATOMY", 98, 102]]], ["The laboratory findings were as follows: hemoglobin, 8.7 g/dL; WBC count, 3,930/mm3; absolute neutrophil count, 260/mm3; platelet count, 160\u00d7103/mm3; protein, 4.4 g/dL; albumin, 2.9 g/dL; AST, 658 U/L; ALT, 162 U/L; \u03b3-GT, 147 U/L; CK, 321 U/L; LDH, 1,324 U/L; ferritin, 2,581 ng/dL; and CRP, 0.3 mg/dL.", [["WBC", "ANATOMY", 63, 66], ["neutrophil", "ANATOMY", 94, 104], ["platelet", "ANATOMY", 121, 129], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 41, 51], ["neutrophil", "CELL", 94, 104], ["platelet", "CELL", 121, 129], ["albumin", "GENE_OR_GENE_PRODUCT", 169, 176], ["AST", "SIMPLE_CHEMICAL", 188, 191], ["\u03b3-GT", "GENE_OR_GENE_PRODUCT", 216, 220], ["CK", "GENE_OR_GENE_PRODUCT", 231, 233], ["LDH", "GENE_OR_GENE_PRODUCT", 244, 247], ["ferritin", "GENE_OR_GENE_PRODUCT", 260, 268], ["CRP", "GENE_OR_GENE_PRODUCT", 287, 290], ["hemoglobin", "PROTEIN", 41, 51], ["albumin", "PROTEIN", 169, 176], ["AST", "PROTEIN", 188, 191], ["ALT", "PROTEIN", 202, 205], ["GT", "PROTEIN", 218, 220], ["CK", "PROTEIN", 231, 233], ["LDH", "PROTEIN", 244, 247], ["ferritin", "PROTEIN", 260, 268], ["CRP", "PROTEIN", 287, 290], ["hemoglobin", "TEST", 41, 51], ["dL", "TEST", 59, 61], ["WBC count", "TEST", 63, 72], ["mm3", "TEST", 80, 83], ["absolute neutrophil count", "TEST", 85, 110], ["mm3", "TEST", 116, 119], ["platelet count", "TEST", 121, 135], ["mm3", "TEST", 145, 148], ["protein", "TEST", 150, 157], ["dL", "TEST", 165, 167], ["albumin", "TEST", 169, 176], ["g", "TEST", 182, 183], ["dL", "TEST", 184, 186], ["AST", "TEST", 188, 191], ["U/L", "TEST", 197, 200], ["ALT", "TEST", 202, 205], ["U/L", "TEST", 211, 214], ["\u03b3", "TEST", 216, 217], ["GT", "TEST", 218, 220], ["U/L", "TEST", 226, 229], ["CK", "TEST", 231, 233], ["U/L", "TEST", 239, 242], ["LDH", "TEST", 244, 247], ["U/L", "TEST", 255, 258], ["ferritin", "TEST", 260, 268], ["ng/dL", "TEST", 276, 281], ["CRP", "TEST", 287, 290], ["neutrophil count", "OBSERVATION", 94, 110], ["dL", "ANATOMY", 279, 281]]], ["Intravenous immunoglobulin (IVIG) was administrated because severe systemic inflammatory responses were considered in the patient.", [["immunoglobulin", "GENE_OR_GENE_PRODUCT", 12, 26], ["IVIG", "SIMPLE_CHEMICAL", 28, 32], ["patient", "ORGANISM", 122, 129], ["immunoglobulin", "PROTEIN", 12, 26], ["patient", "SPECIES", 122, 129], ["Intravenous immunoglobulin (IVIG)", "TREATMENT", 0, 33], ["severe systemic inflammatory responses", "PROBLEM", 60, 98], ["severe", "OBSERVATION_MODIFIER", 60, 66], ["systemic", "OBSERVATION_MODIFIER", 67, 75], ["inflammatory", "OBSERVATION", 76, 88]]], ["After IVIG treatment, the patient's fever subsided gradually and the erythematous rash disappeared.", [["erythematous", "ANATOMY", 69, 81], ["fever", "DISEASE", 36, 41], ["rash", "DISEASE", 82, 86], ["IVIG", "SIMPLE_CHEMICAL", 6, 10], ["patient", "ORGANISM", 26, 33], ["erythematous rash", "PATHOLOGICAL_FORMATION", 69, 86], ["patient", "SPECIES", 26, 33], ["IVIG treatment", "TREATMENT", 6, 20], ["the patient's fever", "PROBLEM", 22, 41], ["the erythematous rash", "PROBLEM", 65, 86], ["erythematous", "OBSERVATION_MODIFIER", 69, 81], ["rash", "OBSERVATION", 82, 86]]], ["The patient was discharged on day 8 of admission.2.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["Case 2 ::: Case reportsA 25-day-old female neonate was admitted to Gyeongsang National University Hospital due to high fever and poor feeding.", [["fever", "DISEASE", 119, 124], ["neonate", "ORGANISM", 43, 50], ["high fever", "PROBLEM", 114, 124], ["poor feeding", "PROBLEM", 129, 141], ["high", "OBSERVATION_MODIFIER", 114, 118], ["fever", "OBSERVATION", 119, 124]]], ["She was born without incident at full-term gestational age, and her birth weight was 2,900 g.", [["her birth weight", "TEST", 64, 80]]], ["She had no known sick contacts.", [["known sick contacts", "PROBLEM", 11, 30], ["no", "UNCERTAINTY", 8, 10], ["sick contacts", "OBSERVATION", 17, 30]]], ["The patient displayed abdominal distension and loose stool, but no localized signs and symptoms were noted.", [["abdominal", "ANATOMY", 22, 31], ["stool", "ANATOMY", 53, 58], ["abdominal distension", "DISEASE", 22, 42], ["patient", "ORGANISM", 4, 11], ["abdominal", "ORGANISM_SUBDIVISION", 22, 31], ["stool", "ORGANISM_SUBSTANCE", 53, 58], ["patient", "SPECIES", 4, 11], ["abdominal distension", "PROBLEM", 22, 42], ["loose stool", "PROBLEM", 47, 58], ["localized signs and symptoms", "PROBLEM", 67, 95], ["abdominal", "ANATOMY", 22, 31], ["distension", "OBSERVATION", 32, 42], ["loose stool", "OBSERVATION", 47, 58]]], ["The patient's vital signs were as follows: heart rate, 158 beats/min; respiratory rate, 48 breaths/min; and body temperature, 38.4\u2103.", [["heart", "ANATOMY", 43, 48], ["respiratory", "ANATOMY", 70, 81], ["body", "ANATOMY", 108, 112], ["patient", "ORGANISM", 4, 11], ["heart", "ORGAN", 43, 48], ["body", "ORGANISM_SUBDIVISION", 108, 112], ["patient", "SPECIES", 4, 11], ["The patient's vital signs", "TEST", 0, 25], ["heart rate", "TEST", 43, 53], ["beats/min", "TEST", 59, 68], ["respiratory rate", "TEST", 70, 86], ["breaths", "TEST", 91, 98], ["body temperature", "TEST", 108, 124]]], ["All laboratory findings at the time of admission were within the normal range.", [["All laboratory findings", "TEST", 0, 23], ["normal range", "OBSERVATION", 65, 77]]], ["No CSF pleocytosis or pyuria was observed.", [["pleocytosis", "DISEASE", 7, 18], ["pyuria", "DISEASE", 22, 28], ["CSF", "GENE_OR_GENE_PRODUCT", 3, 6], ["CSF pleocytosis", "PROBLEM", 3, 18], ["pyuria", "PROBLEM", 22, 28], ["CSF", "OBSERVATION_MODIFIER", 3, 6], ["pleocytosis", "OBSERVATION", 7, 18], ["pyuria", "OBSERVATION", 22, 28]]], ["Conservative antibiotics (ampicillin/sulbactam and gentamycin) were administered because the patient appeared ill.2.", [["ampicillin/sulbactam", "CHEMICAL", 26, 46], ["gentamycin", "CHEMICAL", 51, 61], ["ampicillin", "CHEMICAL", 26, 36], ["sulbactam", "CHEMICAL", 37, 46], ["gentamycin", "CHEMICAL", 51, 61], ["ampicillin", "SIMPLE_CHEMICAL", 26, 36], ["sulbactam", "SIMPLE_CHEMICAL", 37, 46], ["gentamycin", "SIMPLE_CHEMICAL", 51, 61], ["patient", "ORGANISM", 93, 100], ["patient", "SPECIES", 93, 100], ["Conservative antibiotics", "TREATMENT", 0, 24], ["ampicillin", "TREATMENT", 26, 36], ["sulbactam", "TREATMENT", 37, 46], ["gentamycin)", "TREATMENT", 51, 62], ["ill", "PROBLEM", 110, 113], ["ill", "OBSERVATION", 110, 113]]], ["Case 2 ::: Case reportsWe detected no viruses causing gastroenteritis, including rotavirus, norovirus, astrovirus, and enterovirus, and serologic studies for cytomegalovirus, rubella virus, Toxoplasma, and herpes simplex virus were negative.", [["gastroenteritis", "DISEASE", 54, 69], ["rotavirus, norovirus, astrovirus, and enterovirus", "DISEASE", 81, 130], ["cytomegalovirus, rubella virus", "DISEASE", 158, 188], ["Toxoplasma, and herpes simplex virus", "DISEASE", 190, 226], ["astrovirus", "ORGANISM", 103, 113], ["cytomegalovirus", "ORGANISM", 158, 173], ["rubella virus", "ORGANISM", 175, 188], ["Toxoplasma", "ORGANISM", 190, 200], ["herpes simplex virus", "ORGANISM", 206, 226], ["rubella virus", "SPECIES", 175, 188], ["herpes simplex virus", "SPECIES", 206, 226], ["rotavirus", "SPECIES", 81, 90], ["rubella virus", "SPECIES", 175, 188], ["herpes simplex virus", "SPECIES", 206, 226], ["viruses", "PROBLEM", 38, 45], ["gastroenteritis", "PROBLEM", 54, 69], ["rotavirus", "PROBLEM", 81, 90], ["norovirus", "PROBLEM", 92, 101], ["astrovirus", "PROBLEM", 103, 113], ["enterovirus", "PROBLEM", 119, 130], ["serologic studies", "TEST", 136, 153], ["cytomegalovirus", "PROBLEM", 158, 173], ["rubella virus", "PROBLEM", 175, 188], ["Toxoplasma", "PROBLEM", 190, 200], ["herpes simplex virus", "PROBLEM", 206, 226], ["no", "UNCERTAINTY", 35, 37], ["viruses", "OBSERVATION", 38, 45], ["gastroenteritis", "OBSERVATION", 54, 69]]], ["HPeV-3 was detected in the patient's CSF by PCR, but no other viruses were detected in respiratory or CSF specimens.", [["respiratory", "ANATOMY", 87, 98], ["CSF specimens", "ANATOMY", 102, 115], ["HPeV-3", "GENE_OR_GENE_PRODUCT", 0, 6], ["patient", "ORGANISM", 27, 34], ["CSF", "GENE_OR_GENE_PRODUCT", 37, 40], ["CSF specimens", "ORGANISM_SUBSTANCE", 102, 115], ["HPeV-3", "DNA", 0, 6], ["patient", "SPECIES", 27, 34], ["HPeV", "TEST", 0, 4], ["the patient's CSF", "TEST", 23, 40], ["PCR", "TEST", 44, 47], ["other viruses", "PROBLEM", 56, 69], ["CSF specimens", "TEST", 102, 115], ["viruses", "OBSERVATION", 62, 69]]], ["An erythematous rash and edema were observed on the patient's hands and feet at day 4 of admission (Fig. 1), with the rash being more obvious on her feet.", [["edema", "ANATOMY", 25, 30], ["feet", "ANATOMY", 149, 153], ["rash", "DISEASE", 16, 20], ["edema", "DISEASE", 25, 30], ["rash", "DISEASE", 118, 122], ["edema", "PATHOLOGICAL_FORMATION", 25, 30], ["patient", "ORGANISM", 52, 59], ["hands", "ORGANISM_SUBDIVISION", 62, 67], ["feet", "ORGANISM_SUBDIVISION", 72, 76], ["feet", "ORGANISM_SUBDIVISION", 149, 153], ["patient", "SPECIES", 52, 59], ["An erythematous rash", "PROBLEM", 0, 20], ["edema", "PROBLEM", 25, 30], ["the rash", "PROBLEM", 114, 122], ["erythematous", "OBSERVATION_MODIFIER", 3, 15], ["rash", "OBSERVATION", 16, 20], ["edema", "OBSERVATION", 25, 30], ["hands", "ANATOMY", 62, 67], ["feet", "ANATOMY", 72, 76], ["rash", "OBSERVATION", 118, 122], ["more obvious", "OBSERVATION_MODIFIER", 129, 141], ["feet", "ANATOMY", 149, 153]]], ["Fever persisted for 5 days of admission.", [["Fever", "DISEASE", 0, 5], ["Fever", "PROBLEM", 0, 5]]], ["The laboratory findings on day 5 of admission were as follows: hemoglobin, 13.9 g/dL; WBC count, 12,810/mm3; absolute neutrophil count, 1,690/mm3; platelet count, 161\u00d7103/mm3; AST, 317 U/L; ALT, 75 U/L; \u03b3-GT, 238 U/L; LDH, 946 U/L; ferritin, 630 ng/mL; and CRP, 0.6 mg/dL.", [["WBC", "ANATOMY", 86, 89], ["neutrophil", "ANATOMY", 118, 128], ["platelet", "ANATOMY", 147, 155], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 63, 73], ["neutrophil", "CELL", 118, 128], ["platelet", "CELL", 147, 155], ["\u03b3-GT", "GENE_OR_GENE_PRODUCT", 203, 207], ["LDH", "GENE_OR_GENE_PRODUCT", 218, 221], ["ferritin", "GENE_OR_GENE_PRODUCT", 232, 240], ["CRP", "GENE_OR_GENE_PRODUCT", 257, 260], ["hemoglobin", "PROTEIN", 63, 73], ["AST", "PROTEIN", 176, 179], ["ALT", "PROTEIN", 190, 193], ["GT", "PROTEIN", 205, 207], ["LDH", "PROTEIN", 218, 221], ["ferritin", "PROTEIN", 232, 240], ["CRP", "PROTEIN", 257, 260], ["hemoglobin", "TEST", 63, 73], ["dL", "TEST", 82, 84], ["WBC count", "TEST", 86, 95], ["mm3", "TEST", 104, 107], ["absolute neutrophil count", "TEST", 109, 134], ["mm3", "TEST", 142, 145], ["platelet count", "TEST", 147, 161], ["mm3", "TEST", 171, 174], ["AST", "TEST", 176, 179], ["U/L", "TEST", 185, 188], ["ALT", "TEST", 190, 193], ["U/L", "TEST", 198, 201], ["\u03b3", "TEST", 203, 204], ["GT", "TEST", 205, 207], ["U/L", "TEST", 213, 216], ["LDH", "TEST", 218, 221], ["U/L", "TEST", 227, 230], ["ferritin", "TEST", 232, 240], ["ng/mL", "TEST", 246, 251], ["CRP", "TEST", 257, 260], ["neutrophil count", "OBSERVATION", 118, 134]]], ["The patient's fever gradually subsided at day 6 of admission without IVIG administration.", [["fever", "DISEASE", 14, 19], ["patient", "ORGANISM", 4, 11], ["IVIG", "SIMPLE_CHEMICAL", 69, 73], ["patient", "SPECIES", 4, 11], ["The patient's fever", "PROBLEM", 0, 19], ["IVIG administration", "TREATMENT", 69, 88]]], ["The patient was discharged on day 7 of admission.DiscussionHere, we report HPeV-3 infection in 2 neonates who had prolonged fever with palmar-plantar erythema.", [["palmar", "ANATOMY", 135, 141], ["plantar", "ANATOMY", 142, 149], ["infection", "DISEASE", 82, 91], ["fever", "DISEASE", 124, 129], ["erythema", "DISEASE", 150, 158], ["patient", "ORGANISM", 4, 11], ["HPeV-3", "CELL", 75, 81], ["neonates", "ORGANISM", 97, 105], ["patient", "SPECIES", 4, 11], ["HPeV", "PROBLEM", 75, 79], ["3 infection in 2 neonates", "PROBLEM", 80, 105], ["prolonged fever", "PROBLEM", 114, 129], ["palmar-plantar erythema", "PROBLEM", 135, 158], ["palmar", "ANATOMY", 135, 141], ["plantar", "ANATOMY", 142, 149], ["erythema", "OBSERVATION", 150, 158]]], ["Elevated AST, LDH, and ferritin levels were characteristic laboratory findings in both cases, suggesting tissue damage caused by hypercytokinemia.", [["tissue", "ANATOMY", 105, 111], ["tissue damage", "DISEASE", 105, 118], ["hypercytokinemia", "DISEASE", 129, 145], ["AST", "GENE_OR_GENE_PRODUCT", 9, 12], ["LDH", "GENE_OR_GENE_PRODUCT", 14, 17], ["ferritin", "GENE_OR_GENE_PRODUCT", 23, 31], ["tissue", "TISSUE", 105, 111], ["AST", "PROTEIN", 9, 12], ["LDH", "PROTEIN", 14, 17], ["ferritin", "PROTEIN", 23, 31], ["Elevated AST", "PROBLEM", 0, 12], ["LDH", "TEST", 14, 17], ["ferritin levels", "TEST", 23, 38], ["tissue damage", "PROBLEM", 105, 118], ["hypercytokinemia", "PROBLEM", 129, 145], ["AST", "ANATOMY", 9, 12], ["LDH", "ANATOMY", 14, 17], ["ferritin", "ANATOMY", 23, 31], ["suggesting", "UNCERTAINTY", 94, 104], ["tissue damage", "OBSERVATION", 105, 118], ["hypercytokinemia", "OBSERVATION", 129, 145]]], ["IVIG was administered in case 1 because severe systemic inflammatory responses were considered in the patient.", [["IVIG", "SIMPLE_CHEMICAL", 0, 4], ["patient", "ORGANISM", 102, 109], ["patient", "SPECIES", 102, 109], ["IVIG", "TREATMENT", 0, 4], ["severe systemic inflammatory responses", "PROBLEM", 40, 78], ["severe", "OBSERVATION_MODIFIER", 40, 46], ["systemic", "OBSERVATION_MODIFIER", 47, 55], ["inflammatory", "OBSERVATION", 56, 68]]], ["Case 2 displayed a milder clinical presentation, and the patient recovered spontaneously.DiscussionAlthough HPeV-3 has been known for only a decade, this virus has attracted the concern and attention of pediatricians.", [["HPeV-3", "CHEMICAL", 108, 114], ["patient", "ORGANISM", 57, 64], ["HPeV-3", "GENE_OR_GENE_PRODUCT", 108, 114], ["patient", "SPECIES", 57, 64], ["HPeV", "TEST", 108, 112], ["this virus", "PROBLEM", 149, 159]]], ["Associations between this virus and severe diseases such as sepsis-like illness and meningoencephalitis in neonates and young infants have been widely described3).", [["sepsis", "DISEASE", 60, 66], ["illness", "DISEASE", 72, 79], ["meningoencephalitis", "DISEASE", 84, 103], ["neonates", "ORGANISM", 107, 115], ["infants", "ORGANISM", 126, 133], ["infants", "SPECIES", 126, 133], ["this virus", "PROBLEM", 21, 31], ["severe diseases", "PROBLEM", 36, 51], ["sepsis", "PROBLEM", 60, 66], ["illness", "PROBLEM", 72, 79], ["meningoencephalitis", "PROBLEM", 84, 103], ["severe", "OBSERVATION_MODIFIER", 36, 42], ["diseases", "OBSERVATION", 43, 51], ["sepsis", "OBSERVATION", 60, 66], ["meningoencephalitis", "OBSERVATION", 84, 103]]], ["However, the principle features of sepsis-like conditions are also common in severe infectious diseases caused by other pathogens, particularly enteroviruses.", [["sepsis", "DISEASE", 35, 41], ["infectious diseases", "DISEASE", 84, 103], ["enteroviruses", "DISEASE", 144, 157], ["sepsis", "PROBLEM", 35, 41], ["severe infectious diseases", "PROBLEM", 77, 103], ["other pathogens", "PROBLEM", 114, 129], ["enteroviruses", "PROBLEM", 144, 157], ["sepsis", "OBSERVATION", 35, 41], ["severe", "OBSERVATION_MODIFIER", 77, 83], ["infectious", "OBSERVATION", 84, 94], ["pathogens", "OBSERVATION", 120, 129]]], ["A prospective study showed that it was not possible to distinguish neonatal HPeV infection (most are HPeV-3) from enterovirus infection on the basis of clinical signs5).", [["HPeV infection", "DISEASE", 76, 90], ["enterovirus infection", "DISEASE", 114, 135], ["enterovirus", "ORGANISM", 114, 125], ["HPeV", "SPECIES", 76, 80], ["A prospective study", "TEST", 0, 19], ["neonatal HPeV infection", "PROBLEM", 67, 90], ["HPeV", "TEST", 101, 105], ["enterovirus infection", "PROBLEM", 114, 135], ["HPeV", "OBSERVATION_MODIFIER", 76, 80], ["infection", "OBSERVATION", 81, 90], ["infection", "OBSERVATION", 126, 135]]], ["Although an association between a distinctive pattern of white matter injury and HPeV-3 encephalitis has been suggested10), this pattern is also seen in enterovirus meningoencephalitis11).", [["white matter", "ANATOMY", 57, 69], ["white matter injury", "DISEASE", 57, 76], ["encephalitis", "DISEASE", 88, 100], ["enterovirus meningoencephalitis", "DISEASE", 153, 184], ["HPeV-3", "GENE_OR_GENE_PRODUCT", 81, 87], ["white matter injury", "PROBLEM", 57, 76], ["HPeV", "PROBLEM", 81, 85], ["encephalitis", "PROBLEM", 88, 100], ["enterovirus meningoencephalitis", "PROBLEM", 153, 184], ["white matter injury", "OBSERVATION", 57, 76]]], ["PCR is commonly used to diagnose viral infections; however, PCR for HPeV-3 is not commercially available6).", [["viral infections", "DISEASE", 33, 49], ["HPeV-3", "GENE_OR_GENE_PRODUCT", 68, 74], ["PCR", "TEST", 0, 3], ["viral infections", "PROBLEM", 33, 49], ["PCR", "TEST", 60, 63], ["HPeV", "TEST", 68, 72]]], ["Thus, the diagnosis of HPeV-3 infection is difficult in current clinical practice.", [["infection", "DISEASE", 30, 39], ["HPeV-3", "ORGANISM", 23, 29], ["HPeV-3", "SPECIES", 23, 29], ["HPeV", "PROBLEM", 23, 27], ["3 infection", "PROBLEM", 28, 39], ["HPeV", "OBSERVATION", 23, 27], ["infection", "OBSERVATION", 30, 39]]], ["In Korea, only a few studies have been conducted on clinical features of HPeV-3 infection9).DiscussionRecently, distinctive clinical features, including palmar-plantar erythema and hyperferritinemia, have been suggested as diagnostic indicators of an HPeV-3 infection4678).", [["palmar", "ANATOMY", 153, 159], ["plantar", "ANATOMY", 160, 167], ["erythema", "DISEASE", 168, 176], ["hyperferritinemia", "DISEASE", 181, 198], ["infection", "DISEASE", 258, 267], ["HPeV-3", "GENE_OR_GENE_PRODUCT", 73, 79], ["a few studies", "TEST", 15, 28], ["HPeV", "PROBLEM", 73, 77], ["distinctive clinical features", "PROBLEM", 112, 141], ["palmar-plantar erythema", "PROBLEM", 153, 176], ["hyperferritinemia", "PROBLEM", 181, 198], ["an HPeV-3 infection", "PROBLEM", 248, 267], ["palmar", "ANATOMY", 153, 159], ["plantar", "ANATOMY", 160, 167], ["erythema", "OBSERVATION", 168, 176], ["hyperferritinemia", "OBSERVATION", 181, 198]]], ["Although a rash was known to frequently accompany HPeV-3 infection2), the characteristics of the rash attracted little attention as a diagnostic clue.", [["rash", "DISEASE", 11, 15], ["rash", "DISEASE", 97, 101], ["HPeV-3", "GENE_OR_GENE_PRODUCT", 50, 56], ["a rash", "PROBLEM", 9, 15], ["HPeV", "PROBLEM", 50, 54], ["the rash", "PROBLEM", 93, 101]]], ["Recent studies have described distinctive palmar-plantar erythema or reddening of skin rashes in neonates and infants with an HPeV-3 infection47).", [["palmar", "ANATOMY", 42, 48], ["plantar", "ANATOMY", 49, 56], ["skin", "ANATOMY", 82, 86], ["erythema", "DISEASE", 57, 65], ["skin rashes", "DISEASE", 82, 93], ["palmar", "ORGANISM_SUBDIVISION", 42, 48], ["skin", "ORGAN", 82, 86], ["neonates", "ORGANISM", 97, 105], ["infants", "ORGANISM", 110, 117], ["infants", "SPECIES", 110, 117], ["Recent studies", "TEST", 0, 14], ["distinctive palmar-plantar erythema", "PROBLEM", 30, 65], ["reddening of skin rashes in neonates", "PROBLEM", 69, 105], ["an HPeV", "PROBLEM", 123, 130], ["distinctive", "OBSERVATION_MODIFIER", 30, 41], ["palmar", "ANATOMY", 42, 48], ["plantar", "ANATOMY", 49, 56], ["erythema", "OBSERVATION", 57, 65], ["reddening", "OBSERVATION_MODIFIER", 69, 78], ["skin", "ANATOMY", 82, 86], ["rashes", "OBSERVATION", 87, 93]]], ["As observed in our study, the characteristic rash is erythematous and limited to the palms and soles47).", [["palms", "ANATOMY", 85, 90], ["soles", "ANATOMY", 95, 100], ["rash", "DISEASE", 45, 49], ["rash", "PATHOLOGICAL_FORMATION", 45, 49], ["palms", "ORGANISM_SUBDIVISION", 85, 90], ["our study", "TEST", 15, 24], ["the characteristic rash", "PROBLEM", 26, 49], ["erythematous", "PROBLEM", 53, 65], ["rash", "OBSERVATION", 45, 49], ["erythematous", "OBSERVATION", 53, 65]]], ["Yuzurihara et al.4) reported nine neonates and infants with HPeV-3 infection.", [["infection", "DISEASE", 67, 76], ["neonates", "ORGANISM", 34, 42], ["infants", "ORGANISM", 47, 54], ["HPeV-3", "ORGANISM", 60, 66], ["infants", "SPECIES", 47, 54], ["HPeV", "PROBLEM", 60, 64], ["3 infection", "PROBLEM", 65, 76], ["infection", "OBSERVATION", 67, 76]]], ["The median age of onset in the patients was 31 days4).", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39]]], ["In 5 of 9 patients (55%), palmar-plantar reddening appeared on day 3 after fever onset, on average, and fever persisted for 3\u20135 days (median, 4 days)4).", [["palmar", "ANATOMY", 26, 32], ["plantar", "ANATOMY", 33, 40], ["fever", "DISEASE", 75, 80], ["fever", "DISEASE", 104, 109], ["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["palmar-plantar reddening", "PROBLEM", 26, 50], ["fever onset", "PROBLEM", 75, 86], ["fever", "PROBLEM", 104, 109], ["palmar", "ANATOMY", 26, 32], ["plantar", "ANATOMY", 33, 40], ["reddening", "OBSERVATION", 41, 50]]], ["Shoji et al.7) also reported palmar-plantar erythema in 12 of 15 neonates (80%) and young infants with an HPeV-3 infection.", [["palmar-plantar erythema", "ANATOMY", 29, 52], ["erythema", "DISEASE", 44, 52], ["infection", "DISEASE", 113, 122], ["palmar-plantar erythema", "PATHOLOGICAL_FORMATION", 29, 52], ["infants", "ORGANISM", 90, 97], ["HPeV-3", "GENE_OR_GENE_PRODUCT", 106, 112], ["infants", "SPECIES", 90, 97], ["palmar-plantar erythema", "PROBLEM", 29, 52], ["an HPeV-3 infection", "PROBLEM", 103, 122], ["palmar", "ANATOMY", 29, 35], ["plantar", "ANATOMY", 36, 43], ["erythema", "OBSERVATION", 44, 52], ["HPeV", "OBSERVATION", 106, 110], ["infection", "OBSERVATION", 113, 122]]], ["Fever persisted for a median of 3 days (range, 1\u20134 days), and the distinctive skin rash developed at a mean of 3 days (range, 1\u20135 days) after fever onset7).", [["skin", "ANATOMY", 78, 82], ["Fever", "DISEASE", 0, 5], ["rash", "DISEASE", 83, 87], ["fever", "DISEASE", 142, 147], ["skin", "ORGAN", 78, 82], ["Fever", "PROBLEM", 0, 5], ["the distinctive skin rash", "PROBLEM", 62, 87], ["fever onset7", "PROBLEM", 142, 154], ["distinctive", "OBSERVATION_MODIFIER", 66, 77], ["skin", "ANATOMY", 78, 82], ["rash", "OBSERVATION", 83, 87]]], ["In our cases, the rash developed at 4\u20135 days after fever onset.", [["rash", "DISEASE", 18, 22], ["fever", "DISEASE", 51, 56], ["rash", "PATHOLOGICAL_FORMATION", 18, 22], ["the rash", "PROBLEM", 14, 22], ["fever onset", "PROBLEM", 51, 62], ["rash", "OBSERVATION", 18, 22]]], ["Thus, palmar-plantar erythema or reddening seemed to develop just before defervescence, approximately 3\u20135 days after fever onset.", [["palmar", "ANATOMY", 6, 12], ["plantar", "ANATOMY", 13, 20], ["erythema", "DISEASE", 21, 29], ["fever", "DISEASE", 117, 122], ["palmar-plantar erythema", "PROBLEM", 6, 29], ["reddening", "PROBLEM", 33, 42], ["fever onset", "PROBLEM", 117, 128], ["palmar", "ANATOMY", 6, 12], ["plantar", "ANATOMY", 13, 20], ["erythema", "OBSERVATION", 21, 29], ["reddening", "OBSERVATION", 33, 42]]], ["This pattern of fever and rash is also seen in exanthema subitum caused by human herpes virus (HHV)-612).", [["exanthema subitum", "ANATOMY", 47, 64], ["fever", "DISEASE", 16, 21], ["rash", "DISEASE", 26, 30], ["exanthema subitum", "DISEASE", 47, 64], ["human herpes virus", "DISEASE", 75, 93], ["exanthema subitum", "ORGANISM", 47, 64], ["human herpes virus", "ORGANISM", 75, 93], ["HHV)-612", "ORGANISM", 95, 103], ["human", "SPECIES", 75, 80], ["herpes virus", "SPECIES", 81, 93], ["exanthema subitum", "SPECIES", 47, 64], ["human herpes virus", "SPECIES", 75, 93], ["HHV", "SPECIES", 95, 98], ["fever", "PROBLEM", 16, 21], ["rash", "PROBLEM", 26, 30], ["exanthema subitum", "PROBLEM", 47, 64], ["human herpes virus", "PROBLEM", 75, 93], ["fever", "OBSERVATION", 16, 21], ["rash", "OBSERVATION", 26, 30]]], ["HHV-6 viremia can be detected during the febrile period (after 2 days of illness, before the onset of the rash), and anti-HHV-6 antibodies are first detected around the time of the rash onset (3 days of illness)12).", [["viremia", "DISEASE", 6, 13], ["febrile", "DISEASE", 41, 48], ["rash", "DISEASE", 106, 110], ["rash", "DISEASE", 181, 185], ["illness", "DISEASE", 203, 210], ["HHV-6", "ORGANISM", 0, 5], ["anti-HHV-6 antibodies", "GENE_OR_GENE_PRODUCT", 117, 138], ["anti-HHV-6 antibodies", "PROTEIN", 117, 138], ["HHV-6", "SPECIES", 0, 5], ["HHV", "PROBLEM", 0, 3], ["viremia", "PROBLEM", 6, 13], ["illness", "PROBLEM", 73, 80], ["the rash", "PROBLEM", 102, 110], ["anti-HHV-6 antibodies", "TEST", 117, 138], ["the rash onset", "PROBLEM", 177, 191], ["viremia", "OBSERVATION", 6, 13]]], ["The rash in exanthema subitum is thought to result from antigen-antibody complexes12).", [["exanthema subitum", "ANATOMY", 12, 29], ["rash", "DISEASE", 4, 8], ["exanthema subitum", "DISEASE", 12, 29], ["antigen-antibody complexes12", "PROTEIN", 56, 84], ["exanthema subitum", "SPECIES", 12, 29], ["The rash in exanthema subitum", "PROBLEM", 0, 29], ["antigen-antibody complexes", "TEST", 56, 82], ["rash", "OBSERVATION", 4, 8]]], ["A similar pathogenic mechanism of exanthem subitum might function in the rash observed with HPeV-3 infection.", [["exanthem subitum", "ANATOMY", 34, 50], ["rash", "DISEASE", 73, 77], ["infection", "DISEASE", 99, 108], ["exanthem subitum", "ORGANISM", 34, 50], ["rash", "PATHOLOGICAL_FORMATION", 73, 77], ["HPeV-3", "GENE_OR_GENE_PRODUCT", 92, 98], ["exanthem subitum", "SPECIES", 34, 50], ["HPeV-3", "SPECIES", 92, 98], ["exanthem subitum", "PROBLEM", 34, 50], ["the rash", "PROBLEM", 69, 77], ["HPeV", "PROBLEM", 92, 96], ["3 infection", "PROBLEM", 97, 108], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["pathogenic", "OBSERVATION_MODIFIER", 10, 20], ["exanthem", "OBSERVATION_MODIFIER", 34, 42], ["rash", "OBSERVATION", 73, 77], ["infection", "OBSERVATION", 99, 108]]], ["If so, palmar-plantar erythema might be a sign of clinical improvement in patients with an HPeV-3 infection.", [["palmar", "ANATOMY", 7, 13], ["plantar", "ANATOMY", 14, 21], ["erythema", "DISEASE", 22, 30], ["infection", "DISEASE", 98, 107], ["patients", "ORGANISM", 74, 82], ["HPeV-3", "ORGANISM", 91, 97], ["patients", "SPECIES", 74, 82], ["palmar-plantar erythema", "PROBLEM", 7, 30], ["an HPeV-3 infection", "PROBLEM", 88, 107], ["palmar", "ANATOMY", 7, 13], ["plantar", "ANATOMY", 14, 21], ["erythema", "OBSERVATION", 22, 30], ["HPeV", "OBSERVATION", 91, 95], ["infection", "OBSERVATION", 98, 107]]], ["Or, microvascular endothelial cells of the palms and soles might be susceptible to this virus.", [["microvascular endothelial cells", "ANATOMY", 4, 35], ["palms", "ANATOMY", 43, 48], ["soles", "ANATOMY", 53, 58], ["microvascular endothelial cells", "CELL", 4, 35], ["palms", "ORGANISM_SUBDIVISION", 43, 48], ["soles", "ORGANISM_SUBDIVISION", 53, 58], ["microvascular endothelial cells", "CELL_TYPE", 4, 35], ["this virus", "PROBLEM", 83, 93], ["microvascular", "ANATOMY", 4, 17], ["endothelial cells", "OBSERVATION", 18, 35], ["palms", "ANATOMY", 43, 48], ["soles", "ANATOMY", 53, 58]]], ["Compared with other HPeVs, HPeV-3 is known to use a different receptor to enter cells2).", [["cells2", "ANATOMY", 80, 86], ["HPeV-3", "GENE_OR_GENE_PRODUCT", 27, 33], ["cells2", "GENE_OR_GENE_PRODUCT", 80, 86], ["HPeVs", "PROTEIN", 20, 25], ["HPeV", "PROTEIN", 27, 31], ["cells2", "PROTEIN", 80, 86], ["other HPeVs", "TEST", 14, 25], ["HPeV", "TEST", 27, 31]]], ["However, there are no studies about immediate antibody responses after HPeV-3 infection as well as susceptibility of this virus to microvascular endothelial cells of the palm and soles.", [["microvascular endothelial cells", "ANATOMY", 131, 162], ["palm", "ANATOMY", 170, 174], ["soles", "ANATOMY", 179, 184], ["infection", "DISEASE", 78, 87], ["HPeV-3", "ORGANISM", 71, 77], ["microvascular endothelial cells", "CELL", 131, 162], ["palm", "ORGANISM_SUBDIVISION", 170, 174], ["soles", "ORGANISM_SUBDIVISION", 179, 184], ["microvascular endothelial cells", "CELL_TYPE", 131, 162], ["HPeV", "SPECIES", 71, 75], ["studies", "TEST", 22, 29], ["immediate antibody responses", "TEST", 36, 64], ["HPeV", "PROBLEM", 71, 75], ["3 infection", "PROBLEM", 76, 87], ["this virus", "PROBLEM", 117, 127], ["infection", "OBSERVATION", 78, 87], ["microvascular endothelial cells", "OBSERVATION", 131, 162], ["palm", "ANATOMY_MODIFIER", 170, 174], ["soles", "ANATOMY", 179, 184]]], ["The pathogenesis of the distinctive rash in HPeV-3 infection is still unknown.DiscussionHyperferritinemia seems to be another diagnostic clue for HPeV-3 infection.", [["rash", "DISEASE", 36, 40], ["infection", "DISEASE", 51, 60], ["Hyperferritinemia", "DISEASE", 88, 105], ["infection", "DISEASE", 153, 162], ["rash", "PATHOLOGICAL_FORMATION", 36, 40], ["HPeV-3", "ORGANISM", 44, 50], ["HPeV-3", "ORGANISM", 146, 152], ["HPeV-3", "SPECIES", 44, 50], ["HPeV-3", "SPECIES", 146, 152], ["the distinctive rash", "PROBLEM", 20, 40], ["HPeV", "PROBLEM", 44, 48], ["3 infection", "PROBLEM", 49, 60], ["Hyperferritinemia", "PROBLEM", 88, 105], ["HPeV", "PROBLEM", 146, 150], ["3 infection", "PROBLEM", 151, 162], ["distinctive", "OBSERVATION_MODIFIER", 24, 35], ["rash", "OBSERVATION", 36, 40], ["HPeV", "OBSERVATION", 44, 48], ["infection", "OBSERVATION", 51, 60], ["infection", "OBSERVATION", 153, 162]]], ["A recent study showed that the ferritin level was significantly higher in patients with HPeV-3 infection (mean, 2,437 ng/mL) than in those infected with other pathogens, including enterovirus (mean, 552 ng/mL) and respiratory syncytial virus (mean, 237 ng/mL)6).", [["infection", "DISEASE", 95, 104], ["respiratory syncytial virus", "DISEASE", 214, 241], ["ferritin", "GENE_OR_GENE_PRODUCT", 31, 39], ["patients", "ORGANISM", 74, 82], ["HPeV-3", "GENE_OR_GENE_PRODUCT", 88, 94], ["enterovirus", "ORGANISM", 180, 191], ["respiratory syncytial virus", "ORGANISM", 214, 241], ["ferritin", "PROTEIN", 31, 39], ["patients", "SPECIES", 74, 82], ["respiratory syncytial virus", "SPECIES", 214, 241], ["A recent study", "TEST", 0, 14], ["the ferritin level", "TEST", 27, 45], ["HPeV", "PROBLEM", 88, 92], ["3 infection", "PROBLEM", 93, 104], ["mean", "TEST", 106, 110], ["other pathogens", "PROBLEM", 153, 168], ["enterovirus", "PROBLEM", 180, 191], ["respiratory syncytial virus", "PROBLEM", 214, 241], ["respiratory syncytial", "ANATOMY", 214, 235]]], ["They suggested that ferritin level over than 1,000 ng/mL might be significant findings of HPeV-3 infection6).", [["ferritin", "GENE_OR_GENE_PRODUCT", 20, 28], ["HPeV-3", "GENE_OR_GENE_PRODUCT", 90, 96], ["ferritin", "PROTEIN", 20, 28], ["ferritin level", "TEST", 20, 34], ["HPeV", "PROBLEM", 90, 94], ["HPeV", "OBSERVATION", 90, 94]]], ["Ferritin levels were high on days 4\u20135 after fever onset6), consistent with the time of defervescence.", [["fever", "DISEASE", 44, 49], ["Ferritin", "GENE_OR_GENE_PRODUCT", 0, 8], ["Ferritin", "PROTEIN", 0, 8], ["Ferritin levels", "TEST", 0, 15], ["fever onset6", "PROBLEM", 44, 56], ["defervescence", "PROBLEM", 87, 100], ["consistent with", "UNCERTAINTY", 59, 74], ["defervescence", "OBSERVATION", 87, 100]]], ["That study also found that the WBC and platelet counts were significantly lower in HPeV-3 infection than in other infections6).", [["WBC", "ANATOMY", 31, 34], ["platelet", "ANATOMY", 39, 47], ["infection", "DISEASE", 90, 99], ["WBC", "CELL", 31, 34], ["platelet", "CELL", 39, 47], ["HPeV-3", "GENE_OR_GENE_PRODUCT", 83, 89], ["WBC", "CELL_TYPE", 31, 34], ["platelet", "CELL_TYPE", 39, 47], ["HPeV-3", "SPECIES", 83, 89], ["That study", "TEST", 0, 10], ["the WBC", "TEST", 27, 34], ["platelet counts", "TEST", 39, 54], ["HPeV", "PROBLEM", 83, 87], ["3 infection", "PROBLEM", 88, 99]]], ["Yuzurihara et al.4) also showed high level of ferritin (median, 2,307 ng/mL) and LDH (median, 643 U/L) in neonates with HPeV-3 infection.", [["infection", "DISEASE", 127, 136], ["ferritin", "GENE_OR_GENE_PRODUCT", 46, 54], ["LDH", "GENE_OR_GENE_PRODUCT", 81, 84], ["HPeV-3", "GENE_OR_GENE_PRODUCT", 120, 126], ["ferritin", "PROTEIN", 46, 54], ["LDH", "PROTEIN", 81, 84], ["HPeV-3", "SPECIES", 120, 126], ["high level of ferritin", "PROBLEM", 32, 54], ["LDH", "TEST", 81, 84], ["U/L)", "TEST", 98, 102], ["neonates", "TEST", 106, 114], ["HPeV", "PROBLEM", 120, 124], ["3 infection", "PROBLEM", 125, 136], ["LDH", "ANATOMY", 81, 84], ["HPeV", "OBSERVATION", 120, 124], ["infection", "OBSERVATION", 127, 136]]], ["Hyperferritinemia, cytopenia, and/or high LDH are assumed to reflect hypercytokinemia6).", [["Hyperferritinemia", "DISEASE", 0, 17], ["cytopenia", "DISEASE", 19, 28], ["LDH", "GENE_OR_GENE_PRODUCT", 42, 45], ["hypercytokinemia6", "GENE_OR_GENE_PRODUCT", 69, 86], ["LDH", "PROTEIN", 42, 45], ["Hyperferritinemia", "PROBLEM", 0, 17], ["cytopenia", "PROBLEM", 19, 28], ["high LDH", "PROBLEM", 37, 45], ["hypercytokinemia6", "PROBLEM", 69, 86], ["cytopenia", "OBSERVATION", 19, 28]]], ["Based on these findings, they suggested HPeV-3 infection should be considered possible causes of hypercytokinemia46).", [["infection", "DISEASE", 47, 56], ["HPeV-3", "GENE_OR_GENE_PRODUCT", 40, 46], ["hypercytokinemia46", "GENE_OR_GENE_PRODUCT", 97, 115], ["HPeV-3 infection", "PROBLEM", 40, 56]]], ["The laboratory findings in our 2 cases were similar to the previous studies46) and characterized by elevated markers of tissue injury, including AST, LDH, and ferritin.", [["tissue", "ANATOMY", 120, 126], ["tissue injury", "DISEASE", 120, 133], ["tissue", "TISSUE", 120, 126], ["AST", "SIMPLE_CHEMICAL", 145, 148], ["LDH", "GENE_OR_GENE_PRODUCT", 150, 153], ["ferritin", "GENE_OR_GENE_PRODUCT", 159, 167], ["AST", "PROTEIN", 145, 148], ["LDH", "PROTEIN", 150, 153], ["ferritin", "PROTEIN", 159, 167], ["the previous studies", "TEST", 55, 75], ["elevated markers of tissue injury", "PROBLEM", 100, 133], ["AST", "TEST", 145, 148], ["LDH", "TEST", 150, 153], ["ferritin", "TEST", 159, 167], ["elevated", "OBSERVATION_MODIFIER", 100, 108], ["markers of tissue", "OBSERVATION_MODIFIER", 109, 126], ["injury", "OBSERVATION", 127, 133], ["LDH", "ANATOMY", 150, 153]]], ["Prolonged fever over than 5 days was observed in both 2 cases.", [["fever", "DISEASE", 10, 15], ["Prolonged fever", "PROBLEM", 0, 15], ["fever", "OBSERVATION", 10, 15]]], ["Thus, as suggestion of the previous studies46), hypercytokinemia might contribute to clinical and laboratory features of our cases, which can be interpreted with severe systemic inflammatory response to HPeV-3 infection.DiscussionManagement of HPeV-3 infection is limited to supportive care.", [["hypercytokinemia", "DISEASE", 48, 64], ["infection", "DISEASE", 210, 219], ["infection", "DISEASE", 251, 260], ["HPeV-3", "GENE_OR_GENE_PRODUCT", 203, 209], ["HPeV-3", "ORGANISM", 244, 250], ["HPeV-3", "SPECIES", 244, 250], ["the previous studies", "TEST", 23, 43], ["hypercytokinemia", "PROBLEM", 48, 64], ["severe systemic inflammatory response", "PROBLEM", 162, 199], ["HPeV", "PROBLEM", 203, 207], ["3 infection", "PROBLEM", 208, 219], ["HPeV", "PROBLEM", 244, 248], ["3 infection", "PROBLEM", 249, 260], ["supportive care", "TREATMENT", 275, 290], ["severe", "OBSERVATION_MODIFIER", 162, 168], ["systemic", "OBSERVATION_MODIFIER", 169, 177], ["inflammatory", "OBSERVATION", 178, 190]]], ["There are no effective antiviral drugs against HPeV13).", [["effective antiviral drugs", "TREATMENT", 13, 38], ["no", "UNCERTAINTY", 10, 12], ["effective", "OBSERVATION_MODIFIER", 13, 22]]], ["IVIG have been used as supportive therapy in the severe cases of HPeV infection based on potential benefit in early IVIG treatment of severe enterovirus infection13).", [["infection", "DISEASE", 70, 79], ["enterovirus infection", "DISEASE", 141, 162], ["IVIG", "SIMPLE_CHEMICAL", 0, 4], ["HPeV", "SPECIES", 65, 69], ["IVIG", "TREATMENT", 0, 4], ["supportive therapy", "TREATMENT", 23, 41], ["HPeV infection", "PROBLEM", 65, 79], ["early IVIG treatment", "TREATMENT", 110, 130], ["severe enterovirus infection", "PROBLEM", 134, 162], ["infection", "OBSERVATION", 70, 79], ["severe", "OBSERVATION_MODIFIER", 134, 140], ["enterovirus", "OBSERVATION", 141, 152]]], ["An anecdotal report showed successful IVIG treatment of HPeV-1 infection in myocarditis in a young infant13).", [["infection", "DISEASE", 63, 72], ["myocarditis", "DISEASE", 76, 87], ["IVIG", "SIMPLE_CHEMICAL", 38, 42], ["HPeV-1", "ORGANISM", 56, 62], ["infant", "SPECIES", 99, 105], ["HPeV-1", "SPECIES", 56, 62], ["successful IVIG treatment", "TREATMENT", 27, 52], ["HPeV", "PROBLEM", 56, 60], ["1 infection", "PROBLEM", 61, 72], ["myocarditis", "PROBLEM", 76, 87], ["myocarditis", "OBSERVATION", 76, 87]]], ["Some researchers suggested that IVIG might be an option for preventing or treating severe HPeV-3 infection based on lower titers of neutralizing antibody in young infants with severe disease related to this virus14).", [["IVIG", "CHEMICAL", 32, 36], ["infection", "DISEASE", 97, 106], ["IVIG", "SIMPLE_CHEMICAL", 32, 36], ["HPeV-3", "ORGANISM", 90, 96], ["infants", "ORGANISM", 163, 170], ["neutralizing antibody", "PROTEIN", 132, 153], ["infants", "SPECIES", 163, 170], ["IVIG", "TREATMENT", 32, 36], ["severe HPeV", "PROBLEM", 83, 94], ["3 infection", "PROBLEM", 95, 106], ["neutralizing antibody", "PROBLEM", 132, 153], ["severe disease", "PROBLEM", 176, 190], ["this virus", "PROBLEM", 202, 212], ["severe", "OBSERVATION_MODIFIER", 176, 182], ["disease", "OBSERVATION", 183, 190]]], ["Commercially available IVIG seems to contain high titers of neutralizing antibody against HPeV-314).", [["HPeV-314", "CHEMICAL", 90, 98], ["IVIG", "SIMPLE_CHEMICAL", 23, 27], ["neutralizing antibody", "PROTEIN", 60, 81], ["HPeV", "PROTEIN", 90, 94], ["HPeV-314", "SPECIES", 90, 98], ["IVIG", "TREATMENT", 23, 27], ["neutralizing antibody", "TEST", 60, 81], ["HPeV", "TEST", 90, 94]]], ["However, a recent study showed most HPeV-3 strains might be difficult to neutralize in vivo by IVIG15).", [["HPeV-3", "GENE_OR_GENE_PRODUCT", 36, 42], ["IVIG15", "PROTEIN", 95, 101], ["a recent study", "TEST", 9, 23], ["HPeV", "TEST", 36, 40]]], ["Thus, it is unclear whether IVIG is a useful treatment for HPeV-3 infection.", [["infection", "DISEASE", 66, 75], ["IVIG", "SIMPLE_CHEMICAL", 28, 32], ["HPeV-3", "ORGANISM", 59, 65], ["HPeV-3", "SPECIES", 59, 65], ["IVIG", "TREATMENT", 28, 32], ["a useful treatment", "TREATMENT", 36, 54], ["HPeV", "PROBLEM", 59, 63], ["3 infection", "PROBLEM", 64, 75], ["infection", "OBSERVATION", 66, 75]]], ["In our case, IVIG was administrated at 5th days of fever, which was coincides with the timing of the end of fever in patients with HPeV-3 infection of other studies (fever duration, 3\u20135 days).", [["fever", "DISEASE", 51, 56], ["fever", "DISEASE", 108, 113], ["infection", "DISEASE", 138, 147], ["fever", "DISEASE", 166, 171], ["IVIG", "SIMPLE_CHEMICAL", 13, 17], ["patients", "ORGANISM", 117, 125], ["HPeV-3", "ORGANISM", 131, 137], ["patients", "SPECIES", 117, 125], ["IVIG", "TREATMENT", 13, 17], ["fever", "PROBLEM", 51, 56], ["fever", "PROBLEM", 108, 113], ["HPeV", "PROBLEM", 131, 135], ["other studies", "TEST", 151, 164], ["fever duration", "PROBLEM", 166, 180], ["fever", "OBSERVATION", 108, 113]]], ["Thus, we do not conclude whether IVIG is responsible in symptoms improvement in our case 1 or not.", [["IVIG", "SIMPLE_CHEMICAL", 33, 37], ["IVIG", "TREATMENT", 33, 37], ["symptoms", "PROBLEM", 56, 64]]], ["Considering disease severity in neonatal HPeV infection, development of antiviral agent and randomized studies to prove the efficacy of IVIG treatment in HPeV-3 infection will be necessary.DiscussionIn clinical practice where virology testing is not easily accessible, clinical features like palmar-plantar erythema and/or hyperferritinemia might be helpful to diagnose HPeV-3 infection.", [["palmar", "ANATOMY", 292, 298], ["plantar", "ANATOMY", 299, 306], ["HPeV infection", "DISEASE", 41, 55], ["infection", "DISEASE", 161, 170], ["erythema", "DISEASE", 307, 315], ["hyperferritinemia", "DISEASE", 323, 340], ["infection", "DISEASE", 377, 386], ["IVIG", "SIMPLE_CHEMICAL", 136, 140], ["HPeV-3", "ORGANISM", 154, 160], ["palmar", "ORGANISM_SUBDIVISION", 292, 298], ["HPeV-3", "GENE_OR_GENE_PRODUCT", 370, 376], ["HPeV", "SPECIES", 41, 45], ["HPeV-3", "SPECIES", 154, 160], ["HPeV-3", "SPECIES", 370, 376], ["disease severity", "PROBLEM", 12, 28], ["neonatal HPeV infection", "PROBLEM", 32, 55], ["antiviral agent", "TREATMENT", 72, 87], ["randomized studies", "TEST", 92, 110], ["IVIG treatment", "TREATMENT", 136, 150], ["HPeV", "PROBLEM", 154, 158], ["3 infection", "PROBLEM", 159, 170], ["virology testing", "TEST", 226, 242], ["palmar-plantar erythema", "PROBLEM", 292, 315], ["hyperferritinemia", "PROBLEM", 323, 340], ["HPeV", "PROBLEM", 370, 374], ["3 infection", "PROBLEM", 375, 386], ["HPeV infection", "OBSERVATION", 41, 55], ["palmar", "ANATOMY", 292, 298], ["plantar", "ANATOMY", 299, 306], ["erythema", "OBSERVATION", 307, 315], ["infection", "OBSERVATION", 377, 386]]], ["We recommend testing for ferritin in febrile neonatal patients with palmar-plantar erythema.", [["palmar", "ANATOMY", 68, 74], ["plantar", "ANATOMY", 75, 82], ["febrile", "DISEASE", 37, 44], ["erythema", "DISEASE", 83, 91], ["ferritin", "GENE_OR_GENE_PRODUCT", 25, 33], ["patients", "ORGANISM", 54, 62], ["plantar erythema", "PATHOLOGICAL_FORMATION", 75, 91], ["ferritin", "PROTEIN", 25, 33], ["patients", "SPECIES", 54, 62], ["testing", "TEST", 13, 20], ["ferritin", "TEST", 25, 33], ["palmar-plantar erythema", "PROBLEM", 68, 91], ["palmar", "ANATOMY", 68, 74], ["plantar", "ANATOMY", 75, 82], ["erythema", "OBSERVATION", 83, 91]]], ["However, additional studies will be necessary to demonstrate the diagnostic value of these features in HPeV-3 infection.", [["infection", "DISEASE", 110, 119], ["HPeV-3", "ORGANISM", 103, 109], ["HPeV-3", "SPECIES", 103, 109], ["additional studies", "TEST", 9, 27], ["HPeV", "PROBLEM", 103, 107], ["3 infection", "PROBLEM", 108, 119], ["HPeV", "OBSERVATION", 103, 107], ["infection", "OBSERVATION", 110, 119]]], ["If these findings are unique to HPeV-3 infection, pathogenic mechanisms should be studied.", [["infection", "DISEASE", 39, 48], ["HPeV-3", "ORGANISM", 32, 38], ["HPeV-3", "SPECIES", 32, 38], ["HPeV", "PROBLEM", 32, 36], ["3 infection", "PROBLEM", 37, 48], ["pathogenic mechanisms", "PROBLEM", 50, 71], ["infection", "OBSERVATION", 39, 48]]]], "PMC7120488": [["14.1 Intravasale infectiesInfecties in het hart en de bloedbaan worden intravasale of endovasculaire infectiesgenoemd.", [["Intravasale infecties", "PROBLEM", 5, 26], ["endovasculaire infectiesgenoemd", "PROBLEM", 86, 117], ["endovasculaire infectiesgenoemd", "OBSERVATION", 86, 117]]], ["De circulatie van bloed door het hart is essentieel voor de aanvoer van zuurstof en voedingstoffen naar weefsel en organen en voor de afvoer van afvalstoffen.", [["De circulatie van bloed door het hart is essentieel voor de aanvoer van zuurstof en voedingstoffen naar weefsel en organen en voor de afvoer van afvalstoffen", "SPECIES", 0, 157]]], ["In principe bevat het intravasale systeem geen micro-organismen.", [["micro-organismen", "PROBLEM", 47, 63]]], ["Als micro-organismen in de bloedbaan komen, worden ze snel verspreid, hetzij vrij in plasma, hetzij gehecht aan of in de bloedcellen.", [["plasma", "ANATOMY", 85, 91], ["plasma", "ORGANISM_SUBSTANCE", 85, 91], ["Als micro-organismen", "PROBLEM", 0, 20]]], ["Binnen twee minuten bereiken ze dan een capillair systeem waarin ze kunnen achterblijven.", [["Binnen twee minuten bereiken ze dan", "TREATMENT", 0, 35]]], ["In weefsels en organen kunnen ze soms aan specifieke cellen hechten (tropisme ) en na groei specifieke infecties van die weefsels of organen veroorzaken (bijv. hepatitis B-virus in de lever, meningokokken in de meningen).", [["hepatitis B", "DISEASE", 160, 171], ["hepatitis B-virus", "ORGANISM", 160, 177], ["hepatitis B-virus", "SPECIES", 160, 177], ["hepatitis B-virus", "SPECIES", 160, 177], ["hepatitis B", "PROBLEM", 160, 171]]], ["Andere micro-organismen veroorzaken infecties door in het bloed, of de cellen in het bloed (bijv. plasmodiumsoorten, de oorzaak van malaria), in bloedvaten, of in het hart te groeien.", [["malaria", "DISEASE", 132, 139]]], ["Deze infecties worden intravasale infecties genoemd.14.1 Intravasale infectiesOp welke wijze komen micro-organismen in de bloedbaan terecht?", [["Deze infecties", "PROBLEM", 0, 14], ["Intravasale infecties", "PROBLEM", 57, 78]]], ["Dagelijks zijn kortdurend bacteri\u00ebn aanwezig in het bloed, bijvoorbeeld uit de mondholte na tandenpoetsen of uit de darm na defecatie.", [["na", "CHEMICAL", 121, 123]]], ["De bacteri\u00ebmie na tandenpoetsen of defecatie wordt transi\u00ebnt genoemd, omdat na enkele minuten de bacteri\u00ebn door het reticulo-endotheliale systeem zijn geklaard en het bloed weer vrij van bacteri\u00ebn is.14.1 Intravasale infectiesMedische onderzoeken en ingrepen waardoor het slijmvlies wordt beschadigd, kunnen ook resulteren in een transi\u00ebnte bacteri\u00ebmie (Tabel 14.2).", [["na", "CHEMICAL", 15, 17], ["na", "CHEMICAL", 76, 78], ["Intravasale infecties", "PROBLEM", 205, 226]]], ["Door beschadiging van slijmvliezen bij geslachtsverkeer kunnen verwekkers van via bloed overdraagbare aandoeningen, bijvoorbeeld hepatitis B-virus en hiv, ook de bloedbaan bereiken.", [["hepatitis B", "DISEASE", 129, 140], ["aandoeningen", "TREATMENT", 102, 114], ["hepatitis B", "TREATMENT", 129, 140]]], ["Via een steek van bloedzuigende insecten (muggen, vlooien, luizen, mijten en teken) kunnen virussen, bacteri\u00ebn, protozo\u00ebn en sommige parasieten de bloedbaan bereiken.14.1 Intravasale infectiesEen derde oorzaak van de aanwezigheid van micro-organismen in de bloedbaan is een bestaande infectie in weefsels of organen.", [["vlooien", "TREATMENT", 50, 57], ["bacteri\u00ebn", "TREATMENT", 101, 110], ["protozo\u00ebn", "TREATMENT", 112, 121], ["Intravasale infecties", "PROBLEM", 171, 192], ["een bestaande", "OBSERVATION", 270, 283]]], ["Vanuit de infectiehaard bereiken micro-organismen via lymfogene afvoer de bloedbaan en kan, indien het een bacteri\u00eble infectie betreft, secundair een bacteri\u00ebmie ontstaan.14.1 Intravasale infectiesUrineweg- en luchtweginfecties zijn dikwijls deporte d\u2019entr\u00e9e voor een bacteri\u00ebmie.14.1 Intravasale infectiesIntravasale infecties worden onderscheiden in primaire en secundaire infecties.", [["Intravasale infecties", "TEST", 176, 197], ["Urineweg", "TEST", 197, 205], ["Intravasale infecties", "PROBLEM", 285, 306]]], ["Primaire intravasale infecties ontstaan in de bloedbaan.", [["Primaire intravasale infecties", "PROBLEM", 0, 30]]], ["Men spreekt van een secundaire infectievan de bloedbaan als de primaire infectiehaard buiten de bloedbaan is gelegen.", [["Men", "SPECIES", 0, 3]]], ["Primaire intravasale infecties kunnen het gevolg zijn van een beschadiging van het capillaire bed in weefsel of van het endotheel van hart of bloedvaten.", [["bloedvaten", "CHEMICAL", 142, 152], ["Primaire intravasale infecties kunnen het gevolg zijn van een beschadiging van het capillaire", "SPECIES", 0, 93], ["Primaire intravasale infecties", "PROBLEM", 0, 30]]], ["Micro-organismen, meestal bacteri\u00ebn of gisten en veelal transi\u00ebnt aanwezig in de circulatie, kunnen ter plaatse van de beschadigingen hechten en uitgroeien.", [["Micro-organismen", "TEST", 0, 16]]], ["Bijvoorbeeld bij jonge kinderen kan door een trap tegen de enkel bij het voetballen het capillaire bed van de metafyse van een groeiend scheenbeen worden beschadigd.", [["een trap", "TREATMENT", 41, 49]]], ["Een transi\u00ebnte bacteri\u00ebmie doorStaphylococcus aureus kan aanleiding geven tot een ernstige infectie van het bot (osteomyelitis).", [["osteomyelitis", "DISEASE", 113, 126], ["Een transi\u00ebnte bacteri\u00ebmie doorStaphylococcus aureus", "ORGANISM", 0, 52], ["bacteri\u00ebmie doorStaphylococcus aureus", "SPECIES", 15, 52], ["Een transi\u00ebnte bacteri\u00ebmie doorStaphylococcus aureus kan aanleiding geven tot een ernstige infectie van het bot", "SPECIES", 0, 111], ["Een transi\u00ebnte bacteri\u00ebmie doorStaphylococcus aureus kan", "TREATMENT", 0, 56], ["osteomyelitis", "PROBLEM", 113, 126], ["osteomyelitis", "OBSERVATION", 113, 126]]], ["Endocarditis is een primaire intravasale infectie die zich bevindt op of in het endotheel van het hart, het endocardium.", [["endocardium", "ANATOMY", 108, 119], ["Endocarditis", "DISEASE", 0, 12], ["het endocardium", "TISSUE", 104, 119], ["Endocarditis", "PROBLEM", 0, 12], ["endocardium", "ANATOMY", 108, 119]]], ["Endarteriitis is een infectie die zich ontwikkelt op het endotheel van een arterie.", [["Endarteriitis", "DISEASE", 0, 13], ["Endarteriitis", "PROBLEM", 0, 13]]], ["Een infectie van een vene wordt aangeduid als purulente (trombo)flebitis.", [["Een infectie van een vene wordt aangeduid als purulente (trombo)flebitis", "SPECIES", 0, 72], ["als purulente (trombo)flebitis", "PROBLEM", 42, 72]]], ["Ook ge\u00efmplanteerde biomaterialen \u2013 bijvoorbeeld een hartkunstklep of een in de bloedbaan aangebrachte kunststof katheter, waarop zich gemakkelijk micro-organismen hechten \u2013 zijn vaak de oorzaak van primaire intravasale infecties.14.1 Intravasale infectiesIndien klinische verschijnselen ontstaan door in de bloedbaan circulerende micro-organismen, is er sprake van sepsis .14.2 Sepsis, oud en nieuw\u2018Deze pati\u00ebnt heeft een positieve bloedkweek.\u2019", [["sepsis", "DISEASE", 365, 371], ["Sepsis", "DISEASE", 378, 384], ["Intravasale infecties", "PROBLEM", 234, 255], ["van sepsis", "PROBLEM", 361, 371], ["Sepsis", "PROBLEM", 378, 384], ["Sepsis", "OBSERVATION", 378, 384]]], ["\u2018Mijnheer E. heeft een sepsis.\u2019", [["sepsis", "DISEASE", 23, 29], ["een sepsis", "PROBLEM", 19, 29], ["een sepsis", "OBSERVATION", 19, 29]]], ["\u2018Pati\u00ebnt D. in het hoekbed lijkt een ernstige sepsis te krijgen.\u2019", [["sepsis", "DISEASE", 46, 52], ["sepsis te krijgen", "TREATMENT", 46, 63], ["sepsis", "OBSERVATION", 46, 52]]], ["Dagelijks zijn deze termen op verpleegafdelingen te horen.", [["Dagelijks", "TREATMENT", 0, 9]]], ["Ook buiten het ziekenhuis kunnen pati\u00ebnten septisch worden of een sepsis krijgen.", [["sepsis", "DISEASE", 66, 72], ["een sepsis krijgen", "PROBLEM", 62, 80], ["een sepsis", "OBSERVATION", 62, 72]]], ["Wat is de betekenis van deze termen?14.2 Sepsis, oud en nieuwTot voor kort werden septische verschijnselen toegeschreven aan de aanwezigheid van micro-organismen, van microbi\u00eble bestanddelen of van toxische producten in de bloedbaan: een bloedvergiftiging.", [["Sepsis", "DISEASE", 41, 47], ["Sepsis", "PROBLEM", 41, 47], ["Sepsis", "OBSERVATION", 41, 47], ["een bloedvergiftiging", "OBSERVATION", 234, 255]]], ["De diagnose sepsis werd ook gebruikt als uit het klinisch microbiologisch laboratorium de melding kwam dat de bloedkweken van een pati\u00ebnt positief waren.", [["sepsis", "DISEASE", 12, 18], ["sepsis", "PROBLEM", 12, 18], ["sepsis", "OBSERVATION", 12, 18]]], ["Dit komt doordat 30-50% van de pati\u00ebnten met septische verschijnselen een (gelokaliseerde) bacteri\u00eble infectie heeft waarbij bacteri\u00ebn niet in de bloedbaan circuleren.", [["Dit komt doordat", "TREATMENT", 0, 16], ["een (gelokaliseerde)", "TREATMENT", 70, 90], ["bacteri\u00eble infectie", "PROBLEM", 91, 110]]], ["Bloedkweken van pati\u00ebnten die septisch zijn door een infectie ten gevolge van virussen, protozo\u00ebn of parasieten, zijn ook vrijwel altijd negatief en pati\u00ebnten met een infectie door gisten of schimmels meestal.", [["een infectie", "TREATMENT", 49, 61], ["protozo\u00ebn", "TREATMENT", 88, 97], ["parasieten", "TREATMENT", 101, 111], ["zijn", "TREATMENT", 113, 117]]], ["Bovendien komen septische verschijnselen ook voor bij niet-ge\u00efnfecteerde pati\u00ebnten (figuur 14.1).", [["Bovendien", "TREATMENT", 0, 9]]], ["Vanzelfsprekend zijn de bloedkweken van deze laatste groep pati\u00ebnten ook negatief.14.2 Sepsis, oud en nieuwTegenwoordig worden bovengenoemde ziekteverschijnselen aangeduid als klinische manifestaties van een gegeneraliseerd ontstekingsproces, gedefinieerd als SIRS, de afkorting van systemisch inflammatoire-responssyndroom (Tabel 14.1).", [["Sepsis", "DISEASE", 87, 93], ["SIRS", "DISEASE", 260, 264], ["Vanzelfsprekend zijn", "TREATMENT", 0, 20], ["Sepsis", "PROBLEM", 87, 93], ["Sepsis", "OBSERVATION", 87, 93]]], ["SIRS kan velerlei oorzaken hebben (figuur 14.1), onder andere systemische of gelokaliseerde infecties.", [["SIRS", "DISEASE", 0, 4], ["kan velerlei oorzaken", "SPECIES", 5, 26], ["SIRS", "TEST", 0, 4], ["gelokaliseerde infecties", "PROBLEM", 77, 101]]], ["Wanneer SIRS het gevolg is van een infectie spreekt men, afhankelijk van de ernst van het klinisch beeld, van sepsis, ernstige sepsis of septische shock (zie Tabel 14.1).", [["SIRS", "DISEASE", 8, 12], ["sepsis", "DISEASE", 110, 116], ["sepsis", "DISEASE", 127, 133], ["septische shock", "DISEASE", 137, 152], ["men", "ORGANISM", 52, 55], ["men", "SPECIES", 52, 55], ["van sepsis", "PROBLEM", 106, 116], ["septische shock", "PROBLEM", 137, 152], ["sepsis", "OBSERVATION", 127, 133]]], ["SIRS kan bij infecties echter ontbreken, zelfs bij aanwezigheid van bacteri\u00ebn in de bloedbaan.", [["SIRS", "DISEASE", 0, 4], ["SIRS", "PROBLEM", 0, 4]]], ["Ook virussen (viremie), gisten en schimmels (fungemie) en parasieten (parasitemie) kunnen in de bloedbaan circuleren zonder dat er tekenen van SIRS zijn (figuur 14.1).", [["gisten en schimmels (fungemie)", "TREATMENT", 24, 54]]], ["Verschijnselen van SIRS kunnen zelfs ontstaan zonder dat er sprake is van een infectie, bijvoorbeeld ten gevolge van weefselschade door een ongeval of verbranding, of door de inwerking van uit de pancreas (alvleesklier) vrijgekomen enzymen in het kader van een pancreatitis (een chemisch ge\u00efnduceerde ontsteking).14.2 Sepsis, oud en nieuwWaardoor ontstaan de verschijnselen van SIRS?", [["pancreas", "ANATOMY", 196, 204], ["pancreatitis", "DISEASE", 261, 273], ["Sepsis", "DISEASE", 318, 324], ["SIRS", "DISEASE", 378, 382], ["pancreas", "ORGAN", 196, 204], ["vrijgekomen enzymen", "PROBLEM", 220, 239], ["pancreatitis", "PROBLEM", 261, 273], ["Sepsis", "PROBLEM", 318, 324], ["pancreas", "ANATOMY", 196, 204], ["pancreatitis", "OBSERVATION", 261, 273], ["Sepsis", "OBSERVATION", 318, 324]]], ["SIRS is het gevolg van de activatie van endotheelcellen van de bloedvaten, de reticulo-endotheliale cellen in milt en lever en alveolaire macrofagen in de longen.", [["SIRS", "DISEASE", 0, 4], ["SIRS", "PROBLEM", 0, 4]]], ["De activatie, die leidt tot productie van ontstekingsmediatoren en stollingsfactoren, kan worden teweeggebracht door in de bloedbaan circulerende micro-organismen, maar ook door microbi\u00eble bestanddelen (celwandcomponenten, toxinen) en pro-inflammatoire ontstekingsmediatoren (zie ook hoofdstuk 10.1007/978-90-313-7944-6_1) die vanuit ge\u00efnfecteerde of getraumatiseerde weefsels in de bloedbaan kunnen terechtkomen.14.2 Sepsis, oud en nieuwElke infectie en trauma van weefsels gaat gepaard met een ontstekingsreactie en wordt aangeduid met het achtervoegsel -itis.", [["Sepsis", "DISEASE", 418, 424], ["trauma", "DISEASE", 455, 461], ["achtervoegsel -itis", "DISEASE", 542, 561], ["Sepsis", "PROBLEM", 418, 424], ["Sepsis", "OBSERVATION", 418, 424]]], ["Ook rondom bestanddelen van micro-organismen, dode micro-organismen, microbi\u00eble toxinen en andere corpora aliena ontstaat een microkosmos waarin mediatoren (cytokinen) een ontstekingsreactie induceren.", [["micro-organismen", "TEST", 51, 67], ["microbi\u00eble", "TEST", 69, 79], ["toxinen", "TEST", 80, 87], ["aliena", "TEST", 106, 112], ["een microkosmos", "TREATMENT", 122, 137]]], ["Voor een bespreking van het mechanisme van de ontstekingsreactie wordt verwezen naar hoofdstuk 10.1007/978-90-313-7944-6_1.14.2 Sepsis, oud en nieuwHeeft een pati\u00ebnt een SIRS-reactie waarbij hemodynamische afwijkingen en stoornissen van diverse organen ontstaan, dan is er sprake van ernstige sepsis en kan een septische shock optreden (zie Tabel 14.1).", [["Sepsis", "DISEASE", 128, 134], ["sepsis", "DISEASE", 293, 299], ["Voor een bespreking van het mechanisme van de ontstekingsreactie wordt verwezen naar hoofdstuk 10.1007/978-90-313-7944-6_1.14.2", "SPECIES", 0, 127], ["Sepsis", "PROBLEM", 128, 134], ["een SIRS", "PROBLEM", 166, 174], ["reactie", "PROBLEM", 175, 182], ["sepsis", "PROBLEM", 293, 299]]], ["Bij ernstige sepsis is vrijwel elk orgaansysteem en elke orgaanfunctie gestoord.14.2 Sepsis, oud en nieuw", [["sepsis", "DISEASE", 13, 19], ["Sepsis", "DISEASE", 85, 91], ["Bij ernstige sepsis", "PROBLEM", 0, 19], ["Sepsis", "PROBLEM", 85, 91], ["sepsis", "OBSERVATION", 13, 19], ["Sepsis", "OBSERVATION", 85, 91]]]], "a6206c4af33491a76902a2e129e9e2846b08725a": [["General experimental methodsNMR spectra were acquired at room temperature on commercial instruments (Bruker Avance 300 MHz, Bruker AMX 400 MHz or Bruker Avance II+ 600 MHz) and chemical shifts (\u03b4) are reported in parts per million (ppm) referenced to tetramethylsilane (0.00 ppm for 1 H), or the internal (NMR) solvent signal (77.", [["tetramethylsilane", "CHEMICAL", 251, 268], ["tetramethylsilane", "CHEMICAL", 251, 268], ["H", "CHEMICAL", 285, 286], ["tetramethylsilane", "SIMPLE_CHEMICAL", 251, 268], ["Bruker AMX", "TREATMENT", 124, 134]]], ["High resolution mass spectra were acquired on a quadrupole orthogonal acceleration time-of-flight mass spectrometer (Synapt G2 HDMS, Waters, Milford, MA).", [["High resolution mass spectra", "PROBLEM", 0, 28], ["a quadrupole orthogonal acceleration time", "TEST", 46, 87], ["resolution", "OBSERVATION_MODIFIER", 5, 15], ["mass", "OBSERVATION", 16, 20]]], ["For column chromatography 70-230 mesh silica 60 (E. M. Merck) was used as the stationary phase.", [["silica", "CHEMICAL", 38, 44], ["column chromatography", "TEST", 4, 25], ["mesh silica", "TREATMENT", 33, 44]]], ["Chemicals received from commercial sources were used without further purification.", [["further purification", "TREATMENT", 61, 81]]], ["Reaction solvents (toluene) were used as received from commercial sources.General procedure for the preparation of substituted 1,2,3-triazolesTo an oven-dried screw-capped reaction tube equipped with a magnetic stirring bar the ketone (1 eq), amine (2.8 eq), 4-nitrophenyl azide (2 eq), acetic acid (10 mol%) and 4 \u00c5 molecular sieves (50 mg) were added.", [["toluene", "CHEMICAL", 19, 26], ["1,2,3-triazoles", "CHEMICAL", 127, 142], ["ketone", "CHEMICAL", 228, 234], ["amine", "CHEMICAL", 243, 248], ["4-nitrophenyl azide", "CHEMICAL", 259, 278], ["acetic acid", "CHEMICAL", 287, 298], ["toluene", "CHEMICAL", 19, 26], ["1,2,3-triazoles", "CHEMICAL", 127, 142], ["ketone", "CHEMICAL", 228, 234], ["amine", "CHEMICAL", 243, 248], ["4-nitrophenyl azide", "CHEMICAL", 259, 278], ["acetic acid", "CHEMICAL", 287, 298], ["toluene", "SIMPLE_CHEMICAL", 19, 26], ["substituted 1,2,3-triazoles", "SIMPLE_CHEMICAL", 115, 142], ["ketone", "SIMPLE_CHEMICAL", 228, 234], ["1 eq)", "SIMPLE_CHEMICAL", 236, 241], ["amine", "SIMPLE_CHEMICAL", 243, 248], ["4-nitrophenyl azide", "SIMPLE_CHEMICAL", 259, 278], ["2 eq)", "SIMPLE_CHEMICAL", 280, 285], ["acetic acid", "SIMPLE_CHEMICAL", 287, 298], ["Reaction solvents (toluene)", "TREATMENT", 0, 27], ["General procedure", "TREATMENT", 74, 91], ["substituted 1,2,3-triazoles", "TREATMENT", 115, 142], ["an oven-dried screw-capped reaction tube", "TREATMENT", 145, 185], ["a magnetic stirring bar the ketone", "TREATMENT", 200, 234], ["nitrophenyl azide", "TREATMENT", 261, 278], ["acetic acid", "TREATMENT", 287, 298], ["4 \u00c5 molecular sieves", "TREATMENT", 313, 333], ["dried screw", "OBSERVATION", 153, 164], ["reaction tube", "OBSERVATION", 172, 185]]], ["The reaction mixture was dissolved in toluene (0.3M) and stirred at 100 \u00b0C for 18 hours.", [["toluene", "CHEMICAL", 38, 45], ["0.3M", "CHEMICAL", 47, 51], ["toluene", "CHEMICAL", 38, 45], ["toluene", "SIMPLE_CHEMICAL", 38, 45], ["The reaction mixture", "TREATMENT", 0, 20]]], ["The crude reaction mixture was then directly purified by column chromatography (silica gel) at first with dichloromethane (DCM) as eluent to remove all 4-nitroaniline formed during the reaction followed by using a mixture of heptane and ethyl acetate as eluent to afford the corresponding 1,2,3-triazoles as yellow oil.General procedure for the preparation of substituted 1,2,3-triazolesEthyl-1,7-dibenzyl-5-phenyl-4,5,6,7-tetrahydro-1H- [1-(4-fluorobenzyl)-5-(4-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridine (18h):Yellow oil (89%).", [["silica gel", "CHEMICAL", 80, 90], ["dichloromethane", "CHEMICAL", 106, 121], ["DCM", "CHEMICAL", 123, 126], ["4-nitroaniline", "CHEMICAL", 152, 166], ["heptane", "CHEMICAL", 225, 232], ["ethyl acetate", "CHEMICAL", 237, 250], ["1,2,3-triazoles", "CHEMICAL", 289, 304], ["1,2,3-triazolesEthyl-1,7-dibenzyl-5-phenyl-4,5,6,7-tetrahydro-1H- [1-(4-fluorobenzyl)-5-(4-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridine", "CHEMICAL", 372, 540], ["silica gel", "CHEMICAL", 80, 90], ["dichloromethane", "CHEMICAL", 106, 121], ["DCM", "CHEMICAL", 123, 126], ["4-nitroaniline", "CHEMICAL", 152, 166], ["heptane", "CHEMICAL", 225, 232], ["ethyl acetate", "CHEMICAL", 237, 250], ["1,2,3-triazoles", "CHEMICAL", 289, 304], ["1,2,3-triazolesEthyl-1,7-dibenzyl-5-phenyl-4,5,6,7-tetrahydro-1H- [1-(4-fluorobenzyl)-5-(4-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridine", "CHEMICAL", 372, 540], ["silica", "SIMPLE_CHEMICAL", 80, 86], ["dichloromethane", "SIMPLE_CHEMICAL", 106, 121], ["DCM", "SIMPLE_CHEMICAL", 123, 126], ["4-nitroaniline", "SIMPLE_CHEMICAL", 152, 166], ["heptane", "SIMPLE_CHEMICAL", 225, 232], ["ethyl acetate", "SIMPLE_CHEMICAL", 237, 250], ["1,2,3-triazoles", "SIMPLE_CHEMICAL", 289, 304], ["yellow oil", "SIMPLE_CHEMICAL", 308, 318], ["1,2,3-triazolesEthyl-1,7-dibenzyl-5-phenyl-4,5,6,7-tetrahydro-1H- [1-(4-fluorobenzyl)-5-(4-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridine", "SIMPLE_CHEMICAL", 372, 540], ["Yellow oil", "SIMPLE_CHEMICAL", 547, 557], ["The crude reaction mixture", "TREATMENT", 0, 26], ["column chromatography (silica gel", "TREATMENT", 57, 90], ["dichloromethane (DCM", "TREATMENT", 106, 126], ["nitroaniline", "TREATMENT", 154, 166], ["a mixture of heptane", "TREATMENT", 212, 232], ["ethyl acetate", "TREATMENT", 237, 250], ["triazoles", "TREATMENT", 295, 304], ["General procedure", "TREATMENT", 319, 336], ["triazolesEthyl", "TREATMENT", 378, 392], ["dibenzyl", "TREATMENT", 397, 405], ["phenyl", "TREATMENT", 408, 414], ["tetrahydro-1H", "TREATMENT", 423, 436], ["fluorobenzyl)", "TREATMENT", 444, 457], ["(trifluoromethyl)phenyl)", "TREATMENT", 463, 487], ["triazolo", "TREATMENT", 517, 525], ["c]pyridine", "TREATMENT", 530, 540]]], ["1 >100 >100 >100 >100 >100 >100 >100 18d \u00b5M \u2265100 >100 >100 >100 >100 >100 >100 18c \u00b5M >100 >100 >100 >100 >100 >100 >100 18b \u00b5M >100 >100 >100 >100 >100 >100 >100 18e \u00b5M >100 >100 >100 >100 >100 16 45 18f \u00b5M >100 >100 >100 >100 >100 >100 8,9 18g \u00b5M >100 >100 >100 >100 >100 >100 >100 18h \u00b5M 100 >100 >100 >100 >100 >100 >100 18i \u00b5M 100 >100 >100 >100 >100 >100 11,95 18j \u00b5M1-(3-fluorobenzyl)-5-(4-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridine (18i): Yellow oil (85%14a \u00b5M \u226520 >100 >100 >100 >100 >100 >100 14b \u00b5M \u2265100 >100 >100 >100 >100 >100 >100 14c \u00b5M >100 >100 >100 >100 >100 >100 >100 14d \u00b5M \u2265100 >100 >100 >100 >100 >100 8,95 14e \u00b5M \u2265100 >100 >100 >100 >100 >100 >100 14f \u00b5M >100 >100 >100 >100 >100 >100 >100 14g \u00b5M >100 >100 >100 >100 >100 >100 >100 14h \u00b5M >100 >100 >100 >100 >100 >100 >100 14i \u00b5M >100 >100 >100 >100 >100 >100 >100 14j \u00b5M >100 >100 >100 >100 >100 >100 >100 14k \u00b5M 100 >100 >100 >100 >100 >100 >100 14l \u00b5M \u2265100 >100 >100 >100 >100 >100 >100 14m \u00b5M \u226520 >100 >100 >100 >100 >100 >100 14n \u00b5M >100 >100 >100 >100 >100 >100 9,45 14o \u00b5M >100 >100 >100 >100 >100 >100 >100 14p \u00b5M \u226520 >100 >100 >100 >100 >100 >100 14q \u00b5M >100 >100 >100 >100 >100 >100 9,45 14r \u00b5M >100 >100 >100 >100 >100 >100 >100 18a \u00b5M>100 >100 >100 >100 >100 >100 >100 18k \u00b5M >100 >100 >100 >100 >100 >100 >100 18l \u00b5M \u2265100 >100 >100 >100 >100 >100 >100 Brivudin \u00b5M >250 0,Molecular modeling studiesThe initial structures of the modeled structures were constructed usingMolecular modeling studiesMarvinSketch v. 16", [["M1-(3-fluorobenzyl)-5-(4-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridine", "CHEMICAL", 372, 474], ["M1-(3-fluorobenzyl)-5-(4-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridine", "CHEMICAL", 372, 474], ["M1-(3-fluorobenzyl)-5-(4-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridine", "SIMPLE_CHEMICAL", 372, 474], ["18i", "SIMPLE_CHEMICAL", 476, 479], ["Yellow oil", "SIMPLE_CHEMICAL", 482, 492], ["b \u00b5M", "TEST", 123, 127], ["\u00b5M", "TEST", 167, 169], ["\u00b5M", "TEST", 205, 207], ["\u00b5M", "TEST", 246, 248], ["\u00b5M", "TEST", 329, 331], ["trifluoromethyl)phenyl)-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridine", "TREATMENT", 398, 474], ["Yellow oil", "TEST", 482, 492], ["\u00b5M", "TEST", 836, 838], ["\u00b5M", "TEST", 878, 880], ["k \u00b5M", "TEST", 918, 922], ["\u00b5M", "TEST", 961, 963], ["\u00b5M", "TEST", 1003, 1005], ["\u00b5M", "TEST", 1044, 1046], ["\u00b5M", "TEST", 1086, 1088], ["\u00b5M", "TEST", 1128, 1130], ["\u00b5M", "TEST", 1169, 1171], ["\u00b5M", "TEST", 1211, 1213], ["k \u00b5M", "TEST", 1292, 1296], ["\u00b5M", "TEST", 1336, 1338], ["Brivudin \u00b5M", "TEST", 1374, 1385], ["Molecular modeling studies", "TEST", 1393, 1419], ["Molecular modeling studies", "TEST", 1490, 1516]]]], "930a2d6e4352c54c73f57e4c7ae93411cfe65195": [["IntroductionIn the recent years, many authors have shown the interest in developing meshfree methods to overcome some difficulties.", [["some difficulties", "PROBLEM", 113, 130]]], ["These methods provide the possibility to avoid mesh generation and connectivity between the nodes which require a considerable computation time.", [["mesh generation and connectivity between the nodes", "PROBLEM", 47, 97], ["mesh", "OBSERVATION", 47, 51], ["nodes", "OBSERVATION", 92, 97]]], ["Nevertheless, not all mesh-free methods have this advantage.", [["mesh", "OBSERVATION", 22, 26]]], ["The first one concerns the meshfree methods based on weak formulation that still require a background mesh like the Diffuse Element Method (DEM) [1] , Element Free Galerking (EFG) [2] and Point Interpolation Method (PIM) [3] etc. The second category of mesh-free methods is based on strong formulation.", [["the meshfree methods", "TREATMENT", 23, 43], ["weak formulation", "TREATMENT", 53, 69], ["a background mesh", "TREATMENT", 89, 106], ["the Diffuse Element Method (DEM)", "TREATMENT", 112, 144], ["Element Free Galerking (EFG)", "TREATMENT", 151, 179], ["Point Interpolation Method (PIM)", "TREATMENT", 188, 220], ["mesh-free methods", "TREATMENT", 253, 270], ["mesh", "OBSERVATION", 102, 106], ["Diffuse", "OBSERVATION_MODIFIER", 116, 123], ["mesh", "OBSERVATION", 253, 257]]], ["This category don't need a background mesh and the numerical integration [4, 5] .IntroductionThe Weighted Least Squares (WLS) approximation is wildly used in data fitting [6] .", [["a background mesh", "TREATMENT", 25, 42], ["The Weighted Least Squares (WLS) approximation", "TREATMENT", 93, 139], ["mesh", "OBSERVATION", 38, 42]]], ["Wallstedt et al. [7] took advantage of the concepts of weighted least squares surface estimation and implicit surface definition to more precisely define the region of integration for solid mechanic's simulations that are performed within a PIC framework.", [["surface", "ANATOMY", 110, 117], ["surface estimation", "TEST", 78, 96], ["implicit surface definition", "PROBLEM", 101, 128], ["solid mechanic's simulations", "TREATMENT", 184, 212], ["a PIC framework", "TREATMENT", 239, 254]]], ["Onate et al. [8] presented an approach termed generically the 'Finite Point Method' based on a Weighted Least Square Interpolation of point data and point collocation for evaluating the approximation integrals.", [["point data", "TEST", 134, 144], ["point collocation", "PROBLEM", 149, 166], ["the approximation integrals", "TEST", 182, 209]]], ["Baeza et al. [9] have presented a technique based on the application of a variant of the Lagrange extrapolation through the computation of weights capable of detecting regions with discontinuities.", [["a technique", "TREATMENT", 32, 43], ["the Lagrange extrapolation", "TREATMENT", 85, 111]]], ["Recently several authors developed a high order continuation using the Moving Least Squares approximation [10] as a discretization method under a strong formulation to solve various non linear problems [11] [12] [13] [14] [15] [16] [17] [18] [19] .", [["[11] [12] [13] [14] [15] [16] [17] [18]", "CHEMICAL", 202, 241], ["[11] [12] [13] [14] [15] [16] [17] [18] [19]", "SIMPLE_CHEMICAL", 202, 246], ["a discretization method", "TREATMENT", 114, 137], ["a strong formulation", "TREATMENT", 144, 164], ["various non linear problems", "PROBLEM", 174, 201]]], ["Other authors used a high order continuation using Radial Point Interpolation method under a strong formulation [20] .IntroductionIn this paper, a new numerical approach is proposed.", [["Radial Point Interpolation method", "TREATMENT", 51, 84], ["a strong formulation", "TREATMENT", 91, 111], ["a new numerical approach", "TREATMENT", 145, 169]]], ["This approach combines a high order continuation [21] and the Weighted Least Squared (WLS) as a discretization method.", [["This approach", "TREATMENT", 0, 13], ["a high order continuation", "TREATMENT", 23, 48], ["a discretization method", "TREATMENT", 94, 117]]], ["Thanks to the development of the main variables into Taylor series, non-linear elastic problem is transformed into a succession of linear differential equations with the same tangent operator followed of a continuation technique is used to obtain the whole solution.", [["non-linear elastic problem", "PROBLEM", 68, 94], ["linear differential equations", "TREATMENT", 131, 160], ["the same tangent operator", "TREATMENT", 166, 191], ["a continuation technique", "TREATMENT", 204, 228], ["the whole solution", "TREATMENT", 247, 265], ["main", "OBSERVATION_MODIFIER", 33, 37], ["elastic", "OBSERVATION_MODIFIER", 79, 86], ["linear", "OBSERVATION_MODIFIER", 131, 137]]], ["The performance of this proposed approach is illustrated on examples of non-linear elasticity problems.", [["this proposed approach", "TREATMENT", 19, 41], ["non-linear elasticity problems", "PROBLEM", 72, 102], ["non-linear", "OBSERVATION_MODIFIER", 72, 82], ["elasticity", "OBSERVATION", 83, 93]]], ["A comparison has been held between the proposed approach, the High Order Continuation coupled with Moving Least Squares (HOC-MLS) and the High Order Continuation coupled with Finite Element Method (HOC-FEM).Description of Weighted Least Squares (WLS) and Moving Least Squares (MLS) MethodsIn this section, we present in detail the description of the approximations by the Weighted Least Squares and by the Mobile Least Squares methods.Weighted Least Squares ApproximationThe Weighted Least Squares (WLS) approximation is highly used for data fitting [6] .", [["Finite Element Method (HOC-FEM)", "TREATMENT", 175, 206], ["FEM", "ANATOMY", 202, 205]]]], "PMC7105187": [["IntroductionThe concept of the lysosome as a cellular compartment for the degradation of biological macromolecules, as set in place by the seminal work of De Duve, represents a foundation of modern cell biology [1].", [["lysosome", "ANATOMY", 31, 39], ["cellular compartment", "ANATOMY", 45, 65], ["seminal", "ANATOMY", 139, 146], ["cell", "ANATOMY", 198, 202], ["lysosome", "CELLULAR_COMPONENT", 31, 39], ["cellular", "CELLULAR_COMPONENT", 45, 53], ["cell", "CELL", 198, 202], ["biological macromolecules", "TREATMENT", 89, 114]]], ["In fact, the lysosomal compartment provides the perfect \u2018home\u2019 for more than 50 hydrolytic enzymes that are most stable and show their greatest activity within the acidic interior of the lysosome.", [["lysosomal compartment", "ANATOMY", 13, 34], ["lysosome", "ANATOMY", 187, 195], ["lysosome", "CELLULAR_COMPONENT", 187, 195], ["hydrolytic enzymes", "PROTEIN", 80, 98], ["50 hydrolytic enzymes", "TEST", 77, 98], ["lysosomal compartment", "OBSERVATION", 13, 34], ["stable", "OBSERVATION_MODIFIER", 113, 119], ["greatest", "OBSERVATION_MODIFIER", 135, 143], ["activity", "OBSERVATION_MODIFIER", 144, 152], ["lysosome", "OBSERVATION", 187, 195]]], ["On the other hand, the lysosomal membranes lock the destructive enzymes within the lysosomal vesicles, thus providing protection for the other cellular compartments.", [["lysosomal membranes", "ANATOMY", 23, 42], ["lysosomal vesicles", "ANATOMY", 83, 101], ["cellular compartments", "ANATOMY", 143, 164], ["lysosomal membranes", "CELLULAR_COMPONENT", 23, 42], ["lysosomal vesicles", "CELLULAR_COMPONENT", 83, 101], ["cellular", "CELL", 143, 151], ["destructive enzymes", "PROTEIN", 52, 71], ["the destructive enzymes", "TEST", 48, 71], ["lysosomal membranes", "ANATOMY", 23, 42], ["destructive", "OBSERVATION_MODIFIER", 52, 63], ["lysosomal vesicles", "ANATOMY", 83, 101]]], ["Among the hydrolases of the acidic cellular compartment are multiple peptide-bond cleaving proteases.", [["cellular compartment", "ANATOMY", 35, 55], ["cellular compartment", "CELLULAR_COMPONENT", 35, 55], ["multiple peptide-bond cleaving proteases", "PROTEIN", 60, 100], ["multiple peptide-bond cleaving proteases", "PROBLEM", 60, 100], ["acidic", "OBSERVATION_MODIFIER", 28, 34], ["cellular compartment", "OBSERVATION", 35, 55], ["multiple", "OBSERVATION_MODIFIER", 60, 68], ["bond cleaving", "OBSERVATION", 77, 90]]], ["A so-called \u2018catheptic activity\u2019 (derived from the Greek Kath\u00e9psein, meaning to digest or to boil down) was initially discovered in the acidic gastric juice during the 1920s [2].", [["gastric juice", "ANATOMY", 143, 156], ["gastric juice", "ORGANISM_SUBSTANCE", 143, 156]]], ["Following this tradition many of the primarily intracellular proteases that exhibit optimal proteolytic activity in acidified vesicles, i.e. \u2018classical\u2019 lysosomes, endosomes, multivesicular bodies, and acidic secretory vesicles, have been named \u2018cathepsins\u2019.", [["intracellular", "ANATOMY", 47, 60], ["vesicles", "ANATOMY", 126, 134], ["lysosomes", "ANATOMY", 153, 162], ["endosomes", "ANATOMY", 164, 173], ["multivesicular bodies", "ANATOMY", 175, 196], ["secretory vesicles", "ANATOMY", 209, 227], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 47, 60], ["vesicles", "CELLULAR_COMPONENT", 126, 134], ["\u2019 lysosomes", "CELLULAR_COMPONENT", 151, 162], ["endosomes", "CELLULAR_COMPONENT", 164, 173], ["multivesicular bodies", "CELLULAR_COMPONENT", 175, 196], ["acidic secretory vesicles", "CELLULAR_COMPONENT", 202, 227], ["cathepsins", "GENE_OR_GENE_PRODUCT", 246, 256], ["intracellular proteases", "PROTEIN", 47, 70], ["cathepsins", "PROTEIN", 246, 256], ["this tradition", "TREATMENT", 10, 24], ["the primarily intracellular proteases", "PROBLEM", 33, 70], ["optimal proteolytic activity in acidified vesicles", "PROBLEM", 84, 134], ["acidic secretory vesicles", "PROBLEM", 202, 227], ["acidified vesicles", "OBSERVATION", 116, 134], ["multivesicular bodies", "OBSERVATION", 175, 196], ["acidic", "OBSERVATION_MODIFIER", 202, 208], ["secretory vesicles", "OBSERVATION", 209, 227]]], ["However, today cathepsins are classified based on their structure and catalytic type into serine (cathepsins A and G), aspartic (cathepsins D and E), and cysteine cathepsins.", [["serine", "CHEMICAL", 90, 96], ["cysteine", "CHEMICAL", 154, 162], ["cathepsins", "GENE_OR_GENE_PRODUCT", 15, 25], ["serine", "AMINO_ACID", 90, 96], ["cathepsins A", "GENE_OR_GENE_PRODUCT", 98, 110], ["G", "GENE_OR_GENE_PRODUCT", 115, 116], ["aspartic", "AMINO_ACID", 119, 127], ["cathepsins D", "GENE_OR_GENE_PRODUCT", 129, 141], ["E", "GENE_OR_GENE_PRODUCT", 146, 147], ["cysteine cathepsins", "GENE_OR_GENE_PRODUCT", 154, 173], ["cathepsins", "PROTEIN", 15, 25], ["cathepsins A and G", "PROTEIN", 98, 116], ["cathepsins D and E", "PROTEIN", 129, 147], ["cysteine cathepsins", "PROTEIN", 154, 173], ["aspartic (cathepsins D and E)", "TREATMENT", 119, 148], ["cysteine cathepsins", "TREATMENT", 154, 173]]], ["The latter constitute the largest cathepsin family, with 11 proteases in humans annotated as clan CA, family C1a: cathepsins B, C/DPP1, F, H, K, L, O, S, W, V, and Z/X [3].", [["cathepsin", "GENE_OR_GENE_PRODUCT", 34, 43], ["humans", "ORGANISM", 73, 79], ["CA", "GENE_OR_GENE_PRODUCT", 98, 100], ["C1a", "GENE_OR_GENE_PRODUCT", 109, 112], ["cathepsins B", "GENE_OR_GENE_PRODUCT", 114, 126], ["C", "GENE_OR_GENE_PRODUCT", 128, 129], ["DPP1", "GENE_OR_GENE_PRODUCT", 130, 134], ["cathepsin family", "PROTEIN", 34, 50], ["proteases", "PROTEIN", 60, 69], ["clan CA", "PROTEIN", 93, 100], ["C1a", "PROTEIN", 109, 112], ["cathepsins B", "PROTEIN", 114, 126], ["C", "PROTEIN", 128, 129], ["DPP1", "PROTEIN", 130, 134], ["F", "PROTEIN", 136, 137], ["H", "PROTEIN", 139, 140], ["K", "PROTEIN", 142, 143], ["L", "PROTEIN", 145, 146], ["O", "PROTEIN", 148, 149], ["S", "PROTEIN", 151, 152], ["W", "PROTEIN", 154, 155], ["V", "PROTEIN", 157, 158], ["Z", "PROTEIN", 164, 165], ["X", "PROTEIN", 166, 167], ["humans", "SPECIES", 73, 79], ["humans", "SPECIES", 73, 79], ["cathepsins", "TEST", 114, 124], ["DPP1", "TEST", 130, 134], ["H", "TEST", 139, 140], ["K", "TEST", 142, 143], ["largest", "OBSERVATION_MODIFIER", 26, 33], ["cathepsin", "OBSERVATION", 34, 43]]], ["To complicate matters more, the lysosomal compartment contains additional proteases that are not named cathepsins, such as the aspartic protease Napsin, which is related to cathepsins D and E, and the cysteine protease asparagine endopeptidase (AEP, also named legumain; clan CD, family C13).", [["lysosomal compartment", "ANATOMY", 32, 53], ["asparagine", "CHEMICAL", 219, 229], ["cysteine", "CHEMICAL", 201, 209], ["asparagine", "CHEMICAL", 219, 229], ["cathepsins", "GENE_OR_GENE_PRODUCT", 103, 113], ["Napsin", "GENE_OR_GENE_PRODUCT", 145, 151], ["cathepsins D", "GENE_OR_GENE_PRODUCT", 173, 185], ["E", "GENE_OR_GENE_PRODUCT", 190, 191], ["asparagine endopeptidase", "GENE_OR_GENE_PRODUCT", 219, 243], ["legumain", "GENE_OR_GENE_PRODUCT", 261, 269], ["clan CD", "GENE_OR_GENE_PRODUCT", 271, 278], ["proteases", "PROTEIN", 74, 83], ["cathepsins", "PROTEIN", 103, 113], ["aspartic protease", "PROTEIN", 127, 144], ["Napsin", "PROTEIN", 145, 151], ["cathepsins D and E", "PROTEIN", 173, 191], ["cysteine protease asparagine endopeptidase", "PROTEIN", 201, 243], ["AEP", "PROTEIN", 245, 248], ["legumain", "PROTEIN", 261, 269], ["clan CD", "PROTEIN", 271, 278], ["additional proteases", "PROBLEM", 63, 83], ["the aspartic protease Napsin", "TREATMENT", 123, 151], ["cathepsins D and E", "TREATMENT", 173, 191], ["the cysteine protease asparagine endopeptidase", "TREATMENT", 197, 243]]], ["Recently, interesting \u2018non-canonical\u2019 physiological and pathological functions in the cytosol, the nucleus, and even mitochondria have been established for almost all of these lysosomal proteases [4], [5], [6], [7], [8].", [["cytosol", "ANATOMY", 86, 93], ["nucleus", "ANATOMY", 99, 106], ["mitochondria", "ANATOMY", 117, 129], ["cytosol", "CELLULAR_COMPONENT", 86, 93], ["nucleus", "CELLULAR_COMPONENT", 99, 106], ["mitochondria", "CELLULAR_COMPONENT", 117, 129], ["[5], [6], [7]", "SIMPLE_CHEMICAL", 201, 214], ["[8]", "SIMPLE_CHEMICAL", 216, 219], ["lysosomal proteases", "PROTEIN", 176, 195], ["these lysosomal proteases", "TEST", 170, 195], ["nucleus", "ANATOMY", 99, 106]]], ["Cathepsins have also been found secreted to the extracellular milieu where these proteases are often contributing to the pathogenesis of diseases such as arthritis and cancer [9], [10], [11], [12], [13], [14], [15], [16], [17], [18].", [["extracellular", "ANATOMY", 48, 61], ["cancer", "ANATOMY", 168, 174], ["Cathepsins", "CHEMICAL", 0, 10], ["arthritis", "DISEASE", 154, 163], ["cancer", "DISEASE", 168, 174], ["[10], [11], [12], [13], [14], [15], [16], [17", "CHEMICAL", 180, 225], ["Cathepsins", "GENE_OR_GENE_PRODUCT", 0, 10], ["extracellular milieu", "CELLULAR_COMPONENT", 48, 68], ["cancer", "CANCER", 168, 174], ["[10], [11], [12], [13], [14], [15], [16], [17], [18]", "SIMPLE_CHEMICAL", 180, 232], ["Cathepsins", "PROTEIN", 0, 10], ["proteases", "PROTEIN", 81, 90], ["Cathepsins", "TREATMENT", 0, 10], ["these proteases", "TREATMENT", 75, 90], ["the pathogenesis of diseases", "PROBLEM", 117, 145], ["arthritis", "PROBLEM", 154, 163], ["cancer", "PROBLEM", 168, 174], ["diseases", "OBSERVATION", 137, 145], ["arthritis", "OBSERVATION", 154, 163], ["cancer", "OBSERVATION", 168, 174]]], ["However, with regard to De Duve we will focus this review on recent work concerning specific functions of individual serine-, cysteine-, and aspartate-type \u2018acidic\u2019 proteases and also their combined \u2018networking\u2019 actions.", [["cysteine", "CHEMICAL", 126, 134], ["aspartate", "CHEMICAL", 141, 150], ["serine", "CHEMICAL", 117, 123], ["cysteine", "CHEMICAL", 126, 134], ["aspartate", "CHEMICAL", 141, 150], ["serine", "AMINO_ACID", 117, 123], ["cysteine", "AMINO_ACID", 126, 134], ["aspartate", "SIMPLE_CHEMICAL", 141, 150], ["acidic\u2019 proteases", "PROTEIN", 157, 174], ["individual serine", "TEST", 106, 123], ["cysteine", "TEST", 126, 134]]], ["The \u2018lysosome\u2019, however, is no longer a stand alone organelle; complex mechanisms regulate the biogenesis of lysosomes and the delivery of degradation-prone substrates into the lumen of this organelle [19].", [["lysosomes", "ANATOMY", 109, 118], ["lumen", "ANATOMY", 177, 182], ["organelle", "ANATOMY", 191, 200], ["lysosomes", "CELLULAR_COMPONENT", 109, 118], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 177, 182], ["organelle", "CELLULAR_COMPONENT", 191, 200], ["the delivery of degradation", "TREATMENT", 123, 150], ["no longer", "UNCERTAINTY", 28, 37], ["lumen", "ANATOMY_MODIFIER", 177, 182]]], ["Hence, we organize our discussion of cathepsin functions along the main delivery routes into lysosomes, i.e. endo- and phagocytosis as well as the autophagy pathways.Cathepsins in receptor-mediated endocytosis and growth factor signaling ::: Involvement of endolysosomal proteases in endocytosisA main function of the endolysosomal compartment is the modulation and termination of signal transduction pathways by dissociating growth factors from their receptors and then subsequently degrading them and/or recycling them to the plasma membrane [23].", [["lysosomes", "ANATOMY", 93, 102], ["endolysosomal", "ANATOMY", 257, 270], ["endolysosomal compartment", "ANATOMY", 318, 343], ["plasma membrane", "ANATOMY", 528, 543], ["Cathepsins", "CHEMICAL", 166, 176], ["cathepsin", "GENE_OR_GENE_PRODUCT", 37, 46], ["lysosomes", "CELLULAR_COMPONENT", 93, 102], ["Cathepsins", "GENE_OR_GENE_PRODUCT", 166, 176], ["plasma membrane", "CELLULAR_COMPONENT", 528, 543], ["cathepsin", "PROTEIN", 37, 46], ["Cathepsins", "PROTEIN", 166, 176], ["growth factor", "PROTEIN", 214, 227], ["endolysosomal proteases", "PROTEIN", 257, 280], ["growth factors", "PROTEIN", 426, 440], ["cathepsin functions", "TREATMENT", 37, 56], ["endo", "TEST", 109, 113], ["phagocytosis", "PROBLEM", 119, 131], ["Cathepsins", "TREATMENT", 166, 176], ["endolysosomal proteases in endocytosis", "PROBLEM", 257, 295], ["dissociating growth factors", "PROBLEM", 413, 440], ["endocytosis", "OBSERVATION", 198, 209], ["endolysosomal proteases", "OBSERVATION", 257, 280], ["endocytosis", "OBSERVATION", 284, 295], ["main", "OBSERVATION_MODIFIER", 297, 301], ["endolysosomal compartment", "OBSERVATION", 318, 343]]], ["It was reported that cathepsin B is responsible for the degradation of epidermal growth factor (EGF) in the liver as well as for the degradation of internalized EGF receptor complexes [24].", [["liver", "ANATOMY", 108, 113], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 21, 32], ["epidermal growth factor", "GENE_OR_GENE_PRODUCT", 71, 94], ["EGF", "GENE_OR_GENE_PRODUCT", 96, 99], ["liver", "ORGAN", 108, 113], ["EGF receptor", "GENE_OR_GENE_PRODUCT", 161, 173], ["cathepsin B", "PROTEIN", 21, 32], ["epidermal growth factor", "PROTEIN", 71, 94], ["EGF", "PROTEIN", 96, 99], ["EGF receptor complexes", "PROTEIN", 161, 183], ["cathepsin B", "TREATMENT", 21, 32], ["epidermal growth factor (EGF) in the liver", "PROBLEM", 71, 113], ["internalized EGF receptor complexes", "TREATMENT", 148, 183], ["epidermal", "OBSERVATION_MODIFIER", 71, 80], ["growth", "OBSERVATION_MODIFIER", 81, 87], ["liver", "ANATOMY", 108, 113]]], ["In further studies, insulin-like growth factor-I (IGF-I) was identified as another target of endolysosomal degradation.", [["endolysosomal", "ANATOMY", 93, 106], ["insulin-like growth factor-I", "GENE_OR_GENE_PRODUCT", 20, 48], ["IGF-I", "GENE_OR_GENE_PRODUCT", 50, 55], ["endolysosomal", "CELLULAR_COMPONENT", 93, 106], ["insulin-like growth factor-I", "PROTEIN", 20, 48], ["IGF-I", "PROTEIN", 50, 55], ["further studies", "TEST", 3, 18], ["insulin", "TEST", 20, 27], ["endolysosomal degradation", "PROBLEM", 93, 118], ["endolysosomal degradation", "OBSERVATION", 93, 118]]], ["Furthermore, the inhibition of cysteine proteases by the compounds E64 and the cell permeable Ca074Me, which is more specific for cathepsin B, altered the receptor trafficking and signaling of several tumor cell lines [25].", [["cell", "ANATOMY", 79, 83], ["tumor cell lines", "ANATOMY", 201, 217], ["cysteine", "CHEMICAL", 31, 39], ["E64", "CHEMICAL", 67, 70], ["Ca074Me", "CHEMICAL", 94, 101], ["tumor", "DISEASE", 201, 206], ["cysteine", "CHEMICAL", 31, 39], ["cysteine", "AMINO_ACID", 31, 39], ["E64", "SIMPLE_CHEMICAL", 67, 70], ["cell", "CELL", 79, 83], ["Ca074Me", "GENE_OR_GENE_PRODUCT", 94, 101], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 130, 141], ["tumor cell lines", "CELL", 201, 217], ["cysteine proteases", "PROTEIN", 31, 49], ["cathepsin B", "PROTEIN", 130, 141], ["tumor cell lines", "CELL_LINE", 201, 217], ["cysteine proteases", "TREATMENT", 31, 49], ["the cell permeable Ca074Me", "TEST", 75, 101], ["cathepsin B", "PROBLEM", 130, 141], ["several tumor cell lines", "TREATMENT", 193, 217], ["several", "OBSERVATION_MODIFIER", 193, 200], ["tumor cell lines", "OBSERVATION", 201, 217]]], ["Treatment with these lysosomal protease inhibitors also led to inhibition of lysosomal degradation of IGF-I and to abrogated IGF-I receptor signaling by reduction of IGF-I receptor levels on the cell surface [25].", [["lysosomal", "ANATOMY", 77, 86], ["cell surface", "ANATOMY", 195, 207], ["lysosomal", "CELLULAR_COMPONENT", 77, 86], ["IGF-I", "GENE_OR_GENE_PRODUCT", 102, 107], ["IGF-I receptor", "GENE_OR_GENE_PRODUCT", 125, 139], ["IGF-I receptor", "GENE_OR_GENE_PRODUCT", 166, 180], ["cell surface", "CELLULAR_COMPONENT", 195, 207], ["IGF-I", "PROTEIN", 102, 107], ["IGF-I receptor", "PROTEIN", 125, 139], ["IGF-I receptor", "PROTEIN", 166, 180], ["Treatment", "TREATMENT", 0, 9], ["these lysosomal protease inhibitors", "TREATMENT", 15, 50], ["lysosomal degradation of IGF", "TREATMENT", 77, 105], ["IGF", "TEST", 166, 169]]], ["Earlier, the same group had shown that treatment of cancer cells with the general cysteine cathepsin inhibitor E64 blocked their invasiveness and decreased liver metastasis [26].", [["cancer cells", "ANATOMY", 52, 64], ["liver", "ANATOMY", 156, 161], ["cancer", "DISEASE", 52, 58], ["E64", "CHEMICAL", 111, 114], ["decreased liver metastasis", "DISEASE", 146, 172], ["cysteine", "CHEMICAL", 82, 90], ["E64", "CHEMICAL", 111, 114], ["cancer cells", "CELL", 52, 64], ["cysteine cathepsin", "GENE_OR_GENE_PRODUCT", 82, 100], ["E64", "SIMPLE_CHEMICAL", 111, 114], ["liver", "ORGAN", 156, 161], ["cancer cells", "CELL_TYPE", 52, 64], ["cancer cells", "PROBLEM", 52, 64], ["the general cysteine cathepsin inhibitor", "TREATMENT", 70, 110], ["their invasiveness", "PROBLEM", 123, 141], ["decreased liver metastasis", "PROBLEM", 146, 172], ["cancer cells", "OBSERVATION", 52, 64], ["invasiveness", "OBSERVATION_MODIFIER", 129, 141], ["decreased", "OBSERVATION_MODIFIER", 146, 155], ["liver", "ANATOMY", 156, 161], ["metastasis", "OBSERVATION", 162, 172]]], ["It was later demonstrated that the protease responsible for IGF-I degradation was cathepsin B [27].", [["IGF-I", "GENE_OR_GENE_PRODUCT", 60, 65], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 82, 93], ["protease", "PROTEIN", 35, 43], ["IGF-I", "PROTEIN", 60, 65], ["cathepsin B", "PROTEIN", 82, 93], ["the protease", "TREATMENT", 31, 43], ["IGF", "TEST", 60, 63]]], ["However, cathepsin B is not the only protease implicated in selective growth factor degradation.", [["cathepsin B", "GENE_OR_GENE_PRODUCT", 9, 20], ["cathepsin B", "PROTEIN", 9, 20], ["protease", "PROTEIN", 37, 45], ["growth factor", "PROTEIN", 70, 83], ["selective growth factor degradation", "PROBLEM", 60, 95], ["selective", "OBSERVATION_MODIFIER", 60, 69], ["growth", "OBSERVATION_MODIFIER", 70, 76]]], ["For example, the aspartic protease cathepsin D was identified as being responsible for the endosomal degradation of insulin into two major primary end products [28], while in cathepsin L deficient fibroblasts the insulin-like growth factor binding protein 3 (IGFBP-3) accumulates in the culture medium due to decreased intracellular degradation [29].", [["endosomal", "ANATOMY", 91, 100], ["fibroblasts", "ANATOMY", 197, 208], ["intracellular", "ANATOMY", 319, 332], ["cathepsin D", "GENE_OR_GENE_PRODUCT", 35, 46], ["endosomal", "CELLULAR_COMPONENT", 91, 100], ["insulin", "GENE_OR_GENE_PRODUCT", 116, 123], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 175, 186], ["insulin-like growth factor binding protein 3", "GENE_OR_GENE_PRODUCT", 213, 257], ["IGFBP-3", "GENE_OR_GENE_PRODUCT", 259, 266], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 319, 332], ["aspartic protease cathepsin D", "PROTEIN", 17, 46], ["insulin", "PROTEIN", 116, 123], ["cathepsin L deficient fibroblasts", "CELL_TYPE", 175, 208], ["insulin-like growth factor binding protein 3", "PROTEIN", 213, 257], ["IGFBP-3", "PROTEIN", 259, 266], ["the aspartic protease cathepsin D", "PROBLEM", 13, 46], ["the endosomal degradation of insulin", "TREATMENT", 87, 123], ["cathepsin L deficient fibroblasts the insulin", "TREATMENT", 175, 220], ["binding protein", "TEST", 240, 255], ["IGFBP", "TEST", 259, 264], ["the culture medium", "TEST", 283, 301], ["decreased intracellular degradation", "PROBLEM", 309, 344], ["fibroblasts", "OBSERVATION", 197, 208], ["decreased", "OBSERVATION_MODIFIER", 309, 318], ["intracellular degradation", "OBSERVATION", 319, 344]]], ["Furthermore, the proliferation of primary keratinocytes from cathepsin L null mice is hyper-responsive to EGF stimulation [30].", [["keratinocytes", "ANATOMY", 42, 55], ["keratinocytes", "CELL", 42, 55], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 61, 72], ["EGF", "GENE_OR_GENE_PRODUCT", 106, 109], ["primary keratinocytes", "CELL_TYPE", 34, 55], ["EGF", "PROTEIN", 106, 109], ["mice", "SPECIES", 78, 82], ["primary keratinocytes", "PROBLEM", 34, 55], ["cathepsin L null mice", "TREATMENT", 61, 82], ["hyper", "PROBLEM", 86, 91], ["EGF stimulation", "TREATMENT", 106, 121], ["proliferation", "OBSERVATION_MODIFIER", 17, 30]]], ["Tracing the fate of radioactively labeled EGF in keratinocytes revealed that cathepsin L deficient cells exhibit enhanced recycling of intact growth factor to the medium and to the plasma membrane (Fig. 1).", [["keratinocytes", "ANATOMY", 49, 62], ["cells", "ANATOMY", 99, 104], ["plasma membrane", "ANATOMY", 181, 196], ["EGF", "GENE_OR_GENE_PRODUCT", 42, 45], ["keratinocytes", "CELL", 49, 62], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 77, 88], ["cells", "CELL", 99, 104], ["plasma membrane", "CELLULAR_COMPONENT", 181, 196], ["EGF", "PROTEIN", 42, 45], ["keratinocytes", "CELL_TYPE", 49, 62], ["cathepsin L deficient cells", "CELL_TYPE", 77, 104], ["growth factor", "PROTEIN", 142, 155], ["radioactively labeled EGF in keratinocytes", "TEST", 20, 62], ["cathepsin L deficient cells", "PROBLEM", 77, 104], ["intact growth factor", "PROBLEM", 135, 155], ["intact growth", "OBSERVATION_MODIFIER", 135, 148], ["plasma membrane", "ANATOMY", 181, 196]]], ["In addition, it has been shown that treatment with medium conditioned by cathepsin L deficient keratinocytes results in higher keratinocyte proliferation than with medium from cultured wild-type keratinocytes [30].", [["keratinocytes", "ANATOMY", 95, 108], ["keratinocyte", "ANATOMY", 127, 139], ["keratinocytes", "ANATOMY", 195, 208], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 73, 84], ["keratinocytes", "CELL", 95, 108], ["keratinocyte", "CELL", 127, 139], ["keratinocytes", "CELL", 195, 208], ["cathepsin L deficient keratinocytes", "CELL_TYPE", 73, 108], ["cultured wild-type keratinocytes", "CELL_LINE", 176, 208], ["treatment with medium conditioned", "TREATMENT", 36, 69], ["cathepsin L deficient keratinocytes", "TREATMENT", 73, 108], ["higher keratinocyte proliferation", "PROBLEM", 120, 153], ["type keratinocytes", "PROBLEM", 190, 208], ["higher", "OBSERVATION_MODIFIER", 120, 126], ["keratinocyte proliferation", "OBSERVATION", 127, 153]]], ["Further studies revealed the activation of a number of positive regulators and down-regulation of inhibitors in growth factor signaling pathways in cathepsin L deficient keratinocytes [31].", [["keratinocytes", "ANATOMY", 170, 183], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 148, 159], ["positive regulators", "PROTEIN", 55, 74], ["growth factor", "PROTEIN", 112, 125], ["cathepsin L deficient keratinocytes", "CELL_TYPE", 148, 183], ["Further studies", "TEST", 0, 15], ["positive regulators", "PROBLEM", 55, 74], ["inhibitors", "TREATMENT", 98, 108], ["growth factor signaling pathways", "PROBLEM", 112, 144], ["cathepsin L deficient keratinocytes", "PROBLEM", 148, 183]]], ["In fact, it was shown in vivo that levels of active Ras were significantly elevated in the skin of cathepsin L null mice [31].", [["skin", "ANATOMY", 91, 95], ["Ras", "GENE_OR_GENE_PRODUCT", 52, 55], ["skin", "ORGAN", 91, 95], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 99, 110], ["Ras", "PROTEIN", 52, 55], ["cathepsin L", "PROTEIN", 99, 110], ["mice", "SPECIES", 116, 120], ["active Ras", "PROBLEM", 45, 55], ["significantly elevated", "PROBLEM", 61, 83], ["active", "OBSERVATION_MODIFIER", 45, 51], ["Ras", "OBSERVATION", 52, 55], ["skin", "ANATOMY", 91, 95]]], ["Hyperactive Ras is central in many cancer-promoting signaling processes, such as the MAP-kinase and Akt/PKB pathways [32].", [["cancer", "ANATOMY", 35, 41], ["cancer", "DISEASE", 35, 41], ["Ras", "GENE_OR_GENE_PRODUCT", 12, 15], ["cancer", "CANCER", 35, 41], ["MAP-kinase", "GENE_OR_GENE_PRODUCT", 85, 95], ["Akt", "GENE_OR_GENE_PRODUCT", 100, 103], ["PKB", "GENE_OR_GENE_PRODUCT", 104, 107], ["Ras", "PROTEIN", 12, 15], ["MAP-kinase", "PROTEIN", 85, 95], ["Akt", "PROTEIN", 100, 103], ["PKB", "PROTEIN", 104, 107], ["Hyperactive Ras", "PROBLEM", 0, 15], ["central in many cancer", "PROBLEM", 19, 41], ["promoting signaling processes", "PROBLEM", 42, 71], ["the MAP", "TEST", 81, 88], ["kinase", "TEST", 89, 95], ["Akt/PKB pathways", "TEST", 100, 116], ["Ras", "OBSERVATION", 12, 15], ["central", "OBSERVATION_MODIFIER", 19, 26], ["many", "OBSERVATION_MODIFIER", 30, 34], ["cancer", "OBSERVATION", 35, 41]]], ["In agreement with this, both pathways have been found to be activated in cathepsin L deficient keratinocytes as well.", [["keratinocytes", "ANATOMY", 95, 108], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 73, 84], ["keratinocytes", "CELL", 95, 108], ["cathepsin L deficient keratinocytes", "CELL_LINE", 73, 108], ["cathepsin L deficient keratinocytes", "TREATMENT", 73, 108]]], ["The activation of Akt by phosphorylation was further enhanced upon incubation of the cathepsin L deficient cells in medium conditioned by cathepsin L deficient keratinocytes, supporting autocrine Akt stimulation caused by the absence of the protease [31].", [["cells", "ANATOMY", 107, 112], ["keratinocytes", "ANATOMY", 160, 173], ["Akt", "GENE_OR_GENE_PRODUCT", 18, 21], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 85, 96], ["cells", "CELL", 107, 112], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 138, 149], ["keratinocytes", "CELL", 160, 173], ["Akt", "GENE_OR_GENE_PRODUCT", 196, 199], ["Akt", "PROTEIN", 18, 21], ["cathepsin L deficient cells", "CELL_LINE", 85, 112], ["cathepsin L deficient keratinocytes", "CELL_TYPE", 138, 173], ["Akt", "PROTEIN", 196, 199], ["protease", "PROTEIN", 241, 249], ["the cathepsin L deficient cells", "TREATMENT", 81, 112], ["cathepsin L deficient keratinocytes", "TREATMENT", 138, 173], ["autocrine Akt stimulation", "TREATMENT", 186, 211]]], ["These findings fit the observation made in the K14-HPV16 mouse model of skin cancer, where the loss of cathepsin L surprisingly leads to an enhanced tumor phenotype.", [["skin cancer", "ANATOMY", 72, 83], ["tumor", "ANATOMY", 149, 154], ["skin cancer", "DISEASE", 72, 83], ["tumor", "DISEASE", 149, 154], ["K14", "GENE_OR_GENE_PRODUCT", 47, 50], ["mouse", "ORGANISM", 57, 62], ["skin cancer", "CANCER", 72, 83], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 103, 114], ["tumor", "CANCER", 149, 154], ["K14", "PROTEIN", 47, 50], ["cathepsin L", "PROTEIN", 103, 114], ["mouse", "SPECIES", 57, 62], ["mouse", "SPECIES", 57, 62], ["the observation", "TEST", 19, 34], ["skin cancer", "PROBLEM", 72, 83], ["the loss of cathepsin L", "PROBLEM", 91, 114], ["an enhanced tumor phenotype", "PROBLEM", 137, 164], ["skin", "ANATOMY", 72, 76], ["cancer", "OBSERVATION", 77, 83], ["loss", "OBSERVATION_MODIFIER", 95, 99], ["enhanced", "OBSERVATION_MODIFIER", 140, 148], ["tumor", "OBSERVATION", 149, 154]]], ["As summarized in Fig. 1, these data suggest that impaired degradation and enhanced recycling of plasma membrane receptors and their ligands in the absence of cathepsin L result in increased proliferation of basal keratinocytes.", [["plasma membrane", "ANATOMY", 96, 111], ["basal keratinocytes", "ANATOMY", 207, 226], ["impaired degradation", "DISEASE", 49, 69], ["plasma membrane", "CELLULAR_COMPONENT", 96, 111], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 158, 169], ["basal keratinocytes", "CELL", 207, 226], ["plasma membrane receptors", "PROTEIN", 96, 121], ["cathepsin L", "PROTEIN", 158, 169], ["basal keratinocytes", "CELL_TYPE", 207, 226], ["these data", "TEST", 25, 35], ["impaired degradation", "PROBLEM", 49, 69], ["plasma membrane receptors", "TREATMENT", 96, 121], ["cathepsin L", "TREATMENT", 158, 169], ["increased proliferation of basal keratinocytes", "PROBLEM", 180, 226], ["impaired", "OBSERVATION", 49, 57], ["increased", "OBSERVATION_MODIFIER", 180, 189], ["proliferation", "OBSERVATION_MODIFIER", 190, 203], ["basal keratinocytes", "OBSERVATION", 207, 226]]], ["This in turn leads to epidermal hyperproliferation and periodic hair loss in cathepsin L deficient mice.", [["epidermal", "ANATOMY", 22, 31], ["hair", "ANATOMY", 64, 68], ["hair loss", "DISEASE", 64, 73], ["epidermal", "TISSUE", 22, 31], ["hair", "ORGAN", 64, 68], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 77, 88], ["cathepsin L", "PROTEIN", 77, 88], ["mice", "SPECIES", 99, 103], ["epidermal hyperproliferation", "PROBLEM", 22, 50], ["periodic hair loss", "PROBLEM", 55, 73], ["cathepsin L deficient mice", "TREATMENT", 77, 103], ["epidermal", "OBSERVATION_MODIFIER", 22, 31], ["hyperproliferation", "OBSERVATION", 32, 50], ["periodic", "OBSERVATION_MODIFIER", 55, 63], ["hair loss", "OBSERVATION", 64, 73]]], ["In addition, the sustained oncogenic signaling in keratinocytes of cathepsin L deficient K14-HPV16 skin cancer mice results in an overall aggravated progression of the tumor [31], [33], [34].", [["keratinocytes", "ANATOMY", 50, 63], ["skin cancer", "ANATOMY", 99, 110], ["tumor", "ANATOMY", 168, 173], ["skin cancer", "DISEASE", 99, 110], ["tumor", "DISEASE", 168, 173], ["keratinocytes", "CELL", 50, 63], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 67, 78], ["K14", "GENE_OR_GENE_PRODUCT", 89, 92], ["tumor", "CANCER", 168, 173], ["keratinocytes", "CELL_TYPE", 50, 63], ["K14", "PROTEIN", 89, 92], ["mice", "SPECIES", 111, 115], ["cathepsin", "TEST", 67, 76], ["K14", "TEST", 89, 92], ["HPV16 skin cancer", "PROBLEM", 93, 110], ["an overall aggravated progression of the tumor", "PROBLEM", 127, 173], ["oncogenic", "OBSERVATION_MODIFIER", 27, 36], ["skin", "ANATOMY", 99, 103], ["cancer", "OBSERVATION", 104, 110], ["overall", "OBSERVATION_MODIFIER", 130, 137], ["aggravated", "OBSERVATION_MODIFIER", 138, 148], ["progression", "OBSERVATION_MODIFIER", 149, 160], ["tumor", "OBSERVATION", 168, 173]]], ["Taken together, lysosomal cathepsins play an important role not only in bulk protein degradation but, by degrading growth factors and their receptors, are also involved in receptor-trafficking and -signaling.Cathepsins in low density lipoprotein (LDL) degradation and atherosclerosis ::: Involvement of endolysosomal proteases in endocytosisThe LDL receptor binds apolipoprotein B-100 of the cholesterol-rich LDL particle, resulting in endocytosis of the LDL/receptor complex and its delivery to the endolysosome, where LDL dissociates from the receptor and cholesterol is released into the cell for membrane synthesis, steroidogenesis and bile acid synthesis.", [["lysosomal", "ANATOMY", 16, 25], ["endolysosomal", "ANATOMY", 303, 316], ["endolysosome", "ANATOMY", 500, 512], ["cell", "ANATOMY", 591, 595], ["membrane", "ANATOMY", 600, 608], ["atherosclerosis", "DISEASE", 268, 283], ["apolipoprotein B-100", "CHEMICAL", 364, 384], ["cholesterol", "CHEMICAL", 392, 403], ["cholesterol", "CHEMICAL", 558, 569], ["bile acid", "CHEMICAL", 640, 649], ["cholesterol", "CHEMICAL", 392, 403], ["cholesterol", "CHEMICAL", 558, 569], ["bile acid", "CHEMICAL", 640, 649], ["lysosomal cathepsins", "GENE_OR_GENE_PRODUCT", 16, 36], ["Cathepsins", "SIMPLE_CHEMICAL", 208, 218], ["low density lipoprotein", "SIMPLE_CHEMICAL", 222, 245], ["LDL", "SIMPLE_CHEMICAL", 247, 250], ["LDL receptor", "GENE_OR_GENE_PRODUCT", 345, 357], ["apolipoprotein B-100", "GENE_OR_GENE_PRODUCT", 364, 384], ["cholesterol", "SIMPLE_CHEMICAL", 392, 403], ["LDL", "SIMPLE_CHEMICAL", 409, 412], ["LDL", "GENE_OR_GENE_PRODUCT", 455, 458], ["LDL", "SIMPLE_CHEMICAL", 520, 523], ["cholesterol", "SIMPLE_CHEMICAL", 558, 569], ["cell", "CELL", 591, 595], ["membrane", "CELLULAR_COMPONENT", 600, 608], ["bile acid", "SIMPLE_CHEMICAL", 640, 649], ["lysosomal cathepsins", "PROTEIN", 16, 36], ["growth factors", "PROTEIN", 115, 129], ["LDL", "PROTEIN", 247, 250], ["endolysosomal proteases", "PROTEIN", 303, 326], ["LDL receptor", "PROTEIN", 345, 357], ["LDL", "PROTEIN", 455, 458], ["receptor complex", "PROTEIN", 459, 475], ["LDL", "PROTEIN", 520, 523], ["lysosomal cathepsins", "TREATMENT", 16, 36], ["bulk protein degradation", "PROBLEM", 72, 96], ["Cathepsins", "TREATMENT", 208, 218], ["atherosclerosis", "PROBLEM", 268, 283], ["endolysosomal proteases in endocytosis", "PROBLEM", 303, 341], ["The LDL receptor", "TEST", 341, 357], ["apolipoprotein B", "TEST", 364, 380], ["the cholesterol", "TEST", 388, 403], ["LDL particle", "TEST", 409, 421], ["endocytosis of the LDL/receptor complex", "PROBLEM", 436, 475], ["LDL dissociates", "PROBLEM", 520, 535], ["membrane synthesis", "TREATMENT", 600, 618], ["steroidogenesis", "TREATMENT", 620, 635], ["bile acid synthesis", "TREATMENT", 640, 659], ["low density", "OBSERVATION_MODIFIER", 222, 233], ["atherosclerosis", "OBSERVATION", 268, 283], ["endolysosomal proteases", "OBSERVATION", 303, 326], ["endocytosis", "OBSERVATION_MODIFIER", 330, 341], ["LDL particle", "OBSERVATION", 409, 421], ["endocytosis", "OBSERVATION", 436, 447], ["LDL", "ANATOMY", 455, 458], ["bile", "ANATOMY", 640, 644]]], ["The LDL receptor is recycled to the plasma membrane for subsequent cycles of endocytosis, resulting in a decrease in cholesterol levels in the blood [35].", [["plasma membrane", "ANATOMY", 36, 51], ["blood", "ANATOMY", 143, 148], ["cholesterol", "CHEMICAL", 117, 128], ["cholesterol", "CHEMICAL", 117, 128], ["LDL receptor", "GENE_OR_GENE_PRODUCT", 4, 16], ["plasma membrane", "CELLULAR_COMPONENT", 36, 51], ["cholesterol", "SIMPLE_CHEMICAL", 117, 128], ["blood", "ORGANISM_SUBSTANCE", 143, 148], ["LDL receptor", "PROTEIN", 4, 16], ["The LDL receptor", "TEST", 0, 16], ["endocytosis", "PROBLEM", 77, 88], ["a decrease in cholesterol levels", "PROBLEM", 103, 135], ["endocytosis", "OBSERVATION", 77, 88], ["decrease", "OBSERVATION_MODIFIER", 105, 113]]], ["LDL receptor expression is regulated by intracellular cholesterol levels.", [["intracellular", "ANATOMY", 40, 53], ["cholesterol", "CHEMICAL", 54, 65], ["cholesterol", "CHEMICAL", 54, 65], ["LDL receptor", "GENE_OR_GENE_PRODUCT", 0, 12], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 40, 53], ["cholesterol", "SIMPLE_CHEMICAL", 54, 65], ["LDL receptor", "PROTEIN", 0, 12], ["LDL receptor expression", "TEST", 0, 23], ["intracellular cholesterol levels", "TEST", 40, 72], ["intracellular cholesterol", "OBSERVATION", 40, 65]]], ["Mutations of either the LDL receptor or its ligand, the apolipoprotein B-100, results in decreased ability of the cell to import cholesterol, causing hypercholesterolemia and, subsequently, cardiovascular disease [36], [37].", [["cell", "ANATOMY", 114, 118], ["cardiovascular", "ANATOMY", 190, 204], ["apolipoprotein B-100", "CHEMICAL", 56, 76], ["cholesterol", "CHEMICAL", 129, 140], ["hypercholesterolemia", "DISEASE", 150, 170], ["cardiovascular disease", "DISEASE", 190, 212], ["cholesterol", "CHEMICAL", 129, 140], ["LDL receptor", "GENE_OR_GENE_PRODUCT", 24, 36], ["apolipoprotein B-100", "GENE_OR_GENE_PRODUCT", 56, 76], ["cell", "CELL", 114, 118], ["cholesterol", "SIMPLE_CHEMICAL", 129, 140], ["LDL receptor", "PROTEIN", 24, 36], ["the apolipoprotein B", "TEST", 52, 72], ["hypercholesterolemia", "PROBLEM", 150, 170], ["cardiovascular disease", "PROBLEM", 190, 212], ["hypercholesterolemia", "OBSERVATION", 150, 170]]], ["Early work suggested that the proteases responsible for lysosomal LDL degradation might be the endolysosomal cathepsins B and D [38], [39].", [["lysosomal", "ANATOMY", 56, 65], ["endolysosomal", "ANATOMY", 95, 108], ["lysosomal LDL", "GENE_OR_GENE_PRODUCT", 56, 69], ["endolysosomal cathepsins B", "GENE_OR_GENE_PRODUCT", 95, 121], ["proteases", "PROTEIN", 30, 39], ["lysosomal LDL", "PROTEIN", 56, 69], ["endolysosomal cathepsins B", "PROTEIN", 95, 121], ["the proteases", "PROBLEM", 26, 39], ["lysosomal LDL degradation", "PROBLEM", 56, 81]]], ["Van Lenten et al. showed that it is primarily cathepsin D which cleaves the apolipoprotein B under normal conditions, and proposed that the accumulation of cholesteryl esters in macrophages in atherosclerosis might be due to the fact that at high concentrations of LDL the number of LDL\u2013receptor complexes reaching the compartment for hydrolysis is rate-limiting [39].", [["macrophages", "ANATOMY", 178, 189], ["cholesteryl esters", "CHEMICAL", 156, 174], ["atherosclerosis", "DISEASE", 193, 208], ["cholesteryl esters", "CHEMICAL", 156, 174], ["cathepsin D", "GENE_OR_GENE_PRODUCT", 46, 57], ["apolipoprotein B", "GENE_OR_GENE_PRODUCT", 76, 92], ["cholesteryl esters", "SIMPLE_CHEMICAL", 156, 174], ["macrophages", "CELL", 178, 189], ["LDL", "SIMPLE_CHEMICAL", 265, 268], ["LDL\u2013receptor complexes", "GENE_OR_GENE_PRODUCT", 283, 305], ["cathepsin D", "PROTEIN", 46, 57], ["apolipoprotein B", "PROTEIN", 76, 92], ["macrophages", "CELL_TYPE", 178, 189], ["LDL", "PROTEIN", 265, 268], ["LDL\u2013receptor complexes", "PROTEIN", 283, 305], ["primarily cathepsin D", "PROBLEM", 36, 57], ["the accumulation of cholesteryl esters", "PROBLEM", 136, 174], ["macrophages", "PROBLEM", 178, 189], ["atherosclerosis", "PROBLEM", 193, 208], ["hydrolysis", "PROBLEM", 335, 345], ["cholesteryl esters", "OBSERVATION", 156, 174], ["atherosclerosis", "OBSERVATION", 193, 208], ["might be due to", "UNCERTAINTY", 209, 224]]], ["Cathepsin D has also been identified as the relevant protease for the degradation of another complex of the LDL-receptor family, namely the t-PA/PAI-1 (tissue-type plasminogen activator/plasminogen activator inhibitor-1) complex which is highly important for the regulation of fibrinolysis [40].", [["Cathepsin D", "GENE_OR_GENE_PRODUCT", 0, 11], ["LDL-receptor", "GENE_OR_GENE_PRODUCT", 108, 120], ["t-PA", "GENE_OR_GENE_PRODUCT", 140, 144], ["PAI-1", "GENE_OR_GENE_PRODUCT", 145, 150], ["tissue-type plasminogen activator/plasminogen activator inhibitor-1", "GENE_OR_GENE_PRODUCT", 152, 219], ["Cathepsin D", "PROTEIN", 0, 11], ["protease", "PROTEIN", 53, 61], ["LDL-receptor family", "PROTEIN", 108, 127], ["t-PA/PAI-1", "PROTEIN", 140, 150], ["tissue-type plasminogen activator", "PROTEIN", 152, 185], ["plasminogen activator inhibitor-1) complex", "PROTEIN", 186, 228], ["Cathepsin D", "TREATMENT", 0, 11], ["the relevant protease", "TREATMENT", 40, 61], ["the t-PA/PAI", "TREATMENT", 136, 148], ["tissue-type plasminogen activator/plasminogen activator inhibitor", "TREATMENT", 152, 217]]], ["It was demonstrated that the t-PA/PAI-1 complex is internalized by human monocytes via a member of the LDL receptor family, followed by degradation through cathepsin D after delivery to the lysosomes.Cathepsins in low density lipoprotein (LDL) degradation and atherosclerosis ::: Involvement of endolysosomal proteases in endocytosisIt was later shown that macrophages as well as intimal smooth muscle cells in atheroma contained abundant immunoreactive cysteine cathepsins K and S contributing to ECM remodeling due to their elastinolytic and collagenolytic activity [41].", [["monocytes", "ANATOMY", 73, 82], ["lysosomes", "ANATOMY", 190, 199], ["endolysosomal", "ANATOMY", 295, 308], ["macrophages", "ANATOMY", 357, 368], ["intimal smooth muscle cells", "ANATOMY", 380, 407], ["atheroma", "ANATOMY", 411, 419], ["ECM", "ANATOMY", 498, 501], ["atherosclerosis", "DISEASE", 260, 275], ["atheroma", "DISEASE", 411, 419], ["K", "CHEMICAL", 474, 475], ["cysteine", "CHEMICAL", 454, 462], ["t-PA", "GENE_OR_GENE_PRODUCT", 29, 33], ["PAI-1", "GENE_OR_GENE_PRODUCT", 34, 39], ["human", "ORGANISM", 67, 72], ["monocytes", "CELL", 73, 82], ["LDL receptor", "GENE_OR_GENE_PRODUCT", 103, 115], ["cathepsin D", "GENE_OR_GENE_PRODUCT", 156, 167], ["lysosomes", "CELLULAR_COMPONENT", 190, 199], ["Cathepsins", "SIMPLE_CHEMICAL", 200, 210], ["low density lipoprotein", "SIMPLE_CHEMICAL", 214, 237], ["LDL", "SIMPLE_CHEMICAL", 239, 242], ["macrophages", "CELL", 357, 368], ["intimal smooth muscle cells", "CELL", 380, 407], ["atheroma", "MULTI-TISSUE_STRUCTURE", 411, 419], ["cysteine cathepsins K", "GENE_OR_GENE_PRODUCT", 454, 475], ["ECM", "CELLULAR_COMPONENT", 498, 501], ["t-PA", "PROTEIN", 29, 33], ["PAI-1 complex", "PROTEIN", 34, 47], ["human monocytes", "CELL_TYPE", 67, 82], ["LDL receptor family", "PROTEIN", 103, 122], ["cathepsin D", "PROTEIN", 156, 167], ["LDL", "PROTEIN", 239, 242], ["endolysosomal proteases", "PROTEIN", 295, 318], ["macrophages", "CELL_TYPE", 357, 368], ["intimal smooth muscle cells", "CELL_TYPE", 380, 407], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 67, 72], ["the t-PA/PAI", "TEST", 25, 37], ["delivery", "TREATMENT", 174, 182], ["Cathepsins", "TREATMENT", 200, 210], ["atherosclerosis", "PROBLEM", 260, 275], ["endolysosomal proteases in endocytosis", "PROBLEM", 295, 333], ["macrophages", "PROBLEM", 357, 368], ["intimal smooth muscle cells", "PROBLEM", 380, 407], ["atheroma", "PROBLEM", 411, 419], ["immunoreactive cysteine cathepsins K", "PROBLEM", 439, 475], ["ECM remodeling", "PROBLEM", 498, 512], ["their elastinolytic and collagenolytic activity", "PROBLEM", 520, 567], ["low density", "OBSERVATION_MODIFIER", 214, 225], ["atherosclerosis", "OBSERVATION", 260, 275], ["endolysosomal proteases", "OBSERVATION", 295, 318], ["endocytosis", "OBSERVATION_MODIFIER", 322, 333], ["macrophages", "OBSERVATION", 357, 368], ["intimal", "ANATOMY", 380, 387], ["smooth muscle cells", "OBSERVATION", 388, 407], ["atheroma", "OBSERVATION", 411, 419], ["abundant", "OBSERVATION_MODIFIER", 430, 438], ["immunoreactive cysteine", "OBSERVATION", 439, 462]]], ["Both proteases were upregulated upon stimulation with the atheroma-associated inflammatory cytokines interleukin-1\u03b2 (IL-1\u03b2) or interferon-\u03b3 [41].", [["atheroma", "ANATOMY", 58, 66], ["atheroma", "DISEASE", 58, 66], ["atheroma", "PATHOLOGICAL_FORMATION", 58, 66], ["interleukin-1\u03b2", "GENE_OR_GENE_PRODUCT", 101, 115], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 117, 122], ["interferon-\u03b3", "GENE_OR_GENE_PRODUCT", 127, 139], ["proteases", "PROTEIN", 5, 14], ["atheroma-associated inflammatory cytokines", "PROTEIN", 58, 100], ["interleukin-1\u03b2 (IL-1\u03b2", "PROTEIN", 101, 122], ["interferon", "PROTEIN", 127, 137], ["the atheroma", "PROBLEM", 54, 66], ["inflammatory cytokines interleukin", "TEST", 78, 112], ["IL", "TEST", 117, 119], ["interferon", "TEST", 127, 137], ["atheroma", "OBSERVATION", 58, 66], ["inflammatory", "OBSERVATION_MODIFIER", 78, 90]]], ["In a subsequent study the involvement of cathepsin S in atherosclerosis was demonstrated in mice with a double deficiency in cathepsin S and the LDL receptor [42].", [["atherosclerosis", "DISEASE", 56, 71], ["cathepsin S", "GENE_OR_GENE_PRODUCT", 41, 52], ["mice", "ORGANISM", 92, 96], ["cathepsin S", "GENE_OR_GENE_PRODUCT", 125, 136], ["LDL receptor", "GENE_OR_GENE_PRODUCT", 145, 157], ["cathepsin S", "PROTEIN", 41, 52], ["cathepsin S", "PROTEIN", 125, 136], ["LDL receptor", "PROTEIN", 145, 157], ["mice", "SPECIES", 92, 96], ["mice", "SPECIES", 92, 96], ["a subsequent study", "TEST", 3, 21], ["cathepsin S", "PROBLEM", 41, 52], ["atherosclerosis", "PROBLEM", 56, 71], ["a double deficiency in cathepsin S", "PROBLEM", 102, 136], ["the LDL receptor", "TEST", 141, 157], ["atherosclerosis", "OBSERVATION", 56, 71], ["double deficiency", "OBSERVATION", 104, 121]]], ["In this mouse model the lack of cathepsin S reduced atherosclerosis by more than 50% after 8 and 12 weeks of an atherogenic diet, and by an additional 30% after 26 weeks.", [["atherosclerosis", "DISEASE", 52, 67], ["mouse", "ORGANISM", 8, 13], ["cathepsin S", "GENE_OR_GENE_PRODUCT", 32, 43], ["cathepsin S", "PROTEIN", 32, 43], ["mouse", "SPECIES", 8, 13], ["mouse", "SPECIES", 8, 13], ["cathepsin S reduced atherosclerosis", "PROBLEM", 32, 67], ["an atherogenic diet", "TREATMENT", 109, 128], ["reduced", "OBSERVATION_MODIFIER", 44, 51], ["atherosclerosis", "OBSERVATION", 52, 67], ["atherogenic", "OBSERVATION", 112, 123]]], ["The authors of this work proposed several mechanisms to explain these results such as the contribution of secreted cathepsin S to the proteolysis of the elastic lamina, ECM and basement membrane of blood vessels, thereby disturbing the vessels' structural integrity.", [["elastic lamina", "ANATOMY", 153, 167], ["ECM", "ANATOMY", 169, 172], ["basement membrane", "ANATOMY", 177, 194], ["blood vessels", "ANATOMY", 198, 211], ["vessels", "ANATOMY", 236, 243], ["cathepsin S", "GENE_OR_GENE_PRODUCT", 115, 126], ["elastic lamina", "CELLULAR_COMPONENT", 153, 167], ["ECM", "CELLULAR_COMPONENT", 169, 172], ["basement membrane", "CELLULAR_COMPONENT", 177, 194], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 198, 211], ["vessels", "MULTI-TISSUE_STRUCTURE", 236, 243], ["cathepsin S", "PROTEIN", 115, 126], ["secreted cathepsin S", "PROBLEM", 106, 126], ["elastic lamina", "ANATOMY", 153, 167], ["blood vessels", "ANATOMY", 198, 211], ["vessels", "ANATOMY", 236, 243], ["structural", "OBSERVATION_MODIFIER", 245, 255], ["integrity", "OBSERVATION_MODIFIER", 256, 265]]], ["An additional suggestion was an altered immune response due to defective antigen presentation of CD1-positive \u2018foamy\u2019 macrophages [42].", [["macrophages", "ANATOMY", 118, 129], ["CD1", "GENE_OR_GENE_PRODUCT", 97, 100], ["CD1", "PROTEIN", 97, 100], ["foamy\u2019 macrophages", "CELL_TYPE", 111, 129], ["an altered immune response", "PROBLEM", 29, 55], ["CD1", "TEST", 97, 100]]], ["Recently, a mechanism linking macrophage cathepsins B and L to atherosclerosis was proposed [43].", [["macrophage", "ANATOMY", 30, 40], ["atherosclerosis", "DISEASE", 63, 78], ["macrophage", "CELL", 30, 40], ["cathepsins B", "GENE_OR_GENE_PRODUCT", 41, 53], ["macrophage cathepsins B", "PROTEIN", 30, 53], ["atherosclerosis", "PROBLEM", 63, 78], ["atherosclerosis", "OBSERVATION", 63, 78]]], ["These experiments revealed impairment in the inflammatory response after intraperitoneal injection of cholesterol crystals in mice deficient in either components of the NLRP3 inflammasome, cathepsin B, cathepsin L or IL-1\u03b2.", [["intraperitoneal", "ANATOMY", 73, 88], ["cholesterol", "CHEMICAL", 102, 113], ["cholesterol", "CHEMICAL", 102, 113], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 73, 88], ["cholesterol", "SIMPLE_CHEMICAL", 102, 113], ["mice", "ORGANISM", 126, 130], ["NLRP3", "GENE_OR_GENE_PRODUCT", 169, 174], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 189, 200], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 202, 213], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 217, 222], ["NLRP3 inflammasome", "PROTEIN", 169, 187], ["cathepsin B", "PROTEIN", 189, 200], ["cathepsin L or IL-1\u03b2", "PROTEIN", 202, 222], ["mice", "SPECIES", 126, 130], ["mice", "SPECIES", 126, 130], ["These experiments", "TEST", 0, 17], ["impairment", "PROBLEM", 27, 37], ["the inflammatory response", "PROBLEM", 41, 66], ["intraperitoneal injection of cholesterol crystals", "TREATMENT", 73, 122], ["mice deficient", "PROBLEM", 126, 140], ["the NLRP3 inflammasome", "TREATMENT", 165, 187], ["cathepsin B, cathepsin L or IL", "TREATMENT", 189, 219], ["impairment", "OBSERVATION_MODIFIER", 27, 37], ["inflammatory", "OBSERVATION_MODIFIER", 45, 57]]], ["The proposed pathway involves lysosomal damage after uptake of cholesterol crystals by macrophages.", [["lysosomal", "ANATOMY", 30, 39], ["macrophages", "ANATOMY", 87, 98], ["lysosomal damage", "DISEASE", 30, 46], ["cholesterol", "CHEMICAL", 63, 74], ["cholesterol", "CHEMICAL", 63, 74], ["lysosomal", "CELLULAR_COMPONENT", 30, 39], ["cholesterol crystals", "SIMPLE_CHEMICAL", 63, 83], ["macrophages", "CELL", 87, 98], ["macrophages", "CELL_TYPE", 87, 98], ["lysosomal damage", "PROBLEM", 30, 46], ["uptake of cholesterol crystals", "TREATMENT", 53, 83], ["lysosomal damage", "OBSERVATION", 30, 46], ["cholesterol crystals", "OBSERVATION", 63, 83], ["macrophages", "ANATOMY", 87, 98]]], ["In consequence, the cathepsins are released to the cytosol where they activate the NLRP3 inflammasome by an as yet unknown mechanism.", [["cytosol", "ANATOMY", 51, 58], ["cathepsins", "GENE_OR_GENE_PRODUCT", 20, 30], ["cytosol", "CELLULAR_COMPONENT", 51, 58], ["NLRP3", "GENE_OR_GENE_PRODUCT", 83, 88], ["cathepsins", "PROTEIN", 20, 30], ["NLRP3", "PROTEIN", 83, 88], ["the cathepsins", "TREATMENT", 16, 30]]], ["The caspase 1 activity of the activated NLRP3 inflammasome selectively processes the pro-inflammatory IL-1\u03b2, which is a hallmark of the inflammatory micromilieu that propagates atherosclerotic lesions.\u2018Acidic\u2019 proteases generate or destroy antigenic peptides ::: Role of endosomal proteolysis in antigen presentation and infectionThe presentation of self and antigenic peptides by MHC class II molecules is an exclusive feature of APCs such as dendritic cells (DCs), macrophages, and B cells.", [["atherosclerotic lesions", "ANATOMY", 177, 200], ["endosomal", "ANATOMY", 271, 280], ["APCs", "ANATOMY", 431, 435], ["dendritic cells", "ANATOMY", 444, 459], ["DCs", "ANATOMY", 461, 464], ["macrophages", "ANATOMY", 467, 478], ["B cells", "ANATOMY", 484, 491], ["atherosclerotic lesions", "DISEASE", 177, 200], ["infection", "DISEASE", 321, 330], ["caspase 1", "GENE_OR_GENE_PRODUCT", 4, 13], ["NLRP3", "GENE_OR_GENE_PRODUCT", 40, 45], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 102, 107], ["atherosclerotic lesions", "PATHOLOGICAL_FORMATION", 177, 200], ["endosomal", "CELLULAR_COMPONENT", 271, 280], ["MHC class II", "GENE_OR_GENE_PRODUCT", 381, 393], ["APCs", "CELL", 431, 435], ["dendritic cells", "CELL", 444, 459], ["DCs", "CELL", 461, 464], ["macrophages", "CELL", 467, 478], ["B cells", "CELL", 484, 491], ["caspase 1", "PROTEIN", 4, 13], ["NLRP3 inflammasome", "PROTEIN", 40, 58], ["pro-inflammatory IL-1\u03b2", "PROTEIN", 85, 107], ["Acidic\u2019 proteases", "PROTEIN", 202, 219], ["MHC class II molecules", "PROTEIN", 381, 403], ["APCs", "CELL_TYPE", 431, 435], ["dendritic cells", "CELL_TYPE", 444, 459], ["DCs", "CELL_TYPE", 461, 464], ["macrophages", "CELL_TYPE", 467, 478], ["B cells", "CELL_TYPE", 484, 491], ["The caspase", "TREATMENT", 0, 11], ["the activated NLRP3 inflammasome", "TREATMENT", 26, 58], ["the inflammatory micromilieu", "PROBLEM", 132, 160], ["atherosclerotic lesions", "PROBLEM", 177, 200], ["endosomal proteolysis", "PROBLEM", 271, 292], ["infection", "PROBLEM", 321, 330], ["self and antigenic peptides", "PROBLEM", 350, 377], ["APCs", "PROBLEM", 431, 435], ["dendritic cells", "PROBLEM", 444, 459], ["macrophages", "PROBLEM", 467, 478], ["B cells", "PROBLEM", 484, 491], ["pro-inflammatory", "OBSERVATION_MODIFIER", 85, 101], ["inflammatory", "OBSERVATION_MODIFIER", 136, 148], ["atherosclerotic", "OBSERVATION_MODIFIER", 177, 192], ["lesions", "OBSERVATION", 193, 200], ["endosomal proteolysis", "OBSERVATION", 271, 292], ["infection", "OBSERVATION", 321, 330], ["dendritic cells", "OBSERVATION", 444, 459], ["B cells", "OBSERVATION", 484, 491]]], ["APCs can efficiently take up material from the extracellular space by phagocytosis, pinocytosis or receptor-mediated endocytosis.", [["APCs", "ANATOMY", 0, 4], ["extracellular space", "ANATOMY", 47, 66], ["APCs", "CELL", 0, 4], ["extracellular space", "CELLULAR_COMPONENT", 47, 66], ["APCs", "CELL_TYPE", 0, 4], ["APCs", "PROBLEM", 0, 4], ["phagocytosis", "PROBLEM", 70, 82], ["pinocytosis", "PROBLEM", 84, 95], ["receptor-mediated endocytosis", "PROBLEM", 99, 128], ["endocytosis", "OBSERVATION", 117, 128]]], ["As shown in Fig. 2, ingested material is directed to the endosomal compartment where proteins get processed and degraded by \u2018acidic\u2019 proteases, e.g. cathepsins.", [["endosomal compartment", "ANATOMY", 57, 78], ["endosomal compartment", "CELLULAR_COMPONENT", 57, 78], ["cathepsins", "GENE_OR_GENE_PRODUCT", 149, 159], ["\u2018acidic\u2019 proteases", "PROTEIN", 124, 142], ["cathepsins", "PROTEIN", 149, 159], ["cathepsins", "TREATMENT", 149, 159]]], ["Peptides generated by these enzymes are subsequently presented at the cell surface by MHC class II molecules, activating CD4 positive (CD4+) T helper cells in the case of exogenous pathogens.\u2018Acidic\u2019 proteases generate or destroy antigenic peptides ::: Role of endosomal proteolysis in antigen presentation and infectionDCs are the most potent APCs because of their ability to migrate to the lymph nodes after activation to foster an adaptive immune response [44].", [["cell surface", "ANATOMY", 70, 82], ["T helper cells", "ANATOMY", 141, 155], ["endosomal", "ANATOMY", 261, 270], ["APCs", "ANATOMY", 344, 348], ["lymph nodes", "ANATOMY", 392, 403], ["cell surface", "CELLULAR_COMPONENT", 70, 82], ["CD4", "GENE_OR_GENE_PRODUCT", 121, 124], ["CD4", "GENE_OR_GENE_PRODUCT", 135, 138], ["T helper cells", "CELL", 141, 155], ["endosomal", "CELLULAR_COMPONENT", 261, 270], ["antigen", "GENE_OR_GENE_PRODUCT", 286, 293], ["APCs", "CELL", 344, 348], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 392, 403], ["enzymes", "PROTEIN", 28, 35], ["MHC class II molecules", "PROTEIN", 86, 108], ["CD4", "PROTEIN", 121, 124], ["CD4", "PROTEIN", 135, 138], ["T helper cells", "CELL_TYPE", 141, 155], ["Acidic\u2019 proteases", "PROTEIN", 192, 209], ["APCs", "CELL_TYPE", 344, 348], ["these enzymes", "TEST", 22, 35], ["exogenous pathogens", "PROBLEM", 171, 190], ["endosomal proteolysis", "PROBLEM", 261, 282], ["infectionDCs", "PROBLEM", 311, 323], ["exogenous pathogens", "OBSERVATION", 171, 190], ["endosomal proteolysis", "OBSERVATION", 261, 282], ["lymph nodes", "OBSERVATION", 392, 403]]], ["It is therefore important that antigenic peptides remain preserved in DCs rather than becoming destroyed.", [["DCs", "ANATOMY", 70, 73], ["DCs", "CELL", 70, 73], ["DCs", "CELL_TYPE", 70, 73], ["antigenic peptides", "TREATMENT", 31, 49]]], ["In agreement with this it was demonstrated that DCs can regulate endosomal pH through the activity of NADPH oxidase 2, whose products alkalinize the pH and therefore limit antigen degradation by \u2018acidic\u2019 proteases [45].", [["DCs", "ANATOMY", 48, 51], ["endosomal", "ANATOMY", 65, 74], ["NADPH", "CHEMICAL", 102, 107], ["NADPH", "CHEMICAL", 102, 107], ["DCs", "CELL", 48, 51], ["endosomal", "CELLULAR_COMPONENT", 65, 74], ["NADPH oxidase 2", "GENE_OR_GENE_PRODUCT", 102, 117], ["DCs", "CELL_TYPE", 48, 51], ["NADPH oxidase 2", "PROTEIN", 102, 117], ["\u2018acidic\u2019 proteases", "PROTEIN", 195, 213], ["endosomal pH", "TEST", 65, 77], ["NADPH oxidase", "TREATMENT", 102, 115], ["the pH", "TEST", 145, 151]]], ["Furthermore, the immunogenicity of proteins is highly dependent on their susceptibility to endolysosomal proteases as enhanced protein degradation leads to strong attenuation of the adaptive immune response [46].\u2018Acidic\u2019 proteases generate or destroy antigenic peptides ::: Role of endosomal proteolysis in antigen presentation and infectionThe identification of antigenic peptides specifically generated or destroyed by one particular protease is, however, difficult as a result of functional redundancy between endolysosomal proteases.", [["endolysosomal", "ANATOMY", 91, 104], ["endosomal", "ANATOMY", 282, 291], ["endolysosomal", "ANATOMY", 513, 526], ["infection", "DISEASE", 332, 341], ["endosomal", "CELLULAR_COMPONENT", 282, 291], ["endolysosomal proteases", "PROTEIN", 91, 114], ["Acidic\u2019 proteases", "PROTEIN", 213, 230], ["protease", "PROTEIN", 436, 444], ["endolysosomal proteases", "PROTEIN", 513, 536], ["the immunogenicity of proteins", "PROBLEM", 13, 43], ["endolysosomal proteases", "PROBLEM", 91, 114], ["enhanced protein degradation", "PROBLEM", 118, 146], ["endosomal proteolysis", "PROBLEM", 282, 303], ["infection", "PROBLEM", 332, 341], ["antigenic peptides", "PROBLEM", 363, 381], ["functional redundancy between endolysosomal proteases", "PROBLEM", 483, 536], ["highly dependent", "OBSERVATION_MODIFIER", 47, 63], ["endosomal proteolysis", "OBSERVATION", 282, 303], ["infection", "OBSERVATION", 332, 341], ["functional redundancy", "OBSERVATION", 483, 504], ["endolysosomal proteases", "OBSERVATION", 513, 536]]], ["Asparagine endopeptidase (AEP, also called legumain), for example, has been proposed to degrade the autoantigen myelin basic protein (MBP) peptide 85\u201399 in a human Epstein Barr Virus-transformed (EBV) B cell line, thereby removing it from the peptide repertoire which induces tolerance to self antigens in the thymus [47].", [["EBV) B cell line", "ANATOMY", 196, 212], ["thymus", "ANATOMY", 310, 316], ["Asparagine", "CHEMICAL", 0, 10], ["Asparagine", "CHEMICAL", 0, 10], ["legumain", "CHEMICAL", 43, 51], ["Asparagine endopeptidase", "GENE_OR_GENE_PRODUCT", 0, 24], ["AEP", "SIMPLE_CHEMICAL", 26, 29], ["legumain", "GENE_OR_GENE_PRODUCT", 43, 51], ["myelin basic protein (MBP) peptide 85\u201399", "GENE_OR_GENE_PRODUCT", 112, 152], ["human", "ORGANISM", 158, 163], ["Epstein Barr Virus", "ORGANISM", 164, 182], ["EBV", "ORGANISM", 196, 199], ["B cell line", "CELL", 201, 212], ["thymus", "ORGAN", 310, 316], ["Asparagine endopeptidase", "PROTEIN", 0, 24], ["AEP", "PROTEIN", 26, 29], ["legumain", "PROTEIN", 43, 51], ["autoantigen myelin basic protein", "PROTEIN", 100, 132], ["MBP", "PROTEIN", 134, 137], ["human Epstein Barr Virus-transformed (EBV) B cell line", "CELL_LINE", 158, 212], ["self antigens", "PROTEIN", 289, 302], ["human", "SPECIES", 158, 163], ["human Epstein Barr Virus", "SPECIES", 158, 182], ["Asparagine endopeptidase (AEP", "PROBLEM", 0, 29], ["MBP) peptide", "TEST", 134, 146], ["a human Epstein Barr Virus", "PROBLEM", 156, 182], ["B cell line", "TREATMENT", 201, 212], ["the peptide repertoire", "TREATMENT", 239, 261], ["cell line", "OBSERVATION", 203, 212], ["thymus", "ANATOMY", 310, 316]]], ["In contrast, in another study which used the same cell line but a different AEP inhibitor there was no change in the T cell response to MBP peptide 85\u201399 detected [48].", [["cell line", "ANATOMY", 50, 59], ["T cell", "ANATOMY", 117, 123], ["cell line", "CELL", 50, 59], ["T cell", "CELL", 117, 123], ["MBP", "GENE_OR_GENE_PRODUCT", 136, 139], ["cell line", "CELL_LINE", 50, 59], ["MBP", "PROTEIN", 136, 139], ["another study", "TEST", 16, 29], ["the same cell line", "TREATMENT", 41, 59], ["a different AEP inhibitor", "TREATMENT", 64, 89], ["MBP peptide", "TEST", 136, 147], ["cell line", "OBSERVATION", 50, 59], ["no", "UNCERTAINTY", 100, 102], ["change", "OBSERVATION_MODIFIER", 103, 109]]], ["However, it was claimed that in these cells the neutrophil serine protease cathepsin G, which is taken up by human B lymphoblastic cells via endocytosis, degrades MBP [49].", [["cells", "ANATOMY", 38, 43], ["B lymphoblastic cells", "ANATOMY", 115, 136], ["lymphoblastic", "DISEASE", 117, 130], ["serine", "CHEMICAL", 59, 65], ["cells", "CELL", 38, 43], ["neutrophil", "CELL", 48, 58], ["cathepsin G", "GENE_OR_GENE_PRODUCT", 75, 86], ["human", "ORGANISM", 109, 114], ["B lymphoblastic cells", "CELL", 115, 136], ["MBP", "GENE_OR_GENE_PRODUCT", 163, 166], ["neutrophil serine protease cathepsin G", "PROTEIN", 48, 86], ["human B lymphoblastic cells", "CELL_TYPE", 109, 136], ["MBP", "PROTEIN", 163, 166], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 109, 114], ["the neutrophil serine protease cathepsin G", "TREATMENT", 44, 86], ["MBP", "TEST", 163, 166], ["lymphoblastic cells", "OBSERVATION", 117, 136]]], ["In contrast to peptide degradation, AEP specifically cleaves the microbial tetanus toxin antigen for presentation via MHC class II molecules in both a murine as well as in a human B cell line.", [["B cell line", "ANATOMY", 180, 191], ["AEP", "SIMPLE_CHEMICAL", 36, 39], ["murine", "ORGANISM", 151, 157], ["human", "ORGANISM", 174, 179], ["B cell line", "CELL", 180, 191], ["AEP", "PROTEIN", 36, 39], ["microbial tetanus toxin antigen", "PROTEIN", 65, 96], ["MHC class II molecules", "PROTEIN", 118, 140], ["human B cell line", "CELL_LINE", 174, 191], ["murine", "SPECIES", 151, 157], ["human", "SPECIES", 174, 179], ["human", "SPECIES", 174, 179], ["AEP", "TEST", 36, 39], ["the microbial tetanus toxin antigen", "TEST", 61, 96], ["a human B cell line", "TREATMENT", 172, 191], ["cell line", "OBSERVATION", 182, 191]]], ["In line with this, inhibition of AEP activity or mutation of AEP cleavage sites in the tetanus toxin antigen led to a reduction in the T cell response to the antigenic peptide [48], [50], [51].", [["T cell", "ANATOMY", 135, 141], ["AEP", "GENE_OR_GENE_PRODUCT", 33, 36], ["tetanus toxin antigen", "GENE_OR_GENE_PRODUCT", 87, 108], ["T cell", "CELL", 135, 141], ["AEP", "PROTEIN", 33, 36], ["AEP cleavage sites", "PROTEIN", 61, 79], ["tetanus toxin antigen", "PROTEIN", 87, 108], ["AEP activity", "TREATMENT", 33, 45], ["mutation of AEP cleavage sites", "PROBLEM", 49, 79], ["the tetanus toxin antigen", "TEST", 83, 108], ["a reduction", "TREATMENT", 116, 127], ["the antigenic peptide", "TEST", 154, 175]]], ["Recently, however, immunization of AEP deficient mice with tetanus toxin antigen showed no differences in endpoint analyses of the immune response in comparison to WT mice [52].", [["tetanus toxin antigen", "CHEMICAL", 59, 80], ["AEP deficient mice", "ORGANISM", 35, 53], ["tetanus toxin antigen", "GENE_OR_GENE_PRODUCT", 59, 80], ["mice", "ORGANISM", 167, 171], ["AEP", "PROTEIN", 35, 38], ["tetanus toxin antigen", "PROTEIN", 59, 80], ["mice", "SPECIES", 49, 53], ["mice", "SPECIES", 167, 171], ["mice", "SPECIES", 49, 53], ["mice", "SPECIES", 167, 171], ["immunization of AEP deficient mice", "TEST", 19, 53], ["tetanus toxin antigen", "TEST", 59, 80]]], ["Hence, AEP appears to be dispensable for the presentation of antigenic tetanus toxin peptides by murine DCs, although its activity might accelerate the kinetics of the presentation of tetanus toxin antigen [52].", [["DCs", "ANATOMY", 104, 107], ["tetanus toxin antigen", "CHEMICAL", 184, 205], ["AEP", "SIMPLE_CHEMICAL", 7, 10], ["tetanus toxin peptides", "GENE_OR_GENE_PRODUCT", 71, 93], ["murine", "ORGANISM", 97, 103], ["DCs", "CELL", 104, 107], ["tetanus toxin antigen", "GENE_OR_GENE_PRODUCT", 184, 205], ["AEP", "PROTEIN", 7, 10], ["murine DCs", "CELL_TYPE", 97, 107], ["tetanus toxin antigen", "PROTEIN", 184, 205], ["murine", "SPECIES", 97, 103], ["AEP", "TEST", 7, 10], ["antigenic tetanus toxin peptides", "TREATMENT", 61, 93], ["tetanus toxin antigen", "TEST", 184, 205], ["appears to be", "UNCERTAINTY", 11, 24]]], ["Besides AEP, other endolysosomal cathepsins such as the aspartic cathepsins E and D, as well as the cysteine type cathepsins, have been under intense scrutiny with regard to peptide generation for MHC class II mediated antigen presentation.", [["endolysosomal", "ANATOMY", 19, 32], ["cysteine", "CHEMICAL", 100, 108], ["endolysosomal cathepsins", "GENE_OR_GENE_PRODUCT", 19, 43], ["aspartic cathepsins E", "GENE_OR_GENE_PRODUCT", 56, 77], ["D", "GENE_OR_GENE_PRODUCT", 82, 83], ["cysteine type cathepsins", "GENE_OR_GENE_PRODUCT", 100, 124], ["MHC class II", "GENE_OR_GENE_PRODUCT", 197, 209], ["AEP", "PROTEIN", 8, 11], ["endolysosomal cathepsins", "PROTEIN", 19, 43], ["aspartic cathepsins E and D", "PROTEIN", 56, 83], ["cysteine type cathepsins", "PROTEIN", 100, 124], ["MHC class II", "PROTEIN", 197, 209], ["AEP", "PROBLEM", 8, 11], ["other endolysosomal cathepsins", "PROBLEM", 13, 43], ["the aspartic cathepsins E and D", "TREATMENT", 52, 83], ["the cysteine type cathepsins", "TREATMENT", 96, 124], ["endolysosomal cathepsins", "OBSERVATION", 19, 43]]], ["It has been shown that exogenous material is selectively targeted to cathepsin S in human DCs [53].", [["DCs", "ANATOMY", 90, 93], ["cathepsin S", "GENE_OR_GENE_PRODUCT", 69, 80], ["human", "ORGANISM", 84, 89], ["DCs", "CELL", 90, 93], ["cathepsin S", "PROTEIN", 69, 80], ["human DCs", "CELL_TYPE", 84, 93], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 84, 89], ["exogenous material", "PROBLEM", 23, 41], ["exogenous material", "OBSERVATION", 23, 41]]], ["This might be due to an early fusion of phagosomes with vesicles of the MHC class II compartment which predominantly contain proteolytically active cathepsin S as has been shown for primary murine APCs [54].", [["phagosomes", "ANATOMY", 40, 50], ["vesicles", "ANATOMY", 56, 64], ["MHC class II compartment", "ANATOMY", 72, 96], ["APCs", "ANATOMY", 197, 201], ["phagosomes", "CELLULAR_COMPONENT", 40, 50], ["vesicles", "CELLULAR_COMPONENT", 56, 64], ["cathepsin S", "GENE_OR_GENE_PRODUCT", 148, 159], ["murine", "ORGANISM", 190, 196], ["APCs", "CELL", 197, 201], ["MHC class II", "PROTEIN", 72, 84], ["cathepsin S", "PROTEIN", 148, 159], ["primary murine APCs", "CELL_TYPE", 182, 201], ["murine", "SPECIES", 190, 196], ["an early fusion of phagosomes", "PROBLEM", 21, 50], ["might be due to", "UNCERTAINTY", 5, 20], ["early", "OBSERVATION_MODIFIER", 24, 29], ["fusion", "OBSERVATION", 30, 36], ["proteolytically", "OBSERVATION_MODIFIER", 125, 140], ["active", "OBSERVATION_MODIFIER", 141, 147], ["cathepsin", "OBSERVATION", 148, 157]]], ["However, in terms of peptide generation for MHC class II presentation the evidence for a non-redundant role of cathepsin S in APCs is quite limited [55].", [["APCs", "ANATOMY", 126, 130], ["cathepsin S", "GENE_OR_GENE_PRODUCT", 111, 122], ["APCs", "CELL", 126, 130], ["MHC class II", "PROTEIN", 44, 56], ["cathepsin S", "PROTEIN", 111, 122], ["APCs", "CELL_TYPE", 126, 130]]], ["Thus, deciphering the contribution of a single endolysosomal protease to the generation or destruction of antigenic peptides might be elusive as it varies according to the combination of proteases expressed within the particular cell type studied [52], [54], [56], [57].\u2018Acidic\u2019 proteases generate or destroy antigenic peptides ::: Role of endosomal proteolysis in antigen presentation and infectionUsing protease deficient mouse models, it was shown that cathepsin D and the cysteine protease cathepsin B are dispensable for antigen presentation [58].", [["endolysosomal", "ANATOMY", 47, 60], ["cell", "ANATOMY", 229, 233], ["endosomal", "ANATOMY", 340, 349], ["infection", "DISEASE", 390, 399], ["cysteine", "CHEMICAL", 476, 484], ["cell", "CELL", 229, 233], ["endosomal", "CELLULAR_COMPONENT", 340, 349], ["mouse", "ORGANISM", 424, 429], ["cathepsin D", "GENE_OR_GENE_PRODUCT", 456, 467], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 494, 505], ["endolysosomal protease", "PROTEIN", 47, 69], ["proteases", "PROTEIN", 187, 196], ["Acidic\u2019 proteases", "PROTEIN", 271, 288], ["protease", "PROTEIN", 405, 413], ["cathepsin D", "PROTEIN", 456, 467], ["cysteine protease cathepsin B", "PROTEIN", 476, 505], ["mouse", "SPECIES", 424, 429], ["mouse", "SPECIES", 424, 429], ["a single endolysosomal protease", "TREATMENT", 38, 69], ["destruction of antigenic peptides", "PROBLEM", 91, 124], ["proteases", "PROBLEM", 187, 196], ["endosomal proteolysis", "PROBLEM", 340, 361], ["infection", "PROBLEM", 390, 399], ["protease deficient mouse models", "TREATMENT", 405, 436], ["cathepsin D", "TREATMENT", 456, 467], ["the cysteine protease cathepsin B", "TREATMENT", 472, 505], ["endosomal proteolysis", "OBSERVATION", 340, 361], ["infection", "OBSERVATION", 390, 399]]], ["Consistent with these findings, transplantation of cathepsin D deficient bone marrow into irradiated mice caused no impaired immune response of these chimera to two different antigens in comparison to WT mice [59].", [["bone marrow", "ANATOMY", 73, 84], ["cathepsin D", "GENE_OR_GENE_PRODUCT", 51, 62], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 73, 84], ["mice", "ORGANISM", 101, 105], ["mice", "ORGANISM", 204, 208], ["cathepsin D", "PROTEIN", 51, 62], ["mice", "SPECIES", 101, 105], ["mice", "SPECIES", 204, 208], ["mice", "SPECIES", 101, 105], ["mice", "SPECIES", 204, 208], ["transplantation of cathepsin D deficient bone marrow into irradiated mice", "TREATMENT", 32, 105], ["impaired immune response", "PROBLEM", 116, 140], ["no", "UNCERTAINTY", 113, 115], ["impaired", "OBSERVATION_MODIFIER", 116, 124], ["immune response", "OBSERVATION", 125, 140]]], ["However, chemical inhibition or genetic ablation of cathepsin D actually results in enhanced presentation of antigenic peptides derived from myoglobin, a known cathepsin D substrate.", [["cathepsin D", "GENE_OR_GENE_PRODUCT", 52, 63], ["myoglobin", "GENE_OR_GENE_PRODUCT", 141, 150], ["cathepsin D", "GENE_OR_GENE_PRODUCT", 160, 171], ["cathepsin D", "PROTEIN", 52, 63], ["myoglobin", "PROTEIN", 141, 150], ["cathepsin D substrate", "PROTEIN", 160, 181], ["antigenic peptides", "PROBLEM", 109, 127], ["a known cathepsin D substrate", "TREATMENT", 152, 181]]], ["In this setting myoglobin is processed by residual aspartic proteolytic activity, which was assigned to cathepsin E. Hence, a picture is emerging in which cathepsin D degrades protein substrates completely, while the structurally related cathepsin E generates peptides sufficient for MHC class II presentation [60].", [["myoglobin", "GENE_OR_GENE_PRODUCT", 16, 25], ["cathepsin E.", "GENE_OR_GENE_PRODUCT", 104, 116], ["cathepsin D", "GENE_OR_GENE_PRODUCT", 155, 166], ["cathepsin E", "GENE_OR_GENE_PRODUCT", 238, 249], ["MHC class II", "GENE_OR_GENE_PRODUCT", 284, 296], ["myoglobin", "PROTEIN", 16, 25], ["cathepsin D", "PROTEIN", 155, 166], ["cathepsin E", "PROTEIN", 238, 249], ["MHC class II", "PROTEIN", 284, 296], ["residual aspartic proteolytic activity", "PROBLEM", 42, 80], ["cathepsin D degrades protein substrates", "PROBLEM", 155, 194], ["residual", "OBSERVATION_MODIFIER", 42, 50], ["aspartic proteolytic activity", "OBSERVATION", 51, 80]]], ["The primarily destructive role of cathepsin D in antigen presentation is further demonstrated by its ability to initiate degradation of the renal Goodpasture autoantigen, which is a specific isoform of type IV collagen and causes Goodpasture disease [61].", [["renal", "ANATOMY", 140, 145], ["Goodpasture disease", "DISEASE", 230, 249], ["cathepsin D", "GENE_OR_GENE_PRODUCT", 34, 45], ["antigen", "GENE_OR_GENE_PRODUCT", 49, 56], ["renal", "ORGAN", 140, 145], ["type IV collagen", "GENE_OR_GENE_PRODUCT", 202, 218], ["cathepsin D", "PROTEIN", 34, 45], ["renal Goodpasture autoantigen", "PROTEIN", 140, 169], ["type IV collagen", "PROTEIN", 202, 218], ["cathepsin D in antigen presentation", "PROBLEM", 34, 69], ["the renal Goodpasture autoantigen", "PROBLEM", 136, 169], ["type IV collagen", "TREATMENT", 202, 218], ["Goodpasture disease", "PROBLEM", 230, 249], ["primarily", "OBSERVATION_MODIFIER", 4, 13], ["destructive", "OBSERVATION_MODIFIER", 14, 25], ["cathepsin", "OBSERVATION", 34, 43], ["renal", "ANATOMY", 140, 145], ["Goodpasture", "OBSERVATION", 146, 157], ["Goodpasture", "OBSERVATION", 230, 241]]], ["During degradation of the Goodpasture autoantigen major self epitopes are destroyed, providing a reasonable explanation as to how \u2018Goodpasture\u2019 autoreactive T cells escape the negative T cell selection process within the thymus [61].", [["T cells", "ANATOMY", 157, 164], ["T cell", "ANATOMY", 185, 191], ["thymus", "ANATOMY", 221, 227], ["Goodpasture", "DISEASE", 26, 37], ["Goodpasture", "DISEASE", 131, 142], ["autoreactive T cells", "CELL", 144, 164], ["T cell", "CELL", 185, 191], ["thymus", "ORGAN", 221, 227], ["Goodpasture autoantigen major self epitopes", "PROTEIN", 26, 69], ["autoreactive T cells", "CELL_TYPE", 144, 164], ["thymus", "ANATOMY", 221, 227]]], ["Hence, a subtle balance between peptide generation and protein degradation in the MHC class II compartment is of utmost importance for proper antigen presentation.\u2018Acidic\u2019 proteases generate or destroy antigenic peptides ::: Role of endosomal proteolysis in antigen presentation and infectionThe activation of cytotoxic T cells depends on the presentation of endogenous peptides bound to MHC class I molecules by almost all cell types of the body.", [["endosomal", "ANATOMY", 233, 242], ["cytotoxic T cells", "ANATOMY", 310, 327], ["cell", "ANATOMY", 424, 428], ["body", "ANATOMY", 442, 446], ["infection", "DISEASE", 283, 292], ["endosomal", "CELLULAR_COMPONENT", 233, 242], ["cytotoxic T cells", "CELL", 310, 327], ["cell", "CELL", 424, 428], ["body", "ORGANISM_SUBDIVISION", 442, 446], ["MHC class II", "PROTEIN", 82, 94], ["Acidic\u2019 proteases", "PROTEIN", 164, 181], ["cytotoxic T cells", "CELL_TYPE", 310, 327], ["MHC class I molecules", "PROTEIN", 388, 409], ["a subtle balance between peptide generation", "PROBLEM", 7, 50], ["protein degradation", "PROBLEM", 55, 74], ["endosomal proteolysis", "PROBLEM", 233, 254], ["infection", "PROBLEM", 283, 292], ["cytotoxic T cells", "PROBLEM", 310, 327], ["endogenous peptides", "PROBLEM", 359, 378], ["endosomal proteolysis", "OBSERVATION", 233, 254], ["infection", "OBSERVATION", 283, 292], ["cytotoxic T cells", "OBSERVATION", 310, 327], ["all cell types", "OBSERVATION", 420, 434], ["body", "ANATOMY", 442, 446]]], ["These peptides are mainly generated by the proteasome in the cytosol and are transported by TAP (transporter associated with antigen processing) into the ER.", [["cytosol", "ANATOMY", 61, 68], ["ER", "ANATOMY", 154, 156], ["cytosol", "CELLULAR_COMPONENT", 61, 68], ["TAP", "GENE_OR_GENE_PRODUCT", 92, 95], ["antigen", "GENE_OR_GENE_PRODUCT", 125, 132], ["ER", "GENE_OR_GENE_PRODUCT", 154, 156], ["proteasome", "PROTEIN", 43, 53], ["TAP", "PROTEIN", 92, 95], ["ER", "PROTEIN", 154, 156]]], ["APCs, however, are able to present \u2018foreign\u2019 exogenous peptides on MHC class I molecules via both TAP-dependent and TAP-independent pathways, a process generally termed cross presentation [62].", [["APCs", "ANATOMY", 0, 4], ["APCs", "CELL", 0, 4], ["MHC class I", "GENE_OR_GENE_PRODUCT", 67, 78], ["TAP", "GENE_OR_GENE_PRODUCT", 98, 101], ["TAP", "GENE_OR_GENE_PRODUCT", 116, 119], ["APCs", "CELL_TYPE", 0, 4], ["MHC class I molecules", "PROTEIN", 67, 88], ["TAP", "PROTEIN", 98, 101], ["TAP", "PROTEIN", 116, 119]]], ["Although the TAP-independent \u2018vacuolar\u2019 cross presentation mechanisms are still insufficiently understood, it is reasonable to assume that endolysosomal proteases play a role [63].", [["vacuolar", "ANATOMY", 30, 38], ["endolysosomal", "ANATOMY", 139, 152], ["TAP", "GENE_OR_GENE_PRODUCT", 13, 16], ["vacuolar", "CELLULAR_COMPONENT", 30, 38], ["TAP", "PROTEIN", 13, 16], ["endolysosomal proteases", "PROTEIN", 139, 162], ["the TAP", "TEST", 9, 16]]], ["For instance, the extracellular portions of transmembrane proteins are turned over in the lumen of the endolysosome while aspartic cathepsins can contribute to the MHC class I presentation of antigenic peptides derived from these transmembrane proteins [64].", [["extracellular portions", "ANATOMY", 18, 40], ["transmembrane", "ANATOMY", 44, 57], ["lumen", "ANATOMY", 90, 95], ["endolysosome", "ANATOMY", 103, 115], ["transmembrane", "ANATOMY", 230, 243], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 18, 31], ["transmembrane", "CELLULAR_COMPONENT", 44, 57], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 90, 95], ["cathepsins", "GENE_OR_GENE_PRODUCT", 131, 141], ["transmembrane proteins", "PROTEIN", 44, 66], ["endolysosome", "PROTEIN", 103, 115], ["aspartic cathepsins", "PROTEIN", 122, 141], ["MHC class I", "PROTEIN", 164, 175], ["transmembrane proteins", "PROTEIN", 230, 252], ["transmembrane proteins", "PROBLEM", 44, 66], ["aspartic cathepsins", "PROBLEM", 122, 141], ["antigenic peptides", "PROBLEM", 192, 210], ["these transmembrane proteins", "TEST", 224, 252], ["lumen", "ANATOMY_MODIFIER", 90, 95]]], ["In addition, cathepsin S processes ovalbumin and influenza virus antigens for subsequent peptide presentation on MHC class I molecules in vivo, which is restricted to TAP-independent MHC class I cross presentation [65], [66].", [["cathepsin S", "GENE_OR_GENE_PRODUCT", 13, 24], ["ovalbumin", "GENE_OR_GENE_PRODUCT", 35, 44], ["influenza virus", "ORGANISM", 49, 64], ["TAP", "GENE_OR_GENE_PRODUCT", 167, 170], ["cathepsin S", "PROTEIN", 13, 24], ["ovalbumin", "PROTEIN", 35, 44], ["influenza virus antigens", "PROTEIN", 49, 73], ["MHC class I molecules", "PROTEIN", 113, 134], ["TAP", "PROTEIN", 167, 170], ["MHC class I", "PROTEIN", 183, 194], ["influenza virus", "SPECIES", 49, 64], ["cathepsin S processes ovalbumin", "TREATMENT", 13, 44], ["influenza virus antigens", "PROBLEM", 49, 73]]], ["Recent experiments on the presentation of endocytosed hen egg white lysozyme derived peptides revealed that cathepsin S dependent cross presentation on MHC class I occurs in early endosomal compartments, while the late endosomal compartment targets peptides solely to MHC class II complexes [67].Endolysosomal proteases process the invariant chain of MHC class II molecules ::: Role of endosomal proteolysis in antigen presentation and infection", [["endosomal compartments", "ANATOMY", 180, 202], ["endosomal compartment", "ANATOMY", 219, 240], ["endosomal", "ANATOMY", 386, 395], ["infection", "DISEASE", 436, 445], ["egg white lysozyme derived peptides", "GENE_OR_GENE_PRODUCT", 58, 93], ["cathepsin S", "GENE_OR_GENE_PRODUCT", 108, 119], ["MHC class I", "GENE_OR_GENE_PRODUCT", 152, 163], ["endosomal compartments", "CELLULAR_COMPONENT", 180, 202], ["late", "CELLULAR_COMPONENT", 214, 218], ["endosomal compartment", "CELLULAR_COMPONENT", 219, 240], ["MHC class II", "GENE_OR_GENE_PRODUCT", 268, 280], ["endosomal", "CELLULAR_COMPONENT", 386, 395], ["cathepsin S", "PROTEIN", 108, 119], ["MHC class I", "PROTEIN", 152, 163], ["MHC class II complexes", "PROTEIN", 268, 290], ["Endolysosomal proteases", "PROTEIN", 296, 319], ["invariant chain", "PROTEIN", 332, 347], ["MHC class II molecules", "PROTEIN", 351, 373], ["hen", "SPECIES", 54, 57], ["endocytosed hen egg white lysozyme derived peptides", "PROBLEM", 42, 93], ["cathepsin S dependent", "PROBLEM", 108, 129], ["Endolysosomal proteases process", "PROBLEM", 296, 327], ["endosomal proteolysis", "PROBLEM", 386, 407], ["infection", "PROBLEM", 436, 445], ["early", "OBSERVATION_MODIFIER", 174, 179], ["endosomal compartments", "OBSERVATION", 180, 202], ["chain", "OBSERVATION_MODIFIER", 342, 347], ["endosomal proteolysis", "OBSERVATION", 386, 407], ["infection", "OBSERVATION", 436, 445]]]], "8d80a2a11a6ddd082f8beafa72bbab38b0f9d665": [["I. INTRODUCTIONOver the last two decades, three coronaviruses have caused deadly epidemics, threatening the global human population.", [["coronaviruses", "ORGANISM", 48, 61], ["human", "ORGANISM", 115, 120], ["human", "SPECIES", 115, 120], ["human", "SPECIES", 115, 120], ["deadly epidemics", "PROBLEM", 74, 90], ["deadly", "OBSERVATION_MODIFIER", 74, 80], ["epidemics", "OBSERVATION", 81, 90]]], ["The severe acute respiratory syndrome coronavirus (SARS-CoV) caused an outbreak in 2003, and a related Middle-East respiratory syndrome coronavirus (MERS-CoV) caused an outbreak in 2012.", [["acute respiratory syndrome coronavirus", "DISEASE", 11, 49], ["SARS-CoV)", "DISEASE", 51, 60], ["Middle-East respiratory syndrome coronavirus", "DISEASE", 103, 147], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 4, 49], ["SARS-CoV", "ORGANISM", 51, 59], ["Middle-East respiratory syndrome coronavirus", "ORGANISM", 103, 147], ["MERS-CoV", "ORGANISM", 149, 157], ["severe acute respiratory syndrome coronavirus", "SPECIES", 4, 49], ["SARS-CoV", "SPECIES", 51, 59], ["Middle-East respiratory syndrome coronavirus", "SPECIES", 103, 147], ["MERS-CoV", "SPECIES", 149, 157], ["The severe acute respiratory syndrome coronavirus", "PROBLEM", 0, 49], ["a related Middle-East respiratory syndrome coronavirus", "PROBLEM", 93, 147], ["severe", "OBSERVATION_MODIFIER", 4, 10], ["acute", "OBSERVATION_MODIFIER", 11, 16], ["respiratory syndrome coronavirus", "OBSERVATION", 17, 49], ["Middle", "ANATOMY_MODIFIER", 103, 109], ["respiratory syndrome", "OBSERVATION", 115, 135]]], ["Today the world is facing the pandemic of the Coronavirus Disease 2019 (COVID- 19) , caused by a novel coronavirus SARS-CoV-2, which shares about 82% genome sequence identity with the original SARS-CoV 1 .", [["Coronavirus Disease", "DISEASE", 46, 65], ["COVID- 19", "CHEMICAL", 72, 81], ["SARS", "DISEASE", 193, 197], ["COVID- 19", "CELL", 72, 81], ["coronavirus SARS-CoV-2", "ORGANISM", 103, 125], ["SARS-CoV 1", "ORGANISM", 193, 203], ["SARS-CoV 1", "DNA", 193, 203], ["coronavirus SARS-CoV", "SPECIES", 103, 123], ["Coronavirus Disease 2019 (COVID- 19", "SPECIES", 46, 81], ["SARS-CoV", "SPECIES", 193, 201], ["the Coronavirus Disease", "PROBLEM", 42, 65], ["COVID", "TEST", 72, 77], ["a novel coronavirus SARS", "PROBLEM", 95, 119], ["Coronavirus", "ANATOMY", 46, 57]]], ["All three viruses are thought to have originated from animal reservoirs and zoonotic transmission into the human population has led to the outbreaks 2 .", [["human", "ORGANISM", 107, 112], ["human", "SPECIES", 107, 112], ["human", "SPECIES", 107, 112], ["All three viruses", "PROBLEM", 0, 17], ["viruses", "OBSERVATION", 10, 17], ["thought to have", "UNCERTAINTY", 22, 37], ["reservoirs", "OBSERVATION_MODIFIER", 61, 71]]], ["Currently, no effective treatment exists for any of the three coronavirus diseases; thus, there is an urgent need to understand the potential therapeutic targets and develop inhibition strategies.I. INTRODUCTIONFollowing the release of the coronavirus genome from the acidic endosome, the replicase polyproteins are translated and subsequently self-cleaved by two cysteine proteases to produce the functional non-structural proteins (Nsps) that are required for viral replication.", [["acidic endosome", "ANATOMY", 268, 283], ["coronavirus diseases", "DISEASE", 62, 82], ["cysteine", "CHEMICAL", 364, 372], ["coronavirus", "ORGANISM", 240, 251], ["acidic endosome", "CELLULAR_COMPONENT", 268, 283], ["Nsps", "GENE_OR_GENE_PRODUCT", 434, 438], ["coronavirus genome", "DNA", 240, 258], ["acidic endosome", "PROTEIN", 268, 283], ["replicase polyproteins", "PROTEIN", 289, 311], ["cysteine proteases", "PROTEIN", 364, 382], ["non-structural proteins", "PROTEIN", 409, 432], ["Nsps", "PROTEIN", 434, 438], ["effective treatment", "TREATMENT", 14, 33], ["the three coronavirus diseases", "PROBLEM", 52, 82], ["inhibition strategies", "TREATMENT", 174, 195], ["the coronavirus genome", "PROBLEM", 236, 258], ["the acidic endosome", "TREATMENT", 264, 283], ["the replicase polyproteins", "PROBLEM", 285, 311], ["two cysteine proteases", "TREATMENT", 360, 382], ["viral replication", "TREATMENT", 462, 479], ["no", "UNCERTAINTY", 11, 13], ["coronavirus diseases", "OBSERVATION", 62, 82], ["coronavirus genome", "OBSERVATION", 240, 258], ["replicase polyproteins", "OBSERVATION", 289, 311]]], ["The papain-like protease (PLpro) located in Nsp3 produces Nsp1, Nsp2, and Nsp3, while the 3C-like or main protease located in Nsp5 cleaves 11 sites downstream of Nsp4.", [["papain-like protease", "GENE_OR_GENE_PRODUCT", 4, 24], ["PLpro", "GENE_OR_GENE_PRODUCT", 26, 31], ["Nsp3", "GENE_OR_GENE_PRODUCT", 44, 48], ["Nsp1", "GENE_OR_GENE_PRODUCT", 58, 62], ["Nsp2", "GENE_OR_GENE_PRODUCT", 64, 68], ["Nsp3", "GENE_OR_GENE_PRODUCT", 74, 78], ["3C", "GENE_OR_GENE_PRODUCT", 90, 92], ["Nsp5", "GENE_OR_GENE_PRODUCT", 126, 130], ["Nsp4", "GENE_OR_GENE_PRODUCT", 162, 166], ["papain-like protease", "PROTEIN", 4, 24], ["PLpro", "PROTEIN", 26, 31], ["Nsp3", "PROTEIN", 44, 48], ["Nsp1", "PROTEIN", 58, 62], ["Nsp2", "PROTEIN", 64, 68], ["Nsp3", "PROTEIN", 74, 78], ["3C", "PROTEIN", 90, 92], ["protease", "PROTEIN", 106, 114], ["Nsp5", "PROTEIN", 126, 130], ["Nsp4", "PROTEIN", 162, 166], ["The papain-like protease (PLpro)", "TREATMENT", 0, 32], ["Nsp1", "PROBLEM", 58, 62], ["Nsp2", "PROBLEM", 64, 68], ["Nsp3", "PROBLEM", 74, 78], ["the 3C", "TREATMENT", 86, 92], ["main protease", "TREATMENT", 101, 114], ["Nsp4", "PROBLEM", 162, 166], ["Nsp4", "OBSERVATION", 162, 166]]], ["[2] [3] [4] [5] [6] In addition to the proteolytic function, CoV PLpro counteracts the host cell innate immune response by deactivating signaling cascades that lead to the impairment of production of pro-inflammatory cytokines and interferons.", [["cell", "ANATOMY", 92, 96], ["[2] [3] [4] [5] [6]", "SIMPLE_CHEMICAL", 0, 19], ["CoV PLpro", "SIMPLE_CHEMICAL", 61, 70], ["host cell", "CELL", 87, 96], ["interferons", "GENE_OR_GENE_PRODUCT", 231, 242], ["CoV PLpro", "PROTEIN", 61, 70], ["pro-inflammatory cytokines", "PROTEIN", 200, 226], ["interferons", "PROTEIN", 231, 242], ["the proteolytic function", "TEST", 35, 59], ["CoV PLpro", "TREATMENT", 61, 70], ["deactivating signaling cascades", "PROBLEM", 123, 154], ["pro-inflammatory cytokines", "TREATMENT", 200, 226], ["interferons", "TREATMENT", 231, 242], ["host cell", "OBSERVATION_MODIFIER", 87, 96], ["pro-inflammatory cytokines", "OBSERVATION", 200, 226]]], ["7, 8 The former is accomplished through a deubiquitinating (DUB) activity which leads to the removal of ubiquitin from signaling proteins, 9 and latter through the deISa) Electronic mail: jana.shen@rx.umaryland.edu Gylating activity which leads to the removal of ISG15 from IRF3.", [["DUB", "GENE_OR_GENE_PRODUCT", 60, 63], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 104, 113], ["ISG15", "GENE_OR_GENE_PRODUCT", 263, 268], ["IRF3", "GENE_OR_GENE_PRODUCT", 274, 278], ["DUB", "PROTEIN", 60, 63], ["ubiquitin", "PROTEIN", 104, 113], ["signaling proteins", "PROTEIN", 119, 137], ["deISa", "PROTEIN", 164, 169], ["ISG15", "PROTEIN", 263, 268], ["IRF3", "PROTEIN", 274, 278], ["a deubiquitinating (DUB) activity", "TREATMENT", 40, 73], ["the removal of ubiquitin from signaling proteins", "TREATMENT", 89, 137], ["Gylating activity", "PROBLEM", 215, 232], ["the removal of ISG15 from IRF3", "TREATMENT", 248, 278]]], ["10 Thus, PLpro is a critical player in the viral life cycle and as such an attractive drug target for stopping COVID-19 and other coronavirus outbreaks.I. INTRODUCTIONMost recently, the first (and only) two X-ray structures of SARS-CoV-2 PLpro were determined (PDB 6W9C and 6WRH, Osipiuk, Joachimiak et al., to be published).", [["PLpro", "CHEMICAL", 9, 14], ["coronavirus outbreaks", "DISEASE", 130, 151], ["PLpro", "GENE_OR_GENE_PRODUCT", 9, 14], ["coronavirus", "ORGANISM", 130, 141], ["PLpro", "PROTEIN", 9, 14], ["an attractive drug target", "TREATMENT", 72, 97], ["stopping COVID", "TREATMENT", 102, 116], ["other coronavirus outbreaks", "PROBLEM", 124, 151], ["SARS", "TEST", 227, 231], ["CoV", "TEST", 232, 235], ["PDB", "TEST", 261, 264]]], ["The PLpro monomer (about 300 residues), which is the predominant form in solution 11 , is comprised of an independent Nterminal ubiquitin-like (Ubl) domain (first 62 residues) and a C-terminal catalytic domain ( Fig. 1a and b) .", [["PLpro", "CHEMICAL", 4, 9], ["C", "CHEMICAL", 182, 183], ["PLpro", "GENE_OR_GENE_PRODUCT", 4, 9], ["PLpro monomer", "PROTEIN", 4, 17], ["Nterminal ubiquitin-like (Ubl) domain", "PROTEIN", 118, 155], ["first 62 residues", "PROTEIN", 157, 174], ["C-terminal catalytic domain", "PROTEIN", 182, 209], ["Fig. 1a and b", "PROTEIN", 212, 225], ["The PLpro monomer", "TREATMENT", 0, 17], ["an independent Nterminal ubiquitin", "PROBLEM", 103, 137], ["a C-terminal catalytic domain", "PROBLEM", 180, 209], ["Nterminal ubiquitin", "OBSERVATION", 118, 137]]], ["The latter folds in a canonical thumb-palm-fingers like structure, with the Ubl domain anchored to the thumb.", [["thumb", "ANATOMY", 103, 108], ["thumb", "ORGANISM_SUBDIVISION", 103, 108], ["canonical thumb-palm-fingers like structure", "PROTEIN", 22, 65], ["Ubl domain", "PROTEIN", 76, 86], ["the Ubl domain", "TREATMENT", 72, 86], ["latter", "OBSERVATION_MODIFIER", 4, 10], ["folds", "OBSERVATION_MODIFIER", 11, 16], ["canonical", "ANATOMY_MODIFIER", 22, 31], ["thumb", "ANATOMY", 32, 37], ["palm", "ANATOMY", 38, 42], ["fingers", "ANATOMY", 43, 50], ["thumb", "ANATOMY", 103, 108]]], ["The interface between the thumb (residue 107-113, 162-168) and palm (residue 269-279) forms the substrate binding site leading to the catalytic triad of the active site comprised of Cys111, His272, and Asp286 (Fig. 1b) .", [["residue 269-279", "CHEMICAL", 69, 84], ["Cys111", "CHEMICAL", 182, 188], ["His272", "CHEMICAL", 190, 196], ["Asp", "CHEMICAL", 202, 205], ["Cys111", "GENE_OR_GENE_PRODUCT", 182, 188], ["His272", "AMINO_ACID", 190, 196], ["Asp286", "AMINO_ACID", 202, 208], ["substrate binding site", "PROTEIN", 96, 118], ["catalytic triad", "PROTEIN", 134, 149], ["Cys111", "PROTEIN", 182, 188], ["the substrate binding site", "PROBLEM", 92, 118], ["Cys111", "TEST", 182, 188], ["His272", "TEST", 190, 196], ["Asp", "TEST", 202, 205], ["thumb", "ANATOMY", 26, 31], ["active", "OBSERVATION_MODIFIER", 157, 163], ["site", "OBSERVATION_MODIFIER", 164, 168]]], ["The substrate binding site is solvent exposed and flanked by a flexible \u03b2 -hairpin loop called the blocking loop 2 or BL2 (G266-G271).", [["BL2", "GENE_OR_GENE_PRODUCT", 118, 121], ["substrate binding site", "DNA", 4, 26], ["\u03b2 -hairpin loop", "PROTEIN", 72, 87], ["BL2", "PROTEIN", 118, 121], ["G266", "PROTEIN", 123, 127], ["G271", "PROTEIN", 128, 132], ["The substrate binding site", "PROBLEM", 0, 26], ["a flexible \u03b2 -hairpin loop", "TREATMENT", 61, 87], ["the blocking loop", "TREATMENT", 95, 112]]], ["The fingers subdomain contains a zinc finger coordinated by four cysteines, which upholds the structural integrity and is essential for the PLpro activity 12 .", [["zinc", "CHEMICAL", 33, 37], ["cysteines", "CHEMICAL", 65, 74], ["fingers subdomain", "PROTEIN", 4, 21], ["zinc finger", "PROTEIN", 33, 44], ["fingers", "ANATOMY", 4, 11], ["subdomain", "ANATOMY_MODIFIER", 12, 21], ["zinc finger", "OBSERVATION", 33, 44], ["structural", "OBSERVATION_MODIFIER", 94, 104], ["integrity", "OBSERVATION_MODIFIER", 105, 114]]], ["The structure of SARS-CoV-2 PLpro is nearly identical to that of SARS-CoV PLpro 13 , as expected from the highly similar sequences (96% similarity and 83% identity, Fig. 1c ).", [["SARS", "DISEASE", 17, 21], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 17, 27], ["SARS-CoV-2 PLpro", "DNA", 17, 33], ["SARS-CoV", "SPECIES", 17, 25], ["SARS-CoV", "SPECIES", 65, 73], ["SARS", "PROBLEM", 17, 21], ["CoV", "TEST", 22, 25], ["CoV PLpro", "TEST", 70, 79], ["SARS", "OBSERVATION", 17, 21]]], ["In contrast, although the structure of MERS-CoV PLpro overlays well with the SARS-CoV PLpro structures, small differences are visible (Fig. 1a) , as expected from the larger sequence differences (66% similarity and 30% identity with SARS-CoV PLpro, Fig. 1c ).I. INTRODUCTIONAll three CoV PLpros are rich in Cys and His residues.", [["Cys", "CHEMICAL", 307, 310], ["His", "CHEMICAL", 315, 318], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 39, 47], ["CoV", "ORGANISM", 284, 287], ["Cys", "AMINO_ACID", 307, 310], ["MERS-CoV PLpro", "DNA", 39, 53], ["CoV PLpros", "DNA", 284, 294], ["MERS-CoV", "SPECIES", 39, 47], ["SARS-CoV", "SPECIES", 77, 85], ["SARS-CoV", "SPECIES", 233, 241], ["the SARS", "TEST", 73, 81], ["SARS", "TEST", 233, 237], ["CoV PLpro", "TREATMENT", 238, 247], ["INTRODUCTIONAll three CoV PLpros", "TREATMENT", 262, 294], ["His residues", "PROBLEM", 315, 327], ["small", "OBSERVATION_MODIFIER", 104, 109]]], ["SARS-CoV/CoV-2 PLpro contains 8/11 Cys and 11/9 His, while MERS-CoV PLpro contains 14 Cys and 10 His residues (Fig. 1c) .", [["SARS", "DISEASE", 0, 4], ["Cys", "CHEMICAL", 35, 38], ["His", "CHEMICAL", 48, 51], ["Cys", "CHEMICAL", 86, 89], ["His", "CHEMICAL", 97, 100], ["SARS-CoV", "ORGANISM", 0, 8], ["CoV-2", "ORGANISM", 9, 14], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 59, 67], ["SARS-CoV/CoV-2 PLpro", "DNA", 0, 20], ["MERS", "PROTEIN", 59, 63], ["CoV PLpro", "PROTEIN", 64, 73], ["SARS-CoV", "SPECIES", 0, 8], ["MERS-CoV", "SPECIES", 59, 67], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 9, 12], ["CoV PLpro", "TREATMENT", 64, 73]]], ["Among them, 5 Cys and 2 His residues are conserved among all three PLpros, including the catalytic Cys and His.", [["Cys", "CHEMICAL", 14, 17], ["His", "CHEMICAL", 24, 27], ["Cys", "CHEMICAL", 99, 102], ["His", "CHEMICAL", 107, 110], ["PLpros", "GENE_OR_GENE_PRODUCT", 67, 73], ["PLpros", "PROTEIN", 67, 73], ["catalytic Cys and His", "PROTEIN", 89, 110], ["the catalytic Cys", "TREATMENT", 85, 102]]], ["Cys and His have model pK a 's of 8.6 and 6.5, re-spectively; thus, in model compounds or peptides at physiological pH 7.4, they are both predominantly neutral, i.e., Cys is protonated and His is singly protonated.", [["Cys", "CHEMICAL", 167, 170], ["Cys", "CHEMICAL", 0, 3], ["His", "CHEMICAL", 8, 11], ["Cys", "CHEMICAL", 167, 170], ["His", "CHEMICAL", 189, 192], ["Cys", "AMINO_ACID", 0, 3], ["Cys", "AMINO_ACID", 167, 170], ["Cys", "TEST", 0, 3], ["model pK a 's", "TEST", 17, 30], ["peptides at physiological pH", "TEST", 90, 118], ["predominantly", "OBSERVATION_MODIFIER", 138, 151], ["neutral", "OBSERVATION_MODIFIER", 152, 159], ["protonated", "OBSERVATION", 174, 184]]], ["However, in the protein environment, a small pK a downshift for Cys or upshift for His may occur, leading to a significant population of or a complete switch to the alternative protonation state, i.e., negatively charged, deprotonated Cys and positively charged, doubly protonated His.I. INTRODUCTIONProtonation state switch is an important energy transduction mechanism to enable functionally required conformational changes in biology.", [["Cys", "CHEMICAL", 64, 67], ["Cys", "CHEMICAL", 235, 238], ["Cys", "CHEMICAL", 64, 67], ["His", "CHEMICAL", 83, 86], ["Cys", "CHEMICAL", 235, 238], ["His.I.", "CHEMICAL", 281, 287], ["Cys", "AMINO_ACID", 64, 67], ["deprotonated Cys", "SIMPLE_CHEMICAL", 222, 238], ["small", "OBSERVATION_MODIFIER", 39, 44]]], ["For example, the coronavirus spike protein makes use of protonation state switches to induce large conformational changes required for membrane fusion 14, 15 .", [["membrane", "ANATOMY", 135, 143], ["membrane", "CELLULAR_COMPONENT", 135, 143], ["coronavirus spike protein", "PROTEIN", 17, 42], ["membrane fusion 14, 15", "PROTEIN", 135, 157], ["the coronavirus spike protein", "PROBLEM", 13, 42], ["protonation state switches", "TREATMENT", 56, 82], ["large conformational changes", "PROBLEM", 93, 121], ["membrane fusion", "TREATMENT", 135, 150], ["coronavirus spike", "OBSERVATION", 17, 34]]], ["Our previous work demonstrated that proton-coupled conformational dynamics can be studied by continuous constant pH molecular dynamics (CpHMD) simulations 16 to obtain deeper understanding of the structure-function relationships 17 and inhibition mechanisms 18-20 of aspartyl proteases.I. INTRODUCTIONTowards understanding the (possibly) proton-coupled structure-function relationship and assisting broad-spectrum inhibitor design, here we report the pK a calculations and preliminary assessment of proton-coupled conformational dynamics of SARS-CoV-2 PLpro in comparison to SARS-CoV and MERS-CoV PLpros.", [["aspartyl proteases", "GENE_OR_GENE_PRODUCT", 267, 285], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 575, 583], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 588, 596], ["aspartyl proteases", "PROTEIN", 267, 285], ["SARS-CoV", "SPECIES", 575, 583], ["MERS-CoV", "SPECIES", 588, 596], ["proton-coupled conformational dynamics", "TREATMENT", 36, 74], ["inhibition mechanisms", "TEST", 236, 257], ["aspartyl proteases", "TREATMENT", 267, 285], ["broad-spectrum inhibitor design", "TREATMENT", 399, 430], ["a calculations", "TEST", 454, 468], ["preliminary assessment", "TEST", 473, 495], ["SARS", "PROBLEM", 541, 545], ["CoV", "TEST", 546, 549], ["PLpro", "TREATMENT", 552, 557], ["SARS", "PROBLEM", 575, 579], ["CoV", "TEST", 580, 583], ["CoV PLpros", "TREATMENT", 593, 603]]], ["The work employed the recent GPU implementation 21 of the GB-Neck2 implicit-solvent based CpHMD method 22 as well as the conventional fixed-charged MD in Amber18 23 .", [["Amber18 23", "CELL_LINE", 154, 164]]], ["The simulations allowed us to determine the protonation states of all titratable sites, including the catalytic Cys-His-Asp triad, offering a timely knowledge to facilitate MD studies of PLpros in the community.", [["Cys", "CHEMICAL", 112, 115], ["His", "CHEMICAL", 116, 119], ["Asp", "CHEMICAL", 120, 123], ["PLpros", "SIMPLE_CHEMICAL", 187, 193], ["all titratable sites", "TREATMENT", 66, 86], ["the catalytic Cys", "TEST", 98, 115], ["Asp triad", "PROBLEM", 120, 129]]], ["Importantly, we tested a hypothesis regarding the proton-coupled conformational plasticity of the BL2 loop, which modulates substrate and inhibitor binding.", [["BL2", "GENE_OR_GENE_PRODUCT", 98, 101], ["BL2 loop", "PROTEIN", 98, 106], ["the proton-coupled conformational plasticity of the BL2 loop", "TREATMENT", 46, 106], ["BL2 loop", "ANATOMY", 98, 106]]], ["The contrasting features among the three CoV PLpros have implications for designing broadspectrum antiviral inhibitors.II. METHODS AND PROTOCOLSa.", [["II", "CHEMICAL", 119, 121], ["CoV", "ORGANISM", 41, 44], ["CoV PLpros", "PROTEIN", 41, 51], ["designing broadspectrum antiviral inhibitors", "TREATMENT", 74, 118]]], ["The coordinates were retrieved from the protein data bank (PDB): SARS-CoV PLpro (PDB 2FE8 13 ), SARS-CoV-2 PLpro (PDB 6W9C, Osipiuk, Joachimiak et al., to be published), and MERS-CoV PLpro (PDB 4RNA 24 ).", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 174, 182], ["MERS", "PROTEIN", 174, 178], ["CoV PLpro", "PROTEIN", 179, 188], ["PDB 4RNA 24", "PROTEIN", 190, 201], ["SARS-CoV", "SPECIES", 65, 73], ["MERS-CoV", "SPECIES", 174, 182], ["SARS", "PROBLEM", 65, 69], ["PDB", "TEST", 81, 84], ["SARS", "TEST", 96, 100], ["CoV", "TEST", 101, 104], ["PLpro (PDB 6W9C", "TREATMENT", 107, 122], ["Osipiuk", "TREATMENT", 124, 131], ["CoV PLpro (PDB 4RNA", "TREATMENT", 179, 198]]], ["If multiple chains were available in the xray crystal structure, only the first chain was used.", [["xray crystal structure", "PROTEIN", 41, 63], ["multiple chains", "PROBLEM", 3, 18], ["the xray crystal structure", "TEST", 37, 63]]], ["Any small molecules or solvent were removed.", [["Any small molecules", "PROBLEM", 0, 19], ["small", "OBSERVATION_MODIFIER", 4, 9], ["molecules", "OBSERVATION", 10, 19], ["solvent", "OBSERVATION_MODIFIER", 23, 30]]], ["For each structure, the acetylated N-terminus and amidated C-terminus along with all missing hydrogens were added using the CHARMM program (C36b2) 25 .", [["N", "CHEMICAL", 35, 36], ["C", "CHEMICAL", 59, 60], ["acetylated N-terminus", "PROTEIN", 24, 45], ["amidated C-terminus", "PROTEIN", 50, 69], ["the acetylated N-terminus", "TREATMENT", 20, 45], ["amidated C-terminus", "TREATMENT", 50, 69], ["all missing hydrogens", "TREATMENT", 81, 102], ["the CHARMM program", "TREATMENT", 120, 138]]], ["In the crystal structure of SARS-CoV-2 PLpro (PDB 6W9C), a disulfide bond is present in the fingers subdomain in place of a zinc ion.", [["zinc", "CHEMICAL", 124, 128], ["disulfide", "CHEMICAL", 59, 68], ["zinc", "CHEMICAL", 124, 128], ["zinc ion", "SIMPLE_CHEMICAL", 124, 132], ["PLpro", "PROTEIN", 39, 44], ["PDB 6W9C", "PROTEIN", 46, 54], ["fingers subdomain", "PROTEIN", 92, 109], ["SARS", "PROBLEM", 28, 32], ["CoV", "TEST", 33, 36], ["2 PLpro (PDB 6W9C", "TREATMENT", 37, 54], ["a disulfide bond", "TREATMENT", 57, 73], ["a zinc ion", "TREATMENT", 122, 132], ["SARS", "OBSERVATION", 28, 32], ["fingers", "ANATOMY", 92, 99], ["zinc ion", "OBSERVATION", 124, 132]]], ["Considering that zinc ion cannot be represented in implicit-solvent simulations, we removed the zinc ion and added an analogous disulfide linkage between the closest non-adjacent cysteine pairs in all other structures to maintain the integrity of the fingers subdomain.", [["zinc", "CHEMICAL", 17, 21], ["zinc", "CHEMICAL", 96, 100], ["zinc", "CHEMICAL", 17, 21], ["zinc", "CHEMICAL", 96, 100], ["disulfide", "CHEMICAL", 128, 137], ["cysteine", "CHEMICAL", 179, 187], ["zinc ion", "SIMPLE_CHEMICAL", 17, 25], ["cysteine", "AMINO_ACID", 179, 187], ["non-adjacent cysteine pairs", "PROTEIN", 166, 193], ["fingers subdomain", "PROTEIN", 251, 268], ["zinc ion", "PROBLEM", 17, 25], ["the zinc ion", "TREATMENT", 92, 104], ["an analogous disulfide linkage", "TREATMENT", 115, 145], ["cysteine pairs", "OBSERVATION", 179, 193], ["fingers", "ANATOMY", 251, 258]]], ["The disulfide linkage should not affect the pK a 's of discussed residues, as they are located far away in other subdomains (Fig. 1a) .", [["disulfide", "CHEMICAL", 4, 13]]], ["Following the addition of hydrogens and disulfide bridge, the structure was subject to a 20-step energy minimization with the heavy atoms restrained, and a 20-step energy minimization with all atoms restrained but the disulfide bonded cysteine pairs.", [["hydrogens", "CHEMICAL", 26, 35], ["disulfide", "CHEMICAL", 40, 49], ["disulfide", "CHEMICAL", 218, 227], ["cysteine", "CHEMICAL", 235, 243], ["hydrogens", "SIMPLE_CHEMICAL", 26, 35], ["cysteine", "AMINO_ACID", 235, 243], ["disulfide bonded cysteine pairs", "PROTEIN", 218, 249], ["hydrogens and disulfide bridge", "TREATMENT", 26, 56], ["a 20-step energy minimization", "TREATMENT", 87, 116], ["the heavy atoms restrained", "TREATMENT", 122, 148], ["a 20-step energy minimization", "TREATMENT", 154, 183], ["all atoms restrained", "TREATMENT", 189, 209], ["the disulfide bonded cysteine pairs", "PROBLEM", 214, 249]]], ["From there the force field parameters and coordinate files were constructed from the CHARMM output with the LEAP utility in AMBER.", [["the force field parameters", "TEST", 11, 37], ["the CHARMM output", "TEST", 81, 98], ["AMBER", "OBSERVATION", 124, 129]]], ["23 The ff14sb force field 26 was used to represent the protein, and the GB-Neck2 (igb=8) implicit-solvent model 27 was used to represent solvent.", [["The ff14sb force field", "TEST", 3, 25], ["the protein", "TEST", 51, 62], ["the GB", "TEST", 68, 74], ["igb", "TEST", 82, 85], ["GB", "ANATOMY", 72, 74]]], ["The mbondi3 intrinsic Born radii were modified for improving titration simulations of His 28 and Cys 29 sidechains.", [["His", "CHEMICAL", 86, 89], ["Cys", "CHEMICAL", 97, 100], ["The mbondi3 intrinsic Born radii", "TREATMENT", 0, 32]]], ["The structure was then energy minimized and equilibrated in the GB-Neck2 implicit solvent 27 , following our previous protocol 21 .", [["GB", "ANATOMY", 64, 66]]], ["The energy minimization was performed using the steepest decent algorithm for 5000 steps and the conjugate-gradient algorithm for 1000 steps.", [["the conjugate-gradient algorithm", "TREATMENT", 93, 125]]], ["The equilibration was performed at pH 7 in four stages, each having 2000 MD steps with gradually decreased restraining force constants of 5, 2, 1, and 0 kcal/mol/ 2 .", [["The equilibration", "TEST", 0, 17]]], ["The final structure was used for CpHMD titration simulations.II. METHODS AND PROTOCOLSb. pH replica-exchange CpHMD simulations.", [["II", "CHEMICAL", 61, 63], ["CpHMD", "SIMPLE_CHEMICAL", 33, 38], ["CpHMD titration simulations", "TREATMENT", 33, 60], ["pH replica", "TEST", 89, 99], ["exchange CpHMD", "OBSERVATION", 100, 114]]], ["The titration simulations were performed using the GPU-accelerated GBNeck2-CpHMD method 28, 30 in the pmemd engine of AMBER18.", [["GBNeck2", "CHEMICAL", 67, 74], ["AMBER18", "SIMPLE_CHEMICAL", 118, 125], ["GBNeck2", "PROTEIN", 67, 74], ["AMBER18", "PROTEIN", 118, 125], ["The titration simulations", "TEST", 0, 25], ["the GPU", "TEST", 47, 54]]], ["23 An asynchronous version (Liu, Harris, Shen, unpublished) of the pH replica-exchange protocol 16 was implemented to allow replica exchange to be performed on a single GPU card.", [["the pH replica", "TREATMENT", 63, 77], ["exchange protocol", "TREATMENT", 78, 95]]], ["Our previous work showed that pH replicaexchange enhances both protonation and conformational state sampling, allowing pK a 's to rapidly converge.", [["Our previous work", "TEST", 0, 17], ["pH replicaexchange", "PROBLEM", 30, 48], ["conformational state sampling", "TEST", 79, 108]]], ["16, 30, 31 In the protocol, 9 pH replicas were placed at pH values ranging from pH 4.5 to 8.5 at an interval of 0.5 pH units.", [["pH replicas", "TEST", 30, 41], ["pH values", "TEST", 57, 66], ["pH", "TEST", 80, 82]]], ["An exchange of two adjacent pH conditions was attempted every 1000 MD steps (or 2 ps).", [["two adjacent pH conditions", "TREATMENT", 15, 41], ["pH conditions", "OBSERVATION", 28, 41]]], ["Each replica was run for 55 ns, resulting in an aggregate time of 495 ns for each.", [["55 ns", "TREATMENT", 25, 30]]], ["The \u03bb values were recorded after each exchange attempt.", [["The \u03bb values", "TEST", 0, 12]]], ["All sidechains of Asp, Glu, His, Cys, and Lys were allowed to titrate, with their titration model parameters taken from our previous work.", [["Asp", "CHEMICAL", 18, 21], ["Glu", "CHEMICAL", 23, 26], ["Asp", "CHEMICAL", 18, 21], ["Glu", "CHEMICAL", 23, 26], ["His", "CHEMICAL", 28, 31], ["Cys", "CHEMICAL", 33, 36], ["Lys", "CHEMICAL", 42, 45], ["Asp", "AMINO_ACID", 18, 21], ["Glu", "AMINO_ACID", 23, 26], ["His", "AMINO_ACID", 28, 31], ["Cys", "AMINO_ACID", 33, 36], ["Lys", "AMINO_ACID", 42, 45], ["Asp", "TEST", 18, 21], ["Glu", "TEST", 23, 26], ["Cys", "TEST", 33, 36], ["Lys", "TEST", 42, 45], ["their titration model parameters", "TEST", 76, 108]]], ["[28] [29] [30] An ionic strength of 0.15 M was used to represent the physiological salt condition.", [["[28] [29] [30", "SIMPLE_CHEMICAL", 0, 13], ["An ionic strength", "TEST", 15, 32], ["the physiological salt condition", "PROBLEM", 65, 97], ["salt condition", "OBSERVATION", 83, 97]]], ["Simulations were run at a temperature of 300 K and an effectively infinite cutoff (999 \u00c5) for nonbonded interactions.", [["a temperature", "TEST", 24, 37], ["nonbonded interactions", "PROBLEM", 94, 116]]], ["SHAKE was used to constrain bonds involving hydrogens to allow for a 2-fs time step.II. METHODS AND PROTOCOLSc.", [["SHAKE", "CHEMICAL", 0, 5], ["II", "CHEMICAL", 84, 86], ["SHAKE", "SIMPLE_CHEMICAL", 0, 5]]], ["To support the findings from the GB-CpHMD simulations, two all-atom MD simulations were carried out for SARS-CoV-2 PLpro (PDB 6W9C), using the predicted protonation states for Asp, Glu, His, Cys, and Lys at pH 8.5.", [["Asp", "CHEMICAL", 176, 179], ["Glu", "CHEMICAL", 181, 184], ["Asp", "CHEMICAL", 176, 179], ["Glu", "CHEMICAL", 181, 184], ["His", "CHEMICAL", 186, 189], ["Cys", "CHEMICAL", 191, 194], ["Lys", "CHEMICAL", 200, 203], ["PDB 6W9C", "SIMPLE_CHEMICAL", 122, 130], ["Asp", "AMINO_ACID", 176, 179], ["Glu", "AMINO_ACID", 181, 184], ["His", "AMINO_ACID", 186, 189], ["Cys", "AMINO_ACID", 191, 194], ["Lys", "AMINO_ACID", 200, 203], ["SARS", "PROBLEM", 104, 108], ["CoV", "TEST", 109, 112], ["Asp", "TEST", 176, 179], ["Glu", "TEST", 181, 184], ["Cys", "TEST", 191, 194], ["Lys at pH", "TEST", 200, 209]]], ["Two additional runs were carried out using the protonated form of Cys270.", [["Cys270", "CHEMICAL", 66, 72], ["Cys270", "CHEMICAL", 66, 72], ["Cys270", "SIMPLE_CHEMICAL", 66, 72], ["Two additional runs", "TEST", 0, 19], ["Cys270", "TREATMENT", 66, 72]]], ["The protein and water were represented by the ff14SB 26 and TIP3P 32 force fields.", [["water", "SIMPLE_CHEMICAL", 16, 21]]], ["The initial structure was placed in a truncated octahedron box of water molecules.", [["truncated octahedron box", "PROTEIN", 38, 62], ["water molecules", "PROTEIN", 66, 81], ["a truncated octahedron box of water molecules", "TREATMENT", 36, 81], ["water molecules", "OBSERVATION", 66, 81]]], ["A non-bonded cut-off of 8 \u00c5 was used with a time step of 2 fs.", [["A non-bonded cut", "TREATMENT", 0, 16], ["non-bonded", "OBSERVATION_MODIFIER", 2, 12], ["cut", "OBSERVATION_MODIFIER", 13, 16]]], ["The starting structure underwent energy minimization by applying 5000 steps of steepest descent, followed by 5000 steps of conjugate gradient minimization with a force constant of 25 kcal/mol/\u00c5 2 applied to the solute heavy .", [["energy minimization", "TREATMENT", 33, 52], ["conjugate gradient minimization", "TREATMENT", 123, 154], ["energy minimization", "OBSERVATION", 33, 52]]], ["CC-BY-ND 4.0 International license was not certified by peer review) is the author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["Following heating, solvent was equilibrated in the NPT ensemble for 250 ps using the isotropic Berendsen barostat 34 and with the same force constant.", [["the isotropic Berendsen barostat", "TREATMENT", 81, 113]]], ["Subsequently, the restraints were removed and the system was further relaxed for 100 ps in the NPT ensemble.", [["the restraints", "TREATMENT", 14, 28]]], ["Finally, two production runs of 1 \u00b5s each were performed for each system starting from a different random initial velocity seed.", [["two production runs", "TEST", 9, 28], ["a different random initial velocity seed", "PROBLEM", 87, 127]]], ["All analysis was performed with the Amber module CPPTRAJ 35 .", [["All analysis", "TEST", 0, 12], ["the Amber module CPPTRAJ", "TEST", 32, 56]]], ["The first 300 ns from each trajectory was discarded.III. RESULTS AND DISCUSSIONWe performed pH replica-exchange CpHMD simulations to estimate the pK a values of Asp/Glu/His/Cys/Lys sidechains and assess possible proton-coupled dynamics in SARS-CoV, SARS-CoV-2, and MERS-CoV PLpros.", [["Asp", "CHEMICAL", 161, 164], ["Glu", "CHEMICAL", 165, 168], ["Cys", "CHEMICAL", 173, 176], ["Lys", "CHEMICAL", 177, 180], ["Asp", "CHEMICAL", 161, 164], ["Glu", "CHEMICAL", 165, 168], ["His", "CHEMICAL", 169, 172], ["Cys", "CHEMICAL", 173, 176], ["Lys", "CHEMICAL", 177, 180], ["Glu", "AMINO_ACID", 165, 168], ["Lys sidechains", "AMINO_ACID", 177, 191], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 265, 273], ["SARS-CoV", "SPECIES", 239, 247], ["SARS-CoV", "SPECIES", 249, 257], ["MERS-CoV", "SPECIES", 265, 273], ["pH replica", "TREATMENT", 92, 102], ["Asp", "TEST", 161, 164], ["Glu", "TEST", 165, 168], ["His/Cys/Lys sidechains", "TREATMENT", 169, 191], ["proton", "TREATMENT", 212, 218], ["SARS", "PROBLEM", 239, 243], ["CoV", "TEST", 244, 247], ["SARS", "TEST", 249, 253], ["CoV", "TEST", 254, 257]]], ["The titration simulations were conducted in the pH range 4.5-8.5 and lasted 55 ns per replica (aggregate simulation time of 495 ns for each protein).", [["The titration simulations", "TEST", 0, 25], ["the pH range", "TEST", 44, 56]]], ["The protonation states were well converged.", [["protonation states", "OBSERVATION", 4, 22]]], ["Consistent with our previous work 31 , we found that the protonation states of His residues converge rapidly within 10 ns per replica, and those of Cys converge more slowly due to the formation of hydrogen bonds that are not present in the crystal structure (see later discussion).", [["His", "CHEMICAL", 79, 82], ["Cys", "CHEMICAL", 148, 151], ["hydrogen", "CHEMICAL", 197, 205], ["Cys", "AMINO_ACID", 148, 151], ["hydrogen bonds", "SIMPLE_CHEMICAL", 197, 211], ["His residues", "PROBLEM", 79, 91], ["hydrogen bonds", "PROBLEM", 197, 211], ["hydrogen bonds", "OBSERVATION", 197, 211]]], ["The time series analysis of protonation state sampling and replica walks along the pH ladder are given in see supplementary material.", [["protonation state sampling", "TEST", 28, 54], ["replica walks", "TREATMENT", 59, 72], ["the pH ladder", "TREATMENT", 79, 92]]], ["For the ease of discussion, we refer to the \"standard\" protonation states as the default settings in the MD programs, i.e., deprotonated Asp/Glu (negatively charged), deprotonated His (neutral), with one proton on either \u03b4 or \u03b5 nitrogen, protonated Cys (neutral), and protonated Lys (positively charged).", [["Asp", "CHEMICAL", 137, 140], ["Glu", "CHEMICAL", 141, 144], ["Cys", "CHEMICAL", 249, 252], ["Asp", "CHEMICAL", 137, 140], ["Glu", "CHEMICAL", 141, 144], ["His", "CHEMICAL", 180, 183], ["nitrogen", "CHEMICAL", 228, 236], ["Cys", "CHEMICAL", 249, 252], ["Lys", "CHEMICAL", 279, 282], ["Glu", "AMINO_ACID", 141, 144], ["deprotonated His (neutral)", "SIMPLE_CHEMICAL", 167, 193], ["\u03b4", "SIMPLE_CHEMICAL", 221, 222], ["\u03b5 nitrogen", "SIMPLE_CHEMICAL", 226, 236], ["protonated Cys (neutral)", "SIMPLE_CHEMICAL", 238, 262], ["protonated Lys", "SIMPLE_CHEMICAL", 268, 282], ["deprotonated Asp/Glu", "TEST", 124, 144], ["nitrogen", "TREATMENT", 228, 236], ["protonated Cys (neutral)", "TREATMENT", 238, 262], ["protonated Lys", "TREATMENT", 268, 282]]], ["Our simulations showed that several Cys, His residues and one Asp are in the \"non-standard\" protonation state or can switch to this state at physiological pH in all three PLpros (Table I) .", [["Cys", "CHEMICAL", 36, 39], ["Asp", "CHEMICAL", 62, 65], ["Cys", "CHEMICAL", 36, 39], ["His", "CHEMICAL", 41, 44], ["Asp", "CHEMICAL", 62, 65], ["Asp", "AMINO_ACID", 62, 65], ["Our simulations", "TEST", 0, 15], ["several Cys", "PROBLEM", 28, 39], ["His residues", "PROBLEM", 41, 53], ["one Asp", "PROBLEM", 58, 65]]], ["CC-BY-ND 4.0 International license was not certified by peer review) is the author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["Protonation states and hydrogen bond network of the catalytic triad.", [["hydrogen", "CHEMICAL", 23, 31], ["catalytic triad", "PROTEIN", 52, 67], ["hydrogen bond", "OBSERVATION", 23, 36]]], ["We first consider the catalytic triad in SARS-CoV-2 PLpro.", [["SARS", "PROBLEM", 41, 45], ["CoV", "TEST", 46, 49], ["PLpro", "TREATMENT", 52, 57]]], ["The catalytic Cys111 is located in the thumb, His272 is located in the foothill of the palm adjacent the flexible loop BL2, and Asp286 is located at the end of \u03b2 18 (Fig. 1b) .", [["thumb", "ANATOMY", 39, 44], ["Cys111", "GENE_OR_GENE_PRODUCT", 14, 20], ["thumb", "ORGANISM_SUBDIVISION", 39, 44], ["His272", "GENE_OR_GENE_PRODUCT", 46, 52], ["BL2", "GENE_OR_GENE_PRODUCT", 119, 122], ["Asp286", "GENE_OR_GENE_PRODUCT", 128, 134], ["catalytic Cys111", "PROTEIN", 4, 20], ["His272", "PROTEIN", 46, 52], ["BL2", "PROTEIN", 119, 122], ["Asp286", "PROTEIN", 128, 134], ["\u03b2 18", "PROTEIN", 160, 164], ["catalytic Cys111", "OBSERVATION", 4, 20], ["thumb", "ANATOMY", 39, 44], ["palm", "ANATOMY_MODIFIER", 87, 91], ["flexible loop", "OBSERVATION", 105, 118]]], ["Biochemical experiments of SARS-CoV PLpro suggested that the Cys serves as a nucleophile, while the His functions as a general acid with the assistance of a negatively charged Asp 12 ; however, it is unclear whether the reactive nucleophile is the thiolate of the Cys\u00b7 \u00b7 \u00b7His ion pair or the neutral thiole which becomes deprotonated upon binding of the substrate 4 .", [["SARS", "DISEASE", 27, 31], ["Cys", "CHEMICAL", 61, 64], ["Asp", "CHEMICAL", 176, 179], ["thiole", "CHEMICAL", 300, 306], ["Cys", "CHEMICAL", 61, 64], ["His", "CHEMICAL", 100, 103], ["Asp", "CHEMICAL", 176, 179], ["Cys\u00b7 \u00b7 \u00b7His", "CHEMICAL", 264, 275], ["thiole", "CHEMICAL", 300, 306], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 27, 35], ["Cys", "AMINO_ACID", 61, 64], ["thiole", "SIMPLE_CHEMICAL", 300, 306], ["SARS-CoV", "SPECIES", 27, 35], ["SARS", "PROBLEM", 27, 31], ["a nucleophile", "TREATMENT", 75, 88], ["a general acid", "TREATMENT", 117, 131], ["reactive nucleophile", "OBSERVATION", 220, 240], ["deprotonated", "OBSERVATION", 321, 333]]], ["The calculated pK a 's of Cys111 and Asp286 are <4.5, whereas the pK a of His272 is >8.5, indicating that the catalytic triad residues are all in the charged state at physiological pH.", [["Cys111", "CHEMICAL", 26, 32], ["Asp286", "CHEMICAL", 37, 43], ["His272", "CHEMICAL", 74, 80], ["Cys111", "GENE_OR_GENE_PRODUCT", 26, 32], ["Asp286", "AMINO_ACID", 37, 43], ["The calculated pK", "TEST", 0, 17], ["Cys111", "TEST", 26, 32], ["Asp286", "TEST", 37, 43], ["the pK", "TEST", 62, 68], ["the catalytic triad residues", "PROBLEM", 106, 134]]], ["Thus, our data supports the mechanism in which the reactive nucleophile is the thiolate ion, rather than the neutral thiol that needs to be first activated by the substrate.", [["thiol", "CHEMICAL", 117, 122], ["thiolate", "CHEMICAL", 79, 87], ["thiol", "CHEMICAL", 117, 122], ["the thiolate ion", "TREATMENT", 75, 91], ["the neutral thiol", "TREATMENT", 105, 122], ["reactive nucleophile", "OBSERVATION", 51, 71]]], ["4 The CpHMD simulations showed that the Cys-His-Asp triad maintains a catalytic geometry through several hydrogen bonds, which support their protonation states.", [["Cys-His-Asp", "CHEMICAL", 40, 51], ["Cys", "CHEMICAL", 40, 43], ["His", "CHEMICAL", 44, 47], ["Asp", "CHEMICAL", 48, 51], ["hydrogen", "CHEMICAL", 105, 113], ["The CpHMD simulations", "TEST", 2, 23], ["the Cys", "TEST", 36, 43], ["Asp triad", "PROBLEM", 48, 57], ["hydrogen bonds", "OBSERVATION", 105, 119], ["protonation states", "OBSERVATION", 141, 159]]], ["The catalytic His272 forms a hydrogen bond simultaneously with Cys111 and Asp286 in the entire pH range 4.5-8.5, stabilizing His272 in the doubly protonated state and Asp286 and Cys111 in the deprotonated states ( Fig. 2a and d) .", [["His272", "CHEMICAL", 14, 20], ["His272", "CHEMICAL", 125, 131], ["Cys111", "CHEMICAL", 178, 184], ["His272", "CHEMICAL", 14, 20], ["hydrogen", "CHEMICAL", 29, 37], ["Cys111", "CHEMICAL", 63, 69], ["Asp286", "CHEMICAL", 74, 80], ["His272", "CHEMICAL", 125, 131], ["Asp286", "CHEMICAL", 167, 173], ["Cys111", "CHEMICAL", 178, 184], ["His272", "SIMPLE_CHEMICAL", 14, 20], ["Cys111", "SIMPLE_CHEMICAL", 63, 69], ["Asp286", "SIMPLE_CHEMICAL", 74, 80], ["His272", "SIMPLE_CHEMICAL", 125, 131], ["Asp286", "SIMPLE_CHEMICAL", 167, 173], ["Cys111", "SIMPLE_CHEMICAL", 178, 184], ["catalytic His272", "PROTEIN", 4, 20], ["a hydrogen bond", "TEST", 27, 42], ["Cys111", "TEST", 63, 69], ["Asp286", "TEST", 74, 80], ["Asp286", "TEST", 167, 173], ["Cys111", "TEST", 178, 184], ["hydrogen bond", "OBSERVATION", 29, 42]]], ["The doubly protonated form allows His272 to perform its role as a general acid.", [["His272", "CHEMICAL", 34, 40], ["His272", "CHEMICAL", 34, 40], ["His272", "SIMPLE_CHEMICAL", 34, 40], ["a general acid", "TREATMENT", 64, 78], ["protonated", "OBSERVATION", 11, 21]]], ["4 The catalytic Cys111 forms a hydrogen bond not only with His272 but also with the indole nitrogen of Trp106, which provides further stabilization for the thiolate form and explains the significant downshifted pK a relative to the solution value of 8.5 (Table I) .", [["Cys111", "CHEMICAL", 16, 22], ["His272", "CHEMICAL", 59, 65], ["indole nitrogen", "CHEMICAL", 84, 99], ["Trp", "CHEMICAL", 103, 106], ["Cys", "CHEMICAL", 16, 19], ["hydrogen", "CHEMICAL", 31, 39], ["His", "CHEMICAL", 59, 62], ["indole", "CHEMICAL", 84, 90], ["nitrogen", "CHEMICAL", 91, 99], ["Trp", "CHEMICAL", 103, 106], ["Cys111", "AMINO_ACID", 16, 22], ["His272", "SIMPLE_CHEMICAL", 59, 65], ["Trp106", "SIMPLE_CHEMICAL", 103, 109], ["catalytic Cys111", "PROTEIN", 6, 22], ["The catalytic Cys", "TEST", 2, 19], ["a hydrogen bond", "TEST", 29, 44], ["the indole nitrogen of Trp", "TEST", 80, 106], ["the solution value", "TEST", 228, 246]]], ["The Cys111\u00b7 \u00b7 \u00b7Trp106 hydrogen bond is important, as it maintains the position of Trp106; the analogous residue in SARS-CoV PLpro has been hypothesized as the oxyanion hole residue that donates a hydrogen bond to stabilize the negatively charged tetrahedral intermediate developed in the course of peptide hydrolysis.", [["Cys111\u00b7 \u00b7 \u00b7Trp106", "CHEMICAL", 4, 21], ["Trp", "CHEMICAL", 82, 85], ["SARS", "DISEASE", 115, 119], ["PLpro", "CHEMICAL", 124, 129], ["Cys111\u00b7 \u00b7 \u00b7Trp106 hydrogen", "CHEMICAL", 4, 30], ["Trp", "CHEMICAL", 82, 85], ["hydrogen", "CHEMICAL", 196, 204], ["Cys111\u00b7 \u00b7 \u00b7", "SIMPLE_CHEMICAL", 4, 15], ["Trp106", "AMINO_ACID", 15, 21], ["Trp106", "AMINO_ACID", 82, 88], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 115, 123], ["SARS-CoV PLpro", "PROTEIN", 115, 129], ["SARS-CoV", "SPECIES", 115, 123], ["Trp", "TEST", 82, 85], ["the analogous residue in SARS", "PROBLEM", 90, 119], ["CoV PLpro", "TREATMENT", 120, 129], ["the oxyanion hole residue", "PROBLEM", 155, 180], ["a hydrogen bond", "PROBLEM", 194, 209], ["peptide hydrolysis", "TREATMENT", 298, 316]]], ["13 The three hydrogen bond interactions in SARS-CoV-2 PLpro are consistent with those in SARS-Cov PLpro (Fig. 2b) .III. RESULTS AND DISCUSSIONIn MERS-CoV PLpro, Trp106 is replaced with a Leu, which is incapable of forming a hydrogen bond with the catalytic Cys or with the negatively charged intermediate.", [["Trp", "CHEMICAL", 161, 164], ["Leu", "CHEMICAL", 187, 190], ["hydrogen", "CHEMICAL", 13, 21], ["Trp", "CHEMICAL", 161, 164], ["Leu", "CHEMICAL", 187, 190], ["hydrogen", "CHEMICAL", 224, 232], ["Cys", "CHEMICAL", 257, 260], ["Trp", "AMINO_ACID", 161, 164], ["The three hydrogen bond interactions", "PROBLEM", 3, 39], ["SARS", "TEST", 43, 47], ["CoV", "TEST", 48, 51], ["those in SARS", "PROBLEM", 80, 93], ["Cov PLpro (Fig.", "TREATMENT", 94, 109], ["a Leu", "TREATMENT", 185, 190], ["a hydrogen bond", "TREATMENT", 222, 237], ["the catalytic Cys", "TREATMENT", 243, 260], ["hydrogen bond", "OBSERVATION", 13, 26], ["consistent with", "UNCERTAINTY", 64, 79]]], ["The has been hypothesized as a cause for the significantly lower catalytic activity of MERS-CoV as compared to SARS-CoV PLpro 36 .", [["SARS", "DISEASE", 111, 115], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 87, 95], ["MERS-CoV", "SPECIES", 87, 95], ["SARS-CoV", "SPECIES", 111, 119], ["the significantly lower catalytic activity of MERS", "PROBLEM", 41, 91], ["CoV", "PROBLEM", 92, 95], ["SARS", "TEST", 111, 115], ["CoV PLpro", "TEST", 116, 125]]], ["In addition to the missing Cys\u00b7 \u00b7 \u00b7Trp hydrogen bond, CpHMD simulations of MERS-CoV PLpro showed that the hydrogen bond between the catalytic His and Asp is nearly abolished (Fig. 2c) .", [["Cys\u00b7", "CHEMICAL", 27, 31], ["Trp", "CHEMICAL", 35, 38], ["hydrogen", "CHEMICAL", 39, 47], ["hydrogen", "CHEMICAL", 106, 114], ["His", "CHEMICAL", 142, 145], ["Asp", "CHEMICAL", 150, 153], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 75, 83], ["Asp", "AMINO_ACID", 150, 153], ["MERS", "PROTEIN", 75, 79], ["CoV PLpro", "PROTEIN", 80, 89], ["catalytic His", "PROTEIN", 132, 145], ["Trp hydrogen bond", "TEST", 35, 52], ["MERS", "PROBLEM", 75, 79], ["CoV PLpro", "TEST", 80, 89], ["the hydrogen bond", "PROBLEM", 102, 119], ["Asp", "PROBLEM", 150, 153]]], ["The loss of hydrogen bond interactions involving the catalytic His and Cys appears to provide less stabilization to the respective charged states in MERS-CoV PLpro, as suggested by the partial titration at the highest and lowest pH condition, respectively (see supplementary material).", [["hydrogen", "CHEMICAL", 12, 20], ["Cys", "CHEMICAL", 71, 74], ["hydrogen", "CHEMICAL", 12, 20], ["His", "CHEMICAL", 63, 66], ["Cys", "CHEMICAL", 71, 74], ["Cys", "AMINO_ACID", 71, 74], ["MERS-CoV PLpro", "GENE_OR_GENE_PRODUCT", 149, 163], ["MERS-CoV", "SPECIES", 149, 157], ["The loss of hydrogen bond interactions", "PROBLEM", 0, 38], ["CoV PLpro", "TREATMENT", 154, 163], ["loss", "OBSERVATION_MODIFIER", 4, 8], ["hydrogen bond", "OBSERVATION", 12, 25]]], ["To test whether the loss of hydrogen bond network affects the flexibility of the regions near the catalytic triad, we calculated the root-mean-square fluctuations (RMSFs) of the C\u03b1 atoms of the catalytic triad and nearby 5 residues (Fig. 3) .", [["hydrogen", "CHEMICAL", 28, 36], ["C\u03b1", "CHEMICAL", 178, 180], ["catalytic triad", "PROTEIN", 98, 113], ["C\u03b1 atoms", "PROTEIN", 178, 186], ["catalytic triad", "PROTEIN", 194, 209], ["the loss of hydrogen bond network", "PROBLEM", 16, 49], ["the catalytic triad", "PROBLEM", 190, 209], ["hydrogen bond", "OBSERVATION", 28, 41], ["catalytic triad", "OBSERVATION", 98, 113], ["root", "ANATOMY", 133, 137], ["catalytic triad", "OBSERVATION", 194, 209]]], ["Interestingly, the RMSFs of the loop residues that are sequence neighbors of the catalytic triad in MERS-CoV PLpro are increased as compared to those in SARS-CoV-2 and SARS-CoV PLpros, which are similar except for the flexible BL2 loop (267-271) region.", [["MERS-CoV PLpro", "GENE_OR_GENE_PRODUCT", 100, 114], ["SARS-CoV PLpros", "ORGANISM", 168, 183], ["RMSFs", "PROTEIN", 19, 24], ["catalytic triad", "PROTEIN", 81, 96], ["MERS", "PROTEIN", 100, 104], ["CoV PLpro", "PROTEIN", 105, 114], ["BL2 loop (267-271) region", "PROTEIN", 227, 252], ["MERS-CoV", "SPECIES", 100, 108], ["SARS-CoV", "SPECIES", 153, 161], ["SARS-CoV", "SPECIES", 168, 176], ["the loop residues", "PROBLEM", 28, 45], ["the catalytic triad", "PROBLEM", 77, 96], ["SARS", "TEST", 153, 157], ["CoV", "TEST", 158, 161], ["SARS", "TEST", 168, 172], ["CoV PLpros", "TEST", 173, 183], ["the flexible BL2 loop", "TREATMENT", 214, 235], ["loop residues", "OBSERVATION", 32, 45], ["increased", "OBSERVATION_MODIFIER", 119, 128], ["flexible", "ANATOMY_MODIFIER", 218, 226], ["BL2 loop", "OBSERVATION", 227, 235]]], ["The loop (106-116) adjacent to \u03b14 which harbors the catalytic Cys, the BL2 loop next to the catalytic His, and the \u03b2 -hairpin loop next to the catalytic Asp all display enhanced mobility ( Fig. 3a and b) .", [["Cys", "CHEMICAL", 62, 65], ["His", "CHEMICAL", 102, 105], ["Asp", "CHEMICAL", 153, 156], ["\u03b14", "GENE_OR_GENE_PRODUCT", 31, 33], ["\u03b14", "PROTEIN", 31, 33], ["catalytic Cys", "PROTEIN", 52, 65], ["BL2 loop", "PROTEIN", 71, 79], ["catalytic His", "PROTEIN", 92, 105], ["\u03b2", "PROTEIN", 115, 116], ["catalytic Asp", "PROTEIN", 143, 156], ["The loop", "TREATMENT", 0, 8], ["the BL2 loop", "TREATMENT", 67, 79], ["the \u03b2 -hairpin loop", "TREATMENT", 111, 130], ["loop", "OBSERVATION_MODIFIER", 4, 8], ["catalytic Cys", "OBSERVATION", 52, 65], ["enhanced", "OBSERVATION_MODIFIER", 169, 177], ["mobility", "OBSERVATION", 178, 186]]], ["The largest increase in RMSF is seen for the BL2 loop, whereby the RMSF in MERS-CoV PLpro is nearly doubled relative to SARS-CoV-2 PLpro, which shows a somewhat higher mobility than SARS-CoV PLpro.", [["RMSF", "DISEASE", 24, 28], ["RMSF", "DISEASE", 67, 71], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 75, 83], ["SARS-CoV PLpro", "GENE_OR_GENE_PRODUCT", 182, 196], ["RMSF", "PROTEIN", 24, 28], ["BL2 loop", "PROTEIN", 45, 53], ["RMSF", "PROTEIN", 67, 71], ["MERS", "PROTEIN", 75, 79], ["CoV PLpro", "PROTEIN", 80, 89], ["MERS-CoV", "SPECIES", 75, 83], ["SARS-CoV", "SPECIES", 120, 128], ["SARS-CoV", "SPECIES", 182, 190], ["The largest increase in RMSF", "PROBLEM", 0, 28], ["the BL2 loop", "TREATMENT", 41, 53], ["the RMSF in MERS", "PROBLEM", 63, 79], ["SARS", "TEST", 120, 124], ["CoV", "TEST", 125, 128], ["a somewhat higher mobility", "PROBLEM", 150, 176], ["CoV PLpro", "TREATMENT", 187, 196], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["increase", "OBSERVATION_MODIFIER", 12, 20], ["RMSF", "OBSERVATION", 24, 28], ["RMSF", "OBSERVATION", 67, 71], ["somewhat", "OBSERVATION_MODIFIER", 152, 160], ["higher", "OBSERVATION_MODIFIER", 161, 167], ["mobility", "OBSERVATION", 168, 176]]], ["The extremely high flexibility of the BL2 loop in MERS-as compared to SARS-CoV PLpro is consistent with the lack of electron density for the region in the first X-ray structure of the apo MERS-CoV PLpro 36 . b.", [["SARS", "DISEASE", 70, 74], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 70, 78], ["electron", "SIMPLE_CHEMICAL", 116, 124], ["BL2 loop", "PROTEIN", 38, 46], ["MERS", "PROTEIN", 50, 54], ["apo MERS-CoV PLpro 36", "DNA", 184, 205], ["SARS-CoV", "SPECIES", 70, 78], ["The extremely high flexibility of the BL2 loop in MERS", "PROBLEM", 0, 54], ["SARS", "TEST", 70, 74], ["extremely", "OBSERVATION_MODIFIER", 4, 13], ["high", "OBSERVATION_MODIFIER", 14, 18], ["flexibility", "OBSERVATION_MODIFIER", 19, 30], ["loop", "OBSERVATION_MODIFIER", 42, 46], ["consistent with", "UNCERTAINTY", 88, 103], ["electron density", "OBSERVATION", 116, 132], ["first X-ray structure", "OBSERVATION_MODIFIER", 155, 176]]], ["Proton-coupled conformational dynamics of the BL2 loop in SARS-CoV/CoV-2 PLpro.", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 58, 66], ["CoV-2 PLpro", "GENE_OR_GENE_PRODUCT", 67, 78], ["BL2 loop", "PROTEIN", 46, 54], ["PLpro", "PROTEIN", 73, 78], ["SARS-CoV", "SPECIES", 58, 66], ["Proton", "TREATMENT", 0, 6], ["the BL2 loop", "TREATMENT", 42, 54], ["CoV", "TEST", 67, 70], ["PLpro", "TREATMENT", 73, 78]]], ["The BL2 loop is perhaps the most prominent feature of the substrate binding site in SARS-CoV PLpro, as its movement modulates the substrate and inhibitor binding 4 .", [["BL2", "GENE_OR_GENE_PRODUCT", 4, 7], ["SARS-CoV PLpro", "GENE_OR_GENE_PRODUCT", 84, 98], ["BL2", "PROTEIN", 4, 7], ["substrate binding site", "DNA", 58, 80], ["SARS-CoV", "SPECIES", 84, 92], ["the substrate binding site", "PROBLEM", 54, 80], ["CoV PLpro", "TREATMENT", 89, 98], ["BL2 loop", "OBSERVATION", 4, 12], ["most prominent", "OBSERVATION_MODIFIER", 28, 42], ["substrate binding", "OBSERVATION", 58, 75]]], ["Crystal structures show that BL2 is open in the unbound SARS-CoV PLpro and it closes by about 1.5-2 \u00c5 in the bound form, which allows hydrogen bonds to form between Tyr269/Gln270 and the inhibitor 4 .", [["BL2", "CHEMICAL", 29, 32], ["SARS", "DISEASE", 56, 60], ["Gln270", "CHEMICAL", 172, 178], ["hydrogen", "CHEMICAL", 134, 142], ["Tyr269", "CHEMICAL", 165, 171], ["Gln", "CHEMICAL", 172, 175], ["BL2", "SIMPLE_CHEMICAL", 29, 32], ["Tyr269", "SIMPLE_CHEMICAL", 165, 171], ["Gln270", "AMINO_ACID", 172, 178], ["BL2", "PROTEIN", 29, 32], ["SARS-CoV PLpro", "PROTEIN", 56, 70], ["SARS-CoV", "SPECIES", 56, 64], ["Crystal structures", "TEST", 0, 18], ["CoV PLpro", "TREATMENT", 61, 70], ["Tyr269/Gln", "TREATMENT", 165, 175], ["the inhibitor", "TREATMENT", 183, 196]]], ["Upon inspection of the X-ray structures of SARS-CoV-2 PLpro, We noticed that the BL2 loop is open in the pH 7.5 structure (PDB 6W9C) and a zinc ion is found within the binding distance of Cys270; however, in the structure determined at pH 4.5 (PDB 6WRH), the BL2 loop closes in by 1.9 \u00c5 (C\u03b1 distance between Tyr268 and Asp164) and the zinc ion is absent.", [["SARS", "DISEASE", 43, 47], ["zinc", "CHEMICAL", 139, 143], ["Asp164", "CHEMICAL", 319, 325], ["zinc", "CHEMICAL", 335, 339], ["zinc", "CHEMICAL", 139, 143], ["Cys270", "CHEMICAL", 188, 194], ["Tyr268", "CHEMICAL", 308, 314], ["Asp", "CHEMICAL", 319, 322], ["zinc", "CHEMICAL", 335, 339], ["Cys270", "AMINO_ACID", 188, 194], ["zinc", "SIMPLE_CHEMICAL", 335, 339], ["BL2 loop", "PROTEIN", 81, 89], ["PDB 6W9C", "PROTEIN", 123, 131], ["Cys270", "PROTEIN", 188, 194], ["BL2 loop", "PROTEIN", 259, 267], ["the X-ray structures", "TEST", 19, 39], ["SARS", "TEST", 43, 47], ["CoV", "TEST", 48, 51], ["the BL2 loop", "PROBLEM", 77, 89], ["PDB", "TEST", 123, 126], ["a zinc ion", "PROBLEM", 137, 147], ["pH", "TEST", 236, 238], ["PDB", "TEST", 244, 247], ["the BL2 loop", "TEST", 255, 267], ["Asp", "TEST", 319, 322], ["the zinc ion", "TEST", 331, 343], ["loop", "OBSERVATION_MODIFIER", 85, 89], ["open", "OBSERVATION_MODIFIER", 93, 97], ["pH 7.5 structure", "OBSERVATION_MODIFIER", 105, 121], ["zinc ion", "OBSERVATION", 335, 343], ["absent", "OBSERVATION", 347, 353]]], ["CC-BY-ND 4.0 International license was not certified by peer review) is the author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["It is made available under a The copyright holder for this preprint (which this version posted July 1, 2020. we hypothesized that the BL2 loop dynamics is coupled to the titration of C270.", [["C270", "CHEMICAL", 183, 187], ["C270", "CHEMICAL", 183, 187], ["BL2", "GENE_OR_GENE_PRODUCT", 134, 137], ["C270", "SIMPLE_CHEMICAL", 183, 187], ["BL2", "DNA", 134, 137], ["the BL2 loop dynamics", "PROBLEM", 130, 151]]], ["CpHMD titrations gave the pK a 's of 6.7 and 6.9 for Cys270 in SARS-CoV-2 PLpro and the equivalent Cys271 in SARS-CoV PLpro, respectively (Table I) .", [["CpHMD", "SIMPLE_CHEMICAL", 0, 5], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 109, 117], ["PLpro", "PROTEIN", 74, 79], ["Cys271", "PROTEIN", 99, 105], ["SARS-CoV", "SPECIES", 109, 117], ["the pK a 's", "TEST", 22, 33], ["Cys270", "TEST", 53, 59], ["SARS", "TEST", 63, 67], ["CoV", "TEST", 68, 71], ["PLpro", "TREATMENT", 74, 79], ["CoV PLpro", "TREATMENT", 114, 123]]], ["Thus, Cys270/C271 samples both protonated and deprotonated states at physiological pH.", [["Cys270", "CHEMICAL", 6, 12], ["Cys270", "TEST", 6, 12]]], ["The pK a downshifts relative to the model Cys pK a of 8.5 is due to the formation of local hydrogen bonds which favors the thiolate state.", [["Cys", "CHEMICAL", 42, 45], ["hydrogen", "CHEMICAL", 91, 99], ["the model Cys pK", "TEST", 32, 48], ["local hydrogen bonds", "PROBLEM", 85, 105], ["hydrogen bonds", "OBSERVATION", 91, 105]]], ["In the crystal structure of SARS-CoV-2 PLpro, Cys270 does not interact with Thr265.", [["SARS", "DISEASE", 28, 32], ["Thr265", "CHEMICAL", 76, 82], ["Cys270", "CHEMICAL", 46, 52], ["Thr", "CHEMICAL", 76, 79], ["Cys270", "AMINO_ACID", 46, 52], ["Thr265", "AMINO_ACID", 76, 82], ["PLpro", "PROTEIN", 39, 44], ["Cys270", "PROTEIN", 46, 52], ["Thr265", "PROTEIN", 76, 82], ["SARS", "PROBLEM", 28, 32], ["CoV", "TEST", 33, 36], ["SARS", "OBSERVATION", 28, 32]]], ["The titration simulations showed that the distance between Cys270 and Thr265 varies widely between 5 and 15 \u00c5, when Cys270 is protonated (\u03bb value close to 0); however, when Cys270 is deprotonated (\u03bb value close to 1), the distance is locked to 1.5-2.5 \u00c5, indicating the formation of a hydrogen bond (Fig. 4a) .", [["Thr265", "CHEMICAL", 70, 76], ["Cys270", "CHEMICAL", 116, 122], ["Cys270", "CHEMICAL", 173, 179], ["Cys270", "CHEMICAL", 59, 65], ["Thr", "CHEMICAL", 70, 73], ["Cys270", "CHEMICAL", 116, 122], ["Cys270", "CHEMICAL", 173, 179], ["hydrogen", "CHEMICAL", 285, 293], ["Cys270", "GENE_OR_GENE_PRODUCT", 59, 65], ["Thr265", "AMINO_ACID", 70, 76], ["Cys270", "SIMPLE_CHEMICAL", 173, 179], ["The titration simulations", "TEST", 0, 25], ["Cys270", "TEST", 59, 65], ["hydrogen bond", "OBSERVATION", 285, 298]]], ["In addition to the hydroxyl group of Thr265, the deprotonated Cys270 can also accept a hydrogen bond from the backbone amide groups of His272 and Gly271, stabilizing the charged state (Fig. 4b) .", [["hydroxyl", "CHEMICAL", 19, 27], ["Thr265", "CHEMICAL", 37, 43], ["Cys270", "CHEMICAL", 62, 68], ["His272", "CHEMICAL", 135, 141], ["Gly271", "CHEMICAL", 146, 152], ["hydroxyl", "CHEMICAL", 19, 27], ["Thr265", "CHEMICAL", 37, 43], ["Cys270", "CHEMICAL", 62, 68], ["hydrogen", "CHEMICAL", 87, 95], ["amide", "CHEMICAL", 119, 124], ["His272", "CHEMICAL", 135, 141], ["Gly271", "CHEMICAL", 146, 152], ["hydroxyl", "SIMPLE_CHEMICAL", 19, 27], ["Thr265", "SIMPLE_CHEMICAL", 37, 43], ["Cys270", "SIMPLE_CHEMICAL", 62, 68], ["His272", "SIMPLE_CHEMICAL", 135, 141], ["Gly271", "SIMPLE_CHEMICAL", 146, 152], ["a hydrogen bond", "TREATMENT", 85, 100]]], ["The same hydrogen bonds were also formed in the simulations of SARS-CoV PLpro, which explains the similarly downshifted pK a of the equivalent Cys271.III. RESULTS AND DISCUSSIONTo test the hypothesis that protonation/deprotonation of Cys270 modulates the BL2 dynamics, we examined the C\u03b1 distance between Tyr268 on the BL2 loop and the conserved Asp164 next to \u03b17, which represents the width of the S3 subpocket ( Fig. 4c and d) .", [["SARS", "DISEASE", 63, 67], ["Cys271", "CHEMICAL", 143, 149], ["Cys270", "CHEMICAL", 234, 240], ["hydrogen", "CHEMICAL", 9, 17], ["Cys", "CHEMICAL", 143, 146], ["Cys270", "CHEMICAL", 234, 240], ["Tyr268", "CHEMICAL", 305, 311], ["Asp", "CHEMICAL", 346, 349], ["SARS-CoV PLpro", "SIMPLE_CHEMICAL", 63, 77], ["Cys270", "SIMPLE_CHEMICAL", 234, 240], ["BL2", "SIMPLE_CHEMICAL", 255, 258], ["Tyr268", "SIMPLE_CHEMICAL", 305, 311], ["\u03b17", "GENE_OR_GENE_PRODUCT", 361, 363], ["BL2", "PROTEIN", 255, 258], ["BL2 loop", "PROTEIN", 319, 327], ["\u03b17", "PROTEIN", 361, 363], ["Fig. 4c and d)", "PROTEIN", 414, 428], ["SARS-CoV", "SPECIES", 63, 71], ["The same hydrogen bonds", "PROBLEM", 0, 23], ["the BL2 loop", "TREATMENT", 315, 327], ["the conserved Asp", "TEST", 332, 349], ["hydrogen bonds", "OBSERVATION", 9, 23], ["width", "OBSERVATION_MODIFIER", 386, 391], ["S3", "ANATOMY", 399, 401]]], ["The equivalent Tyr269 in SARS-CoV PLpro is an important residue, as it forms a hydrogen bond with the inhibitors that bind to the S3 pocket 4 .", [["SARS", "DISEASE", 25, 29], ["hydrogen", "CHEMICAL", 79, 87], ["Tyr269", "GENE_OR_GENE_PRODUCT", 15, 21], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 25, 33], ["SARS-CoV PLpro", "PROTEIN", 25, 39], ["S3 pocket 4", "PROTEIN", 130, 141], ["SARS-CoV", "SPECIES", 25, 33], ["SARS", "PROBLEM", 25, 29], ["CoV PLpro", "TREATMENT", 30, 39], ["an important residue", "PROBLEM", 43, 63], ["a hydrogen bond", "TREATMENT", 77, 92], ["the inhibitors", "TREATMENT", 98, 112], ["S3", "ANATOMY", 130, 132], ["pocket", "ANATOMY_MODIFIER", 133, 139]]], ["When Cys270 is protonated, the probability distribution of the Tyr268-Asp164 distance covers a broad range of 8-20 \u00c5 with a peak at around 12 \u00c5; however, when Cys270 is depro- tonated, the distribution samples a narrower range of 14-20 \u00c5 with a peak at around 16 \u00c5 (Fig. 4c) .", [["Cys270", "CHEMICAL", 5, 11], ["Cys270", "CHEMICAL", 159, 165], ["Cys270", "CHEMICAL", 5, 11], ["Tyr268", "CHEMICAL", 63, 69], ["Asp", "CHEMICAL", 70, 73], ["Cys270", "CHEMICAL", 159, 165], ["Cys270", "SIMPLE_CHEMICAL", 5, 11], ["Tyr268", "PROTEIN", 63, 69], ["Cys270", "PROTEIN", 159, 165], ["depro- tonated", "PROTEIN", 169, 183], ["broad", "OBSERVATION_MODIFIER", 95, 100], ["narrower", "OBSERVATION_MODIFIER", 212, 220]]], ["Thus, the CpHMD data suggests that the deprotonated Cys270 is correlated with the BL2 conformations that are more open and rigid, which might be attributed to the aforementioned hydrogen bond formation between the deprotonated Cys270 and the surrounding residues.", [["Cys270", "CHEMICAL", 52, 58], ["hydrogen", "CHEMICAL", 178, 186], ["Cys270", "CHEMICAL", 227, 233], ["Cys270", "SIMPLE_CHEMICAL", 52, 58], ["Cys270", "SIMPLE_CHEMICAL", 227, 233], ["the CpHMD data", "TEST", 6, 20], ["the deprotonated Cys270", "PROBLEM", 35, 58], ["the BL2 conformations", "PROBLEM", 78, 99], ["rigid", "PROBLEM", 123, 128], ["the aforementioned hydrogen bond formation", "PROBLEM", 159, 201], ["the deprotonated Cys270", "TREATMENT", 210, 233], ["hydrogen bond", "OBSERVATION", 178, 191], ["deprotonated Cys270", "OBSERVATION", 214, 233]]], ["Turning to SARS-CoV PLpro, Fig. 4c shows that the BL2 movement is coupled to the protonation/deprotonation of the analogous Cys271.", [["SARS", "DISEASE", 11, 15], ["Cys271", "CHEMICAL", 124, 130], ["BL2", "SIMPLE_CHEMICAL", 50, 53], ["Cys271", "SIMPLE_CHEMICAL", 124, 130], ["BL2", "DNA", 50, 53], ["Cys271", "PROTEIN", 124, 130], ["SARS-CoV", "SPECIES", 11, 19], ["CoV PLpro", "TREATMENT", 16, 25], ["Fig. 4c", "TREATMENT", 27, 34], ["the BL2 movement", "PROBLEM", 46, 62]]], ["However, in SARS-CoV PLpro, it appears the BL2 with a deprotonated Cys270 can sample a wider range of 10-20 \u00c5 as compared to SARS-CoV-2 PLpro, although the peak remains around 16 \u00c5.", [["SARS", "DISEASE", 12, 16], ["Cys270", "CHEMICAL", 67, 73], ["SARS-CoV PLpro", "ORGANISM", 12, 26], ["Cys270", "SIMPLE_CHEMICAL", 67, 73], ["BL2", "DNA", 43, 46], ["deprotonated Cys270", "PROTEIN", 54, 73], ["SARS-CoV", "SPECIES", 12, 20], ["SARS", "TEST", 125, 129], ["CoV", "TEST", 130, 133]]], ["The wider range of BL2 movement may be attributed to the somewhat weaker hydrogen bonds involving the deprotonated Cys271.", [["hydrogen", "CHEMICAL", 73, 81], ["Cys271", "CHEMICAL", 115, 121], ["BL2", "GENE_OR_GENE_PRODUCT", 19, 22], ["Cys271", "SIMPLE_CHEMICAL", 115, 121], ["the somewhat weaker hydrogen bonds", "PROBLEM", 53, 87], ["hydrogen bonds", "OBSERVATION", 73, 87]]], ["The movement of the BL2 loop is very similar between SARS-CoV and SARS-CoV-2 PLpros when Cys270 is protonated.III. RESULTS AND DISCUSSIONc.", [["SARS", "DISEASE", 53, 57], ["SARS", "DISEASE", 66, 70], ["Cys270", "CHEMICAL", 89, 95], ["Cys270", "CHEMICAL", 89, 95], ["BL2", "GENE_OR_GENE_PRODUCT", 20, 23], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 53, 61], ["Cys270", "SIMPLE_CHEMICAL", 89, 95], ["BL2 loop", "PROTEIN", 20, 28], ["SARS-CoV", "SPECIES", 53, 61], ["SARS", "TEST", 53, 57], ["SARS", "PROBLEM", 66, 70], ["CoV", "TEST", 71, 74], ["movement", "OBSERVATION_MODIFIER", 4, 12]]], ["Comparison of the BL2 conformation across the three PLpros.", [["BL2", "DNA", 18, 21], ["PLpros", "PROTEIN", 52, 58]]], ["For broad-spectrum inhibitor design, it is important to understand the difference in the BL2 conformation across the three PLpros.", [["BL2", "PROTEIN", 89, 92], ["PLpros", "PROTEIN", 123, 129], ["broad-spectrum inhibitor design", "TREATMENT", 4, 35]]], ["The distributions of the Tyr269/268-Asp165/164 distance for SARS-CoV/CoV-2 and the equiva- lent Thr274-Asp164 distance for MERS-CoV PLpro at physiological pH (Fig. 5a and Fig. 4d) show that the widest position of the BL2 loop is about the same across the three PLpros; however, the BL2 in SARS-CoV-2 PLpro samples the narrowest range, followed by SARS-CoV PLpro and MERS-CoV PLpro which samples the widest range between 5-22 \u00c5.", [["Asp", "CHEMICAL", 103, 106], ["Tyr269/268", "GENE_OR_GENE_PRODUCT", 25, 35], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 60, 68], ["CoV-2", "GENE_OR_GENE_PRODUCT", 69, 74], ["MERS-CoV PLpro", "GENE_OR_GENE_PRODUCT", 123, 137], ["BL2", "GENE_OR_GENE_PRODUCT", 217, 220], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 347, 355], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 366, 374], ["Tyr269/268", "DNA", 25, 35], ["SARS-CoV/CoV-2", "DNA", 60, 74], ["MERS-CoV PLpro", "DNA", 123, 137], ["BL2 loop", "PROTEIN", 217, 225], ["PLpros", "PROTEIN", 261, 267], ["BL2", "DNA", 282, 285], ["MERS", "PROTEIN", 366, 370], ["CoV PLpro", "PROTEIN", 371, 380], ["SARS-CoV", "SPECIES", 60, 68], ["MERS-CoV", "SPECIES", 123, 131], ["SARS-CoV", "SPECIES", 289, 297], ["SARS-CoV", "SPECIES", 347, 355], ["MERS-CoV", "SPECIES", 366, 374], ["the Tyr269/268", "TEST", 21, 35], ["SARS", "TEST", 60, 64], ["CoV", "TEST", 65, 68], ["CoV", "TEST", 69, 72], ["the equiva", "TEST", 79, 89], ["MERS", "TEST", 123, 127], ["CoV PLpro at physiological pH", "TEST", 128, 157], ["the BL2 loop", "TEST", 213, 225], ["the BL2", "TEST", 278, 285], ["SARS", "TEST", 289, 293], ["CoV", "TEST", 294, 297], ["CoV PLpro", "TREATMENT", 371, 380]]], ["The enhanced flexibility of the BL2 in MERS-CoV PLpro may be attributed to the lack of a Cys equivalent to Cys271/270 in SARS-CoV/CoV-2 PLpro which can form hydrogen bonds with neighboring residues to restrict the loop motion and perhaps also the loosening of the nearby catalytic His which no longer forms double hydrogen bonds as in SARS-CoV/CoV-2 PLpro.III. RESULTS AND DISCUSSIONIn agreement with the BL2 dynamics described with the protonated and deprotonated states of Cys270 (Fig. 4c) and the X-ray structures determined at pH 7.5 (PDB 6W9C) and pH 4.5 (PDB 6WRH), a significant pH dependence is observed with the BL2 dynamics in the simulations of SARS-CoV-2 PLpro (Fig. 5) .", [["SARS", "DISEASE", 656, 660], ["Cys", "CHEMICAL", 89, 92], ["hydrogen", "CHEMICAL", 157, 165], ["His", "CHEMICAL", 281, 284], ["hydrogen", "CHEMICAL", 314, 322], ["Cys270", "CHEMICAL", 475, 481], ["BL2", "GENE_OR_GENE_PRODUCT", 32, 35], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 39, 47], ["Cys271/270", "SIMPLE_CHEMICAL", 107, 117], ["SARS-CoV", "ORGANISM", 121, 129], ["CoV-2 PLpro", "SIMPLE_CHEMICAL", 130, 141], ["hydrogen bonds", "SIMPLE_CHEMICAL", 157, 171], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 335, 343], ["CoV-2 PLpro", "SIMPLE_CHEMICAL", 344, 355], ["Cys270", "SIMPLE_CHEMICAL", 475, 481], ["BL2", "SIMPLE_CHEMICAL", 621, 624], ["BL2", "DNA", 32, 35], ["Cys271/270", "PROTEIN", 107, 117], ["PLpro", "PROTEIN", 350, 355], ["MERS-CoV", "SPECIES", 39, 47], ["SARS-CoV", "SPECIES", 335, 343], ["a Cys", "TEST", 87, 92], ["SARS", "TEST", 121, 125], ["CoV/CoV-2 PLpro", "TREATMENT", 126, 141], ["hydrogen bonds", "PROBLEM", 157, 171], ["neighboring residues", "PROBLEM", 177, 197], ["the loop motion", "TREATMENT", 210, 225], ["the loosening", "PROBLEM", 243, 256], ["double hydrogen bonds", "PROBLEM", 307, 328], ["SARS", "PROBLEM", 335, 339], ["CoV", "TEST", 344, 347], ["PLpro", "TREATMENT", 350, 355], ["the X-ray structures", "TEST", 496, 516], ["pH", "TEST", 531, 533], ["PDB", "TEST", 539, 542], ["pH", "TEST", 553, 555], ["PDB 6WRH", "TEST", 561, 569], ["a significant pH dependence", "PROBLEM", 572, 599], ["the BL2 dynamics", "PROBLEM", 617, 633], ["SARS", "TEST", 656, 660], ["CoV", "TEST", 661, 664], ["flexibility", "OBSERVATION_MODIFIER", 13, 24], ["hydrogen bonds", "OBSERVATION", 157, 171], ["loop motion", "OBSERVATION", 214, 225], ["loosening", "OBSERVATION", 247, 256], ["no longer", "UNCERTAINTY", 291, 300], ["hydrogen bonds", "OBSERVATION", 314, 328], ["significant", "OBSERVATION_MODIFIER", 574, 585], ["pH dependence", "OBSERVATION", 586, 599]]], ["In the simulation at pH 7.5, the BL2 loop samples a state that leaves the S3/S4 subpocket more open, similar to the neutral pH crystal structure (Fig. 5c ).", [["S3", "PROTEIN", 74, 76], ["S4 subpocket", "PROTEIN", 77, 89], ["pH", "TEST", 21, 23], ["the BL2 loop samples", "TEST", 29, 49], ["S3", "ANATOMY", 74, 76], ["S4", "ANATOMY", 77, 79], ["neutral pH", "OBSERVATION_MODIFIER", 116, 126], ["crystal structure", "OBSERVATION", 127, 144]]], ["In the simulation at pH 4.5, the BL2 loop assumes a wide range of dynamics, allowing it to sample a state that leaves the S3/4 subpocket more closed, similar to the low pH crystal structure (Fig. 5c) .III. RESULTS AND DISCUSSIONd.", [["BL2 loop", "PROTEIN", 33, 41], ["S3", "PROTEIN", 122, 124], ["pH", "TEST", 21, 23], ["the BL2 loop", "TEST", 29, 41], ["the low pH crystal structure", "PROBLEM", 161, 189], ["wide", "OBSERVATION_MODIFIER", 52, 56], ["S3", "ANATOMY", 122, 124], ["low pH", "OBSERVATION_MODIFIER", 165, 171]]], ["The Ubl domain contains an Asp with a highly upshifted pK a .", [["Asp", "CHEMICAL", 27, 30], ["Asp", "AMINO_ACID", 27, 30], ["Ubl domain", "PROTEIN", 4, 14], ["an Asp", "PROBLEM", 24, 30], ["Ubl domain", "OBSERVATION", 4, 14], ["Asp", "OBSERVATION", 27, 30]]], ["As expected, nearly all Asp/Glu residues adopt standard protonation states (i.e. charged) at physiological pH; however, Asp12 in SARS-CoV-2 PLpro has a pK a abnormally upshifted from its model pK a of 4.0 to 6.7 (Table I) , making it possible to occasionally sample the protonated state at pH 7.4.", [["Asp", "CHEMICAL", 24, 27], ["Glu", "CHEMICAL", 28, 31], ["Asp12", "CHEMICAL", 120, 125], ["SARS", "DISEASE", 129, 133], ["Asp", "CHEMICAL", 24, 27], ["Glu", "CHEMICAL", 28, 31], ["Asp12", "CHEMICAL", 120, 125], ["Glu", "AMINO_ACID", 28, 31], ["Asp12", "SIMPLE_CHEMICAL", 120, 125], ["Asp12", "PROTEIN", 120, 125], ["Asp12", "TEST", 120, 125], ["SARS", "TEST", 129, 133], ["CoV", "TEST", 134, 137], ["a pK", "TEST", 150, 154], ["pH", "TEST", 290, 292]]], ["Trajectory analysis suggested that this upshift is in part due to the protonated Asp12 acting as a hydrogen bond donor to either (deprotonated) Glu67 or Asn15 (Fig. 6a and c) , which stabilizes the protonated state.", [["Asp12", "CHEMICAL", 81, 86], ["Glu67", "CHEMICAL", 144, 149], ["Asn15", "CHEMICAL", 153, 158], ["Asp12", "CHEMICAL", 81, 86], ["hydrogen", "CHEMICAL", 99, 107], ["Glu67", "CHEMICAL", 144, 149], ["Asn15", "CHEMICAL", 153, 158], ["Asp12", "SIMPLE_CHEMICAL", 81, 86], ["(deprotonated) Glu67", "SIMPLE_CHEMICAL", 129, 149], ["Asn15", "SIMPLE_CHEMICAL", 153, 158], ["Trajectory analysis", "TEST", 0, 19], ["the protonated Asp12", "TREATMENT", 66, 86], ["a hydrogen bond donor", "TREATMENT", 97, 118], ["protonated state", "OBSERVATION", 198, 214]]], ["The two hydrogen bonds are mutually exclusive such that Asp12 is a hydrogen bond donor 82-96% of the time when it is in the protonated state (Fig. 6a) .", [["Asp12", "CHEMICAL", 56, 61], ["hydrogen", "CHEMICAL", 8, 16], ["Asp12", "CHEMICAL", 56, 61], ["hydrogen", "CHEMICAL", 67, 75], ["Asp12", "SIMPLE_CHEMICAL", 56, 61], ["a hydrogen bond donor", "TEST", 65, 86], ["hydrogen bonds", "OBSERVATION", 8, 22]]], ["In addition to hydrogen bonding, Asp12 is buried in a hydrophobic pocket with a very low solvent accessible surface area, which increases as Asp12 becomes deprotonated at higher pH (Fig. 6b) .", [["surface area", "ANATOMY", 108, 120], ["Asp12", "CHEMICAL", 33, 38], ["Asp12", "CHEMICAL", 141, 146], ["hydrogen", "CHEMICAL", 15, 23], ["Asp12", "CHEMICAL", 33, 38], ["Asp12", "CHEMICAL", 141, 146], ["hydrogen", "SIMPLE_CHEMICAL", 15, 23], ["Asp12", "SIMPLE_CHEMICAL", 33, 38], ["Asp12", "SIMPLE_CHEMICAL", 141, 146], ["Asp12", "PROTEIN", 141, 146], ["hydrogen bonding", "TREATMENT", 15, 31], ["Asp12", "TREATMENT", 33, 38], ["a hydrophobic pocket", "PROBLEM", 52, 72], ["a very low solvent accessible surface area", "PROBLEM", 78, 120], ["hydrogen bonding", "OBSERVATION", 15, 31], ["hydrophobic pocket", "OBSERVATION", 54, 72], ["very", "OBSERVATION_MODIFIER", 80, 84], ["low solvent", "OBSERVATION_MODIFIER", 85, 96], ["accessible", "OBSERVATION_MODIFIER", 97, 107], ["surface", "OBSERVATION_MODIFIER", 108, 115], ["increases", "OBSERVATION_MODIFIER", 128, 137], ["deprotonated", "OBSERVATION_MODIFIER", 155, 167]]], ["In SARS-CoV PLpro, the analogous Asp13 experiences a similar degree of hydrogen bonding and solvent sequestration, resulting in a upshifted pK a of 5.9.", [["SARS", "DISEASE", 3, 7], ["Asp13", "CHEMICAL", 33, 38], ["Asp13", "CHEMICAL", 33, 38], ["hydrogen", "CHEMICAL", 71, 79], ["SARS-CoV PLpro", "ORGANISM", 3, 17], ["Asp13", "SIMPLE_CHEMICAL", 33, 38], ["hydrogen", "SIMPLE_CHEMICAL", 71, 79], ["SARS-CoV", "SPECIES", 3, 11], ["CoV PLpro", "TREATMENT", 8, 17], ["hydrogen bonding and solvent sequestration", "PROBLEM", 71, 113], ["a upshifted pK a", "TEST", 128, 144], ["hydrogen bonding", "OBSERVATION", 71, 87], ["solvent sequestration", "OBSERVATION", 92, 113]]], ["In MERS-CoV PLpro, the analogous Asp11 primarily donates a hydrogen bond to Asn15, as the analogous residue to Glu67 is missing (see supplementary material).", [["Asp11", "CHEMICAL", 33, 38], ["Asn15", "CHEMICAL", 76, 81], ["Glu67", "CHEMICAL", 111, 116], ["Asp11", "CHEMICAL", 33, 38], ["hydrogen", "CHEMICAL", 59, 67], ["Asn15", "CHEMICAL", 76, 81], ["Glu67", "CHEMICAL", 111, 116], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 3, 11], ["Asp11", "GENE_OR_GENE_PRODUCT", 33, 38], ["Asn15", "SIMPLE_CHEMICAL", 76, 81], ["Glu67", "SIMPLE_CHEMICAL", 111, 116], ["Asp11", "PROTEIN", 33, 38], ["Asn15", "PROTEIN", 76, 81], ["Glu67", "PROTEIN", 111, 116], ["MERS-CoV", "SPECIES", 3, 11], ["CoV PLpro", "TREATMENT", 8, 17], ["the analogous Asp11", "TREATMENT", 19, 38], ["a hydrogen bond", "TREATMENT", 57, 72], ["the analogous residue", "PROBLEM", 86, 107]]], ["Compared to Asp12/13 in SARS-CoV-2/CoV PLpro, Asp11 is more solvent exposed in the lower pH range (see supplementary material), which may contribute to a smaller degree of pK a upshift of Asp11 in MERS-CoV PLpro as compared to SARS-CoV/CoV-2 PLpro. e.", [["Asp12/13", "GENE_OR_GENE_PRODUCT", 12, 20], ["SARS-CoV-2", "ORGANISM", 24, 34], ["CoV PLpro", "ORGANISM", 35, 44], ["Asp11", "GENE_OR_GENE_PRODUCT", 46, 51], ["Asp11", "GENE_OR_GENE_PRODUCT", 188, 193], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 197, 205], ["SARS-CoV", "ORGANISM", 227, 235], ["CoV-2 PLpro", "ORGANISM", 236, 247], ["Asp12/13", "DNA", 12, 20], ["Asp11", "DNA", 46, 51], ["Asp11", "PROTEIN", 188, 193], ["SARS-CoV", "SPECIES", 24, 32], ["MERS-CoV", "SPECIES", 197, 205], ["SARS-CoV", "SPECIES", 227, 235], ["Asp12/13", "TEST", 12, 20], ["SARS", "TEST", 24, 28], ["CoV", "TEST", 29, 32], ["CoV PLpro", "TEST", 35, 44], ["Asp11", "TEST", 46, 51], ["Asp11 in MERS", "PROBLEM", 188, 201], ["CoV PLpro", "TREATMENT", 202, 211], ["SARS", "TEST", 227, 231], ["CoV", "TEST", 232, 235], ["CoV", "TEST", 236, 239], ["PLpro", "TREATMENT", 242, 247], ["lower", "ANATOMY_MODIFIER", 83, 88], ["smaller degree", "OBSERVATION_MODIFIER", 154, 168]]], ["Histidines that can switch protonation states at physiological pH.", [["Histidines", "CHEMICAL", 0, 10], ["Histidines", "CHEMICAL", 0, 10], ["Histidines", "SIMPLE_CHEMICAL", 0, 10], ["Histidines", "TREATMENT", 0, 10]]], ["CpHMD titrations revealed that three histidines unique to SARS-CoV/CoV-2, H74/73, H90/89, and H176/175 (Fig. 7) , have pK a 's around 7 (Table I) and can sample both protonated and deprotonated states at physiological pH.", [["histidines", "CHEMICAL", 37, 47], ["H176/175", "CHEMICAL", 94, 102], ["CpHMD", "SIMPLE_CHEMICAL", 0, 5], ["SARS-CoV", "ORGANISM", 58, 66], ["CoV-2", "ORGANISM", 67, 72], ["H74/73", "GENE_OR_GENE_PRODUCT", 74, 80], ["SARS-CoV", "SPECIES", 58, 66], ["CpHMD titrations", "TEST", 0, 16], ["SARS", "TEST", 58, 62], ["CoV", "TEST", 63, 66], ["CoV", "TEST", 67, 70], ["Fig.", "TEST", 104, 108], ["pK a 's", "TEST", 119, 126]]], ["His74/73 located on the C-terminal end of \u03b12 in SARS-CoV/CoV-2 has a pK a of 7.3/7.3.", [["C", "CHEMICAL", 24, 25], ["His74/73", "GENE_OR_GENE_PRODUCT", 0, 8], ["\u03b12", "GENE_OR_GENE_PRODUCT", 42, 44], ["SARS-CoV", "ORGANISM", 48, 56], ["CoV-2", "GENE_OR_GENE_PRODUCT", 57, 62], ["His74/73", "DNA", 0, 8], ["C-terminal end", "DNA", 24, 38], ["\u03b12", "PROTEIN", 42, 44], ["SARS-CoV", "SPECIES", 48, 56], ["the C", "TEST", 20, 25], ["SARS", "TEST", 48, 52], ["CoV/CoV", "TEST", 53, 60], ["a pK a", "TEST", 67, 73], ["terminal", "ANATOMY_MODIFIER", 26, 34]]], ["Analysis suggested that the pK a upshift relative to the model value of 6.5 is due to the formation of hydrogen bonds with Phe70/69, Asn129/128 .", [["hydrogen", "CHEMICAL", 103, 111], ["Phe70/69", "CHEMICAL", 123, 131], ["Asn129/128", "CHEMICAL", 133, 143], ["Phe70/69", "SIMPLE_CHEMICAL", 123, 131], ["Asn129/128", "SIMPLE_CHEMICAL", 133, 143], ["Analysis", "TEST", 0, 8], ["the model value", "TEST", 53, 68], ["hydrogen bonds", "OBSERVATION", 103, 117]]], ["CC-BY-ND 4.0 International license was not certified by peer review) is the author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["It is made available under a The copyright holder for this preprint (which this version posted July 1, 2020. . https://doi.org/10.1101/2020.06.30.181305 doi: bioRxiv preprint or a salt bridge with Glu71/70 (see supplementary material), which stabilizes the charged state.", [["Glu71/70", "CHEMICAL", 197, 205], ["Glu71/70", "CHEMICAL", 197, 205], ["Glu71/70", "SIMPLE_CHEMICAL", 197, 205], ["bioRxiv preprint", "TREATMENT", 158, 174], ["a salt bridge", "TREATMENT", 178, 191], ["Glu71", "TREATMENT", 197, 202]]], ["His90/89 located on the Cterminal end of \u03b13 in SARS-CoV/CoV-2 has a pK a of 7.0/6.9.", [["SARS", "DISEASE", 47, 51], ["His90/89", "GENE_OR_GENE_PRODUCT", 0, 8], ["\u03b13", "GENE_OR_GENE_PRODUCT", 41, 43], ["SARS-CoV", "ORGANISM", 47, 55], ["CoV-2", "GENE_OR_GENE_PRODUCT", 56, 61], ["His90/89", "DNA", 0, 8], ["Cterminal end", "DNA", 24, 37], ["\u03b13", "DNA", 41, 43], ["SARS-CoV", "SPECIES", 47, 55], ["CoV/CoV", "TEST", 52, 59], ["a pK a", "TEST", 66, 72]]], ["Analysis showed that a small pK a upshift relative to the model pK a is due to the stabilization of the charged state by the occasional hydrogen bonding with the backbone carbonyl of Ser86/85 or transient salt-bridge interaction with Asp107/108 located near the oxyanion hole of the CoV PLpro (see supplementary material).", [["Ser86/85", "CHEMICAL", 183, 191], ["Asp107/108", "CHEMICAL", 234, 244], ["hydrogen", "CHEMICAL", 136, 144], ["carbonyl", "CHEMICAL", 171, 179], ["Ser86/85", "CHEMICAL", 183, 191], ["Asp107/108", "CHEMICAL", 234, 244], ["Ser86/85", "SIMPLE_CHEMICAL", 183, 191], ["Asp107/108", "SIMPLE_CHEMICAL", 234, 244], ["Asp107/108", "PROTEIN", 234, 244], ["CoV PLpro", "PROTEIN", 283, 292], ["Analysis", "TEST", 0, 8], ["a small pK a upshift", "PROBLEM", 21, 41], ["the occasional hydrogen bonding", "TREATMENT", 121, 152], ["the backbone carbonyl", "TREATMENT", 158, 179], ["transient salt-bridge interaction", "PROBLEM", 195, 228], ["Asp107/108", "TREATMENT", 234, 244], ["the CoV PLpro", "TREATMENT", 279, 292], ["small", "OBSERVATION_MODIFIER", 23, 28], ["pK", "OBSERVATION", 29, 31]]], ["His176/175 is located on the C-terminal end of \u03b17 and opposite to His74/73.", [["C", "CHEMICAL", 29, 30], ["His176/175", "GENE_OR_GENE_PRODUCT", 0, 10], ["\u03b17", "GENE_OR_GENE_PRODUCT", 47, 49], ["His74/73", "GENE_OR_GENE_PRODUCT", 66, 74], ["C-terminal end", "DNA", 29, 43], ["\u03b17", "PROTEIN", 47, 49], ["His74/73", "DNA", 66, 74]]], ["The increased pK a of 7.4/7.3 can also be attributed to local hydrogen bonding, either with His172 in SARS-CoV-1 or Tyr171 in SARS-CoV-2 PLpro (see supplementary material). f.", [["His172", "CHEMICAL", 92, 98], ["SARS-CoV-2 PLpro", "CHEMICAL", 126, 142], ["hydrogen", "CHEMICAL", 62, 70], ["His", "CHEMICAL", 92, 95], ["hydrogen", "SIMPLE_CHEMICAL", 62, 70], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 102, 112], ["Tyr171", "AMINO_ACID", 116, 122], ["f.", "SPECIES", 173, 175], ["The increased pK a", "TEST", 0, 18], ["local hydrogen bonding", "PROBLEM", 56, 78], ["SARS", "TEST", 102, 106], ["CoV", "TEST", 107, 110], ["SARS", "TEST", 126, 130], ["CoV", "TEST", 131, 134], ["PLpro", "TREATMENT", 137, 142], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["hydrogen bonding", "OBSERVATION", 62, 78]]], ["All-atom fixed-charge MD of SARS-CoV-2 PLpro.", [["SARS", "PROBLEM", 28, 32], ["PLpro", "TREATMENT", 39, 44]]], ["To provide support for the protonation states determined by GB-CpHMD titrations and test the proton-coupled dynamics of the BL2 loop, we performed conventional all-atom fixedcharge MD simulations of SARS-CoV-2 PLpro with the catalytic sidechains fixed in the charged states and Cys270 fixed in the protonated or deprotonated state.", [["SARS", "DISEASE", 199, 203], ["Cys270", "CHEMICAL", 278, 284], ["Cys270", "CHEMICAL", 278, 284], ["2 PLpro", "SIMPLE_CHEMICAL", 208, 215], ["Cys270", "SIMPLE_CHEMICAL", 278, 284], ["BL2 loop", "PROTEIN", 124, 132], ["SARS", "TEST", 199, 203], ["CoV", "TEST", 204, 207], ["the catalytic sidechains", "TREATMENT", 221, 245]]], ["All other residues were fixed in the standard protonation states.", [["All other residues", "PROBLEM", 0, 18], ["residues", "OBSERVATION", 10, 18]]], ["Two 1-\u00b5s trajectories were obtained with each Cys270 protonation state.", [["Cys270", "CHEMICAL", 46, 52]]], ["Consistent with the GB-CpHMD simulations at physiological pH, the catalytic triad remained very stable, with the hydrogen bond between His272 and Cys111 being the strongest, followed by the His272\u00b7 \u00b7 \u00b7Asp286 and Cys111\u00b7 \u00b7 \u00b7Trp106 hydrogen bonds, as shown in the hydrogen bond occupancy plots (Fig. 8a) .", [["His272", "CHEMICAL", 135, 141], ["Cys111", "CHEMICAL", 146, 152], ["hydrogen", "CHEMICAL", 113, 121], ["His272", "CHEMICAL", 135, 141], ["Cys", "CHEMICAL", 146, 149], ["His272", "CHEMICAL", 190, 196], ["Asp286", "CHEMICAL", 201, 207], ["Cys111", "CHEMICAL", 212, 218], ["Trp106", "CHEMICAL", 223, 229], ["hydrogen", "CHEMICAL", 230, 238], ["hydrogen", "CHEMICAL", 262, 270], ["His272", "SIMPLE_CHEMICAL", 135, 141], ["Cys111", "AMINO_ACID", 146, 152], ["Asp286", "GENE_OR_GENE_PRODUCT", 201, 207], ["Cys111\u00b7 \u00b7 \u00b7Trp106", "SIMPLE_CHEMICAL", 212, 229], ["the catalytic triad", "TEST", 62, 81], ["the hydrogen bond", "TEST", 109, 126], ["Cys", "TEST", 146, 149], ["very", "OBSERVATION_MODIFIER", 91, 95], ["stable", "OBSERVATION", 96, 102]]], ["Interestingly, while the effect of Cys270 protonation/deprotonation appears negligible for the latter two hydrogen bonds (occupancy change is below 5%) , protonation of Cys270 weakens the His272\u00b7 \u00b7 \u00b7Cys111 hydrogen bond (occupancy decreases by over 20%).", [["Cys270", "CHEMICAL", 35, 41], ["Cys270", "CHEMICAL", 169, 175], ["Cys270", "CHEMICAL", 35, 41], ["hydrogen", "CHEMICAL", 106, 114], ["Cys270", "CHEMICAL", 169, 175], ["His272", "CHEMICAL", 188, 194], ["Cys", "CHEMICAL", 199, 202], ["hydrogen", "CHEMICAL", 206, 214], ["Cys270", "SIMPLE_CHEMICAL", 35, 41], ["Cys270", "SIMPLE_CHEMICAL", 169, 175], ["His272", "PROTEIN", 188, 194], ["Cys270 protonation/deprotonation", "TREATMENT", 35, 67], ["the latter two hydrogen bonds (occupancy change", "PROBLEM", 91, 138], ["hydrogen bonds", "OBSERVATION", 106, 120]]], ["This decrease is consistent with the GB-CpHMD data, which shows that the catalytic His\u00b7 \u00b7 \u00b7Cys hydrogen bond is significantly weakened below pH 6 as Cys270 becomes fully protonated in SARS-CoV-2 PLpro (Fig. 2a) .III. RESULTS AND DISCUSSIONTo test the effect of Cys270 titration on the BL2 conformation, we calculated the probability distribution of the C\u03b1 distance between Tyr268 and Asp164.", [["Asp164", "CHEMICAL", 384, 390], ["His\u00b7", "CHEMICAL", 83, 87], ["Cys", "CHEMICAL", 91, 94], ["hydrogen", "CHEMICAL", 95, 103], ["Cys270", "CHEMICAL", 149, 155], ["Cys270", "CHEMICAL", 261, 267], ["Tyr268", "CHEMICAL", 373, 379], ["Asp", "CHEMICAL", 384, 387], ["Cys270", "SIMPLE_CHEMICAL", 149, 155], ["Cys270", "SIMPLE_CHEMICAL", 261, 267], ["C\u03b1", "GENE_OR_GENE_PRODUCT", 353, 355], ["Tyr268", "SIMPLE_CHEMICAL", 373, 379], ["Asp164", "AMINO_ACID", 384, 390], ["BL2", "DNA", 285, 288], ["the catalytic His\u00b7", "TEST", 69, 87], ["Cys hydrogen bond", "TEST", 91, 108], ["significantly weakened", "PROBLEM", 112, 134], ["pH", "TEST", 141, 143], ["SARS", "TEST", 184, 188], ["CoV", "TEST", 189, 192], ["Cys270 titration", "TREATMENT", 261, 277], ["Asp", "TEST", 384, 387], ["consistent with", "UNCERTAINTY", 17, 32]]], ["For the trajectories with protonated Cys270, the distribution displays a single peak at about 11 \u00c5; however, for the trajectories with deprotonated Cys270, a second peak appears at about 17 \u00c5 (Fig. 8b) .", [["Cys270", "CHEMICAL", 37, 43], ["Cys270", "CHEMICAL", 148, 154], ["Cys270", "SIMPLE_CHEMICAL", 37, 43], ["Cys270", "SIMPLE_CHEMICAL", 148, 154], ["Cys270", "PROTEIN", 148, 154], ["a second peak", "TEST", 156, 169]]], ["This data indicates that deprotonated Cys270 is correlated with the more open BL2 loop conformations, consistent with the findings from the GB-CpHMD simulations (Fig. 4c) Occupancies of the His272\u00b7 \u00b7 \u00b7Asp286, His272\u00b7 \u00b7 \u00b7Cys111, and Cys111\u00b7 \u00b7 \u00b7Trp106 hydrogen bonds from the simulations with Cys270 fixed in the protonated (orange) or deprotonated (red) state.", [["Cys270", "CHEMICAL", 38, 44], ["Cys270", "CHEMICAL", 291, 297], ["Cys270", "CHEMICAL", 38, 44], ["His272", "CHEMICAL", 190, 196], ["Asp", "CHEMICAL", 201, 204], ["His272", "CHEMICAL", 209, 215], ["Cys", "CHEMICAL", 220, 223], ["Cys", "CHEMICAL", 232, 235], ["Trp106", "CHEMICAL", 243, 249], ["hydrogen", "CHEMICAL", 250, 258], ["Cys270", "CHEMICAL", 291, 297], ["Cys270", "SIMPLE_CHEMICAL", 38, 44], ["\u00b7 \u00b7Asp286", "SIMPLE_CHEMICAL", 198, 207], ["His272\u00b7 \u00b7 \u00b7Cys111", "AMINO_ACID", 209, 226], ["Cys111\u00b7 \u00b7 \u00b7Trp106 hydrogen bonds", "SIMPLE_CHEMICAL", 232, 264], ["Cys270", "SIMPLE_CHEMICAL", 291, 297], ["BL2", "PROTEIN", 78, 81], ["His272", "PROTEIN", 190, 196], ["This data", "TEST", 0, 9], ["the more open BL2 loop conformations", "PROBLEM", 64, 100], ["the GB", "TEST", 136, 142], ["Asp", "TEST", 201, 204], ["His272", "TEST", 209, 215], ["Cys", "TEST", 220, 223], ["Cys", "TEST", 232, 235], ["\u00b7", "TEST", 240, 241], ["hydrogen bonds", "TEST", 250, 264], ["the simulations", "TEST", 270, 285], ["Cys270", "TEST", 291, 297], ["consistent with", "UNCERTAINTY", 102, 117], ["GB", "ANATOMY", 140, 142]]], ["The calculations combined the data from two independent 1-\u00b5s trajectories.", [["The calculations", "TEST", 0, 16], ["the data", "TEST", 26, 34]]], ["The first 300 ns data were discarded. b) Probability distribution of the C\u03b1 distance between Tyr268 and Asp164 from the simulations with Cys270 fixed in the protonated (orange) or deprotonated (red) state.CONCLUDING DISCUSSIONThe protonation states and possible proton-coupled conformational dynamics of SARS-CoV-2 PLpro were investigated in comparison to SARS-CoV and MERS-CoV PLpros, using the GPU-accelerated GBNeck2-CpHMD titration simulations with a new asynchronous pH replica-exchange scheme as well as conventional all-atom MD.", [["Asp164", "CHEMICAL", 104, 110], ["Cys270", "CHEMICAL", 137, 143], ["Tyr268", "CHEMICAL", 93, 99], ["Asp", "CHEMICAL", 104, 107], ["Cys270", "CHEMICAL", 137, 143], ["Asp164", "AMINO_ACID", 104, 110], ["MERS-CoV PLpros", "SIMPLE_CHEMICAL", 369, 384], ["GBNeck2", "SIMPLE_CHEMICAL", 412, 419], ["GBNeck2", "PROTEIN", 412, 419], ["SARS-CoV", "SPECIES", 356, 364], ["MERS-CoV", "SPECIES", 369, 377], ["the C\u03b1 distance", "TEST", 69, 84], ["Asp", "TEST", 104, 107], ["deprotonated (red) state", "PROBLEM", 180, 204], ["proton", "TREATMENT", 262, 268], ["SARS", "PROBLEM", 304, 308], ["CoV", "TEST", 309, 312], ["PLpro", "TREATMENT", 315, 320], ["SARS", "TEST", 356, 360], ["CoV PLpros", "TREATMENT", 374, 384], ["the GPU", "TEST", 392, 399], ["accelerated GBNeck2", "TREATMENT", 400, 419], ["CpHMD titration simulations", "TREATMENT", 420, 447], ["a new asynchronous pH replica", "TREATMENT", 453, 482], ["distribution", "OBSERVATION_MODIFIER", 53, 65]]], ["The simulations showed that the catalytic Cys, His, and Asp are charged in the entire simulation pH range of 4.5-8.5 for all three PLpros, which supports the mechanism in which the reactive nucleophile is the thiolate ion and the catalytic His serves as a general acid stabilized by the catalytic aspartate.", [["Cys", "CHEMICAL", 42, 45], ["Asp", "CHEMICAL", 56, 59], ["PLpros", "CHEMICAL", 131, 137], ["aspartate", "CHEMICAL", 297, 306], ["Cys", "CHEMICAL", 42, 45], ["His", "CHEMICAL", 47, 50], ["Asp", "CHEMICAL", 56, 59], ["PLpros", "CHEMICAL", 131, 137], ["thiolate", "CHEMICAL", 209, 217], ["His", "CHEMICAL", 240, 243], ["aspartate", "CHEMICAL", 297, 306], ["His", "SIMPLE_CHEMICAL", 47, 50], ["Asp", "AMINO_ACID", 56, 59], ["PLpros", "SIMPLE_CHEMICAL", 131, 137], ["aspartate", "SIMPLE_CHEMICAL", 297, 306], ["catalytic aspartate", "PROTEIN", 287, 306], ["The simulations", "TEST", 0, 15], ["the catalytic Cys", "TEST", 28, 45], ["Asp", "TEST", 56, 59], ["reactive nucleophile", "OBSERVATION", 181, 201]]], ["The catalytic triad in SARS-CoV-2/CoV PLpro forms a hydrogen bond network among themselves and with a nearby Trp which serves as an oxyanion hole residue to stabilize the tetrahedral intermediate developed in the peptide hydrolysis.", [["Trp", "CHEMICAL", 109, 112], ["hydrogen", "CHEMICAL", 52, 60], ["Trp", "CHEMICAL", 109, 112], ["CoV", "ORGANISM", 34, 37], ["Trp", "AMINO_ACID", 109, 112], ["CoV PLpro", "PROTEIN", 34, 43], ["The catalytic triad", "PROBLEM", 0, 19], ["SARS", "TEST", 23, 27], ["CoV", "TEST", 28, 31], ["a hydrogen bond network", "TREATMENT", 50, 73], ["an oxyanion hole residue", "TREATMENT", 129, 153], ["the tetrahedral intermediate", "PROBLEM", 167, 195], ["the peptide hydrolysis", "TREATMENT", 209, 231], ["oxyanion hole", "OBSERVATION", 132, 145], ["peptide hydrolysis", "OBSERVATION", 213, 231]]], ["In contrast, the hydrogen bond with Trp is missing and the hydrogen bond between the catalytic .", [["Trp", "CHEMICAL", 36, 39], ["hydrogen", "CHEMICAL", 17, 25], ["Trp", "CHEMICAL", 36, 39], ["hydrogen", "CHEMICAL", 59, 67], ["Trp", "AMINO_ACID", 36, 39], ["hydrogen bond", "OBSERVATION", 17, 30], ["hydrogen bond", "OBSERVATION", 59, 72], ["catalytic", "OBSERVATION_MODIFIER", 85, 94]]], ["CC-BY-ND 4.0 International license was not certified by peer review) is the author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["It is made available under a The copyright holder for this preprint (which this version posted July 1, 2020. . https://doi.org/10.1101/2020.06.30.181305 doi: bioRxiv preprint His and Asp is nearly abolished in MERS-CoV PLpro, consistent with the significantly lower catalytic activity compared to SARS-CoV PLpro 36 .", [["His", "CHEMICAL", 175, 178], ["Asp", "CHEMICAL", 183, 186], ["Asp", "AMINO_ACID", 183, 186], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 210, 218], ["MERS-CoV", "SPECIES", 210, 218], ["SARS-CoV", "SPECIES", 297, 305], ["bioRxiv", "TREATMENT", 158, 165], ["Asp", "TEST", 183, 186], ["the significantly lower catalytic activity", "PROBLEM", 242, 284], ["CoV PLpro", "TEST", 302, 311]]], ["Interestingly, the lack of a hydrogen bond network for the catalytic triad in MERS-CoV PLpro is correlated with increased mobility of nearby loop residues, particular the BL2 loop.CONCLUDING DISCUSSIONThe simulations revealed that several titratable residues have shifted pK a values such that they switch between two protonation states at physiological pH.", [["hydrogen", "CHEMICAL", 29, 37], ["hydrogen", "CHEMICAL", 29, 37], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 78, 86], ["catalytic triad", "PROTEIN", 59, 74], ["MERS-CoV PLpro", "PROTEIN", 78, 92], ["BL2 loop", "PROTEIN", 171, 179], ["a hydrogen bond network", "TREATMENT", 27, 50], ["the catalytic triad", "PROBLEM", 55, 74], ["CoV PLpro", "TREATMENT", 83, 92], ["increased mobility of nearby loop residues", "PROBLEM", 112, 154], ["The simulations", "TEST", 201, 216], ["several titratable residues", "PROBLEM", 231, 258], ["loop residues", "OBSERVATION", 141, 154], ["BL2 loop", "OBSERVATION", 171, 179]]], ["These include three His and one Cys residues unique to SARS-CoV-2/CoV and one Asp residue common to all three PLpros (Table I) .", [["His", "CHEMICAL", 20, 23], ["Cys", "CHEMICAL", 32, 35], ["Asp", "CHEMICAL", 78, 81], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 55, 65], ["CoV", "GENE_OR_GENE_PRODUCT", 66, 69], ["SARS-CoV-2/CoV", "PROTEIN", 55, 69], ["PLpros", "PROTEIN", 110, 116], ["Table I", "PROTEIN", 118, 125], ["SARS", "TEST", 55, 59], ["CoV", "TEST", 60, 63], ["CoV", "PROBLEM", 66, 69], ["one Asp residue", "PROBLEM", 74, 89]]], ["Of particular interest is Cys270/271 on the flexible BL2 loop of SARS-CoV-2/CoV, which has a pK a of 6.7/6.9 and samples both the standard thiol and charged thiolate forms at neutral pH.", [["thiol", "CHEMICAL", 139, 144], ["thiol", "CHEMICAL", 139, 144], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 65, 75], ["CoV", "ORGANISM", 76, 79], ["thiol", "SIMPLE_CHEMICAL", 139, 144], ["BL2 loop", "PROTEIN", 53, 61], ["SARS", "TEST", 65, 69], ["CoV", "TEST", 70, 73], ["a pK a", "TEST", 91, 97]]], ["CpHMD simulations showed that the BL2 loop samples an open or a closed conformational ensemble with deprotonated or protonated Cys270/271, respectively, consistent with two crystal structures of SARS-CoV-2 PLpro determined at neutral and low pH conditions and the conventional all-atom MD trajectories of SARS-CoV-2 PLpro with either deprotonated or protonated Cys270.", [["Cys270", "CHEMICAL", 361, 367], ["SARS-CoV-2 PLpro", "SIMPLE_CHEMICAL", 305, 321], ["protonated Cys270", "SIMPLE_CHEMICAL", 350, 367], ["CpHMD simulations", "TEST", 0, 17], ["the BL2 loop samples", "PROBLEM", 30, 50], ["two crystal structures of SARS", "PROBLEM", 169, 199], ["CoV", "TEST", 200, 203], ["low pH conditions", "PROBLEM", 238, 255], ["SARS", "TEST", 305, 309], ["CoV", "TEST", 310, 313], ["consistent with", "UNCERTAINTY", 153, 168], ["low pH", "OBSERVATION_MODIFIER", 238, 244]]], ["Thus, the simulation data and experiment together support our hypothesis that the BL2 loop conformation is coupled to the titration of C270/271 in SARS-CoV-2/CoV PLpro.CONCLUDING DISCUSSIONAn induced fit mechanism, by which BL2 closes in to form hydrogen bonds with the inhibitor, has been proposed in designing potent inhibitors targeting the S3/S4 pocket of SARS-CoV PLpro 4 .", [["SARS", "DISEASE", 360, 364], ["hydrogen", "CHEMICAL", 246, 254], ["BL2", "GENE_OR_GENE_PRODUCT", 82, 85], ["SARS-CoV PLpro 4", "GENE_OR_GENE_PRODUCT", 360, 376], ["BL2", "PROTEIN", 82, 85], ["BL2", "PROTEIN", 224, 227], ["S3/S4 pocket", "PROTEIN", 344, 356], ["SARS-CoV PLpro 4", "PROTEIN", 360, 376], ["CoV-2/CoV", "SPECIES", 152, 161], ["SARS-CoV", "SPECIES", 360, 368], ["the simulation data", "TEST", 6, 25], ["our hypothesis", "PROBLEM", 58, 72], ["the BL2 loop conformation", "PROBLEM", 78, 103], ["the titration", "TEST", 118, 131], ["CoV", "TEST", 152, 155], ["CoV PLpro", "TREATMENT", 158, 167], ["the inhibitor", "TREATMENT", 266, 279], ["potent inhibitors", "TREATMENT", 312, 329], ["the S3/S4 pocket", "PROBLEM", 340, 356], ["SARS", "PROBLEM", 360, 364], ["CoV PLpro", "TREATMENT", 365, 374], ["S4", "ANATOMY", 347, 349]]], ["Our finding suggests that in the absence of a ligand, protonation of C270/271 induces the closure of BL2 in SARS-CoV-2/CoV PLpro, which raises the possibility that a conformational selection mechanism may be operative, in which inhibitor binding shifts the BL2 conformational population to the closed form, perhaps by favoring the protonation of C270/271.", [["C270/271", "CHEMICAL", 69, 77], ["C270/271", "CHEMICAL", 69, 77], ["C270/271", "CHEMICAL", 346, 354], ["C270/271", "SIMPLE_CHEMICAL", 69, 77], ["BL2", "GENE_OR_GENE_PRODUCT", 101, 104], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 108, 118], ["CoV", "ORGANISM", 119, 122], ["C270/271", "SIMPLE_CHEMICAL", 346, 354], ["BL2", "PROTEIN", 101, 104], ["CoV PLpro", "PROTEIN", 119, 128], ["BL2", "PROTEIN", 257, 260], ["the closure of BL2 in SARS", "TEST", 86, 112], ["CoV", "TEST", 113, 116], ["a conformational selection mechanism", "PROBLEM", 164, 200], ["the BL2 conformational population", "PROBLEM", 253, 286], ["closure", "OBSERVATION", 90, 97], ["raises the possibility", "UNCERTAINTY", 136, 158]]], ["While the unliganded crystal structures show that BL2 in MERS-CoV PLpro is more open than in SARS-CoV-2/CoV PLpro, CpHMD simulations suggest that BL2 has an increased flexibility in MERS-CoV PLpro and it can sample closed conformations.", [["BL2", "CHEMICAL", 146, 149], ["BL2", "SIMPLE_CHEMICAL", 50, 53], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 57, 65], ["CoV", "ORGANISM", 104, 107], ["BL2", "SIMPLE_CHEMICAL", 146, 149], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 182, 190], ["BL2", "PROTEIN", 50, 53], ["MERS-CoV PLpro", "PROTEIN", 57, 71], ["BL2", "PROTEIN", 146, 149], ["MERS-CoV", "SPECIES", 182, 190], ["the unliganded crystal structures", "TEST", 6, 39], ["BL2 in MERS", "PROBLEM", 50, 61], ["SARS", "TEST", 93, 97], ["CoV", "TEST", 98, 101], ["an increased flexibility in MERS", "PROBLEM", 154, 186], ["CoV PLpro", "TREATMENT", 187, 196], ["increased", "OBSERVATION_MODIFIER", 157, 166], ["flexibility", "OBSERVATION_MODIFIER", 167, 178]]], ["This finding challenges a current hypothesis, according to which SARS-CoV PLpro inhibitors do not bind to MERS-CoV PLpro due to the more open BL2 loop as a result of the sequence difference and one extra residue 24, 37 .", [["SARS", "DISEASE", 65, 69], ["SARS-CoV", "ORGANISM", 65, 73], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 106, 114], ["MERS-CoV PLpro", "PROTEIN", 106, 120], ["BL2 loop", "DNA", 142, 150], ["SARS-CoV", "SPECIES", 65, 73], ["MERS-CoV", "SPECIES", 106, 114], ["a current hypothesis", "PROBLEM", 24, 44], ["CoV PLpro inhibitors", "TREATMENT", 70, 90], ["CoV PLpro", "TREATMENT", 111, 120], ["the more open BL2 loop", "PROBLEM", 128, 150]]], ["A main caveat of our work is the use of the GB-Neck2 implicit-solvent model 27 .", [["main", "OBSERVATION_MODIFIER", 2, 6], ["caveat", "OBSERVATION", 7, 13], ["GB", "ANATOMY", 44, 46]]], ["Although it has been demonstrated in the accurate de novo folding simulations of nearly two dozen small proteins with \u03b1 and \u03b2 topologies 38 , inherent issues such as the lack of solvent granularity may limit the accuracy of detailed conformational representation.", [["dozen small proteins", "PROTEIN", 92, 112], ["\u03b1", "PROTEIN", 118, 119], ["inherent issues", "PROBLEM", 142, 157], ["solvent granularity", "PROBLEM", 178, 197], ["solvent granularity", "OBSERVATION", 178, 197]]], ["Nonetheless, our work provides a starting point for further mechanistic investigations using higher-level approaches such as the all-atom CpHMD 39 and more extensive conformational sampling to assist the structure-based drug design targeting the coronavirus PLpros.SUPPLEMENTARY MATERIALSee supplemental material for convergence analysis, a list of pK a estimates for all titratable residues, and additional hy-drogen bond analysis.ACKNOWLEDGMENTSWe acknowledge final support from the National Institute of Health (GM098818).DATA AVAILABILITYThe data that support the findings of this study as well as raw trajectory files are available from the corresponding author upon reasonable request.", [["SUPPLEMENTARY", "DISEASE", 265, 278], ["hy", "CHEMICAL", 408, 410], ["coronavirus", "ORGANISM", 246, 257], ["PLpros", "GENE_OR_GENE_PRODUCT", 258, 264], ["coronavirus PLpros", "PROTEIN", 246, 264], ["coronavirus", "SPECIES", 246, 257], ["further mechanistic investigations", "TEST", 52, 86], ["higher-level approaches", "TREATMENT", 93, 116], ["extensive conformational sampling", "TREATMENT", 156, 189], ["the coronavirus PLpros", "TREATMENT", 242, 264], ["convergence analysis", "TEST", 317, 337], ["all titratable residues", "TREATMENT", 368, 391], ["additional hy-drogen bond analysis", "TEST", 397, 431], ["this study", "TEST", 580, 590]]]]}